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2 SPANISH SUMMARY 
A pesar de los avances en medicina reproductiva alcanzados durante las últimas 
tres décadas, la esterilidad absoluta de origen uterino (AUFI, por sus siglas en 
inglés), a día de hoy, carece de tratamiento. Ésta,  puede ser causada tanto por 
la ausencia del útero (congénita o adquirida) o la no funcionalidad del mismo 
[1, 2]. Cálculos en el Reino Unido han demostrado que hay alrededor de 12000 
a 15000 mujeres en edad reproductiva con  infertilidad uterina en dicho país 
[3]. No hay cálculos correspondientes a España, pero extrapolando datos sobre 
prevalencia de causas de AUFI, se estima que puede haber alrededor de 2000-
3000 mujeres en edad fértil que no tienen ninguna oportunidad de ser 
biológicamente madres. 
 
Hasta ahora, las únicas opciones para conseguir la maternidad genética en 
mujeres con AUFI son la adopción o la maternidad subrogada (coloquialmente 
llamado vientre de alquiler). Esta última  permite poder  adquirir la maternidad 
genética, aunque  al igual que en la adopción, se debe adquirir la maternidad 
legal. La subrogación gestacional se permite solo en algunos países y 
generalmente conlleva otro tipo de consideraciones de tipo éticas, religiosas, 
sociales y jurídicas en términos de autonomía, pago, de la salud física y 
psíquica de la mujer gestante [4, 5]. En cualquier caso ésta opción es ilegal en 
nuestro contexto nacional. 
 
Se ha sugerido que el trasplante de útero (UTx) podría ser una alternativa a la 
maternidad subrogada para alcanzar maternidad genética. El UTx no sería un 
tipo de trasplante que estuviese destinado a suplir una función vital, sino que 
entraría dentro de la categoría de trasplantes que mejoraran la calidad de vida 
supliendo la función de un órgano faltante, como por ejemplo los trasplantes de 
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extremidades o la cara [6] ya que el objetivo del UTx es tratar la infertilidad, 
que esta asociada con una alteración de la calidad de vida [7]. 
 
Cuando los experimentos de la presente tesis fueron diseñados, la evidencia 
disponible respecto a la fertilidad tras trasplante alogénico e inmunosupresión 
en el contexto del UTx era limitada, no habiendo estudios sobre la viabilidad 
del procedimiento y por tanto tampoco sobre los efectos que éste podría tener 
sobre la descendencia.  
Igualmente existían en la literatura datos contradictorios sobre el efecto del 
trasplante en la fertilidad; mientras que algunos estudios encuentran una 
mejoría de las tasas de embarazo después de un trasplante de órgano sólido, 
otros encuentran una mayor tasa de aborto espontáneo y de resultados 
perinatales adversos.  
 
Por tanto, los diferentes estudios presentados en esta tesis tienen como objetivo 
construir una base de conocimiento pre-clínica sobre la aspectos relacionados 
con la fertilidad después de UTx que puedan cimentar un posterior ensayo 
clínico acorde a las recomendaciones del consenso IDEAL [8]. En los 
siguientes capítulos se describirán seis estudios publicados en 9 manuscritos 
que valoran el efecto del UTx y distintos regímenes inmunosupresores sobre la 
ovulación, la implantación, el desarrollo del embarazo y el fenotipo 
descendencia. Igualmente se presenta un estudio poblacional  que utiliza datos 
epidemiológicos de dos registros completos únicos en el mundo, con más de 
2,500,000 de controles y más de 2000 nacimientos de madres trasplantadas, 
para evaluar el efecto de la inmunosupresión en el resultado del embarazo de 
pacientes trasplantadas de órganos sólidos; y finalmente, esta tesis describe 
también la primera serie de casos de UTx en humanos, llevado a cabo por 
nuestro grupo, con la consiguiente obtención de recién nacido vivo.  
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Los principales hallazgos de los estudios arriba mencionados fueron:  
-Que el inhibidor de la calcineurina ciclosporina-A, pero no tacrolimus, 
disminuye las tasas de ovulación y la implantación en modelos experimentales 
murinos. 
-Que en modelos murinos, el desarrollo evolutivo de las crías nacidas de 
madres trasplantadas de útero (alogénico) es normal desde un punto de vista 
fenotípico.  
-Que en pacientes trasplantadas, el trasplante y la inmunosupresión tienen 
moderado o ningún efecto sobre la aparición de resultados perinatales adversos 
cuando se controlan otros factores de confusión vinculados a la condición basal 
de la madre.  
-En esta tesis se ha demostrado por primera vez que el trasplante de útero es 
una opción viable para el tratamiento de la AUFI, permitiendo obtener nacidos 
vivos tras trasplante alogénico de útero en humanos.  
En resumen, los hallazgos de esta tesis permiten abrir una nueva puerta a la 
maternidad genética para las mujeres que sufren de este tipo de infertilidad, 
especialmente en contextos socio-geográficos donde no se permite la 
subrogación. Igualmente los estudios incluídos en la presente tesis facilitan 
datos de importante relevancia clínica que pueden ser tenidos en cuenta a la 
hora de programar el futuro reproductivo de pacientes trasplantadas de órganos 
sólidos en general.  
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3 ABBREVIATIONS 
• APC: antigen-presenting cells 
• ART: assisted reproductive techniques 
• ATP: Adenosine triphosphate 
• AUFI: absolute uterine factor infertility 
• BMI: body mass index (weight in kg/(size in m)2  
• CaN: calcineurin  
• CINs: calcineurin inhibitors  
• CKD: chronic kidney disease  
• CMV: cytomegalovirus  
• CyA: cyclosporine-A  
• DES: diethylstilbestrol  
• DNA: deoxyribonucleic acid 
• ESHRE: European Society of Human Reproduction and Endocrinology 
• ESRD: end-stage renal disease  
• FIGO: International Federation of Obstetricians and Gynaecologists 
• Gy: Gray. It is a unit of ionizing radiation dose and it is defined as the 
absorption of one joule of radiation energy per one kilogram of matter. 
• h: hours 
• IL: interleukin  
• IUA: intrauterine adhesions  
• IVF: in vitro fertilization 
• LH: luteinizing hormone, 
• MHC: histocompatibility complex  
• MMF: mycophenolate mofetil 
• MRKH: Mayer-Rokitansky-Küster-Hauser  
• mTOR: mammalian target of rapamycin 
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• NODAT: new onset diabetes after transplantation  
• PER: Perfadex® (preservation solution)  
• pET: personalized embryo transfer  
• RIN: ringer acetate  
• SIR: standardized incidence ratios  
• SET: single ET  
• TCR: T cell receptor 
• uNK: uterine natural killer cells  
• UTx: uterus transplantation 
• UW: University of Wisconsin (preservation solution) 
• WOI: window of implantation  
• WNT: wingless/int 
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4 INTRODUCTION 
Despite major breakthroughs in infertility treatment and assisted reproduction 
over the last 25 years, absolute uterine factor infertility (AUFI) still lacks 
reliable treatment. Today, the options for motherhood for uterine factor infertile 
patients are gestational surrogacy or adoption, the former being the only way to 
achieve genetic motherhood.  Unfortunately for AUFI patients, surrogacy is not 
considered a legal option in many countries, including Spain and Sweden. In 
this scenario, AUFI patients can choose to adopt, accept their infertility, or 
travel to a different country to undergo a procedure considered illegal in their 
own country. This latter option carries the additional risk that the authorities of 
the country of residency will deny citizenship to newborns [9].  
Advances in the field of transplantation surgery, such as the introduction in the 
early 1980s of the first calcineurin inhibitor, cyclosporine, as an effective 
immunosuppressant greatly improved long-term survival for most types of solid 
organ transplants [10]. The presence of optimized immunosuppressant 
protocols, which are also able to control rejection of strongly immunogenic 
tissues [11], has allowed the successful achievement of various types of 
vascularized composite tissue transplantations of, for example, the face, hand, 
forearm, abdominal wall, and larynx [12]. This group of transplantations are of 
course not vital but are rather quality-of-life-enhancing transplantations. It has 
been proposed that uterus transplantation (UTx) should be incorporated into the 
group of quality-of-life-enhancing transplantations [3, 7], since the aim of the 
procedure is to treat permanent infertility, which is associated with impaired 
quality-of-life [13]. 
The aim of this dissertation is to describe in detail the basic and clinical 
research related to fertility after allogeneic uterus transplantation, from 
experiments carried out in rodents to experience acquired through human 
models.  These experiments include work aimed to characterize the effect of 
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UTx and immunosuppressive regimens on ovulation, implantation, pregnancy 
development and offspring phenotype, while models have utilized 
epidemiological data to evaluate the effect of immunosuppression on the 
pregnancy outcome.  This dissertation also describes the first successful case 
series, carried out by our group, involving a live birth after UTx in human 
patients. 
 
4.1 Potential	patients.	The	absolute	uterine	factor	infertility.	
AUFI refers to a type of infertility that is 100% attributable to the absence of a 
normal uterus, either anatomical or functional, which prevents the implantation 
of an embryo or the ability to carry a term pregnancy. AUFI can be congenital 
or acquired. There are also some uterine abnormalities, whose presence can 
cause variable degrees of infertility or subfertility, although it its difficult to 
prove that such uterine abnormality is the major cause of infertility in each 
specific case. Patients belonging to the latter group may often benefit from 
other established medical or surgical treatments, and uterus transplantation 
should only be considered as the last resort when all other therapeutic options 
have failed.  
Because of the above-mentioned issues, we can describe a cause-specificity 
when it comes to uterine infertility. The prevalence of uterine infertility among 
patients of childbearing age is not exactly known but it is likely to be 
significant, with a recent estimation of 12,000 – 15,000 uterine-infertile patients 
in the United Kingdom [3]. This estimation would indicate the presence of 
more than 150,000 uterine infertile patients in Europe, although obviously only 
a portion of these would have the desire to obtain a pregnancy through uterine 
transplantation (UTx). As a general rule, the more serious the cause 
of uterine infertility, the less prevalent the condition (Table 1). Women lacking 
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an anatomical uterus will naturally belong to the AUFI group. Women with an 
anatomical uterus are considered to have a relative uterine infertility.  
 
Table 1. Main causes of infertility of uterine origin susceptible of being treated by UTx. 
Absolute infertility (only treatable by adoption, surrogacy or UTx) 
Cause Prevalence (%) Related infertility/sterility (%) 
Uterine agenesia 0.0002 100 
Leiomyomas requiring hysterectomy 1 100 
Post-partum hysterectomy 0.04-1.25 100 
Hysterectomy for cervical neoplasia 0.00004-0.0001 100 
Uterine hypoplasia 0.038 100* 
Relative infertility (Patients in who UTx should only be considered as a last-line treatment) 
Cause Prevalence (%) Related infertility/sterility (%) 
Intrauterine adhesions <1 70 
Unicornuate uterus 0.3-0.5 56.3 
Didelphys uterus 0.1-0.3 40 
Leiomyomas 21-26 40 
Septate uterus           0.8-1.4       38 
Bicornuate uterus 0.7-1.3 37.5 
Arcuate uterus 1.3-6.2 17.3 
Prevalences estimated with data from references [14-24] 
**Probably close to o 100%. Estimation done based on case reports. 
4.1.1 Women	with	no	uterus	
Hysterectomy during fertile age is the most prevalent cause of uterine 
infertility. It is the most frequent gynecological surgery with around 600,000 
procedures per year performed in the United States of America, with more than 
40% of these patients being under the age of 44 [25]. There are numerous 
causes motivating a hysterectomy at fertile age; these are described below. 
4.1.1.1 Uterine	neoplasia	
Cervical cancer is, from a global perspective, the most common malignancy of 
the female genital tract. It is caused by a persistent infection of oncogenic HPV 
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strains [26]. Despite current screening programs, cervical cancer affects a large 
proportion of women of fertile age. It is reported that more than 30% of 
cervical cancer patients are diagnosed before 40 years old [20, 27]. The surgical 
treatment of cervical cancer is limited to the initial stages (up to stage IIA). 
Patients with squamous cell carcinoma of the cervix with a size  < 2 cm and 
with invasion depth  < 10 mm can benefit from fertility-sparing surgeries like 
the vaginal trachelectomy [28] or abdominal trachelectomy [29], but for 
patients with more advanced disease, the treatment of their malignancy is 
radical hysterectomy of the uterus and parametria. The ovaries are spared in 
almost all cases occurring during fertile age, since the risk of metastatic spread 
to the ovaries is extremely low for squamous cell carcinoma as well as for 
adenocarcinoma at these stages. 
Other malignancies of the uterus, such as sarcoma or endometrial cancer, are 
very infrequent during the reproductive years and represent less than 3% of 
uterine malignancies in women below the age of 40 [30]. Initial stages of 
endometrial carcinoma of well-differentiated grade can be successfully treated 
by a fertility-sparing approach with high-dose progestins for 3-6 months, which 
should be repeatedly monitored with ultrasound, hysteroscopy and endometrial 
biopsies [31]. Rhabdomyosarcoma of the cervix can also be successfully 
managed with intensive chemotherapy and tumor excision, without the need for 
a hysterectomy [32]. Despite these two examples of fertility-sparing 
approaches, the surgical treatment of endometrial cancer beyond stage I and 
sarcomas typically includes hysterectomy and, in many cases, oophorectomy.   
4.1.1.2 Peripartum	hysterectomy	
Emergency peripartum hysterectomy is performed to save the life of the mother 
in situations of severe bleeding due to uterine rupture, atony, invasive 
malplacentation or uncontrolled bleeding at caesarean section. The incidence of 
hysterectomy in conjunction with birth (either vaginal delivery or cesarean 
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delivery) is around 5 in 10,000 deliveries [18]. Cesarean delivery is an 
independent risk factor for emergency hysterectomy [33]. Although peripartum 
hysterectomy rates have decreased over the last decade, cesarean delivery rates 
have increased, and therefore the total number of peripartum hysterectomies 
remains constant [33]. In a recent population-based study done in the Calgary 
region of Canada, the hysterectomy rate at childbirth decreased from 1.3% to 
0.8% from 1999 to 2006. Nevertheless, during that period there was an 
increased number of deliveries (from 12,370 to 15,720) and an increasing rate 
of cesarean section (from 20.7% to 28.4%). The total number of emergency 
hysterectomies has remained constant (16 hysterectomies performed in 1999 
and 13 in 2006), which is probably due to an increased knowledge and use of 
compression sutures and intrauterine compression balloons to stop bleeding and 
thereby save the uterus [33].  
4.1.1.3 Myoma	requiring	hysterectomy	
Myomas, also known as fibroids, are benign tumors of the muscle layer of the 
uterus. Histologically, fibroids are formed by smooth-muscle cells that are 
clonally expanded and surrounded by a disorganized extracellular matrix, 
which composes the major volume of the myoma and is also responsible for 
most of the continuous tumor expansion [34]. The myoma is hormonally 
dependent, developing after puberty and tending to shrink after menopause. The 
prevalence of uterine myoma increases with age [35] with a frequency of 
around 8% in women between 33 and 40 years [36]. Risk factors associated 
with the presence of myoma include age, African American ethnicity, earlier 
age of menarche, and nulliparity [37]. Myomas are the leading cause of 
hysterectomy in the United States at a cost of up to $34 billion per year [38]. 
Approximately 1% of all women between 30 and 34 years, and around 2.5% of 
those between 35 and 39, are hysterectomized due to fibroids [19]. Symptoms 
such as excessive menstrual bleeding, anemia, and pelvic pain in women with 
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large myomas are the main causes for hysterectomy during the premenopausal 
period. Additionally, myomas [39, 40] are a factor behind infertility (see 
paragraph “myoma not requiring hysterectomy” below).  
4.1.1.4 Mayer-Rokitansky-Küster-Hauser	(MRKH)	Syndrome		
The MRKH syndrome is characterized by the absence of a uterus or the 
presence of a rudimentary solid bipartite uterus, and is always found in 
combination with an absence of the upper two-thirds (superior to the hyminal 
ring) of the vagina. MRKH syndrome accounts for less than 3% of all 
Müllerian malformations [23] and is present in  1:4500 females [41]. There are 
three subtypes of MRKH syndrome: a) The typical form, without any 
extragenital malformation (50% of patients); b) the atypical form, with 
associated malformations in the renal system (20% of patients), and c) the 
severe form, with associated renal and skeletal malformations (30% of 
patients)[42]. Girls with the MRKH syndrome have a normal karyotype and can 
have normal offspring without urogenital malformations when they make use of 
surrogacy using their own eggs [43]. Although the occurrence of the MRKH 
syndrome was thought to be purely sporadic, in familial cases it seems to be 
inherited as an autosomal dominant trait with incomplete penetrance and 
variable expressivity. Different genes from the WNT family and deletions and 
rearrangements in larger DNA regions have been related to this syndrome [44, 
45]. 
Women with the typical MRKH syndrome would be suitable patients for UTx 
in the future. Provided a neovagina of sufficient length exists, it could easily be 
surgically connected to the cervix of a transplanted uterus.  
4.1.2 Women	with	anatomical	(but	not	functional)	uterus	
4.1.2.1 Radiation	damage	
Radiotherapy, given either as total body irradiation or as local irradiation on the 
pelvis, causes considerable (around 60%) reduction in uterine volume [46], and 
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this shrinkage is irreversible [47, 48]. This results in an inability to conceive or 
in an increased rate of miscarriage and late pregnancy loss [49]. In a series of 
15 patients undergoing infradiaphragmatic radiotherapy, Vernaeve et al. found 
similar implantation rates (31%) when compared to a control group (35.8%) 
[50]. Noteworthy was the high rate of adverse perinatal outcome (53%), 
including stillbirth, preterm delivery, preeclampsia and placental abruption. In 
addition to the above-mentioned effects of radiation on the uterus, it should also 
be noted that radiation doses as low as 5 Gy on the ovaries compromise gonadal 
function in most women [51]. Therefore, genetic maternity in this group of 
patients could only be achieved if a fertility preservation technique has been 
carried out before radiotherapy [52]. In the case of a radiation-damaged uterus 
in a prospective UTx patient, the organ could be replaced in a combined 
procedure of hysterectomy and transplantation. During hysterectomy of a 
radiation-injured uterus, the long proximal ends of the uterine arteries and veins 
could be spared to facilitate the transplantation surgery. A concern with this 
type of patient, however, are the surgical difficulties related to scarring, 
adhesions and impaired healing induced by radiation [53].  
4.1.2.2 Myoma	not	requiring	hysterectomy	
The prevalence of myomas in infertile women is much higher than the 
previously mentioned 8% of the general population of women aged 33 to 40 
years. In a study including patients undergoing IVF, the incidence of myomas 
during a one year observation window was 26.7% [54].  
In general, it is accepted that a subserosal leiomyoma does not affect gestation, 
while submucous or intramural leiomyomas, the latter when protruding into the 
endometrial cavity, are associated with decreased rates of implantation and 
pregnancy [34]. When a myoma is intramural and does not distort the 
endometrial cavity, there seems to be a mild negative effect on fertility.  This 
was observed in a recent meta-analysis which showed a 21% relative reduction 
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in live birth rate in women with non-cavity-distorting intramural fibroids 
compared with women without fibroids (RR: 0.79, 95% CI: 0.70– 0.88), and 
this effect remained even when only high quality trials were included in the 
analysis (RR: 0.60, 95% CI: 0.41–0.87) [55].  
With respect to surgical myomectomy of large/multiple intramural myomas, a 
prospective but non-randomized study showed fertility in around 60% of the 
operated patients [56]. Thus, our current practice is to perform a laparoscopy in 
patients with fibroids classified by the International Federation of Obstetricians 
and Gynaecologists (FIGO) as stages 3 to 6 if they have a size (≥4 cm) that can 
easily be identified and removed by laparoscopy (Munro et al., 2011). 
Myomectomy surgery might also be considered for smaller fibroids, especially 
if there are previous failed assisted reproductive techniques (ART) attempts, 
but only if surgery can be performed with a low probability of complication. If 
the endometrial cavity is not reached during a myomectomy surgery, pregnancy 
can be attempted 3 months after surgery. However, if the endometrium is 
visualized during the surgical procedure, it is generally recommended that 6 
months are allowed for uterine healing prior to pregnancy attempts [34]. 
Patients that remain infertile despite myomectomy, including those who have 
undergone hysterectomy [19, 24] because of large symptomatic myomas 
(described in the paragraph “myomas requiring hysterectomy”), belong to the 
group of myoma-related uterine infertile patients that could be treated by UTx.  
4.1.2.3 Asherman’s	syndrome	
Asherman’s syndrome, also known as intrauterine adhesions (IUA), is 
characterized by the presence of intrauterine adhesions in the endometrial 
cavity as a result of a previous damage caused by a variety of factors. The 
prevalence of the syndrome is around 1.5% among fertile-aged females [17], 
leads to a miscarriage rate around 40%, and causes infertility in around 50% of 
women [57]. Asherman’s syndrome is usually secondary to endometritis [58], 
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surgical curettage during legal abortion or postpartum [59], or surgical 
hysteroscopic procedures [60]. The treatment of choice for intrauterine 
adhesions is hysteroscopic adhesiolysis which can effectively cure infertility in 
mild, moderate and severe IUA with approximate rates of 90%, 70% and 30%, 
respectively [16]. From these data it can be estimated that around one-third of 
the total population with IUA have irreversible uterine infertility, and these 
women may be treated by a combined hysterectomy-UTx procedure.  
4.1.2.4 Congenital	uterine	malformations	and	uterine	infertility	
Congenital uterine malformations occur because of disturbances during fetal 
life in the formation, development or fusion of the Müllerian (paramesonephric) 
ducts. The Müllerian duct malformations may cause infertility and also increase 
the risk of adverse obstetric and perinatal outcomes [61]. It is estimated that the 
prevalence of uterine malformations in the general population is around 5-
6.7%, a number which is not so different from that of the infertile population 
(7.3%) [22]. This implies that a majority of these malformations do not have 
any negative impact on fertility, with the most obvious example being the 
partial septum of the uterus, which is surgically correctable as discussed below.  
On the other hand, less prevalent but more severe forms of uterine 
malformations such as the MRKH syndrome, the hypoplastic uterus, the 
unicornuate uterus, the uterus with a complete septum, and the bicornuate 
uterus may have a considerable negative effect on fertility. The prevalence of 
the above-mentioned conditions increases to 16.7% in women with recurrent 
miscarriage [22]. Sorted by prevalence, the most frequent forms of uterine 
malformations are: 
-Septate uterus: This is the most prevalent type of structural congenital uterine 
anomaly among infertile women [22]. It accounts for more than 30% of all 
uterine malformations and is the result of incomplete resorption of the central 
parts of the two fused Müllerian ducts. Spontaneous abortion occurs in about 
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80% of pregnancies in untreated septate uteri [62]. However, hysteroscopic 
resection is an effective treatment of the sepatate uterus which substantially 
decreases the miscarriage rate [62].  
-Bicornuate uterus: This is caused by the absence of fusion of the two 
Müllerian ducts. It accounts for 25% of all uterine malformations [23]. The rate 
of spontaneous abortion among women with bicornuate uteri is around 35% 
[63]. Abdominal metroplasty can result in an 82% live birth rate in women with 
previous miscarriages [21], although this surgery implies a higher risk of 
uterine rupture during pregnancy. There are also series in the literature in which 
similar reproductive outcomes have been described in women with bicornuate 
uterus treated with metroplasty compared to those without surgical intervention 
[64].  
-Unicornuate and uterus didelphys: Together these comprise around 20% of 
uterine malformations [23]. Disturbed development of one of the Müllerian 
ducts can result in the unicornuate uterus, with or without a contralateral 
rudimentary uterine horn. A total failure of fusion of the Müllerian ducts results 
in uterus didelphys, that is, two separate uterine horns without a common 
cavity. The common feature of these two entities is that a given uterine cavity 
(one in the case of the unicornutate uterus, and two in the case of a didelphys 
uterus) usually has a smaller size when compared to a normal uterus, with an 
increased miscarriage rate of 30% and decreased live birth rate of 50% being 
reported [23]. Surgery does not seem to improve the pregnancy potential of the 
unicornuate/dideplhys uterus [65]. Thus, a considerable proportion of these 
patients are unable to carry a pregnancy into the third trimester.  
-Other: T-shaped uterus and hypoplastic uterus are two infrequent forms of 
uterine malformation. T-shaped uterus is mainly caused by exposure to 
diethylstilbestrol (DES) during the fetal life, while hypoplastic uterus is usually 
associated with abnormal karyotypes (e.g. Turner syndrome) or genetic 
abnormalities like the Swyer syndrome [34]. The mechanism(s) underlying the 
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reduced reproductive performance in women with hypoplastic and T-shaped 
uteri might be a reduced uterine blood flow supply, the association with other 
malformations, and/or the absence of a functional myometrial layer [34]. Live 
birth rates ranging from 2 to 21% have been described in this group of patients. 
The arcuate uterus is not included in this review since it could be considered a 
subtle abnormality or a normal variant with minimal or no clinical significance 
[15, 66].  
As pointed out in the previous paragraphs discussing malformation-specific 
pregnancy rates, a considerable portion of patients will remain infertile even 
with corrective surgery, and it is these patients who could benefit from UTx as 
a solution to achieve genetic motherhood.  
4.1.2.5 Functional	dysregulation	of	the	uterus	
Endometrial receptivity is a transient status of the luminal epithelium that 
renders the endometrium suitable for blastocyst attachment, initiating the 
implantation process [34]. The human endometrium is receptive to embryo 
implantation during a narrow time frame of the menstrual cycle referred to as 
the window of implantation (WOI). The WOI in humans usually occurs 3 to 7 
days after progesterone rise, which corresponds to 5 to 7 days after LH surge 
[67]. 
It is known that the WOI can be displaced, causing a mismatch between the 
embryo developmental stage and endometrial receptivity, and thus leading to 
infertility. In the field of IVF, embryo transfer that takes place outside the WOI 
(during pre-receptivity or post-receptivity status), is not conducive to 
implantation and further pregnancy. Nowadays, diagnostic tools provide a 
genetic expression profile of the endometrium, and personalized embryo 
transfer (pET) in a given patient is now possible. Nevertheless, despite the use 
of these tools, 25% of patients remain infertile [68].   
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4.2 Historical	perspective	of	uterus	transplantation	
4.2.1 Previous	attempts	at	uterus	transplantation	in	the	human		
The only two previous attempts of UTx carried out in the human prior to the 
clinical trial done by our group were conducted in 2000 and 2011.  Both cases 
are described in detail in the following paragraphs. 
4.2.1.1 First	attempt	
The first human UTx attempt was undertaken in Saudi Arabia in the year 2000. 
The uterus of a 46-year-old living donor was transplanted into a 26-year-old 
woman, who at the age of 20 had undergone a peripartum hysterectomy [69]. 
The surgery of the donor should be regarded as partly successful since the 
uterus with vascular pedicles could be harvested, although they were of 
insufficient lengths for direct anastomosis to the external iliacs. Although a 
ureteric injury occurred, it was repaired during the procurement surgery. The 
uterus survived for 3 months but was then removed because of necrosis [69].  
No exact details were given concerning the hysterectomy procedure at organ 
procurement, although they naturally had to involve bilateral ureteric 
dissections to release them from the uterine cervix and from the attachments to 
the uterine arteries and veins. However, during uterus retrieval surgery, only 
short pedicles of the uterine arteries and veins were obtained, which required 
these vessels to be lengthened during back-table preparation by end-to-end 
anastomosis of vascular segments (~5 cm length) of the saphenous veins. From 
the report is seems that the uterine veins and uterine arteries were elongated 
with saphenous grafts on each side. It was not mentioned whether this 
corresponded to venous connections to the external iliac veins on each side, or 
if the saphenous extensions of the uterine veins were joined on the back table to 
create only one venous outlet on each side. This latter procedure would 
naturally make the anastomosis surgery faster, thereby decreasing the harmful 
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warm ischemic period. The transplantation procedure was accomplished by 
end-to-side anastomosis of the vessels of the graft to the external iliac vessels 
on both sides. The team that performed this human UTx did not have any 
previous publication record in the UTx field, although they stated in the paper 
that they had practiced the procedure by performing uterus auto-transplantation 
in both goats and baboons previous to the trial [69].  
This transplantation case presented several pitfalls of paramount importance:  
1) The surgical technique was not properly optimized:  
-As mentioned above, eight anastomoses may have been used during surgery 
[69], with each being a potential site for thrombosis. Moreover, the greater 
number of anastomoses, the longer the warm ischemic times, resulting in 
diminished graft survival and functionality [70]. After proper research in 
different animal models, including non-human primates [71] and preclinical 
human studies [72], we learned that UTx can be achieved with as little as 2 
(aorta and vena cava) or 4 anastomoses (2 uterine veins and 2 uterine arteries 
without the need for any extra vascular segment).  
-The Fallopian tubes were kept in the graft [69]: We have learned from non-
human primate experiments [73] that UTx surgery affects the functionality of 
the Fallopian tubes with no patency observed after a six-month follow-up. A 
suboptimal oviductal function may increase the risk of ectopic pregnancy, and 
if this occurs in a graft it will be a very difficult surgery to perform, since it is 
unlikely that laparoscopy can be used, and a laparotomic procedure will involve 
extensive surgery to dissect adhesions before reaching the oviduct of the 
ectopic pregnancy. 
-During the recipient surgery, the cervix was sutured first [69]. This surgical 
gesture limits the graft mobility from the outset and is likely to extend the 
surgical time. 
2) The follow-up of the transplanted patient lacked sensitivity to detect 
rejection:  Fageeh et al. used the CD4/CD8-T-cell ratios in peripheral blood and 
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blood flow by Doppler ultrasound to assess graft rejection [69]. It is quite likely 
that the CD4/CD8 ratio has a low sensitivity for detecting rejection, as does a 
uterine allograft, as previously shown for other transplants [74]. Moreover, 
Doppler measurement of uterine blood flow has not been evaluated as a marker 
of rejection in any animal model.  
 
It is difficult to precisely understand the cause of uterine demise in this human 
case [69, 75]. Thrombosis of the transplanted graft with secondary necrosis is a 
common finding after rejection [76], and once necrosis has occurred it is 
difficult to distinguish the cause. Vascular graft thrombosis is known to be one 
of the earliest events after allotransplantation and rejection [75, 77]. Specific 
anti-endothelial antibodies may cause endothelial disruption and thrombosis 
even in the absence of anti-HLA or anti-ABO antibodies [78]. Thrombosis may 
also be due to suboptimal vascular connections, with the saphenous grafts being 
critical sites in this specific case. In the report [69], the  authors suggested that 
uterine necrosis was not associated with rejection, and instead proposed that 
prolapse of the organ led to kinking of the vessels and secondary thrombosis.  
4.2.1.2 Second	attempt:	
In 2011, the world’s second human UTx was attempted. The team performing 
the procedure was led by a plastic surgeon with previous experience in 
composite tissue allograft transplantation [79]. Although they did not have any 
previous experience in animal models, they claimed to have used the preclinical 
experience reported by our group [80]. In Antalya, Turkey, a 21-year old 
MRKH-patient received a uterus from a 22-year-old deceased donor [80]. The 
recovery from the multi-organ donor lasted 2 hours and the uterus was the first 
organ to be recovered. The fact that the uterus was the prioritized organ is not 
without controversy, as this would lead to the possible decreased quality of 
other vital organs to be harvested, such as the heart, lungs and liver. The 
	 César	Díaz	García	
27	 	
transplantation procedure took 6 hours and included bilateral end-to-side 
anastomosis of the common iliac vessels of the graft to the external iliac 
vessels. Immunosuppression was thymoglobulin for 10 days and then triple-
maintenance therapy by prednisolone, mycophenolate mofetil and tacrolimus. 
Eighteen months after UTx, embryo transfer attempts were initiated. The 
patient has had multiple IVF attempts, but with only two very early 
miscarriages as the end result [81]. The reason for the pregnancy failure in this 
case is unknown, but an important factor to take into consideration is that a 
nulliparous uterus was transplanted, and the capacity to carry a normal 
pregnancy of this uterus has never been demonstrated. This means that there 
may be some uterine-specific factor of this nulliparous woman that caused 
pregnancy failure, which could be structural or biochemical. 
4.2.2 The	IDEAL	concept	
The first two UTx experiences raised an ethical debate [82, 83], and also 
boosted the research activities within the field of UTx [7]. The Saudi Arabian 
case and the debate surrounding it, both in the scientific community and also in 
media, was a clear signal to FIGO to provide some ethical guidelines for the 
development and clinical introduction of Utx [84]. These guidelines highlighted 
safety issues before a new clinical attempt of UTx was carried out in humans, 
with explicit mention of the fact that UTx should only occur after significant 
and adequate research in appropriate large animal models, including primates 
[84]. At that stage, our group had already published more than 16 research 
articles of experiments done in animal models evaluating different aspects of 
UTx [7]. The guiding philosophy of our group has always been that of 
minimizing any risk prior to clinical application. This philosophy is also 
reflected by the IDEAL framework [8, 85, 86], in which surgical innovations 
follow an escalating step-by-step evaluation approach, just like when testing 
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and introducing new pharmaceuticals, before they become a clinical reality. 
The IDEAL acronym stands for:  
-Innovation: This is when a surgical technique is described for the first time. 
This point includes the proof of concept in the form of case-reports, or in the 
form of intensive pre-clinical research when the risks are unacceptable.  
-Development: At this stage, clarification of inclusion an exclusion criteria, 
modifications of the original technique and report of relevant outcomes must be 
done. 
-Exploration: This stage occurs after the first case series. The main outcomes of 
the procedure are usually known, but experience in larger groups of patients 
(usually up to some hundreds) is needed. This is the stage when the procedures 
start to be performed in different centers and learning curves are evaluated. 
Prospective uncontrolled trials should start at this stage. 
-Assessment: At this stage, the new surgical technique should be fully 
developed and can be compared to other treatment alternatives. Randomized 
controlled trials are the default type of study to achieve this goal. Nevertheless, 
these kinds of studies are difficult, unethical or sometimes unnecessary simply 
to demonstrate the superiority of one intervention over the alternative.  
-Long-term study: This stage is devoted to the detection of long-term or 
infrequent adverse effects of the surgical technique. It usually involves the 
creation of patient registries, and it allows for risk adjustment for patients’ 
comorbidity. It also provides a surgeon or surgical unit a means for 
tracing/evaluating their own performance over time. 
The IDEAL guidelines strongly encourage “the use of experimental rather than 
observational designs” [8], and this is how our UTx program was based. The 
first years involved the development of different animal models including 
rodents, different domestic species, non-human primates and human preclinical 
models with the use of non-rejection transplantation models to study aspects of 
surgery, ischemia-reperfusion and pregnancy after syngeneic UTx [70, 87-96]. 
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We also developed animal models of allogeneic UTx to characterize rejection 
processes and immunosuppression protocols, and finally we conducted the 
studies that make up the core of this thesis: Animal models designed to achieve 
the proof of concept of live offspring after allogeneic uterus transplantation 
under immunosuppression [71, 97-102]. All of the preclinical studies 
performed before the experiments included in this thesis are summarized in the 
following paragraphs of the introduction. 
4.2.3 Surgical	techniques	and	surgical	models	
4.2.3.1 Early	studies	on	uterus	transplantation	
In the 1960s and 70s, intensive research was dedicated to tubal factor infertility 
prior to the development of IVF. This research focused on reconstructive 
surgery [103-106], but also investigated methods to replace the affected 
Fallopian tube with a functional one using oviductal transplantation [107-115]. 
This was the origin of the modern research on UTx. At that time, however, our 
knowledge of rejection mechanisms and the immunology of transplantation was 
far inferior to what we know today. These pioneering studies were therefore 
important contributors to our understanding of the surgical technique, the 
selection of the vessels to anastomose, and the assessment of the different 
methods of performing anastomosis. A summary of these experiments and the 
different animal models used follow below. 
-Dog: The first procedure for surgical isolation of the uterus (with oviducts and 
ovaries) followed by reanastomosis was described in the dog [116, 117]. The 
blood vessels from the uterus were isolated up to and including the common 
internal iliac arteries and veins. These experiments were not technically proper 
transplantation experiments since the uterus was connected to the vagina 
throughout the procedure. Nevertheless, they contributed to the development 
and description of the dissection procedure. Later on, utero-tubo-ovarian grafts 
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in the dog were separated from the other vessels of the pelvis [118, 119], but 
were still flushed in situ under warm conditions. Thus, the organ was never 
removed from the abdominal cavity of the animal in these auto-transplantation 
experiments. Reanastomosis was performed end-to-end (ends of the common 
branch of the internal iliac artery) and end-to-side (bilateral internal iliac veins 
to common iliac vein) using 5-0 silk sutures. In these dog models of uterine 
vascular re-anastomosis, a cumulative pregnancy rate of 11% was seen in the 
studies aimed at pregnancy outcome [116, 117, 119].  Subsequent experiments 
described how to include lower portions of the aorta/cava [120, 121] or 
common iliac vessels [118, 122] in the vascular pedicle of the graft. 
A small number of studies in the dog examined omentopexy [108, 123], rather 
than of vascular anastomosis, as a method for vascularization of the uterus. The 
survival of auto-transplanted uteri was much lower after omentopexy than 
vascular anastomosis [119] indicating that the uterus is dependent on immediate 
blood flow and cannot survive in warm ischemic conditions for the few days it 
takes for neovascularization to connect to the vascular bed of the uterus.  
-Rabbit: The experiments carried out in the rabbit model [124] are of limited 
value due to the fact that they were avascular, with transplantation of the uterus 
into the broad ligament, and also by the fact that many of the transplantations 
were done in an allogeneic setting. Thus, the results in terms of graft survival 
were very poor and therefore offered little guidance for future research. 
-Sheep: In this era of preliminary UTx experiments the sheep model was not 
used for uterine transplants. Nevertheless, there were some experiments 
describing vascular anastomosis of the utero-tubal vessels to the carotid artery 
and jugular vein when the uterus with adnexae was transplanted to this 
heterotopic position [125, 126]. The model allowed easy access to the venous 
effluents and was primarily used to study the uterine regulation of corpus 
luteum function. We later adapted part of this technique in our experiments of 
UTx in the sheep model, as discussed further below. 
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-Non-human primates: It is difficult to achieve accurate conclusions from the 
single non-human primate UTx study done in the 1970s. In this study, auto and 
allotransplantations of the uterus were performed in rhesus macaques [127]. 
The limitation of this study was that avascular transplantation was performed, 
with the uterus wrapped inside the omentum, rather than performing proper 
vascular anastomoses. Surprisingly, in the auto-transplanted animals the uteri 
maintained normal size and menstruation occurred. However, no pregnancy 
occurred despite breeding attempts for 10 months [127]. It was suggested that 
the reason for the negative pregnancy results was tubal blockage, caused by 
ischemic injuries during the period between organ procurement and 
reimplantation. In the subset of allogeneic transplanted monkeys that did not 
receive any immunosuppressive therapy, major rejection signs were present 
throughout the uterus and in oviducts, and at later stages full necrosis was 
observed [127].  
4.2.3.2 Modern	studies	on	uterus	transplantation	
The main feature of modern research in UTx (after 1985) is that the different 
potentially harmful events that may lead to unsuccessful transplantation have 
been analyzed separately. This allows conclusions to be drawn concerning each 
individual step of the procedure. These potentially damaging events include 
surgery at organ recover, ischemia-reperfusion damage, surgery at 
transplantation, and of course rejection and possible effects of 
immunosuppressive medication. During this modern era of UTx research, well-
designed experiments have used syngeneic and auto-transplantation models to 
optimize the UTx procedure from a surgical standpoint and to characterize 
ischemic preservation. The data acquired from the above optimally conditioned 
animal models was then used as an experimental control situation, where 
effects of rejection and immunosuppression were added to the allogeneic 
transplantation model in order to characterize the these effects in UTx, separate 
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from the major surgical and ischemic events. More recent research in the UTx 
field has been conducted in several animal models including rodents (mouse, 
rat) [89, 90, 92, 98], large domestic species (sheep, pig) [94, 95, 128, 129], non-
human primates (baboon, macaque) [71, 88, 130, 131], and even in humans [72, 
83, 96, 132]. 
The surgical experience acquired during this period is reviewed in the 
following pages, with specific focus on syngeneic and auto-transplantation 
models. Experience concerning ischemia-reperfusion damage and 
rejection/immunosuppression will be reviewed in the following sections: 
“Rejection in uterus transplantation”, “Resistance to cold ischemia in uterus 
transplantation”, “Resistance to warm ischemia in uterus transplantation” and 
“Immunosuppression”. 
-Mouse: In our group, we initially chose the mouse as a suitable species to 
perform basic UTx research because of the availability of gene-modified 
strains, easy embryo-transfer, and the accessibility of specific recombinant 
proteins and monoclonal antibodies. The retrieval of the uterine graft, with one 
horn excised, included unilateral dissection of a vascular pedicle with the 
uterine vessels and more proximal vessels, all the way up to the mid-abdominal 
section of the aorta and the vena cava [90]. The duration of the uterus retrieval 
procedure decreased from 60 to 45 minutes in the primary experimental series. 
The uterus was kept cold during back-table preparation and during surgical 
preparation of the recipient, with a cold ischemic time of about 35 min. The 
second warm ischemia, during vascular anastomosis, lasted for about 50 
minutes.  
The uterus with vascular pedicles, including vessels from the uterus, and up to 
and incorporating the subrenal parts of the aorta and vena cava (diameters of 
around 0.7 mm and 1.5 mm, respectively), were attached end-to-side (11-0 
nylon sutures) to the aorta/cava of the recipient mouse. In the last series, almost 
90% of the grafts of the surviving animals showed successful transplants [89, 
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91]. In all the experiments the native uterus was kept and served as an internal 
control. The grafted uterus was placed in a heterotopic position, somewhat 
higher up in the abdomen. The initial study kept the cervix inside the abdomen 
to avoid infections ascending through an exteriorized cervix [90]. However, the 
drainage of cervical/uterine cavity fluid was not sufficient in this model and in 
many cases the uterus would become swollen by accumulated fluid. 
Consequently, the surgical method was modified to create at cervical cutaneous 
stoma through the lower abdominal wall [89, 91], which allowed proper 
drainage of uterine/cervical fluid and, importantly, without any ascending 
infections despite the cervical exteriorization. 
-Rat: In the original rat models of uterus transplantation, the uterus was isolated 
en bloc with the ovaries plus oviducts [133, 134] and with vascular trees up to 
and including aortic and caval stumps. The specimens were flushed in situ with 
30 ml of cold Ringer solution and the cold ischemic time was around 30 
minutes. The duration of the second warm ischemia period during attachment 
of the graft is not stated, but can be assumed to be about 60 minutes since the 
total duration for surgeries was approximately 150 minutes [134]. The uterus 
was placed orthotopically with vaginal anastomosis followed by vascular 
connections end-to-side to the aorta and vena cava of the donor with 9-0 sutures 
[134]. In syngeneic transplants [134], all grafts showed revascularization 
lasting at least 3 months.  
In our original rat uterus transplantation model, a graft consisting of the right 
uterine horn, the common uterine cavity, and the cervix was transplanted 
between inbred Lewis rats. This was done by anastomosing the right common 
iliac artery and vein end-to-side to the mid-abdominal part of the aorta and the 
vena cava of the recipient by continuous 10-0 nylon suture [133]. The native 
uterus was left in situ as an internal control and the transplanted uterus was 
placed in a heterotopic position with the vaginal rim of the graft being 
connected to a cutaneous stoma. There was an approximate 30% loss of 
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transplants among the surviving animals (above 95% in the last series of 
experiments), and the cause of graft loss was exclusively due to thrombosis 
formation. The duration of uterus retrieval in the rat was around 60 minutes 
after the initial learning period [133]. The cold ischemia, during preparation of 
the recipient was about 60 minutes. The second warm ischemia period, during 
surgery for vascular anastomosis, was around 90 minutes. In these syngeneic 
transplantation experiments the graft survival was 80% [133].  
-Pig: The pig is physiologically similar to humans and is commonly used for 
surgical training in preparation for human procedures. Our group [94] and 
others [3] have used the pig in experiments involving a supracervical 
hysterectomy and dissections of the uterine vessels to a level above the ureters. 
In our experiments [94], the uterus was flushed with ice cold Ringer Acetate for 
a total time of 1-2 hours. Anastomoses of the uterine vessels were performed 
end-to-end using 6-0, 7-0 or 9-0 interrupted sutures [3, 94]. The uterus was 
fixed to the cervix by interrupted 1-0 polydioxanone [3] or 3-0 polyglactin [94] 
sutures . Less than 20% of the uteri were judged as being well reperfused [94]. 
In the properly reperfused uteri, blood gasses and lactate concentrations in 
uterine blood effluent normalized after 60 minutes. In evaluation of long term 
function, a gradual and progressive thrombosis developed in the uterine vessels 
at the anastomosis sites [3].  
The dissection of the uterine arteries and their proximal vessels can be achieved 
up to the level of the aorta when performed in pig cadavers [135]. This 
approach, in where the internal pelvic vasculature is dissected bilaterally from 
the uterus to the aorta, was used in an allogenic heterotopic model in mini-pigs 
[128]. If a deceased donor was going to be used for UTx, this approach would 
allow obtaining larger vascular patches, permitting easier anastomoses and 
possibly better inflow/outflow to/from the graft due to the larger diameter of the 
vessels. Extended information on the allogeneic mini-pig model can be seen in 
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the paragraph “Characterizing rejection in uterus transplantation-Studies in the 
era of calcineurin inhibitors” further below.  
-Sheep: The uterus of the sheep has one common cavity. This cavity 
communicates with the vagina through the cervix at its proximal portion, and it 
divides into two different horns and oviducts at its distal edge, with the 
fimbriae of the oviducts attached in close proximity to the ovaries. In our 
experiments [87, 93], we surgically excised the right uterine horn and the 
vasculature was only dissected unilaterally. This step aimed to decrease the 
warm ischemic time during surgery by only necessitating unilateral 
anastomosis of the graft pedicle instead of bilateral anastomosis. The internal 
iliac artery was dissected free from its proximal end, just distally to the 
branching of the anterior and posterior divisions. Dissection of the common 
utero-ovarian vein was made from the uterus to the internal iliac vein. The left 
oviduct and the ovary were kept in the specimen to allow for long term fertility 
experiments [95], although this step could have been obviated. The ovarian 
artery was dissected up to its origin in the aorta, with acquisition of an 
ellipsoid-shaped aortic patch (size 1x0.5 cm) including the origin of the ovarian 
artery. The duration of surgery for the procurement was about 3 hours for 
uterus retrieval and about 4 hours when the ovary was also harvested. Flushing 
with the preservation solution Perfadex was performed in situ and the graft was 
cold stored (70 min) before auto-transplantation. The second warm ischemia 
period, during vascular anastomosis, was about 60 minutes. The arterial end of 
the graft was the anterior division of the internal iliac vessel (4 mm diameter), 
which was anastomosed end-to-side to the external iliac artery with a 
continuous 6-0 polypropylene suture. The larger utero-ovarian vein (8 mm 
diameter) was then anastomosed end-to-side to the external iliac vein [87, 93]. 
Outcomes related to ischemia-reperfusion events and fertility are dicussed in 
“Resistance to cold ischemia in uterus transplantation” and “Resistance to 
warm ischemia in uterus transplantation”. 
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Transplantation of the two horns with bilateral anastomosis to the external iliac 
vessels has also been done in the allogeneic setting of a sheep UTx model 
[136]. The surgical technique was different, with a hysterectomy being 
performed with transection of the uterine vessels at a level above the ureters. At 
transplantation, the uterine vessels were joined end-to-end both on the uterine 
arteries and veins [136]. If performed in a human, this end-to-end uterine vessel 
anastomosis technique would only be applicable when a hysterectomy is 
performed in the same surgical session as the transplantation. Examples of this 
would be absolute uterine factor infertility due to severe and untreatable 
intrauterine adhesions or a severely malformed uterus, which cannot carry a 
pregnancy. The results of this model are commented below in the paragraph 
“Characterizing rejection in uterus transplantation-Studies in the era of 
calcineurin inhibitors”. 
-Non-human primates: During the preparation of this dissertation, our group 
carried out different experiments in 
baboons in order to prepare for the 
human uterus transplantation trial. 
Although it is not the specific subject of 
this PhD thesis, a brief summary of this 
experience will be discussed, as it 
contributes to a better understanding of 
the surgical technique presented in 
papers 7, 8 and 9.  
The first series of auto-transplantations 
included 10 baboons. The surgical 
technique was similar to that used to 
perform a radical hysterectomy [88]: 
Figure 1. Detail of the principle of anastomosing 
the ends of the ovarian veins and the anterior 
branches of the internal iliac arteries side-to-side 
to create larger vessel ends for anastomosis to the 
external iliac vessels. 
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through each uterine artery (Paper I), histidine tryptophan-ketoglutarate (HTK) 
of 4oC for 10 minutes (Paper II (initial group)) or preflushed with 5-10 ml of cold 
heparinised saline supplemented with lidocaine, followed by HTK flushing (80 
mm  Hg)   for  30  min  with  a   large  volume  (≈300  ml)  at  4oC (Papers II (modified 
group) and III (live donors)). In Paper III (deceased donors), the flushing was 
done in situ and a large vascular catheter was inserted in the abdominal aorta 
and the graft was perfused with cold heparinized (20.000 IU) UW solution until 
the organ was totally blanched (Table3).  
Following flushing, the largest ovarian vein on each side was identified and the 
venous ends were joined side-to-side by interrupted sutures (9-0 nylon) to cre-
ate a larger vessel. In Papers I and II (initial group) a similar procedure was per-
formed on the uterine artery using interrupted suture (8-0 nylon or prolene). In 
Paper II (modified group) an end-to-end anastomosis (interrupted 8-0 prolene) 
of one of the internal iliac artery ends to the largest posterior branch on the 
contra lateral side was perform d (Fig 3).  
 
Fig 3. Schematic drawing of the vessel anastomoses between a) the side-to-side uni-
fied ovarian veins and uterine arteries to the external iliac vessels in the animals of Pa-
per I and II (initial group) and b) the side-to-side unified ovarian veins and the end-to-
end unified uterine arteries to the external iliac vessels in the animals of Paper II (modi-
fied group). 
a            b  
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The uterus, Fallopian tubes and ovaries were surgically removed and auto-
transplanted into an orthotopic position with vascular connections between the 
anterior portion of the internal iliac artery, and the ovarian veins to the external 
iliac vessels on one side [88]. We bisected and sutured (8-0 suture) the ends of 
the two anterior portions of the internal iliac arteries to create a larger vessel, 
and a similar procedure was used on the two largest ovarian veins with 9-0 
sutures. These two new vessels could then be attached end-to-side to the 
external iliac vessels with 7-0 and 8-0 sutures using a similar procedure as that 
routinely used in renal transplantation (Figure 1). This technique initially 
rendered satisfactory reperfusion of the uterus but with only 2 out of 10 animals 
showing resumed menstruation. In the rest of the animals the uterus had either 
shrunk in size considerably, or completely disappeared leaving only a fibrotic 
scar above the vagina. This was interpreted to indicate that in these 8 animals 
the blood flow had either been insufficient from the start or that thrombosis had 
gradually developed. 
In a follow up study [73], the autologous transplantation technique of the 
baboon was modified with extensive dissections of the ovarian veins.  This was 
done to include their inlets into the vena cava and the left kidney vein in order 
to accomplish a vascular anastomosis with thicker venous walls. Furthermore, 
the arterial anastomosis at transplantation was modified so as to be unilaterally 
end-to-end to the internal iliac artery, and the uterus was flushed with a proper 
preservation solution under cold conditions, rather than the physiological saline 
previously used. The most important modification was probably that the 
anastomosis surgery was now performed by a transplant surgeon. Overall, 60% 
of animals resumed menstruation [73]. These baboons were subjected to repeat 
mating but pregnancies did not occur, which was most likely due to blocked 
oviducts.   
Kisu’s group, working with UTx in Japan, used another non-human primate 
model of UTx: The cynomolgus macaque [130]. They performed autologous 
Fertility	and	immunosuppression	in	allogeneic	uterus	transplantation	
	38	
UTx with bilateral anastomosis of the uterine artery and the deep uterine vein to 
the external iliacs [130]. The study only included two animals and, despite a 
lengthy operation extending over 13 hours, menstruation resumed in the 
surviving animal. In a follow-up study, it was indicated that the complete 
macaque uterus can be adequately perfused with only unilateral anastomosis of 
one uterine artery and one uterine vein, provided that the side of the dominant 
blood flow is chosen [131]. 
-Human: Experiments in the human have also been conducted to develop 
techniques for harvesting the uterus from live and deceased donors. 
In one study investigating the practicability of uterus recovery from deceased 
donors [83], the complete and bilateral internal iliac arteries and veins were 
recovered with 2 out of 7 grafts, and the vascular pedicle included the vessels 
up to the anterior portions of the iliacs in five grafts, but with unilateral loss of 
uterine vessels in twoof these. The uterine recovery was performed by 
gynecologists. In our collaborative group, transplant surgeons have recovered 
uteri from seven multiorgan donors, and in these trials they also recovered 
vascular pedicles including the complete uterine vessels, internal iliac vessels, 
common iliac vessels and lower part of the aorta and vena cava (Tzakis et al., 
our unpublished data). 
In another study evaluating the feasibility of uterus harvesting during 
multiorgan donation [132], seven uteri were retrieved after asking for 
permission in 14 female multiorgan donors. Uteri and the rest of the organs 
were perfused in situ through the femoral artery, and the uterus was retrieved 
after other organs. The vesicocervical and recto-vaginal spaces were dissected 
well below the vaginal fornix, but the graft vascular pedicles were not dissected 
until the graft was on the back-table [132]. The internal iliac vessels could be 
preserved in all cases, with the exception of the first retrieval where one vein 
was lost during organ procurement.  
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We have also recently conducted a study with vascular dissection of the uterine 
arteries and veins at open radical hysterectomy in patients with cervical cancer 
[72].  The study was performed to gain information about whether the uterus 
could be recovered at live donation with long enough vascular pedicles to 
eliminate the need for elongations with saphenous grafts as done in the first 
human UTx attempt [69]. The free lengths of the uterine arteries were almost 
70 mm, and those of the uterine veins were 50 mm or slightly longer. 
Considering that the width of the uterine cervix is about 3-4 cm, these lengths 
would be sufficient for direct bilateral anastomosis to the external iliacs, with 
an estimated distance between the vessels of around 100mm (Figure 2). In the 
event of a postmenopausal live uterus donor, it would also be possible to use 
one or two of the ovarian veins but obviously oophorectomy would have to be 
part of the procedure in such a case.  
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calibrated measuring tape. In addition, the diameters
at the ends of both arteries and veins were measured.
The lengths of the postoperative hospital stays
were noted for all patients in the study group and
control groups. Any surgery-related complications
were registered in the medical records when dis-
charged from the hospital ward and after 6 months.
Results are expressed as medians and ranges.
Differences between groups were analyzed with the
Mann-Whitney U test or the !2; P!.05 was consid-
ered significant. Correlation analyses were per-
formed by Rho Spearman correlation test. Statisti-
cal analyses were conducted with PASW Statistics
(18.0 for Windows).
RESULTS
The patient characteristics (Table 1) and preoperative
comorbidity (Table 2) of the study and control groups
were similar. The duration of the abdominal radical
hysterectomy was approximately 30 minutes longer
in the study group (with vascular dissection) than in
the control group (Table 3). The blood loss was
Fig. 1. Drawings of uterine vein anatomy (A) and of the iliac vessel tree (B) after removal of the uterus. A. The three major
uterine veins that cross the ureter are shown and the common venous trunk (measured by magnetic resonance angiography)
is indicated. B. The inter-external iliac distance, at one third the distance from the bifurcation of the common iliac artery
to the inguinal ligament, is indicated. This would correspond to a distance between proposed bilateral anastomosis sites.
Johannesson. Uterine Vessels and Uterus Transplantation. Obstet Gynecol 2012.
Fig. 2. Magnetic resonance image (MRI) of one patient in the study population. A. Sagittal T2-weighted MRI in the lateral
region of the pelvis with measurement of the main trunk of the uterine vein, from the ostium in the common iliac artery to
the first major division of branches. The cystic structure anterior to the veins is the ovary. B. Sagittal T2-weighted gradient
echo MRI with fat saturation and contrast enhancement in the lateral region of the pelvis. The measurement is of the
contrast-enhanced inner lumen diameter of the main uterine vein, from the ostium in the iliac vein to the first major division
of branches. The heterogeneous rounded structure anterior to the veins is the ovary.
Johannesson. Uterine Vessels and Uterus Transplantation. Obstet Gynecol 2012.
VOL. 119, NO. 6, JUNE 2012 Johannesson et al Uterine Vessels and Uterus Transplantation 2221
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Figure	2A)	Ilustration	of	the	inter-external	iliac	distance,	at	one	third	the	distance	from	the	bifurcation	of	the	common	iliac	artery	to	the	inguinal	ligament,	is	indicated.	This	would	correspond	to	a	distance	between	proposed	bilateral	anastomosis	sites.	Figure	2B)	Me ian	lengths	of	the	uterine	vessels	after	hysterectomy	for	uterine	neoplasia.	The	length	of	arteries	and	veins	were	similar	when	compared	patients	according	to	their	menopausal	status.	
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4.2.4 Rejection	in	uterus	transplantation	
4.2.4.1 The	uterus	is	not	immune	to	rejection	in	the	allogeneic	setting	
The uterus is an organ that varies in its population and activity of immune cells 
during the ovarian cycle [137] and pregnancy [138].  Uterine resident cells of 
the mother’s immune system tolerate a fetus that only shares half of their 
histocompatibility alleles. The mechanisms behind this tolerance of the uterus 
of the gestational products (fetus and placenta) are not fully understood. 
Regulatory T-cells (Druckmann and Druckmann, 2005) and uterine natural 
killer cells [139] seem to play central roles in maintaining such 
immunoprivileged status.  
Some authors have speculated that since the uterus somehow modulates the 
maternal immune response during pregnancy, it could also protect itself from 
immune rejection in a setting of allotransplantation [127]. In the 1970s, using 
the non-human primate as a model, Scott et al. performed allogeneic 
transplantation of subtotal hysterectomy specimens with vascularization 
obtained by omental wrapping and no immunosuppression. After 14 days, 
major rejection signs were present throughout the grafts [127].  
Also in the 1970s, different experiments of allogeneic UTx with the dog as a 
model were carried out. Yonemoto and coworkers proved that pregnant uteri 
were equally rejected when compared to non-pregnant uteri in an allogeneic 
setup [122]. The introduction of immunosuppressants (azathioprine and 
corticoids) that were used during that era of transplant surgery were not able to 
prevent uterine rejection, and rejection signs of variable degrees were seen 
when the grafts were examined at two [120], four [120] or seven weeks [122] 
after transplantation. The initial rejection signs were perivascular accumulation 
of inflammatory cells, followed by later loss of the endometrial lining [122]. In 
late stages, hemorrhage, patchy necrosis, and intravascular thrombosis were 
present [120, 127].  
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Already in the 1980s, a comparative study on rejection of the uterus was 
published with the rabbit as the experimental animal [124]. Does were allocated 
to receive cyclosporine-A or no immunosuppression. In the control group, 
100% of the animals presented rejection signs compared to only 50% of the 
cyclosporine-treated animals [124].  
4.2.4.2 Studies	in	the	era	of	calcineurin	inhibitors	
There exist two studies using a combination of cyclosporine-A (CyA) and 
tacrolimus after allogeneic UTx in the sheep. In one of the studies, ten sheep 
were treated orally with cyclosporine-A and prednisone starting two days 
before surgery [136] and discontinued after 2 weeks. Examination of the 
animals by laparatomy six months after surgery showed pronounced abdominal 
adhesions in seven out of ten animals. In six out of the ten animals the uterus 
could be identified, and all six showed bleeding of the uterine tissue after 
incision into the serosal surface. Histology revealed presence of endometrial 
tissue and myometrium but with patchy lymphocytic infiltration.  
In the second experiment, which was carried out by our group, we used either 
CyA (IV) or tacrolimus (orally) in combination with prednisone (IV) to study 
their effect on the rejection of allotransplanted uteri. We found that the levels of 
CyA fluctuated during the treatment but tacrolimus levels remained fairly stable 
[140]. In both groups inflammatory changes were seen in comparison to auto-
transplanted controls.   
In 2009, Prof. Tzakis’ group published an experiment in which 10 mini-swine 
were transplanted with uterine allografts [128]. The surgical model was a 
heterotopic transplantation of the graft with a vascular pedicle that included the 
bilateral uterine vascularization up to the aorta and vena cava. The animals 
were given tacrolimus IV for the first 12 days and 20 mg/kg/day of methyl 
prednisolone for a month. Then, maintenance immunosuppression was 
achieved with oral cyclosporine-A (10 mg/kg/ day). The animals were followed 
	 César	Díaz	García	
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up for a median time of 5.6 months (range 0.2 to 11.8). Six animals presented 
rejection episodes that were treated with steroids (10 to 20 mg/kg/day) and 
increased doses of oral cyclosporine [128]. After the first rejection episodes, 
methylprednisolone was kept at a dose of 10mg/kg/day for three months and no 
subsequent rejection episodes were registered. 
Despite all of the experiments done in allogeneic UTx, it was not until 2006 
[100] that the rejection process of the transplanted uterine graft was fully 
described in detail, which also proved the interaction between the donor cells 
and the recipient immune system triggers different immune responses that lead 
to rejection, like that seen in any type of allogeneic transplantation. Racho et al. 
and Groth et al. described in detail a time-dependent manner the effector 
mechanisms of uterine rejection in the allogeneic mouse UTx models [100, 
101]. Using a combination of BALB/c donor mice and C57BL/6 recipient mice 
with no immunosuppression, they described how rejection starts by neutrophil 
and CD8+ lymphocyte infiltration of the myometrium on day 2 after 
transplantation and spreads to the endometrium from day 5. CD4+ lymphocytes 
only increase transiently on day 5 after transplant and CD19+ cell density 
remains low throughout the rejection process. The intensity of the rejection 
process can vary between species, as shown in two of our experiments. 
Rejection after fully allogeneic UTx between Brown Norway rat donors and 
Lewis rats recipients was successfully controlled with tacrolimus at 
0.5mg/kg/day [97], while high doses of cyclosporine-A only partially 
suppressed rejection in a semi-allogeneic UTx mouse model (C57BL/6 mice 
were recipients of uteri from F1 hybrids -C57BL/6xCBA/ca donors) [141].  
During the writing of this thesis we performed two sets of experiments 
involving allogeneic UTx in baboons. Both of them involved strong 
immunosuppression protocols similar to that used in composite tissue 
transplantation, including induction with antithymocyte immunoglobulins and 
corticoids, and maintenance with corticoids, tacrolimus and mycophenolate 
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mofetil [71, 142]. In the first experiment, 18 animals (Papio anubis) were 
allocated to receive no immunosuppression (Control group, n=4), tacrolimus in 
monotherapy with target serum levels of 5-10 ng/ml (TAC group, n=4), or the 
full immunosuppression protocol (FULL group, n=10) [142]. All animals with 
evaluable uteri presented variable degrees of rejection despite the 
immunosuppressive medication, with severe and total necrosis seen in all 
groups [142]. In the second experiment, six baboons (Papio hamadryas) 
received uteri from six mismatched donors [71]. Afterwards, they received the 
full immunosuppression protocol (see above). Variable degrees of rejection 
were seen in 5 out of 6 of the animals and only one of them kept an intact 
uterus [71]. One episode of acute rejection was controlled by increasing the 
dose of tacrolimus. The common problems in both experiments which might 
explain the adverse outcomes were that (1) oral immunosuppression was 
needed in much higher doses than in a human setting which is accompanied by 
highly variable serum levels of the immunosuppressants, and (2) 
Immunosuppression-related infections such as cytomegalovirus (CMV) resulted 
in very high mortality rate of 50% in one of the studies [71], and this would not 
be expected in a human setting. 
4.2.5 Resistance	to	cold	ischemia	in	uterus	transplantation	
A critical period in any kind of organ transplantation is the ischemic period, 
which is the time when the organ is disconnected from any kind of vascular 
supply. Absence of oxygen during ischemia results in energy depletion [143, 
144]. However, most of the effector mechanisms of ischemic damage take 
place during reperfusion of the organ when toxic metabolites are flushed out of 
the organ. There are several interconnected mechanisms related to ischemia-
reperfusion injury involving vasoconstriction [145], production of radical 
oxygen species [146, 147], increase of complement factors [148], and 
inflammatory cytokines [149], along with invasion of inflammatory cells  [150] 
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and  cell death [151, 152]. Subsequently, this early post-ischemic inflammatory 
response causes the maturation of immature dendritic cells in the transplant to 
become potent initiators of the adaptive immune response in the recipient [153, 
154]. This influences the process of rejection, with an increased frequency of 
acute rejection events [155, 156], augmented chronic rejection [157], and 
delayed graft function [158]. 
The term warm ischemia is used to describe ischemia under normothermic 
conditions, and cold ischemia describes the period when the organ is chilled to 
around +4°C. In a transplant setting there is a first warm ischemic period during 
organ retrieval, from the time of vascular cross clamping until cold perfusion 
commences. This period is usually fairly short and seldom extends more than 3-
5 minutes.  The second warm ischemic period occurs after cold ischemia, 
during vascular anastomosis. The first warm ischemic period occurs in the 
donor at body temperature, and this period is generally more harmful to the 
organ than the second warm ischemic period when there is partial protection by 
preservation solution and when there is only a gradual increase in organ 
temperature of the organ, during which this ischemic period is situated in the 
recipient [159]. To avoid confusion, the terms first warm ischemia (donor) and 
second warm ischemia (recipient) have been suggested [160]. 
Cold ischemic storage, which is the period after flushing with a cold protective 
buffer, is the most commonly used method for minimizing the damage caused 
by ischemia during the transplantation process. Hypothermia decreases tissue 
metabolism by around 50% for every 10°C decrease in temperature [161]. The 
preservation solutions used for flushing and cold storage are designed to 
provide similar physiological conditions as in the blood in terms of pH and 
osmotic pressure [162].  
It has also been acknowledged that various organs differ markedly in their 
capacity to withstand the harmful effects of hypothermic ischemia. For 
example, maximum recommended cold ischemic time is around 6 hours for the 
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heart and around 36 hours for the kidney and the pancreas. Experience 
regarding the resistance of the uterus to cold ischemia will be reviewed in the 
following paragraphs. Only experiments performed in the syngeneic or auto-
transplantation models will be included to avoid the confounding factor of 
rejection. Avascular transplantation experiments will not be reviewed due to the 
remoteness of this experimental setup to the clinical reality. 
-Mouse: In the initial mouse model of syngeneic, heterotopic uterine 
transplantation by vascular anastomosis [90], the uterus was flushed in situ with 
cold heparinized saline xylocaine. The cold ischemic time was about 35 
minutes, and this was followed by second warm ischemia during vascular 
anastomosis that lasted for about 50 minutes. The graft survival was about 90% 
[90].  To test the limits of cold ischemic preservation, the mouse uterus was 
cold-stored in University of Wisconsin (UW) solution for 24 hours or 48 hours 
[91]. Uteri that had been stored ex vivo for 48 hours became necrotic after 
transplantation, but those preserved for 24 hours looked morphologically 
normal two weeks post–transplantation, and their subsequent functionality was 
demonstrated by the fact that 83% of the animals implanted embryos after 
transfer and later delivered normal offspring [91]. The advantages of the mouse 
model are that inbreeding diminishes the potential effects of factors other than 
ischemia on the histological findings. It also allows studying functionality and 
not only histology. On the other hand the uterine size of the mouse is much 
smaller than that of the human uterus, and this may be a factor to take into 
account when extrapolating the results to the human setting.  
-Rat: Using the rat syngeneic model of heterotopic transplantation between 
inbred Lewis rats [133] rather than the surgically much more difficult mouse 
model (see above) allowed improved reproducibility and decreased operator 
dependency of this UTx model. In this model, the uterus was flushed in situ 
with 2 ml of ice cold heparinized Ringer Acetate supplemented with xylocaine 
	 César	Díaz	García	
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until uterus blanching occurred. Subsequent cold ischemia was performed for 
60 minutes and the duration of warm ischemia (donor) was around 90 minutes. 
In these syngeneic uterine grafts, survival was 80% and only mild oedema and 
a slightly higher neutrophil count within the grafted uterus were noted, as 
compared to the native uterine tissue [133]. 
-Pig: Two studies assessed the viability of the uterus after ischemia-reperfusion, 
with conflicting results being reported. In the first study, Dr. Richard Smith’s 
group performed measurements of oxygen saturation, and Doppler ultrasound 
measured blood flow on the graft after cold storage of the uterus ex vivo for 1 
hour in UW/Celsior solution [3]. In another experiment performed by our 
group, uteri were kept for 1 hour in cold Ringer Acetate [94] ex vivo before 
auto-transplantation. While Doppler perfusion index and oxygen saturation 
measurements suggested satisfactory tissue perfusion in the first study [3], the 
results of the second study indicated that less than 20% of the uteri were 
correctly reperfused [94]. The explanation for such poor results in the latter 
study may have been the use of Ringer Acetate for cold preservation, rather 
than a proper preservation solution. A contributing factor may also be the rather 
long duration (1-2 h) of second warm ischemia during re-anastomosis [94]. 
Although analyses of the venous effluents of the properly reperfused uteri 
showed that blood gasses and lactate concentrations normalized after 60 
minutes and that the levels of thiobarbituric acid-reactive species (indicators of 
oxidative stress) were normal [94], histology demonstrated a notable 
inflammatory response.   
-Sheep: In our sheep model of autologous uterus transplantation [93], two 
solutions for cryopreservation were compared. Uteri were perfused in situ with 
either Ringer Acetate or the preservation solution Perfadex and then cold stored 
ex vivo before auto-transplantation. The cold ischemic time was about 70 
minutes and the second warm ischemia period, during vascular anastomosis, 
was about 60 minutes. During reperfusion (3 h), blood samples were taken from 
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the uterine vein. Parameters related to glucose metabolism, oxidative stress and 
pH levels of the uterine venous blood normalized within 30 minutes in 70% of 
the auto-transplanted uteri [93].  An increase in neutrophil density within the 
uterine tissue was also found, and use of Perfadex partially avoided such 
infiltration.   
-Human: Experiments to minimize ischemia-reperfusion injury during human 
uterus retrievals (n=7) from multi-organ donors [83] used heparin (30,000 IU) 
IV just before retrieval with flushing in situ with cold UW solution through the 
femoral arteries until the effluent was clear. The pelvis was filled with ice slush 
and the vagina was then divided. The duration of warm ischemia (donor) with 
this retrieval procedure was minimal. The uterus was stored in cold ischemic 
conditions for 12 hours. There were no signs of morphological alterations 
during the 12-hour interval of cold ischemia when examined at the light 
microscopy level [83]. However, it is questionable whether any signs of cellular 
damage would be evident at the light microscopy level after such a short 
interval of ischemia and with no reperfusion. In a similar setting of multi-organ 
retrieval, the group of Limoges analyzed uteri stored in Celsior at 4°C for 24 
hours [132]. Histology studies did not find major morphologic changes after 24 
hours of cold ischemia, and apoptosis was rare [132]. Another study performed 
by our group, used electron microscopy to assess the viability of cold-stored 
pieces of human myometrium. Small tissue samples of human uteri were 
subjected to cold (4°C) ischemia (6 and 24 h) in Ringer acetate (RIN), the 
intracellular-like UW solution, or the extracellular-like Perfadex solution 
(PER). Signs of hydropic degeneration and nuclear chromatin changes were 
detected by electron microscopy after 24 hours of storage [96], but analyses of 
contractility, ATP and protein concentrations showed that human myometrial 
tissue remains vital through at least 6 hours of cold preservation in UW or 
Perfadex [96].  
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4.2.6 Resistance	to	warm	ischemia	in	uterus	transplantation	
There are only two experiments evaluating the effects of warm ischemia on 
uterine viability after UTx. In an experiment carried out by our group, 
syngeneic UTx was performed between Lewis rats. The animals were 
synchronized to avoid the possible effects of the estrous cycle on the 
distributions and densities of the uterine leukocytic subpopulations, since 
alterations in these may be an indication of ischemic damage with secondary 
inflammatory changes. Each recipient rat was allocated to receive the uterus 
after a standard warm ischemia time of 70 minutes or after an extended warm 
ischemia time of 300 minutes. Uteri were evaluated on day 3 and day 6 post-
transplantation by visual inspection, examination of vessel patency and 
histological examination. The extended warm ischemia time negatively affected 
tissue viability, with 4 out of 10 animals presenting macroscopic necrosis of the 
graft.  
The great tolerability of the uterus to warm ischemia was also tested in the 
sheep, when auto-transplantation of both the uterus and ovary was conducted 
for fertility purposes [95]. Even with warm ischemia extending over 3 hours, 
the uterus was still able to bear normal pregnancies. 
It is difficult to predict the length of warm ischemia during a complicated case 
of human UTx, but we know that warm ischemia in uneventful cases can last 
around 80 minutes [163]. Although the principles of any kind of solid organ 
transplantation lead us to reduce the warm ischemia times as much as possible, 
extended warm ischemia times up to 3 hours 20 minutes have been described in 
a liver transplantation in the human setting [164]. 
4.2.7 Fertility	after	uterine	syngeneic	and	auto-transplantation	
The aim of any organ transplantation is to re-establish function of the non-
functioning/non-existing organ. Therefore pregnancy with live and healthy 
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offspring is the only and final end-point of UTx. It is important to emphasize 
that when this PhD research started, data on births after UTx were limited to 
syngeneic or auto-transplantation experimental models.  
-Mouse: In the year 2002, the first pregnancy after UTx was reported in a 
mouse model [90]. The transplantation was end-to-side between the vena cava 
and aorta of the recipient. The transplant was heterotopic, which means that the 
uterus was transplanted to a place different from the native pelvic location. In 
this model the native uterus of the recipient was left in place. The cervix of the 
heterotopically transplanted uterus was kept intra-abdominally to prevent 
ascending infections through the cervix of the graft. One mouse underwent 
embryo transfer. Since the complete uterine graft was positioned intra-
abdominally, trans-abdominal embryo transfer was performed via a midline 
laparotomy using thin Pasteur pipette, which was inserted through the 
myometrium. Out of the six transferred blastocysts, three were placed inside the 
native uterus and three inside the graft with pregnancy evaluated 10 days after 
embryo transfer. The results were three fetuses of normal size in the native 
uterus and one fetus in the transplanted uterus, which in addition exhibited an 
absorbed pregnancy. No live offspring were obtained, however, this was not 
part of the study design as the experiments were ended halfway through 
pregnancy. In subsequent experiments, our group demonstrated live offspring 
for the first time using the same model with the minor modification [89, 91] 
that the cervix was connected at a cutaneous stoma of the lower abdomen. 
Thus, endometrial secretions were able to drain from the uterine cavity. Again, 
the native uterus was left in place to act as a control. The pregnancy rates were 
similar in the native (75%) and in the grafted uterus (66%) of the transplanted 
animals [89]. Importantly, the median numbers of fetuses in the pregnant 
animals were similar in the native and transplanted uteri (4 pups). As 
mentioned in the paragraph “Characterizing resistance to cold ischemia in 
uterus transplantation”, cold ischemia up to 24 hours did not negatively 
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influence the capability of a transplanted uterus to carry a normal pregnancy, 
with healthy live offspring obtained in 5 out of 6 transplanted animals [91]. 
The offspring obtained from the experiments described above were 
phenotypically normal. There was no difference in birth weight or length of 
animals, or in placental weights between the groups. Weight trajectory over 8 
weeks was also similar between pups born from native and transplanted uteri 
[89].  
-Rat: Heterotopic UTx in the human would probably present problems related 
to anatomical stability of the uterus if placed outside the pelvis. This is why an 
orthotopic model had to be developed in the rat. The first aim of the research 
project was the development of such a model, which was carried out within the 
experiments of this dissertation. Further details will be given in the methods 
and results sections.  
-Sheep: The sheep was the first large animal model in which fertility was 
reported after UTx, although available data at the time of this research project 
were restricted to a single study. This was an auto-transplantation study in 
which the same animals were donors and recipients [95]. On analogy with the 
rodent model, only one horn of the ovine bicornuate uterus was transplanted in 
the procedure [87, 93, 95]. The graft consisted of the common uterine cavity 
with one uterine horn and also the ipsilateral oviduct and ovary. This also 
allowed for minimal surgical trauma to the oviduct, which is important for 
permitting natural conception. Vascular anastomosis of the anterior portion of 
the internal iliac artery, the utero-ovarian vein, and an aortic patch with the 
ovarian artery were accomplished on the external iliac vessels. Spontaneous 
cyclicity was evidenced and five animals were subjected to natural mating 
some months after transplantation. They were compared to five control animals 
not undergoing any surgery at all. All control animals mated and became 
pregnant with normal offspring. Four of the auto-UTx sheep mated, and 
pregnancies to full term were seen in 3 out of 5 animals [95]. One of these 
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pregnant ewes showed contractions compatible with the initiation of labor, but 
they disappeared after 24 hours. A caesarean section was performed and a 
360°-rotated uterus containing a twin pregnancy was found [95]. The site of the 
torsion was the lower segment, and both lambs died. Uterine torsion at labor is 
a well-known complication in sheep, but it may well be that inadequate fixation 
of the transplanted uterus contributed to the torsion. In this study [95], sizes and 
weights of both lambs and placentae did not differ between the groups.  
-Non-human primates: The higher non-human primates belonging to the group 
old world monkeys, such as the baboon and the macaque, have a simplex uterus 
and a vascularization pattern and a menstrual cyclicity that is close to that of the 
human [165]. This is why these species have been involved in UTx research 
[73, 88, 131, 166, 167]. Only two studies using primates have sought pregnancy 
after transplantation [73, 167]. 
In an auto-transplantation model using the olive baboon (Papio anubis), we 
transplanted the uterus together with the ovaries and Fallopian tubes, the main 
trunks of the internal iliac arteries, and extended dissections of the ovarian 
venous pedicles, including patches of the vena cava and left kidney vein [73]. 
At back-table preparation, the smallest iliac artery end of the graft was coupled 
end-to-end to the contralateral posterior branch of the internal iliac. At 
transplantation, this construct was coupled end-to-end to the proximal remnant 
of the internal iliac artery and the venous patch to the external iliac vein. The 
animal survival was 100%, while 80% of the animals resumed cyclic hormonal 
patterns and 60% of the animals resumed regular menstruation [73]. However, 
no pregnancy occurred despite breeding attempts over several months. Tubal 
blockage was later seen at post-mortem analysis [73]. Because of these results, 
our subsequent experiments in the baboon UTx model did not include the 
Fallopian tubes as part of the graft. Although IVF and embryo transfer has been 
described in baboons, it requires good embryology laboratory facilities and its 
efficiency is quite poor [168].  
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The cynomolgus macaque has also been used for autologous UTx experiments, 
being the first and only primate species in which live offspring have been 
reported [167]. An autologous UTx including unilateral Fallopian tube and 
ovary, and involving bilateral uterine artery anastomosis to external iliac 
arteries, was performed. Venous outflow was through one deep uterine vein and 
the contralateral ovarian vein, which were coupled end-to-side to the external 
iliac veins. Natural mating three months after transplantation resulted in a 
pregnancy that developed normally until placental abruption occurred 143 days 
after mating. A live offspring was delivered, but resuscitation of the neonate 
was not performed due to ethical issues [167]. No major malformation was 
evidenced in the newborn.  
4.3 Immunosuppression	
4.3.1 Principles	of	immunosuppression	and	rejection	in	allogeneic	
transplantation	
4.3.1.1 Types	of	organ	transplantation	
There are four different types of organ transplantation procedures, depending 
on the genetic proximity of the donor and the recipient [169]:  
-Autologous (auto-)transplantation: refers to transplantation of tissue or organs 
from one individual to the same individual. 
-Syngeneic transplantation: refers to transplantation between two individuals 
that are genetically identical (e.g. identical twins) or that are almost genetically 
identical (e.g. inbred strains of animals (mouse/rat)). 
-Allogeneic transplantation: refers to transplantation between two individuals 
that are genetically different. In a clinical setting, solid organ transplantation 
(e.g. kidney, liver or uterus) is usually done between two genetically different 
individuals of the same species.  
-Xenotransplantation: refers to transplantation between individuals from 
different species.  
Fertility	and	immunosuppression	in	allogeneic	uterus	transplantation	
	54	
4.3.1.2 Mechanisms	of	recognition	of	foreign	antigens	
Recognition of foreign molecules by T-lymphocytes occurs when the major 
histocompatibility complex (MHC) of APC (antigen-presenting cells) presents 
antigens to the cell membrane-bound TCR receptors of the lymphocytes [169]. 
There are two main pathways of allorecognition (Figure 3): 1) direct 
allorecognition: when T-lymphocytes from the recipient interact with intact 
MHC molecules from APC of the donor (foreign MHC); 2) Indirect 
allorecognition: when antigens from the donor are processed by APC from the 
recipient and are then subsequently presented to T-lymphocytes through the 
native MHC molecules of the recipient’s APC. The response of the recipient’s 
Figure 3. Mechanisms of allorecognition.  A) During direct allorecognition, which is unique to 
transplantation, T cells recognize intact allogeneic MHC molecules (together with bound endogenous 
peptide) on the surface of donor antigen-presenting cells (APCs) in the graft. Direct recognition by T cells 
of donor alloantigens on donor dendritic cells leads to full T-cell activation and graft rejection. By 
contrast, direct allorecognition by T cells of intact MHC molecules expressed on the surface of 
parenchymal graft cells that lack co-stimulatory activity might render the T cells refractory to further 
stimulation. This can induce a state of T-cell anergy. B) During indirect allorecognition, which is 
analogous to the T-cell response to protein antigens,	alloantigens are recognized as linear peptides in the 
context of recipient MHC class II molecules after they have been processed and presented by recipient 
APCs.			
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immune system to foreign antigens or a foreign MHC results in effector 
mechanisms, including cytokine production, complement activation, 
lymphocyte and endothelial activation, and subsequently cell-mediated and 
antibody-mediated cytotoxicity [169].  
4.3.1.3 Clinical	classification	of	rejection	
From a clinical point of view, rejection responses are generally classified into 
three groups, depending on the interval between transplantation and clinical 
manifestation of rejection [169]: 
- hyperacute rejection occurs within minutes/hours after transplantation  
- acute rejection usually occurs after the first week post-transplantation 
- chronic rejection occurs several months after transplantation  
Although there is not a specific relation between the immunological mechanism 
causing rejection and the time of onset of the clinical signs, hyperacute 
rejection is usually mediated by preformed antibodies and direct allorecognition 
of MHC molecules [170]; acute rejection is mediated by T-cell cytotoxicity and 
macrophage recruitment [171]; and chronic rejection appears to be antibody-
mediated and is characterized by an extended fibrosis of the parenchyma and 
intima proliferation of the vessels of the graft [172]. 
4.3.1.4 Immunosuppressants	
To avoid organ rejection, multi-drug immunosuppression protocols are used.  
*Induction protocol: Used during the perioperative period to eliminate 
circulating cytotoxic lymphocytes [173-175]. The induction protocols usually 
include one or two administrations of polyclonal antibodies (antithymocyte 
globulin) or monoclonal antibodies (basiliximab, daclizumab), together with 
corticoids for a short time.  This is followed by a calcineurin-inhibitor (see 
below), which is usually combined with an antiproliferative (see below) agent 
during the initial months.  
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*Maintenance immunosuppression: long-term immunosuppression is required 
to avoid acute episodes of rejection as well as chronic rejection. Maintenance 
immunosuppression is achieved with a combination of two or three of the 
following groups of drugs [175]:  
-Calcineurin inhibitors (CINs)(cyclosporine, tacrolimus): CINs bind to the 
calcium-dependent serine-threonine-protein-phosphatase, calcineurin (CaN), 
together with the so-called tacrolimus binding proteins (FK506BPs or FKBPs) 
or immunophilins. The immunosuppressive effect of CINs is mainly achieved 
through the interaction of CaN+FKBP12+tacrolimus or CaN+Immunophilin-
A+cyclosporine-A [176]. Such interactions block the phosphatase activity of 
CaN, and prevent dephosphorylation of the transcription factor NFAT, which 
inhibits the expression of interleukin (IL)-2, thereby inhibiting the proliferation 
of activated T-lymphocytes. Apart from this, CINs can affect other biological 
processes by binding different types of immunophilins that are involved in 
modulating the transcriptional activity of different steroidal receptors, and also 
by modulating the activity of the uterine natural killer cells (uNK) that are 
abundant in the endometrial stroma. 
-mTOR inhibitors (sirolimus, everolimus): Sirolimus is a macrolide antibiotic 
produced by the fungus Streptomyces hygroscopicus. Everolimus is the major 
metabolite of sirolimus. These inhibitors block downstream mTOR pathways 
regulating cellular metabolism, growth, and proliferation. Their 
immunosuppressive effect is mainly achieved by inhibition of T-cell 
proliferation and proliferative responses induced by several cytokines [9]. 
-Antimetabolites (azathioprine, mycophenolate mofetil-MMF-): Azathioprine 
acts as a pro-drug for mercaptopurine. It mainly acts through the inhibition of 
the enzyme amidophosphoribosyltransferase, blocking DNA synthesis by 
interfering with purine metabolism. Thus, it most strongly affects proliferating 
cells, such as the T cells and B cells of the immune system, but also 
proliferating bone marrow cells, leading to medullar aplasia [177]. Their 
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metabolites can also block other enzymes involved in different nucleic acid 
metabolism. 
MMF is the precursor of mycophenolic acid, an immunosuppressive compound 
isolated from the fungus Penicillium glaucum that inhibits inosine 
monophosphate dehydrogenase, an enzyme needed for the growth of T cells 
and B cells [178]. 
-Corticosteroids (prednisolone, methyl-prednisolone): These are synthetic 
derivatives of the natural adrenal steroids. Prednisone-derived corticoids 
display a mixed glucocorticoid and mineralocorticoid profile (mainly the 
former). Like the natural corticoids, they act through the cytosolic corticoid 
receptor, modulating a myriad of biological processes that result in the 
interference of inflammatory response, and humoral and cellular immune 
responses [179].  
4.3.2 Side	effects	of	immunosuppression	on	the	patient	
The combination of drugs with different mechanisms of action gives potent 
immunosuppressive effects with low dose-related toxicity [180]. However, 
immunosuppression is not free of side effects. The use of immunosuppressants 
has been related to the development of comorbidities such as kidney disease 
[181], diabetes [182], infections [183] and malignancies [184]. Such 
comorbidities are often a direct consequence of the use of immunosuppressants 
and can compromise directly or indirectly the survival rates of the patients. 
-Chronic kidney disease (CKD): It is a very common complication after any 
kind of solid organ transplantation, regardless of whether the transplantation 
involves the kidney itself. It has been reported that up to 50% of patients 
transplanted with solid organs develop impaired kidney function [185]. There 
are different factors that can influence the progression of the histological and 
functional damage [186]. Many of these factors cannot be modified, like the 
nature of the organ transplanted, the age of the patient, the female gender, or 
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the use of calcineurin and mTOR inhibitors. Calcineurin inhibitors induce 
vascular obliteration, focal hyalinosis of small renal arteries and arterioles, 
global or segmental glomerulosclerosis, tubular atrophy, and striped interstitial 
fibrosis, resulting in higher CKD rates than other immunosuppressants [187].  
The presence of comorbidities, especially impaired kidney function before 
transplantation, can also play a role in the development of CKD post-
transplantation. It should be noted that UTx patients are healthy despite their 
infertility, and that a proper preoperative screening allows for the identification 
of patients at risk.  
-New onset diabetes after transplantation (NODAT): It is a common condition 
affecting up to 24% of transplanted patients within 36 months after 
transplantation [188]. The incidence of NODAT depends on the definition used 
and the presence of other co-morbidities like obesity. NODAT has a severe 
impact on the graft’s and patient’s survival [182, 188] by increasing the 
incidence of cardiovascular events and infections [182]. Immunosuppressive 
agents can cause NODAT through different mechanisms, for example by 
inducing insulin resistance through decreased binding of insulin to insulin 
receptors [189] or by promoting gluconeogenesis [189], but they can also 
reduce the release of insulin by the Langerhans cells of the pancreas [190]. 
-Infections: Immunosuppressed patients are at a higher risk of developing 
infections than the general population [191]. It is difficult to assess the risk of 
infection in a given patient, which can change over the time [183], especially if 
there are modifications in the immunosuppressive therapy. The potential 
sources of infections include donor-derived infections, recipient-derived 
infections, nosocomial infections, and community infections [183]. Since 
infection is the main cause of first-year mortality in solid organ transplantation 
[192], it is of paramount importance to minimize the risk of infection by 
implementing active prophylaxis of the most common etiologies of infection. 
This should be done both to avoid unnecessary delays in diagnosis and to 
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effectively treat infections that can compromise the patient’s survival. The 
immunosuppressed patient presents some particular features that make infection 
management different from that of the non-immunosuppressed patient. Most 
typically, inflammatory responses and seroconversion are usually impaired, 
which delay diagnosis, antimicrobial resistance is increased, and interactions 
between antibiotics and immunosuppressants are also very frequent, boosting 
toxicity of both.  
-Malignancies: Transplanted patients have an incidence ratio of malignancies 
that is double that of non-transplanted patients [184]. For some specific sites 
like the lip, anus, vulva, and skin, the standardized incidence ratios (SIR) are 
increased more than 60 times [184] compared to general population. Factors 
that influence the post-transplant risk of malignancy are the length of exposure 
to immunosuppressive therapy, the intensity of therapy, and even the type of 
immunosuppressant used, with the highest risk associated with the use of 
calcineurin inhibitors, and the lowest risk with the use of mTOR inhibitors 
[193]. In composite tissue transplantation, in which healthy patients are 
transplanted, malignancies have also been reported [194].  
4.3.3 Immunosuppression	and	pregnancy	
Recommendations issued from the American Society of Transplantation held in 
2005 [195] state that pregnancy could be considered one year after solid organ 
transplantation if rejection episodes have not occurred [195, 196]. At present, 
more than 15,000 births from transplanted women under immunosuppression 
have been reported without any noticeable increase in the rate of structural 
malformations. Increased risks of adverse perinatal outcomes have been 
described in voluntary registries [197, 198], but such voluntary registries are 
susceptible to selection bias. In a population-based study on pregnancy 
outcome in transplanted patients carried out in Sweden, higher rates of perinatal 
complications such as preeclampsia (OR: 6.5; 95%CI: 4.4-9.5), preterm birth 
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(OR: 13; 95%CI: 10-17), low birth weight (OR: 16; 95%CI: 12-20), and small 
for gestational age (OR: 6.4; 95%CI: 4.2-9.5) were also reported [199]. 
However, one of the most important findings of this study was that when births 
before and after transplantation were compared, the perinatal outcomes were 
found to be similar [199]. The interpretation was that the major cause of these 
pregnancy complications in transplanted patients is the organ disease that led to 
the transplantation procedure, and not the immunosuppressants or the 
transplantation procedure itself. In our group, we have recently carried out 
another population study in Norway (see paper #6#), involving 195 births after 
transplantation and 2260 birth before transplantation. In this study we were also 
able to compare perinatal results before and after transplantation within the 
same patient, and although the general results were similar to the previous 
Swedish study [199], we found lower rates of preeclampsia, preterm birth, 
growth restriction problems and perinatal mortality (See paper #6#). 
Specific considerations must be made regarding the use of immunosuppression 
during pregnancy: 
-Teratogenicity: some of the immunosuppressive drugs commonly used in solid 
organ transplantation like mycophenolate have teratogenic profiles [200] and 
should be withdrawn before pregnancy. Others, like azathioprine, have not been 
identified as a human teratogen, although anomalies have been reported in 
rodents exposed to the drug in utero [201], and it should therefore only be used 
if alternatives are not available. 
-Pharmacokinetics: Physiological changes during pregnancy involve increased 
volume distribution and induction of different enzyme complexes that result in 
immunosuppressant altered metabolism [202]. These facts mandate that levels 
of immunosuppressive drugs be as low as possible and closely monitored 
during pregnancy. 
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4.4 ART	in	uterus	transplantation	
As mentioned in the previous paragraphs, we learnt from non-human primate 
models that the Fallopian tubes are not functional after UTx. Moreover, the 
inclusion of the oviducts would present a risk for ectopic pregnancy to occur, 
and such a pregnancy would be very difficult to surgically remove since 
adhesions after UTx may be extensive. Thus, a laparoscopic surgical procedure 
may not be feasible as an ectopic pregnancy may bleed profusely and 
necessitate acute surgery. These facts imply that IVF should be the treatment of 
choice before an UTx trial. Ovarian stimulation and oocyte pick-up could be 
performed after transplantation, but due to the complex surgery and possible 
egg and male factor infertility, it is reasonable to complete IVF before 
transplantation. In case of unsuccessful IVF, gamete donation could be 
discussed, but it is critical to have cryopreserved embryos or a large pool of 
mature oocytes before transplantation surgery. Potential candidates for UTx 
have several particularities that must be taken into account before any attempt 
of IVF: 
-The lack of uterus will evidently cause an absence of menstrual bleeding. The 
lack of this physiological indicator of the stage of the ovarian cycle can be 
easily replaced by ultrasound monitoring of the follicular pool, progesterone 
level to confirm ovulation [203], and urinary LH ovulation kits [204]. A long 
protocol may be preferred in this group of patients to assure pituitary down-
regulation before starting a classic ovarian stimulation in the follicular phase. 
Nevertheless we know from fertility preservation programs that ovarian 
stimulation regimens starting in the luteal phase can yield as many mature 
oocytes as a classic stimulation cycle and with similar fertilization rates [205].  
Another implication of the lack of uterus is that FSH should be used with 
caution as an ovarian reserve marker, due to the imprecision in defining the 
early follicular phase. In the clinical routine of our group we prefer to use 
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ultrasound and AMH for this purposes due to their diagnostic performance 
[206].  
-Single ET (SET) prevents adverse perinatal outcomes related to multiple 
pregnancy [207]. UTx is a clinical scenario where the risks of a multiple 
pregnancy are added to those of the immunosuppression and to the potential 
risks of the UTx surgery itself, and whose effects on the pregnant uterus have 
never been evaluated in the human.  
Accordingly, multiple pregnancy should be avoided in UTx, and the best way 
to achieve this goal is to systematically perform SET. The overall pregnancy 
rate after SET transfer of embryos cryopreserved at day 2 was 27% in our 
clinical IVF program. 
-Anatomical and functional particularities related to the ovaries. In MRKH 
patients, some anatomical variation of the ovaries may exist, including 
unilateral ovarian agenesis and bilateral gonadal streaks [42, 208]. Extrapelvic 
location of ovaries, where these organs are positioned at a more cranial position 
and lateral to the external iliac vessels, has also been described in up to 16% of 
the MRKH patients [208]. Patients who have undergone a hysterectomy due to 
cervical cancer might also have undergone oophoropexy. In all of these 
situations, where the ovaries can be situated far from the vaginal vault, 
follicular aspiration for oocyte retrieval can be done through the abdominal 
wall for easier access [209]. From a functional point of view, differences 
between the typical and the atypical form of MRKH may exist. Thus, it has 
been reported that while patients with the typical form have significantly higher 
mean numbers of follicles, oocytes, MII oocytes, fertilization and cleaving 
embryos than patients with the atypical form [210], the clinical pregnancy rate 
is similar in surrogacy programs.  
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4.5 Surrogacy	
The alternatives to UTx for the treatment of infertility are acceptance of the 
infertility, adoption, and gestational surrogacy. The latter is the only option 
among those three that provides a real possibility of achieving genetic 
motherhood. 
Acceptance of infertility has for a long time been the only alternative for 
women without a functioning uterus. This may in some cases lead to a 
permanent fertility crisis, which may involve seeking a second opinion, (e.g. 
“reproductive tourism”), suffering, and psychiatric morbidity and 
accompanying costs for the infertile couple and society.  Adoption is a 
satisfactory alternative for some couples, though many couples have difficulties 
accepting the fact that adoption invariably involves no genetic link to the child. 
Gestational surrogacy involves the use of gametes from the infertile couple to 
generate embryos that are subsequently transferred into the womb of a 
surrogate mother who delivers the baby but who leaves the baby to the 
“commissioning parents”. If the gametes originate from both commissioning 
parents, there is a genetic link between the baby and the commissioning parents 
(full surrogacy). If the gametes originate from only one of the commissioning 
parents (partial surrogacy), there is still a partial genetic link between the baby 
and the commissioning parents. 
In the debate regarding uterus transplantation vs. gestational surrogacy, some 
authors have characterized surrogacy as a less expensive and less medically and 
technically advanced alternative [82, 211, 212]. This statement is unconvincing, 
however, especially considering that surrogacy is not allowed in many 
countries, thereby requiring those couples to resort to commercial surrogacy 
abroad, which increases costs tremendously. The cost of the full process can 
reach 120,000€ in some countries, according to surrogacy advocates 
(http://www.vientredealquilerespaña.es/precios). 
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The medical and psychological consequences of either method is difficult to 
assess, mostly due to the lack of large enough long-term follow-up studies on 
surrogates, recipients and their offspring, and for obvious reasons there is 
currently no such information available on individuals involved in UTx. From 
the scarce information available on surrogacy, the commissioning parents have 
been described as being happy with their choice, especially considering this 
their only chance of biological parenthood, although some reports have 
indicated minor problems when neither of the commissioning parents have a 
genetic link to the offspring [213]. 
The surrogate mothers have reported few problems, except for the occasional 
case when the surrogate has wished to keep the baby she has given birth to. 
Such situations, together with the possibility that the commissioning parents for 
some reason do not wish to or are unable to take care of the baby, are probably 
important reasons why gestational surrogacy has been legally prohibited in 
many countries. An important issue in this context is the commercialization of 
the surrogates, evidenced by articles in the popular press from South-East Asia 
reporting on wealthy westerners who have paid money to Indian clinics, which 
in turn allows potential surrogate mothers to spend the entire pregnancy in the 
clinic under hospital- or hotel-like conditions during which they are subject to 
antenatal care [214]. 
Several arguments have been presented against payment for surrogacy. These 
include insult to human dignity, the instrumentalization of the human body, 
potential exploitation of vulnerable women, and coercion of women. The 
ESHRE guidelines on Ethics and Law make a plea for altruism in gestational 
surrogacy, that is, no payment apart from necessary health care expenses during 
pregnancy, provided that such expenses are not covered by a health insurance 
system, as well as payment for loss of income for the surrogate during 
pregnancy. These guidelines also highlight the fact that there are no studies 
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done so far on the follow-up of children born as a consequence of gestational 
surrogacy. 
4.6 Ethical	aspects	of	uterus	transplantation	
Ethical guidelines for research and development towards human UTx were 
presented by FIGO in 2009 [84]. The procedure has also been discussed from a 
religious standpoint by representatives of the Catholic church [215], as well the 
Islamic religion [69, 216]. In our group, we promoted bimonthly meetings 
within the Ethics forum of Sahlgrenska University Hospital between 2010 and 
2012. These meetings had the goal of preparing the submission of an ethics 
application to the institutional review board before the creation of a human UTx 
trial. In these meetings between representatives of the Ethics board of the 
Sahlgrenska University Hospital and clinicians and researchers of the local UTx 
group, the ethical aspects of this major innovative surgical procedure were 
thoroughly discussed, balancing risks and benefits and discussing the complex 
ethics around UTx. Importantly, all of the team-members, including doctors, 
nurses, practical nurses and secretaries, that would later be involved in the 
human UTx cases participated in these meetings. This was important for 
developing their personal ethical standpoints regarding the UTx trial before 
actively taking part in the clinical and research aspects of the study.  
4.6.1 Risks	of	UTx	
4.6.1.1 Surgical	procedures	
As with any surgical procedure, UTx theoretically carries some risk for both a 
live donor and a graft recipient. In many ways the procedure in the recipient is 
similar to kidney transplantation since the external iliac vessels are also used as 
a site of anastomosis. It must be kept in mind that the recipient of a kidney 
often has an end-stage renal disease (ESRD) with associated morbidity which is 
not likely to be associated with a UTx.  However, complications seen after 
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kidney transplantation, such as lymphocele around the kidney (20%) which 
obstructs urinary outflow, may also occur in UTx. General complications 
associated with any kind of abdominal surgery like bleeding or infection can 
also occur, although this is extremely rare.  
The risks for the donor (if a live donation is performed) are those associated 
with the hysterectomy procedure. Hysterectomy is generally very safe. The 
risks stated in the literature are as follow: bladder injury (0.9%), ureter injury 
(0.06%), intestinal injuries (0.6%), bleeding exceeding 500 ml (2.8%), and 
overall reoperation rate 0.8%. However, for obvious reasons there is no data on 
hysterectomy risk in healthy women with normal uteri. Moreover, a 
hysterectomy for live uterus donation would be a more extensive surgery than 
an elective hysterectomy for benign causes, since all the vascular pedicles have 
to be included. On the other hand, the uterus of a uterine-donating woman 
would not contain myomas or other benign pathologies, which may disturb the 
surgical field. These facts have to be taken into account when discussing the 
risks of hysterectomy at live uterus donation. 
As always, it is imperative to inform the donors and recipients on the surgical 
risks involved, and a written, informed consent is mandatory. 
4.6.1.2 Immunosuppression	
The effects of immunosuppressants on the patient and the future fetus have 
been widely discussed in the paragraphs “Side effects of immunosuppression” 
and “Immunosuppression	 and	 pregnancy”, and they include diabetes, 
hypertension, infections and higher risk of neoplasia. Most of these effects 
appear after long-term use of immunosuppressants, and it should be kept in 
mind that once the graft has achieved its function (live birth of a healthy baby) 
these drugs can be stopped, removing the risk of adverse effects. Regarding the 
fetus, it seems clear that there is a slight risk of preterm delivery and low birth 
weight, as well as a risk of preeclampsia in mothers undergoing solid organ 
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transplantation [217]. As mentioned in the paragraph “Immunosuppression	and	pregnancy”, it is important to note that such effect is probably due to the 
underlying disease motivating transplantation rather than the transplantation or 
the immunosuppression itself [199]. In this study, after birth, there was neither 
a decrease in kidney function in newborns from transplanted mothers, nor any 
detectable disturbance in the immune system of children exposed to 
immunosuppressants in utero, althougth the follow-up time was limited [199]. 
Taken together, human and animal data suggest that there may be an increased 
risk of miscarriage after UTx, but there is no data to support any increased risk 
of congenital malformations [102, 197, 199]. 
4.6.2 Societal,	religious,	and	cultural	attitudes	to	uterus	transplantation	
Society has the obligation to secure the welfare of its people with respect to 
both healthcare and economic growth. In many countries in the western world 
the population is aging and too few young people are contributing to the 
welfare system. Advanced maternal age increases the rate of infertility, and IVF 
is one method for securing individual welfare by improving treatment of this 
age group, and by guaranteeing new individuals able to contribute to the 
welfare of society. Other alternatives for promoting new inhabitants in society 
include adoption or surrogacy. As mentioned above, surrogacy is surrounded by 
religious, ethical and legal restrictions. In some countries surrogacy is legal, 
with some distinctions made if the surrogacy is commercial or altruistic [218]. 
The Catholic church is strongly against gestational surrogacy [219]. In Judaism 
it is believed that the duty of a family is to produce children [220], and so the 
Jewish community does not oppose gestational surrogacy. The Islamic 
interpretations state that only the one who has given birth to a child should be 
the child’s mother, and that it is immoral to introduce a gamete from someone 
who is not the husband [216, 221]. There are, however, some differences 
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between different branches of Islam [222]. However, it seems that gestational 
surrogacy and adoption as we know it in the West is nearly impossible in most 
parts of the Islamic world [222]. 
4.6.3 Introduction	of	UTx	in	a	public	health	system		
The purpose of ethical reflections and analysis is to bring awareness to 
important value conflicts in the introduction of new medical methods. Moral 
principles that apply values and judgments to the practice of medicine (such as 
autonomy of the patient, beneficence not maleficence, and justice), often have 
conflicting effects where one principles opposes another. For example, the 
autonomy of the patient may be confronted by the principle of 
“nonmaleficence” if the patient asks for a treatment or procedure with higher 
risks than potential benefits according to established medical criteria. When it 
comes to the introduction of new treatments in a public health system, there are 
other principles not strictly related to the individual patient but rather to patients 
as a whole. These principles apply to priority and management of health 
politics and try to answer questions like: What can we do, what ought we to do, 
and especially, what can we afford to do considering the lack of resources for 
medical care and cure?  
-The principle of human dignity: “All people are equal in dignity, regardless of 
personal characteristics and functions in society”. This principle focuses on the 
value of a medical treatment for one patient or a specific group of patients. 
From an individual point of view, there is no doubt that UTx is ethically 
defendable, since the procedure gives a woman a biological possibility to give 
birth to a child of her own.  
-The principle of need and solidarity: “Resources should be committed to the 
person or activity most in need of them”. This principle still focuses on the 
value of a medical treatment for one patient or a group of patients. However, 
according to this principle this value must be compared with the needs of other 
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patients requiring medical treatments of different kinds within one medical 
speciality (vertical priority settings) and between different medical specialities 
(horizontal priority settings). Since UTx is not a life-saving treatment but rather 
a quality of life-improving treatment, it is not obvious that UTx is ethically 
defendable from a priority setting perspective.    
-The principle of cost-efficiency: “When choosing between different fields of 
activity and measures, a reasonable relation between cost and effect, measured 
by improved health and improved quality of life, should be aimed for.” This 
principle still focuses on the value of a medical treatment for one patient or a 
group of patients. However, this value emphasizes a reasonable relationship 
between cost and effect, measured by improvements in health and quality of 
life. Therefore, it is of great importance to undertake a close examination from 
a cost-benefit as well as a cost-effective perspective, and also to compare these 
options to the other available alternatives (surrogacy or even adoption). 
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5 AIMS 
The general aim of this thesis was to investigate the effects of 
immunosuppressants on the reproductive system and offspring -in the context 
of uterus transplantation- using different experimental approaches.  More 
specifically, the aim was to provide a proof of concept that allogeneic UTx 
under immunosuppression is a promising treatment that can lead to healthy 
viable offspring.  This was accomplished by combining studies of physiology, 
molecular biology and epidemiology.  The findings of these new experiments, 
combined with previously existing knowledge of UTx, led to a clinical trial 
investigating human allogeneic UTx as a treatment option for AUFI patients. 
 
The specific aims were: 
1. To assess the effect of the calcineurin inhibitor tacrolimus on the ovulation 
rate. 
2. To assess the effect of the calcineurin inhibitor tacrolimus on the 
implantation rate. 
3. To develop an experimental model of allogeneic UTx and 
immunosuppression that allows for natural mating with full-term pregnancy 
that may serve as a proof of concept of functional allogeneic UTx. 
4. To compare the main physiological characteristics of the offspring delivered 
after allogeneic UTx to those of the offspring of control animals. 
5. To determine the effect of transplantation in general, and 
immunosuppression in particular, on the obstetric outcome of human patients 
transplanted with solid organs. 
6. To achieve live offspring following allogeneic UTx in the human. 	  
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6 JUSTIFICATION 
When the studies included in this thesis were designed, no pregnancy had ever 
been described following allogeneic UTx, and consequently there was no 
information available on the potential effects of the procedure on the 
forthcoming offspring. Furthermore, there was conflicting information 
regarding the effect of transplantation on fertility; while some studies found an 
improvement of pregnancy rates after solid organ transplantation, others found 
an increased rate of miscarriage and adverse perinatal outcomes. The objective 
of the different studies presented in this thesis aimed to construct a body of 
knowledge on fertility after UTx that could be used to develop a clinical trial 
based upon solid experimental research. Without this knowledge, any new 
attempts at UTx in humans would have lacked the minimal justifications of 
preparation according to the IDEAL statement [8].   
It must be pointed out that the order in which the papers are presented in this 
thesis is based on the date when the experiments were done and do not 
necessarily match the date of publication. The reason for this is that some of the 
experiments are based on data obtained from previous studies that were not 
published when the latter studies were designed. On the other hand, the 
decision to prioritize papers for publication was based on their potential impact 
on the scientific community. For example, data obtained from the implantation 
and ovulation experiments were used to design the experiments on pregnancy 
after allogeneic UTx, although the latter were published first due to their impact 
on the existing literature.  
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7 ROLE OF THE PhD STUDENT  
-Paper #1# Cyclosporine-A but not tacrolimus decreases implantation rate in 
the mouse: C. D-G. was responsible of the design of the experiment, surgical 
procedures, evaluation of the results, and wrote the major part  of the 
manuscript. 
-Paper #2# Differential effects of the immunosuppressive calcineurin inhibitors 
cyclosporine-A and tacrolimus on ovulation in a murine model: C. D-G. 
designed the study, performed ovarian stimulation and surgeries, analyzed the 
results, and wrote the major part of  the manuscript.  
-Paper #3# Pregnancy after syngeneic uterus transplantation and spontaneous 
mating in the rat: C. D-G. took part in the animal experiments, collected the 
data, and wrote the major part of the manuscript.  
-Paper #4# First report on fertility after allogeneic uterus transplantation: C.D-
G. designed the study and performed surgeries, the follow-up of the animals, 
the retrieval of tissue/blood samples, data analysis, and wrote the major part of 
the manuscript. 
-Paper #5# Pregnancy after allogeneic uterus transplantation in the rat: perinatal 
outcome and growth trajectory: C. D-G. designed the study, did the animal 
handling, and performed surgeries, tissue sample retrieval and synchronization 
of the foster colony. He also followed-up the pups issued from this experiment, 
analyzed the data and wrote the major part of the manuscript. 
-Paper #6# Pregnancy outcome after maternal solid organ transplantation: 
nationwide population-based cohort study over four decades: C.D.G. was 
responsible for the design of the study, statistical analysis, and wrote the major 
part of the manuscript. 
-Papers #7, 8, 9# These reports reflect different time points of the same clinical 
trial. #7# First clinical uterus transplantation trial: a six-month report; #8# 
Uterus transplantation trial: 1-year outcome; #9# Live birth after uterus 
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transplantation: C. D-G. participated in the design of the study, did surgery, 
obtained data, and participated in the writing of the manuscripts. 
In addition to the above-mentioned papers, during the PhD program the 
candidate also obtained a FELASA C certificate to direct animal experiments 
and a Master’s degree on Design and Statistics in Health Science from the 
Universidad Autónoma de Barcelona. He also participated in other research 
projects linked to different aspects of UTx and ovarian transplantation that 
resulted in the publication of multiple review papers and also the following 
original publications: 
1: Morken NH, Díaz-Garcia C, Reisaeter AV, Foss A, Leivestad T, Geiran O, Hervás D, 
Brännström M. Obstetric and neonatal outcome of pregnancies fathered by males on 
immunosuppression after solid organ transplantation. Am J Transplant. 2015;15(6):1666-73. 
2: Tryphonopoulos P, Tzakis AG, Tekin A, Johannesson L, Rivas K, Morales PR, Wagner J, 
Mölne J, Enskog A, Díaz-Garcia C, Dahm-Kähler P, Berho M, Zimberg S, Falcone T, Ruiz P, 
Olausson M, Brännström M. Allogeneic uterus transplantation in baboons: surgical technique 
and challenges to long-term graft survival. Transplantation. 2014 Sep 15;98(5):e51-6.  
3: Olausson M, Johannesson L, Brattgård D, Díaz-Garcia C, Lundmark C, Groth K, 
Marcickiewizc J, Enskog A, Akouri R, Tzakis A, Rogiers X, Janson PO, Brännström M. Ethics 
of uterus transplantation with live donors. Fertil Steril. 2014 Jul;102(1):40-3.  
4: Akhi SN, Díaz-Garcia C, El-Akouri RR, Wranning CA, Mölne J, Brännström M. Uterine 
rejection after allogeneic uterus transplantation in the rat is effectively suppressed by 
tacrolimus. Fertil Steril. 2013 Mar 1;99(3):862-70. 
5: Johannesson L, Enskog A, Mölne J, Díaz-Garcia C, Hanafy A, Dahm-Kähler P, Tekin A, 
Tryphonopoulos P, Morales P, Rivas K, Ruiz P, Tzakis A, Olausson M, Brännström M. 
Preclinical report on allogeneic uterus transplantation in non-human primates. Hum Reprod. 
2013 Jan;28(1):189-98.  
6: Díaz-García C, Akhi SN, Martínez-Varea A, Brännström M. The effect of warm ischemia at 
uterus transplantation in a rat model. Acta Obstet Gynecol Scand. 2013 Feb;92(2):152-9.  
7: Johannesson L, Díaz-Garcia C, Leonhardt H, Dahm-Kähler P, Marcickiewicz J, Olausson 
M, Brännström M. Vascular pedicle lengths after hysterectomy: toward future human uterus 
transplantation. Obstet Gynecol. 2012 Jun;119(6):1219-25. 
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8: Johannesson L, Enskog A, Dahm-Kähler P, Hanafy A, Chai DC, Mwenda JM, Díaz-García 
C, Olausson M, Brännström M. Uterus transplantation in a non-human primate: long-term 
follow-up after autologous transplantation. Hum Reprod. 2012 Jun;27(6):1640-8.  
9: Milenkovic M, Díaz-Garcia C, Wallin A, Brännström M. Viability and function of the 
cryopreserved whole rat ovary: comparison between slow-freezing and vitrification. Fertil 
Steril. 2012 May;97(5):1176-82.  
10: Díaz-García C, Milenkovic M, Groth K, Dahm-Kähler P, Olausson M, Brännström M. 
Ovarian cortex transplantation in the baboon: comparison of four different intra-abdominal 
transplantation sites. Hum Reprod. 2011 Dec;26(12):3303-11.  
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8 STUDY DESIGN OF THE EXPERIMENTS 
In the following paragraphs the general design of the experiments included in 
this thesis are presented. Extended information on the methods used in each 
experiment can be found in the respective paper. 
8.1 Paper	1-	Assessment	of	the	effect	of	calcineurin	inhibitors	on	
implantation		
Figure	4.	Schematic	view	of	the	design	of	the	implantation	experiment.	Vertical	lines	represent	time-lines	(Breeders	generating	embryos	in	dark	blue,	study	animals	in	red).	Animal	manipulations	are	marked	with	arrows.		
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Adult female B6CBAF1 mice (n=43) were randomly allocated to receive daily 
doses of one of the following immunosuppressant treatments: 1) tacrolimus 
0.5mg/kg/day (TAC05 group); 2) tacrolimus 0.2mg/kg/day (TAC02 group); 3) 
cyclosporine-A 10mg/kg/day (CYA10 group); 4) normal saline 0.9% (Control 
group). After induction of pseudo-pregnancy, each animal underwent transfer 
of 14 blastocysts from the same strain (7 blastocyst per horn), and 7 days later 
implantation sites and fetal viability were assessed by direct inspection of the 
uterine cavities. Tissue samples were also taken for natural killer 
(NK)/placentation markers characterization by immunohistochemistry and RT-
PCR. A schematic overview of the study design is shown in Figure 4. 
8.2 Paper	2-Assessment	of	the	effect	of	calcineurin	inhibitors	on	
ovulation		
Immature Sprague-Dawley rats (21 days of age) were randomly allocated (15 
animals/group) to receive one of the following immunosuppressive drugs: 
Group 1-0.9% NaCl (Control); Group 2-cyclosporine-A 10mg/kg/day (CYA10) 
and Group 3-tacrolimus 0.5mg/kg/day (TAC05). All animals were 
synchronized for ovulation at 25 days of age according to our standardized 
protocol for ovulation studies, which consists of administration of 10 IU of 
equine chorionic gonadotrophin (eCG) s.c. at 12:00 on day 25. Forty-eight 
hours later, the rats were administered 10 UI of human chorionic gonadotrophin 
(hCG), with ovulation occurring 10-15 h after hCG administration [223]. 
Twenty hours after inducing ovulation, the animals underwent euthanasia and 
the ovulation rates were assessed by counting the number of oocytes present in 
the Fallopian tubes. Blood samples and both ovaries were also harvested in 
order to perform leukocyte quantification and measurement of calcineurin 
inhibitor (CINs) levels in peripheral blood, and histological and molecular 
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markers of neutrophils and ovulation. A schematic overview of the study design 
is shown in Figure 5. 
 
 
 
Figure	5.	Schematic	view	of	the	design	of	the	ovulation	experiment.	Animals	were	allocated	to	receive	one	of	the	interventions	in	a	three-arm	parallel	design.	Horizontal	lines	represent	time.	Manipulations	of	the	animals	are	marked	with	arrows.	
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8.3 Papers	3	and	4-Development	of	an	experimental	model	of	
allogeneic	uterus	transplantation	allowing	for	pregnancy	
The rat was chosen to develop an allogeneic model of UTx. As compared to our 
previous experience in the mouse, the rat offers a shorter learning curve for the 
surgery and a higher reproducibility between surgeons [133]. On the other 
hand, IVF procedures in the rat are difficult and are less effective than in the 
mouse [224]. For these reasons, it was decided that an orthotopic UTx surgical 
model that allowed for natural mating should be developed. Initially, uteri were 
transplanted between individuals from the same strain (syngeneic 
transplantation) to avoid the effect of the rejection on the outcomes of the 
surgery. Once the surgical model was developed, the findings were used to 
develop a model for the allogeneic setting with immunosuppression. This was 
done in order to carry out the fertility experiments under conditions similar to 
those expected in a clinical setting.  
8.3.1 Development	of	the	surgical	technique	(Paper	3):	
Female virgin Lewis rats were randomly allocated for syngeneic uterine 
transplantation (UTx group; n=27) or removal of the left uterine horn (Sham 
group; n=19). In the donor, a graft was isolated which contained the right 
uterine horn, the common uterine cavity with the cervix, and the upper vagina 
plus a vascular pedicle including the arteries and veins from the right uterine 
vessels up to and including the right common iliac vessels. To allow for natural 
conception, an undisturbed uterine-tubal junction seemed to be a prerequisite. 
Thus anastomosis was performed to connect the major part of the uterine horn 
of the graft to a smaller upper part of the recipient uterine horn. Thus, the donor 
uterine horn was divided 7-8 mm from the Fallopian tube, after cauterizing the 
utero-ovarian pedicle at the same level. The uterus was stored in cold (4°C) 
Perfadex preservation solution (Vitrolife AB, Mölndal, Sweden) during 
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preparation of the recipient. In the recipient, a simple hysterectomy was 
performed, keeping a 7-8 mm segment of the upper portion of the uterus. The 
right common iliac vessels were dissected and the common iliac vessels of the 
graft were anastomosed to the recipient in an end-to-side fashion using two 
hemicontinuous 10-0 nylon sutures (S&T Microsurgery, Neuhausen, 
Switzerland) on each vessel (Figure 6, panel A). The vaginal cuff of the 
transplant was then sutured to the vaginal vault of the recipient and the uterine 
horn of the graft was anastomosed end-to-end (Figure 6, panel B) to the 
remaining cranial uterine segment of the recipient uterus.  
 
Control animals were operated under the same conditions as the transplanted 
rats to remove the right uterine horn. No modifications were made on the 
remaining horn and only blood vessels and nerves coming through the left 
infundibulopelvic ligament were excluded. 
After recovery after surgery, animals mated with males of proven fertility. The 
efficiency of the model was assessed by evaluating the reproductive 
performance and achievement of viable offspring. 
A B 
Figure	6.	 	 A)	 Detail	 of	 the	 anastomosis	 site	 on	 the	 common	 iliac	 vessels	 of	 the	 recipient.	 The	internal	iliac	artery	of	the	graft	is	attached	with	interrupted	sutures	to	the	common	iliac	artery	of	the	recipient.	B)	Schema	of	the	recipient	surgery:	The	graft	is	colored	in	grey,	the	recipient	in	White;	a	detail	of	the	anastomosis	site	is	augmented	in	the	circle.	
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8.3.2 Fertility	experiments	in	an	allogeneic	setting	(Paper	4):	
Twenty adult Lewis rats were randomly allocated to one of the following 
groups: 1) Allogeneic UTx under immunosuppression (UTx-TAC group; n=9); 
2) Sham surgery under immunosuppression (Sham-TAC group; n=5) and 3) 
Sham surgery without any immunosuppression (Sham non-TAC group; n=6). 
The surgical procedures were similar to those described in the previous 
experiments. UTx were performed between female virgin Dark Agouti rats 
(histocompatibility haplotype: RT1av1, RT2b, RT3a, RT7a)—donors—and 
female virgin Lewis rats (histocompatibility haplotype: RT1l, RT2a, RT3a, 
RT7a, RT8b)—recipients. The immunosuppression protocol consisted of 
continuous administration of tacrolimus by means of mini-osmotic pumps to 
achieve a final dose of 0.5 mg/kg/day. All animals were exposed to fertile 
males during one estrous cycle between 35 and 38 days after surgical 
intervention. Mating was confirmed and mated animals underwent cesarean 
section 17 days later to assess both the number of viable and the number of 
resorbed pregnancies.  
8.4 Paper	5-Evaluation	of	the	perinatal	outcome	and	growth	
trajectory	of	the	offspring	issued	from	mothers	transplanted	
from	an	allogeneic	uterus		
In this experiment, data from papers 3 and 4 were used to develop a different 
allogeneic UTx model, allowing for less aggressive immunosuppression. PVG 
female rats were randomly allocated to three different experimental 
interventions: (A) allogeneic UTx under immunosuppressive treatment with 
tacrolimus (UTx+TAC group, n=10), with Virgin Lewis rats 
(histocompatibility haplotype: RT1l, RT2a, RT3a, RT7a, RT8b) used as uterus 
donors and virgin Piebald-Virol-Glaxo (PVG) rats (histocompatibility 
haplotype: RT1c, RT2b, RT3a, RT6a, RT7a, RT8b) used as recipients; (B) 
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surgical removal of the left uterine horn under immunosuppressive treatment 
(Sham+TAC group, n=10); and (C) surgical removal of the left uterine horn 
without any immunosuppressive treatment (Sham group, n=10). In the groups 
receiving immunosuppression (UTx+TAC and Sham+TAC groups), animals 
were given tacrolimus at a dose of 0.4 mg/kg/day for 8 weeks, which was then 
tapered to 0.2 mg/kg/day during the remainder of the experiment. The female 
rats were introduced to males of proven fertility and the mating and pregnancy 
rates, numbers and sex of pups, and weights and perinatal mortality rate were 
recorded and compared.  
Two breeding colonies were used as external control groups for weight: a) pups 
born from PVG females (BC; n=52), and b) and pups born from PVG females 
undergoing an identical immunosuppressive treatment as the experimental 
groups during pregnancy (BC+TAC; n=86). Comparisons were made between 
pups born from the three experimental groups and also between pups born from 
the UTx+TAC group in comparison to those of the breeding colonies. A 
schema of the study design is shown in Figure 7. 
 
 
 
 
Figure	 7.	 Schematic	 view	 of	 the	 study	 design.	 Three	 experimental	 groups	 were	 compared	between	them	and	also	with	two	external	breeding	colonies,	one	receiving	tacrolimus	(BC+TAC)	and	the	other	one	not	(BC).	
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8.5  Paper	6-Evaluation	of	the	perinatal	outcome	of	pregnancies	
mothered	by	transplanted	patients	
In this study, in order to assess the risk of adverse perinatal outcome in 
pregnancies from transplanted mothers, we performed a cross-link cohort study 
between two large population databases that extended over a period of 40 years. 
The first database was the Medical Birth Registry of Norway (MBRN) and the 
second one was the Transplantation registry from Oslo University (TROU). 
Oslo University Hospital has since 1969 kept complete records of all 
transplanted patients in the country within the TROU. Both registries are 
compulsory. All records in the MBRN are matched with the files of the Central 
Person Register (unique identification number given to every Norwegian 
citizen or resident), and are the records of the TROU. Linkage between TROU 
and the MBRN was performed using this unique personal identification 
number. Information about type of transplanted organ and date of transplant 
were collected from the TROU, whereas data on pregnancy, delivery, perinatal 
complications and congenital malformations were obtained from the MBRN.  
The analysis included all female patients that received a transplant during the 
period from January 1969 up to and including 2009. Twin pregnancies and 
transplanted males were identified to exclude any pregnancy emerging from 
couples with both parents being immunosuppressed, and thereby to exclude 
possible influences carried over from the male. Possible confounding factors 
for adverse perinatal outcome were controlled using multivariate regression 
analysis and propensity-scores. 
Comparisons were made between transplanted patients and the general 
population but also within transplanted patients: pregnancies before and after 
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transplantation were compared list-wise between patients and paired-wise 
within the same patient. 
8.6 Papers	7,	8,	9-Description	of	the	first	live	birth	after	
allogeneic	uterus	transplantation	in	the	human	
After the intense preclinical research described in the introduction of this thesis 
and also after the fertility experiments developed during this PhD project, a 
clinical trial in humans was approved by the Regional Human Ethics 
Committee of Sahlgrenska in 2012 and then registered as a clinical trial 
(NCT01844362).  Permit was obtained to perform allogeneic uterus 
transplantation between live donors and recipients in ten patients. The inclusion 
and exclusion criteria are shown Table 2. 
8.6.1 Preoperatory	assessment:	
The screening process included tests to assess the general medical health status, 
psychological health, status of infectious diseases and HLA and HLA-antibody 
screening. It was also designed to assess the suitability of the organ to be 
transplanted and to rule out the presence of pathology in the uterus potentially 
affecting the ability to carry a normal full-term pregnancy. The different parts 
of the screening process were performed by a multidisciplinary team including 
gynecologists, transplant surgeons, psychologists, immunologists, internal 
medicine doctors, anesthesiologists and radiologists.  
An external transplantation board verified all the screening process and took the 
final decision on whether or not to include each independent donor-recipient 
pair. 
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Table 2. Inclusion and exclusion criteria 
 RECIPIENT DONOR 
In
cl
us
io
n < 39 years < 60 years 
Good ovarian reserve (AFC / AMH) Previous normal pregnancy 
IVF ( > 10 embryos cryopreserved) Accomplished child wishes 
E
xc
lu
si
on
 
BMI >30 kg/m2 BMI >30 kg/m2 
Presence of infectious/systemic disease Presence of infectious/systemic disease 
 Uterus with pathology compromising pregnancy 
(myomas <1cm are allowed) 
Major abdominal surgery 
 
8.6.2 IVF	before	transplantation	
A key step of the preoperatory assessment was to rule out any fertility problem 
up to fertilization in order to identify patients having a potential sterility 
background that for obvious reasons (the lack of uterus) should be excluded. 
All patients were treated using the long GnRH-agonist protocol to achieve a 
uniform hormonal situation before gonadotrophin treatment was initiated. The 
agonist treatment (Buserelin, Suprecur, 0.15 mg/dose; Sanofi Aventis AB, 
Bromma, Sweden) was administrated in the midluteal phase based on earlier 
cycle monitoring of estradiol (E2), progesterone (P4), luteinizing hormone 
(LH) and follicle stimulating hormone (FSH), usually 8 to 9 days after positive 
urine LH-testing (ClearBlue, SPD Swiss Precision Diagnostics, GmbH). 
Gonadotrophin doses for stimulation were determined based on age, BMI and 
AFC of the patient, and human menopausal gonadotropin (hMG) (Menopur, 
Ferring AB, Sweden) or recombinant follicle stimulating hormone (rFSH) 
(Gonal-f, Merck Serono, Europe, Ltd, UK) were used. Final follicular and 
oocyte maturation was induced by hCG injection (Ovitrelle, Merck Serono, 
Europe, Ltd, UK or Pregnyl, MSD, Sollentuna, Sweden) and oocyte aspiration 
performed 36 h later using follicle aspiration set with single lumen (Vitrolife 
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Sweden AB, Göteborg,). Oocytes were aspirated vaginally according to our 
routine method [225] using local anesthesia, combined with mild sedation and 
analgesia if needed. In cases when ovaries were not readily reachable via the 
vaginal route, oocytes were aspirated by transcutaneous puncture in local 
anesthesia and mild sedation. Fertilization was performed 4h after oocyte pick-
up and normally fertilised and cleaved embryos were cryopreserved on day 
two, using the slow freezing method and Sydney IVF cryopreservation kit 
(COOK Medical, Limerick, Ireland) or in blastocyst stage using the cryotop 
vitrification kit (Kitazato, Dibimed Biomedical Supply S.L., Valencia, Spain). 
8.6.3 Preoperatory	preparation,	surgery	and	postoperatory	care	
Preoperatory preparation, surgery and postoperative care are described in detail 
in paper number 7. Briefly, anesthesia was administered using a combined 
spinal-general anesthesia. Prophylactic antibiotics consisted of 
piperacillin/tazobactam and thrombosis prophylaxis was achieved with a 
combination of 5,000 IU of dalteparin and 75 mg of acetylsalicylic acid. 
All the surgical procedures in the recipient and the donor were done through a 
mid-line laparotomy. The object of the donor surgery was to isolate the uterus 
together with 10-15mm of the vaginal cuff, a portion of the bladder peritoneum 
and with long vascular pedicles including the bilateral uterine arteries and veins 
up to the internal iliac vessels, with special care to isolate them from their firm 
attachment from the ureters. Then, the graft was gently flushed with HTK 
preservation solution at 4ºC (Custodiol, Nordmedica AS, Gentofte, Denmark). 
The preparation of the recipient to receive the graft included dissection and 
opening of the vaginal vault and the dissection of the external iliac arteries and 
veins bilaterally. The uterine graft was then placed in its orthotopic position in 
the pelvis and their vascular pedicles were anastomosed end-to-side to the 
external iliac vessels. After adequate blood flow through the uterine arteries and 
veins was checked, the vaginal cuff of the graft was sutured to the vaginal vault 
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of the recipient and the uterus was fixed to the pelvis by attaching the 
uterosacral and round ligaments of the graft to those of the recipients. In 
addition to that, the bladder peritoneum kept in the graft was overlapped with 
the recipient’s bladder fundus. 
8.6.4 Immunosuppression	
The recipients received standard immunosuppression protocol for kidney 
transplantation used at Sahlgrenska Transplantation Institute. Induction was 
achieved with a single bolus of methylprednisolone prior to uterine reperfusion 
(500 mg; Solu-Medrol®, Pfizer) and Thymoglobulin ® (i v, 2,5 mg/kg bw; 
Genzyme) or ATG (i v, 5 mg/kg bw; ATG-Fresenius®; Fresenius Medical Care 
Sverige AB,) just prior to UTx and at a second occasion 12h later. 
Postoperative immunosuppression included tacrolimus, (Prograf®/Advagraf®, 
Astellas) with the aim to keep trough levels of 10-15 ng/ml during the first 2 
months, followed by 5-10 ng/ml from the second month and onwards, 
Mycophenolate mofetil (MMF, Cellcept®, Roche,) was given orally as a single 
dose preoperatively (1 g). Starting from postoperative day 1, MMF, was 
administered twice daily aiming for MMF-area under the curve (MMF-AUC) 
trough levels of 40-60 mg×h/L. MMF was discontinued after six months, well 
before any embryo transfer, because of its described teratogenic effects. The 
aim was then to treat the patients with solely tacrolimus or in cases of repeated 
rejection episodes during the initial 6 months to give continuous azathioprine 
instead of MMF. Oral prednisolone (5 mg/day) was also administered during 
the first 5 days post-operatively (Prednisolon, Pfizer, New York, NY, USA). 
8.6.5 Follow-up	
The recipients were monitored twice a week during the first month, once a 
week during the second and third months and thereafter the monitoring was 
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spaced out, depending on decisions on individual patients, according to their 
record of rejection episodes. Follow-up assessment included physical 
examination, gynecological examination, ultrasound examination of the graft 
(2D and Doppler), cervical sampling for cultures and biopsies and blood 
samples to monitor immunosuppressive drug levels, hemoglobin levels, white 
blood cell counts, and tests of kidney as well as liver function. 
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9 RESULTS AND DISCUSSION 
9.1 Paper	1-	Assessment	of	the	effect	of	calcineurin	inhibitors	on	
implantation	
9.1.1 RESULTS	
Clinical outcomes: Pregnancy rate was reduced in animals receiving 
cyclosporine-A (CYA) compared to those receiving tacrolimus or NaCl 
(CYA10: 58.3%, TAC02: 100%, TAC05: 80%, Control: 80%), although 
differences were only significant when compared to the TAC02 group 
(p=0.03). Implantation rate/animal was also significantly lower in the CYA 
group compared to all of the other groups (CYA10: 32.1%[0%-73.2%]; 
Control: 57.1%[32.1%-92.9%]; TAC02: 71.4%[64.3%-92.9%]); TAC05: 78.6 
[37.5%-94.6%]; p<0.001). Pregnancy and implantation rates are shown in 
Figure 8.  
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Figure	8.	Pregnancy	and	implantation	rates	in	animals	receiving	NaCl	0.9%	(Control),	two	different	doses	of	tacrolimus	(TAC02:	0.2mg/kg/day;	TAC05:	0.5mg/kg/day)	or	cyclosporine-A	10	mg/kg/day	(CYA10).	Each	animal	was	transferred	14	donated	embryos	from	a	breeding		colony. Ψ: p<0.001; *: p=0.03 for comparisons between CYA10 and the other groups. 		
*	
Ψ 
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The sizes of the fetuses were similar between groups, with all pups having 
crown-rump lengths between 6-8 mm. 
Uterine Natural Killer-uNK-cells (DBA+) and activated lymphocytes (CD25+) 
characterization: Densities of DBA+ cells in both placenta and decidua of 
pregnant animals were similar between groups. All groups showed surface 
areas with positive staining varying between 3% and 6% in placenta samples 
and 16% and 28% in decidua samples. DBA expression in non-pregnant 
animals was almost absent and restricted to some cells in the subendometrial 
stroma. Uteri from animals treated with cyclosporine-A showed lower densities 
of CD25+ cells (0.38% CYA10) than the other experimental groups (0.84% 
Control, 1.35% TAC0.2 and 1.15% TAC0.5, p<0.05). 
Expression of markers of implantation and placentation: The studied genes 
included markers of vascularization and vascular proliferation (CD31, VEGF-
A), cell adhesion (ICAM-1), presence of uNKs (NKG2D), molecules that 
modulate immune responses in the utero-placental junction and drive the 
implantation and placentation processes such as the non-inflammatory-Th2-like 
cytokines interleukin (IL)-4, IL-5, IL-6, IL-10, IL-13 and leukemia inhibitory 
factor (LIF), and the inflammatory-Th1-like cytokines (tumor necrosis factor 
(TNF)-alpha and TNF-beta). There were no differences regarding the 
expression of any of these genes in either decidua samples or placental samples.  
9.1.2 COMMENTS	
This is the first systematic study evaluating the effect of different CINs and 
providing the accurate calculation of implantation rates, since the exact 
numbers of embryos transferred were known. In previous studies, exposure to 
cyclosporine-A at higher doses (30mg/kg/day) was associated with a lower 
pregnancy rate and decreased implantation rate [102]. An essential limitation of 
that study was that the pregnancies were secondary to natural mating, and thus 
the accurate implantation/pregnancy rate could not be determined given that the 
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number of embryos reaching the uterine cavity was unknown. It is also 
important to highlight that CINs can affect the ovulation rate (see results from 
paper #2#), so the natural mating model is not appropriate for studying 
variables such as implantation.  
The main findings of this study were that cyclosporine-A used within a 
therapeutic range can adversely affect implantation and therefore diminish 
pregnancy rate. This effect was not observed when the animals were exposed to 
tacrolimus. Although both are CINs, this differential effect could be explained 
by the fact that they interact with calcineurin through the intermediation of 
different molecules (FKBP-12 for tacrolimus, cyclophilin-A for cyclosporine) 
(Setkowicz et al., 2004). This causes/may cause different conformational 
changes in the calcineurin subunits, leading to different downstream effects in 
the intracellular signaling pathways (Setkowicz et al., 2004).  
Regarding fetal size, fetal growth retardation is a well-known side effect in 
pregnancies from immunosuppressed mothers (McKay and Josephson, 2006), 
and it has also been evidenced in experimental models after term pregnancies 
(Groth et al., 2010). Nevertheless, in our study, no differences between 
intervention groups were seen. This difference may be explained by the fact 
that fetal weight was studied on pregnancy day +12, indicating that fetal growth 
restriction related to CYA is a late-pregnancy event or that the dose used in our 
study is too low to cause such effect. 
When analyzing uNK markers, markers of vascularization, cell adhesion, or 
shift in the TH1/TH2 profile, we did not find any differences between groups. 
Considered together, these data suggest that CINs have no effect on these key 
players of implantation. On the other hand, CINs have been shown to modulate 
the activity of NKs from other tissue sources (Lin and Kuo, 2008; Morteau et 
al., 2010; Howell et al., 2013; Neudoerfl et al., 2013), and it has also been 
shown that the calcineurin-Nuclear factor of the activated T-cells (CaN-NFAT) 
pathway is required to achieve the typical Th1 to Th2 shift that has been 
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classically described in successful pregnancies (Yamashita et al., 2000). CINs 
impair Th2 cell development more intensively than that of Th1 cells 
(Yamashita et al., 2000), resulting in a promotion of the Th1 pro-inflammatory 
profile. These apparently conflicting results between our experiment and 
previously reported data can be explained by the fact that implantation is a 
complex and highly organized biological process, in which numerous molecular 
mechanisms interact in a synchronized time-and-site-specific manner to enable 
the embryo to properly interact with the decidualized maternal surface 
(Guzeloglu-Kayisli, 2011). In our experiment we were evaluating one specific 
time point (pregnancy day +12), and it is possible that even if we could not 
identify any difference in molecular mechanisms mediating the effect of 
cyclosporine-A at that time-point, it would have existed earlier in pregnancy. 
This could be one underlying mechanism helping to explain the decreased 
implantation rate. Therefore, based on the results of the present experiment, a 
new study is currently ongoing using similar methods but with samples 
obtained on pseudopregnancy day +3. The analysis of these data will provide 
further information enabling us to better characterize the effect of CINs during 
the implantation window. 
9.2 Paper	2-Assessment	of	the	effect	of	calcineurin	inhibitors	on	
ovulation		
9.2.1 RESULTS	
In these experiments, rats exposed to therapeutic doses of cyclosporine-A 
showed a decreased ovulation rate compared to control and tacrolimus-treated 
rats, showing lower median numbers of ovulated oocytes in the Fallopian tubes 
(CYA10 9 [0-22], TAC05 21 [8-41], Control 22 [6-39], p=0.03). There were no 
differences between the control group and tacrolimus-treated animals. The use 
of CINs did not modify the different white blood cell subpopulations in 
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peripheral blood, nor did they modify the amount of neutrophils (measured 
indirectly by ELANE expression), T-lymphocytes (CD4+ and CD8+) or 
macrophages (CD163+). On the other hand, both cyclosporine-A and 
tacrolimus were found to downregulate MPO expression in the ovary. The anti-
proteolytic activity during early post-ovulatory period, measured through 
RUNX2 and TIMP3, was not significantly different between groups. 
9.2.2 COMMENTS	
There are conflicting results in the literature regarding the potential effects of 
transplantation/immunosuppression on ovarian function. While an 
improvement in fertility parameters, usually associated with normalization of 
the hypothalamic-pituitary-ovarian axis function, is experienced after 
transplantation of solid organs [226], ovarian dysfunction in solid organ-
transplanted patients has also been described, with mid-luteal phase defects 
associated with low progesterone levels [227]. Despite these clinical 
observations, to our knowledge there are no experimental studies on the effects 
of immunosuppressive drugs on ovarian function.  
The biologically central process of ovulation has been compared to a local 
inflammatory reaction, since a number of inflammatory mediators, as well as 
some subsets of leukocytes, are essential for carrying out the tissue remodeling 
of the extracellular matrix, blood flow changes [228], and changes within the 
cumulus cells [229]. The intraovarian biochemical changes of ovulation are 
time- and site-specific, and to a large extent involve various types of molecules 
with antagonistic effects to achieve controlled tissue remodeling. Examples of 
these molecules are metalloproteinases secreted by resident white blood cells in 
the ovary, and inhibitors of metalloproteinases secreted by theca cells, 
granulosa and fibroblasts [230]. Like any other inflammatory process, 
immunosuppressive drugs that modify the function of the different leukocyte 
subpopulations could potentially regulate ovulation.  Secretion of 
Fertility	and	immunosuppression	in	allogeneic	uterus	transplantation	
	98	
metalloproteinase inhibitors from ovarian tissue cells could also be regulated by 
immunosuppressants due to the ubiquity of the molecular pathways disrupted 
by these drugs. Therefore, the rationale of this experiment was to assess if CINs 
can influence ovulation, since ovulation is an inflammation-like process.  
Our main finding was that cyclosporine-A, but not tacrolimus, decreases the 
ovulation rate when administered for at least two estrous cycles. These 
differential effects on ovulation by these two types of CINs were unexpected, 
because the main mechanism of both is the specific inhibition of calcineurin, 
with the most common and serious secondary effect being the cessation of 
interleukin-2 release from T-lymphocytes. However, in our previous 
experiment (see results from paper #1#), we already demonstrated this 
dichotomy. Moreover, as previously discussed in paper #1#, the differential 
effects of cyclosporine A and tacrolimus have previously been described in 
other organs and systems [231]. 
The reduction in ovulation rate in the CyA-group does not appear to be 
mediated by any major change in leukocyte infiltration patterns as histological 
examination of the post-ovulatory ovaries did not find any difference in terms 
of numbers and distribution of neutrophils, macrophages or lymphocytes in the 
three experimental groups. Similarly, peripheral leukocyte populations did not 
vary between groups. These two facts indicate that CINs do not affect vascular 
permeability and recruitment of immune cells to the ovary. Although most of 
the evidence available in the literature suggests that CINs may affect the 
chemotaxis and activation of neutrophils and macrophages [232-235], there are 
also studies suggesting the absence of such effect of CINs [236]. These 
differences between studies are likely caused by the different doses and route of 
administration of CINs, the target organ, or the methodology employed. 
We also found decreased expression of MPO in CIN-treated animals, indicating 
that although there is no difference in the number of neutrophils (measured by 
ELANE), their capacity to produce oxygen-reactive species is diminished. This 
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effect is consistent with the data from transplanted patients in whom the 
production of free radical species is decreased by the effect of 
immunosuppressive drugs [237].  
Regarding ovulation markers, we did not find any significant difference 
between groups, which is in contrast to our clinical observations of the reduced 
number of ovulated oocytes in the CYA group. An explanation of this finding 
is that signaling pathways involved in TIMP3 regulation are independent of 
calcineurin regulation [238].  Therefore, the detrimental effect on the ovulation 
rate observed in the group of animals treated with cyclosporine-A seems to be 
independent of the expression of metalloproteinase inhibitors like TIMP3 in 
ovarian tissue. 
It must be highlighted that this study was designed to assess the effect of the 
main variable—the ovulation rate. Given the complexity of the process of 
ovulation, this experiment allowed us to only partially study the mechanisms 
behind such effect. Based on the results, one can rule out that the decrease in 
ovulation rate caused by calcineurin is due to alterations of leukocytes 
subpopulation infiltrations. Moreover, it is unlikely that any imbalance in the 
production of metalloproteinases inhibitors is a factor behind the results. It may 
well be that other factors, such as changes in production of metalloproteinases 
[239], abnormal vascularization [240] or follicle contractility [241] are 
underlying causes of this effect.  
9.3 Papers	3	and	4-Development	of	an	experimental	model	of	
allogeneic	uterus	transplantation	allowing	for	pregnancy	
9.3.1 Development	of	the	surgical	technique	(syngeneic)	
9.3.1.1 RESULTS	
A total of 27 UTx procedures were performed and 19 animals were included in 
the study, resulting in a surgical success rate of 70%. The causes for exclusion 
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of 8 UTx animals were: death due to bleeding within the first three post-
operative days (n=3), unsatisfactory post-operative recovery (n=1) and 
pathological findings (graft thrombosis (n=1), intra-abdominal adhesions (n=1), 
and constricted uterus-uterus anastomosis (n=2) during the check-up surgery. In 
the included animals, the median graft cold ischemia duration was 120 min 
(range: 60-210 min) and the duration of the recipient surgery was 215 min 
(range: 170-270 min). In the Sham group, the duration of surgery was between 
35 and 40 minutes and surgical success was 100%.  
Breeding performance of the two groups is shown in Table 3. The UTx rats 
showed a significantly higher number of resorbed pregnancies and a 
significantly lower number of delivered litters. In 4 out of 7 UTx rats 
parturition was initiated but could not proceed to delivery. There were no 
differences between groups regarding the birth weight and weight of the pups, 
nor in their growth-trajectory (follow-up until post-natal day 60). 
 
Table 3. Breeding performance after UTx and Sham surgery. 
Utx Sham Sig. 
Animals 19 19 n.s. 
Mated (first cycle) 17 16 n.s. 
Pregnant animals 11 12 n.s. 
Successfully delivered litters 1 8 p<0.01 
Total number of pups or fetuses 32 45  
Pups/pregnancy* 3 (2-6) 3.5 (3-7) n.s. 
Number of resorptions 6 0 p<0.01 
Numbers express absolute values (ranges) 
9.3.1.2 	COMMENTS	
In the present study the success rate of this orthotopic surgical model was 
similar to that of previous heterotopic murine models [89-91]. Pregnancy rates 
and litter sizes were similar between groups. Nevertheless, under the 
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assumption that each uterine horn carries half the litter, the median number of 
pups in the present model was lower than that reported by other authors in 
normal animals [242]. This may result from the transplantation procedure itself, 
but might also indicate that insult caused by sham surgery affects the fertility 
potential of the uterus. The increased number of resorbed pregnancies in the 
UTx group may indicate that conditions supporting fetal survival after UTx are 
sub-optimal. When the paper was written, it was not clear whether this was 
caused by altered blood flow, interrupted lymph drainage or denervation, or if it 
was simply an effect of the small sample size. Later experiments (see paper 
#5#) did not find this increase of intrauterine death, suggesting that the 
differences were likely due to the sample size of the experiment.  
One of the main findings was the difference in delivery rates. When the pups 
were examined at euthanasia no differences were noted regarding the fetal size, 
suggesting that all of them reached full-term and that there was a cause that 
motivated arrested parturition. There are two potential explanations for such 
arrest: The lack of innervation of the uterus, since nerve reflexes influence 
parturition in rodents [243], and the presence of scar tissue in the anastomosis 
of the vaginal vault of the recipient along with the vaginal cuff of the graft 
which could have caused a lack of dilatation of the birth canal. Regardless of 
the actual cause, the main conclusion of this experiment was that caesarean 
section should be the preferred way of delivery in future experiments. 
9.3.2 Fertility	experiments	in	an	allogeneic	setting	
9.3.2.1 RESULTS	
Pregnancy rates (defined as number of pregnant females/total number of 
females) were not significantly different between groups (UTx-Tac-group: 5/8 
(62.5%), Sham-Tac-group: 3/5 (60%), Sham-nonTac-group 5/6 (83.3%)). It 
should be noted that in the UTx group, all pregnancy sites were present in the 
uterine graft and none were seen in the small native remnant of the uterine 
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horn. There were no differences between groups in the median [ranges] 
numbers of fetuses per pregnant rat: 1 [0-3] in the UTx-Tac-group, 1 [1-5] in 
the Sham-Tac-group and 3 [1-4] in the Sham-nonTac-group. Resorbed 
pregnancies were seen in 4 out of 5 pregnant rats in the UTx-Tac-group 
(median 1 resorbed pregnancy [0-3]) and in 1 (1 resorbed) out of 4 and 1 (1 
resorbed) out of 5 in the Sham-nonTac-group and Sham-Tac-group, 
respectively. None of the animals showed macroscopic signs of thrombosis 
and/or rejection. Uterine morphology (gross/light microscopy) was similar in 
the uteri of all groups with no signs of inflammation or necrosis in any group.  
Tacrolimus levels (median [ranges]) at the end of the experiment were within 
the same range in the UTx-Tac-group (11.4 ng/ml [4.6-18]) as in the Sham-
Tac-group (9.4 ng/ml [5.7-25]).  
9.3.2.2 COMMENTS	
This experiment proved for the first time that pregnancy after allogeneic uterus 
transplantation was possible. Pregnancy rates were very close to the 70% 
pregnancy rate observed in the syngeneic orthotopic rat model (see paper 
#3#)[92], and were also similar in the number of resorbed pregnancies. As in 
the previous study, the occurrence of resorbed pregnancies, along with a 
pregnancy rate far from 100%, in all groups may suggest implantation defects 
after uterine surgery. 
The tacrolimus levels in the UTx-Tac and Sham-Tac groups were close to the 
upper limit of the therapeutic range. In the liver transplantation program at our 
hospital, the tacrolimus target levels are half of those achieved in this study (5 
ng/ml). 
This experiment was designed to make progress toward the development of a 
allogeneic orthotopic UTx model, and the endpoint was to evaluate the 
presence of implantation sites and the feasibility of pregnancy. Since caesarean 
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sections were scheduled on pregnancy day 17, there is no data on the outcome 
of the offspring for obvious reasons. 
9.4 Paper	5-Evaluation	of	the	perinatal	outcome	and	growth	
trajectory	of	the	offspring	issued	from	mothers	transplanted	
from	an	allogeneic	uterus		
9.4.1 RESULTS	
The surgical success rate was 71% (10/14) in the UTx group and 100% (10/10) 
in the Sham and Sham-Tac groups. The causes for exclusions in the UTx group 
were: one intra-abdominal hemorrhage secondary to leakage from the 
anastomosis site on post-op day 1; one animal died due to anesthetic 
complications while replacing a mini-osmotic pump on post-op day 28; one rat 
presented a necrotic uterus during second-look laparotomy on post-op day 15; 
and one animal was excluded because of extensive, left-sided hydronephrosis 
which was found on post-op day 15.  
Pregnancy rates were higher in the control groups with sham surgery (70% in 
Sham group; 80% Sham+TAC group) than in the UTx+TAC group (50%,), 
although these differences did not reach significance. There were no differences 
between groups regarding number of living pups or neonatal deaths (Table 4). 
Litter sizes of the BC+TAC (13[0-14]) group were significantly larger, 
although also with a greater range, compared to the other experimental groups.  
No differences were observed between groups regarding the macroscopic 
appearance of the uteri. Microscopic examination of the uteri of the non-
pregnant rats showed similar endometrial and myometrial patterns in all 
experimental groups, except for one animal in the Sham+TAC group that 
showed evident fibrosis in all uterine compartments. Thrombi were present in 
both arterial and venous vessels in this animal. Variations of different phases of  
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the estrus cycle were seen in uteri from non-pregnant animals, suggesting that 
these animals were cycling normally. Evaluation of uteri and placentae of 
pregnant animals revealed no major disruptions of placental structures in any of 
the three experimental groups, although the vascular density in both the 
subendometial location and the spongiotrophoblast was lower in the UTx+TAC 
group compared to the Sham group and the Sham+TAC group (Figure 9). 
 
Table 4. Fertility and perinatal outcomes after allogeneic UTx in the rat model 
 UTx SHAM+TAC SHAM BC BC+TAC 
MATING (1ST cycle) 9/10 10/10 8/10 10/10 10/10 
MATING (2ND cycle) 4/6 5/5 6/6 - - 
PREGNANCY RATE 5/10 8/10 7/10 8/10 8/10 
LIVE PUPS 
       Mothers 5/5 8/8 7/7 7/8 6/8 
      Pups  5[1-7] 2.5[1-7] 1[1-5]* 5.5[0-14] 13[0-14]* 
STILLBORNS 
       Mothers 1/5 3/8 0/7 2/8 2/8 
      Pups  0[0-1] 0[0-1] 0 0[0-7] 0[0-4] 
NEONATAL DEATHS 
       Mothers 1/5 2/8 1/7 1/8 1/8 
      Pups  0[0-2] 0[0-2] 0[0-2] 0[0-1] 0[0-1] 
Values are presented as raw data for dichotomic variables and median [range] for continuous variables. 
For each perinatal outcome, “mothers” represent the number of rats whose offspring presented the 
event/number of pregnant rats; “pups” represent the median [range] number of pups per litter size 
presenting the event. 
*Sham vs BC+TAC: p<0.05 
No differences were found between groups when the pattern or expression of 
endothelin receptors A and B were compared (Figure 10). Tacrolimus levels 
were similar between the tacrolimus-treated animals during mid-pregnancy 
(UTx+TAC: 1.88±0.60 ng/ml; Sham+TAC: 1.77±0.49 ng/ml; BC+TAC: 
1.92±0.45 ng/ml; n.s.) and at the time of C-section/laparotomy (UTx+TAC: 
1.50±0.20 ng/ml; Sham+TAC: 1.63±0.63 ng/ml; BC+TAC: 1.71±0.48 ng/ml; 
n.s.). Male pups from UTx+TAC mothers had higher birth weight than male 
offspring from the Sham group (6.2±0.2 g vs 5.3±0.1 g; p<0.001), but not 
compared to Sham+TAC group (5.9±0.6 g). There were no differences between 
experimental groups regarding the birth weight of female offspring 
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(UTx+TAC: 5.5±0.6 g; Sham+TAC: 5.3±0.3 g; Sham: 5.1±0.5 g). When 
compared to animals of the breeding colony, both males and females born from 
UTx+TAC mothers had similar birth weights (UTx-TAC males: 6.2±0.2 g; 
UTx-TAC females: 5.5±0.6 g; BC males: 5.8±0.2 g; BC females: 5.2±0.3 g; 
n.s.). 
 
 
 
Figure 9. Histological sections of uteri from pregnant rats. H.E. staining. A lower vascular density is seen in 
the UTx group. Such decreased vascularization pattern is noticed both in non-implantation sites (1a) and 
implantation sites (1b). L, labyrinth zone; JZ, junctional zone; D, decidual basalis cells; Syn C, 
syncytiotrophoblast cells; Spo C, spongiotrophoblast cells. The maternal vascular compartment (yellow 
arrows). The fetal capillary space  (black arrows) 	
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Figure 10. Endothelin receptor expression in uteri from the experimental groups. Endothelin A (a-
figures) and B-receptors (b-figures) show a similar distribution pattern between groups when detected 
by immunofluorescence staining, being expressed in both epithelial (epi) and stromal (Str) 
compartments. 	
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The proportion of low birth 
weight (LBW) pups did not differ 
significantly between 
experimental groups (UTx+TAC: 
10.5%; Sham: 7.7%; 
Sham+TAC: 11.3%), nor with 
the BC group (10% by 
definition). 
Growth trajectories until post-
natal week 16 are shown in 
Figure 11. No weight differences 
were seen at any time point 
between female offspring from 
the different groups. The male 
offspring from the UTx+TAC 
groups showed a trend toward 
higher weight compared to the 
other experimental groups and to 
the external breeding colony 
controls. This difference was 
significant from postnatal week 
10 (Figure 11 bottom) but not at 
earlier time points.	 
9.4.2 COMMENTS	
The present study evaluates for 
the first time postnatal outcomes 
in an allogeneic UTx setting. The 
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Figure 11. Comparison of weight evolution between 
pups from the different experimental groups and the two 
breeding colonies. The “Y” axis presents the weight in 
grams, the “X” axis presents the age in days. Data are 
presented for female (upper) and male (bottom) 
offspring. 	
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main finding is that the birth weight of offspring is not affected. However, 
vascular density of the uterus was affected, although the placental weights were 
unchanged. Moreover, the postnatal growth of male pups from the UTx+TAC 
group was slightly accelerated after postnatal week 10.  
The fertility rate in the UTx+TAC group of the present study is comparable to 
that of our previous study in an allogeneic rat UTx setting [98]. Animals in all 
three experimental groups of the present study had smaller litter sizes compared 
with animals of the breeding colony. A plausible explanation for this is the 50% 
reduction of potentially implantable endometrium, since all animals of the 
experimental groups had undergone surgical excision of one uterine horn. The 
animals in the breeding colony groups (BC and BC+TAC groups) underwent 
no intervention and had normal bicornuate uteri.  
Overall, our data concerning pregnancy rates suggest that the implantation 
potential of a transplanted uterus is not impaired relative to a native one. This 
effect was not observed in our previous experiments using an allogeneic UTx 
model (paper #4#). An explanation for this could be the lower doses of 
tacrolimus used. However, it could also be an effect of the small sample size of 
the experiments, since in the syngeneic orthotopic model (paper #3#), in which 
immunosuppression was not used, the number of resorbed pregnancies was 
increased. Another fact supporting the hypothesis of a preserved 
implantation/placentation potential is that offspring born from UTx+TAC 
mothers did not show lower birth weights or a higher rate of LBW than 
offspring from the Sham group or the breeding colonies. This, would suggest 
that the blood flow entering the graft is enough to support a normal pregnancy. 
Experimental data in several animal species indicate a direct relationship 
between uterine blood flow and size of offspring. In a model with 
experimentally lowered uterine blood flow during pregnancy in the rat, the 
reduced utero-placental perfusion affected birth weight of the offspring, 
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regardless of whether the reduction began before (day 12) or after (day 14) the 
initiation of the physiological fetal growth increase [244].  
In an allogeneic setting, the effect of immunosuppression to avoid organ 
rejection is an additional non-physiological factor that has to be taken into 
account. In this experiment, tacrolimus doses were lower than in our previous 
experiments using the rat allogeneic model (0.2mg/kg/day vs 0.5 mg/kg/day), 
so they were tacrolimus blood levels (1.88±0.60 ng/ml vs 11.4 ng/ml [4.6-18]).  
The histological analysis revealed that microvessel densities were decreased 
both in the uterus and the placenta of the UTx+TAC group. Importantly, this 
was not seen in the Sham+TAC group, which would indicate that it is solely an 
effect of the surgical tissue trauma, denervation and altered vascular 
supply/drainage after UTx. Despite this change in microvascular density, fetal 
growth was not affected. This could be explained by the fact that the complex 
and not fully understood mechanisms controlling utero-placental blood flow are 
multifaceted [245], and that compensatory mechanisms exist which neutralize 
any possible negative effect on fetal growth by the impaired 
microvascularization mentioned above.  
In the present study we also examined the expression of endothelin and its 
receptor in the uterine tissue. Endothelin is a potent vasoconstrictive substance 
released by endothelial cells, which can be increased as much as threefold in 
utero-placental disorders such as pre-eclampsia and fetal growth restriction 
[246, 247]. Endothelin receptors in patients with pre-eclampsia and LBW 
offspring are usually down-regulated in uteroplacental circulation. This 
probably reflects a mechanism aiming to maintain the maternal blood supply to 
the fetus [245]. In our study, such down-regulation was not seen in any 
placental sample from either group, indicating that endothelin-mediated 
responses in utero-placental circulation are not dysregulated by UTx or 
immunosuppression.  
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The perinatal variables of the present study are limited to perinatal mortality, 
birth weight and weight evolution, and further research is needed to ensure that 
offspring following allogeneic UTx also develop normally at older ages and 
that other aspects of the phenotype also remain normal. Such investigations are 
underway in our research group; the cohort of pups from this study are being 
followed-up for 24 months, which represents two thirds of the life of a rat, and 
aspects such as behavior, metabolism, urinary function and fertility have been 
recorded for phenotype characterization.  
9.5 Paper	6-Evaluation	of	the	perinatal	outcome	of	pregnancies	
mothered	by	transplanted	patients	
9.5.1 RESULTS	
A total of 2511202 births were reported in the general population during the 
time period and 195 births were from 130 mothers after transplantation. The 
majority of pregnancies in the transplanted group occurred among renal 
transplant patients (170 pregnancies, 87%). The other types of organ 
transplantations among the mothers giving birth were kidney+pancreas (7 
pregnancies, 3.6%), kidney+liver (1 pregnancy, 0.5%), liver alone (13 
pregnancies, 6.7%) and thoracic organs (4 pregnancies, 2.1%). The vast 
majority (80.5%) of the 195 deliveries among the transplanted patients occurred 
during the last two decades (after 1990). 
The demographic characteristics of all pregnancies are shown in Table 5. 
Comparisons between pregnancies from the general population and those from 
transplanted mothers are shown in Tables 6 and 7. Up to a 9-fold increased of 
risk of preeclampsia, preterm delivery and instrumental deliveries and 
caesarean section deliveries were observed in pregnancies from transplanted 
patients. Perinatal outcomes of the babies of transplanted mothers showed a 3-
fold increase of risk of being small for gestational age, having low birth weight, 
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intrauterine death and perinatal mortality. It has to be highlighted that no 
increase in the rate of major malformation was seen. 
In the sub-analysis of the type of cesarean section (emergency or elective) with 
recorded data from the time periods 1990-1999 and 2000-2009, the proportion 
of elective, but not of emergency, cesarean section increased both in the 
transplanted group and in the general population (transplanted: 45.7% vs 
60.9%, p<0.001; non-transplanted: 37.5% vs 45.4%, p<0.001).  
The results of the comparison of pregnancy outcomes within transplanted 
patients (pregnancies before vs. pregnancies after transplantation) are shown in 
Tables 8 and	9. In transplanted patients, 1192 transplanted mothers gave birth to 
2260 newborns before transplantation. After controlling for confounding 
factors, no increase in adverse perinatal outcome was found when comparing 
pregnancies before transplantation with pregnancies after transplantation. To 
avoid mixing independent and dependent observations, perinatal outcomes 
were further compared in a pair-wise manner within the same patient giving 
birth after and before transplantation (Table 10). This part of analysis only 
included the most recent birth before transplantation and the first birth after 
transplantation in patients having more than one birth prior to or after 
transplantation. In this analysis births after transplantation showed a lower 
incidence of all adverse perinatal outcomes, although no statistically significant 
differences were evident, except for cesarean section, which was more 
prevalent after transplantation (OR: 3.2, 95%CI: 1.0-10.1). 
When the subgroup of the renal transplant patients was analyzed, similar 
proportions for preeclampsia (20.6%) and preterm delivery (34.1%) were found 
as compared to those of the whole transplant population. The proportions of 
preterm delivery after renal transplantation increased significantly over time, 
but the proportions of preeclampsia in this renal transplant subgroup remained 
constant. 
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Table 5. Demographic characteristics of the general population and pregnancies after 
solid organ transplantation, Norway 1969-2009 
 General population After transplantation  
Fathers 
 
Age group    
      <19 31782 (1.3) 1 (0.5)  
 
 
p<0.001 
      20-24 380835 (15.3) 12 (6.5) 
      25-29 780008 (31.4) 45 (24.2) 
      30-34 709725 (28.6) 47 (25.3) 
      35-39 378431 (15.2) 46 (24.7) 
      40-44 141177 (5.7) 25 (13.4) 
      45-49 44245 (1.8) 4 (2.2) 
      >50 17388 (0.7) 6 (3.2) 
      Total 2483591 (100.0) 186 (100.0)  
Mothers 
 
Age group    
      =<19 143372 (5.7)  2 (1.0)  
 
 
p<0.001 
      20-24 649775 (25.9) 27 (13.0) 
      25-29 857129 (34.1) 58 (29.7) 
      30-34 589846 (23.5) 63 (32.3) 
      35-39 228408 (9.1) 43 (22.1) 
      >=40 42724 (1.7) 2 (1.0) 
      Total 2511154 (100.0) 195 (100.0)  
Parity    
      0 1038409 (41.4) 105 (53.8)  
 
p<0.001 
      1 873136 (34.8) 72 (36.9) 
      2 409303 (16.3) 17 (8.7) 
      3  126986 (5.1) 1 (0.5) 
      >=4 63368 (2.5) 0 (0.0) 
      Total 2511202 (100.0) 195 (100.0)  
Multiple pregnancies    
Births from twin pregnancies 66836 (2.7) 8 (4.7) n.s. 
Total 2511202 (100.0) 195 (100.0)  
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Table 6. Complications during pregnancy and delivery when comparing pregnancies after 
transplant in mothers with pregnancies in the general population, Norway 1969-2009. 
Odds ratios (OR) with 95% confidence intervals (CI) were obtained using logistic 
regression analysis and adjusted for year of birth, mothers and fathers age, parity and 
plurality. 
 195 births after 
transplant 
n (%) 
2511202 
births in the 
general 
population 
n (%) 
Crude  
OR (95% CI) 
Adjusted 
OR (95% CI) 
Preeclampsia 42 (21.6) 77457 (3.1) 8.7 (6.2-12.2) 6.5 (5.0-9.1) 
Preterm delivery (<37 weeks) 66 (34.0) 154027 (6.1) 7.9 (5.8-10.6) 7.1 (5.3-9.6) 
Preterm delivery (<34 weeks) 28 (14.4) 51575 (2.1) 8.0 (5.4-12.0) 7.5 (5.0-11.1) 
Induction of labor 46 (23.7) 387823 (15.4) 1.7 (1.2-2.4) 1.6 (1.2-2.2) 
Operative vaginal delivery 10 (5.2) 170490 (6.8) 1.3 (0.7-2.5) 0.5 (0.2-0.9) 
Caesarean section 121 (62.4) 257660 (10.3) 15.0 (10.8-19.4) 9.7 (7.2-13.0) 
Apgar<7 at 5 min 2 (1.1) 26779 (1.5) 0.7 (0.2-2.9) 0.6 (0.2-2.6) 
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Table 7. Perinatal complications and malformations when pregnancies after transplant 
were compared to pregnancies in the general population, Norway 1969-2009. Odds ratios 
(OR) with 95% confidence intervals (CI) were obtained using logistic regression analysis 
and adjusted for year of birth, mother’s age and parity. Low birth weight was also 
adjusted for gestational age. 
 
 195 births after 
transplant 
n (%) 
2511202 births in the 
general population 
n (%) 
Crude  
OR 
(95% CI) 
Adjusted 
OR 
(95% CI) 
Small for Gestational 
Age (<10 percentile)* 
42 (22.7) 269944 (11.3) 2.3 (1.6-3.2) 2.5 (1.7-3.5) 
Large for Gestational 
Age  (>90 percentile)* 
4 (2.2) 227807 (9.6) 0.2 (0.1-0.6) 0.21 (0.1-0.6) 
Low Birth Weight 57 (29.4) 131130 (5.2) 7.5 (5.5-10.3) 2.7 (1.7-4.1) 
Stillbirth 5 (2.6) 26081 (1.0) 2.5 (1.0-6.1) 2.9 (1.2-7.0) 
Perinatal mortality 7 (3.6) 36554 (1.5) 2.5 (1.2-5.4) 3.2 (1.5-6.7) 
Major malformations 8 (4.1) 52359 (2.1) 2.0 (0.99-4.1) 1.6 (0.8-3.3) 
*Only 185 transplanted patients and 1798146 non-transplanted patients were considered in the analysis of 
this variable 
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Table 8. Complications during pregnancy and delivery when comparing pregnancies after 
and before transplantation, Norway 1967-2009. Odds ratios (OR) with 95% confidence 
intervals (CI) were obtained using logistic regression analysis and adjusted for 
confounders as given. 
 
 2260 births 
before 
transplant 
n (%) 
 
195 births 
after 
transplant 
n (%) 
Crude  
OR 
(95% CI) 
Adjusted 
OR 
(95% CI) 
Preeclampsia 244 (10.8) 42 (21.6) 2.3 (1.6-3.3) 0.97 (0.63-1.49) 
Prelabor rupture of 
membranes 
52 (2.3) 12 (6.2) 2.8 (1.5-5.3) 1.47 (0.67-3.20) 
Bleeding during 
pregnancy 
127 (5.6) 32 (16.5) 3.3 (2.2-5.0) 1.27 (0.77-2.10) 
Preterm delivery (<37 
weeks) 
318 (14.1) 66 (34.0) 3.1 (2.3-4.3) 1.32 (0.91-1.94) 
Induction of labor 489 (21.6) 46 (23.7) 1.1 (0.8-1.6) 0.73 (0.49-1.07) 
Operative vaginal 
delivery 
115 (5.1) 10 (5.2) 1.0 (0.5-2.0) 0.57 (0.27-1.21) 
Caesarean section 342 (15.1) 121 (62.4) 9.3 (6.8-12.7) 2.81 (1.95-4.03) 
All OR are adjusted for year of birth, mother’s age and parity.  
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Table 9. Perinatal complications and malformations when mothers were transplanted, 
before and after transplantation, Norway 1967-2009. Odds ratios (OR) with 95% 
confidence intervals (CI) were obtained using logistic regression analysis and adjusted for 
confounders as given. 
 
 2260 births 
before 
transplant 
n (%) 
195 births 
after 
transplant 
n (%) 
Crude  
OR 
(95% CI) 
Adjusted 
OR 
(95% CI) 
Small for Gestational Age 
(<10 percentile)* 
430 (20.4) 42 (22.7) 1.1 (0.8-1.6) 1.16 (0.76-1.76) 
Large for Gestational Age  
(>90 percentile)* 
175 (8.3) 4 (2.2) 0.2 (0.1-0.7) 0.26 (0.09-0.74) 
Low Birth Weight 325 (14.4) 57 (29.4) 2.5 (1.8-3.5) 1.73 (0.45-1.20) 
Apgar <7 at 5 min* 40 (4.1) 2 (1.1) 0.3 (0.1-1.1) 0.12 (0.03-0.53) 
Stillbirth 75 (3.3) 5 (2.6) 0.8 (0.3-1.9) 0.53 (0.19-1.47) 
Perinatal mortality 106 (4.7) 7 (3.6) 0.8 (0.4-1.7) 0.61 (0.26-1.44) 
Infant death 52 (2.3) 2 (1.0) 0.4 (0.1-1.8) 0.37 (0.08-1.71) 
Major malformations 57 (2.5) 8 (4.1) 1.7 (0.8-3.5) 0.82 (0.34-1.95) 
All OR are adjusted for year of birth, mother’s age and parity. Low birth weight is also adjusted for 
gestational age. 
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Table 10. Complications during pregnancy and delivery and perinatal outcomes when 
comparing pregnancies before and after transplantation in the same patient. Norway 
1969-2009. Odds ratios (OR) with 95% confidence intervals (CI) were obtained using 
logistic regression analysis and adjusted for year of birth, mothers and fathers age, parity 
and plurality. Low birth weight was also adjusted for gestational age. 
 
 26 births after 
transplant 
n (%) 
26 births before 
transplant 
n (%) 
Crude OR 
(95% CI) 
Preeclampsia 5 (19.2) 7 (26.9) 0.6 (0.2-2.4) 
Preterm delivery (<37 
weeks) 
10 (38.5) 10 (38.5) 1 (0.3-3.1) 
Induction of labor 5 (19.2) 11 (42.3) 0.3 (0.1-1.1) 
Operative vaginal delivery 1 (3.8) 3 (11.5) 0.3 (0.0-3.2) 
Caesarean section 19 (73.1) 12 (46.2) 3.2 (1.0-10.1) 
Small for Gestational Age 
(<10 percentile) 
6 (23.1) 8 (30.8) 0.6 (0.2-2.2) 
Large for Gestational Age  
(>90 percentile) 
0 0  
Low Birth Weight 11 (42.3) 13 (50) 0.7 (0.2-2.2) 
Stillbirth 1 (3.8) 5 (19.2) 0.2 (0.0-1.6) 
Perinatal mortality 1 (3.8) 5 (19.2) 0.2 (0.0-1.6) 
Major malformations 1 (3.8) 1 (3.8) 1 (0.1-16.9) 
Only the last birth before transplantation and the first birth after transplantation were considered in the 
analysis. Only crude OR are displayed, given the wide range of the CI for AOR. 
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9.5.2 COMMENTS	
One particular strong point of this study is its uniqueness, of studying a 
complete nationwide population-based study and thereby free of underreporting 
and selection bias as compared to other voluntary registries of pregnancy in 
transplanted patients, like the registries supported by transplant societies mainly 
covering Europe and the USA [197].  
The presence of an increased rate of pregnancy complications, as seen in the 
present study, confirms earlier findings of a generally increased risk of several 
pregnancy-associated problems, when compared to the general population of 
pregnant women. These complications may affect both the transplanted mother 
and her infant. Our finding of 21.6% preeclampsia among the transplanted 
females is somewhat lower than previously reported in large studies of data 
from voluntary registries such as the UK Transplant Pregnancy Registry (36% 
preeclampsia rate) and the US National Transplant Pregnancy Registry (29% 
preeclampsia rate) [196]. On the other hand, the results are similar to those 
from a Swedish population-based study of births after maternal organ 
transplantation [199] (22% preeclampsia rate).  Interestingly, our data shows 
that the proportion of preeclampsia does not increase over time and it could 
thus not explain the observed increase seen in preterm delivery. 
A striking difference in our results compared to previous reports from voluntary 
registry data [196, 197, 248-252] is the much lower rate of preterm delivery 
that we report. The overall rate of preterm delivery in our material of 
transplanted mothers was 34% and a sub-analysis of time trends, revealed an 
increase over time. Previous studies with data mostly accumulated from 
voluntary transplant pregnancy registries from Europe, UK and the US have 
indicated rates of preterm delivery among organ transplanted mothers of around 
50%, but with some variations depending on type of organ transplantation. The 
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very high odds ratio of preterm delivery (7.1) in our material, despite the 
relatively lower rate of preterm birth, is due to a very low rate of preterm 
delivery in the general Norwegian population (6.1 %), which is about half of 
what is reported in the general US population [253]. This difference in overall 
preterm delivery proportion may also be partly dependent on differences in 
routines for delivery of high-risk pregnancies. 
Differences may exist in preterm rate depending on the specific type of 
transplanted organ of the mother. Earlier studies have indicated an increased 
rate of preterm delivery among renal transplant patients as compared to liver or 
heart transplant patients.[197]. However, the proportion of preterm delivery in 
our data was similar when examining renal transplant patients alone as 
compared to the entire group of transplanted women.  
When analyzing births before and after transplantation, we could not detect any 
significant increase in adverse perinatal outcomes after adjustment for 
confounding factors. These data are in line with those published by Kallen and 
coworkers, [199] suggesting that the morbidity status of the patients could be 
the underlying cause of adverse outcomes. Moreover, when comparing births 
within the same patient before and after transplantation, we found a lower rate 
of preeclampsia, preterm birth, growth restriction problems and perinatal 
mortality, indicating that the transplant may have a protective effect on both 
fetus and mother. This could be explained by a better general health of the 
women after transplantation, which of course may be partly counterbalanced by 
possible negative effects of immunosuppression. It bears mentioning that, in 
our series, the incidence of adverse pregnancy events was lower than in that of 
the only previous population study, which compared pregnancies before and 
after transplantation [199] in a Swedish population. This was true, even if we 
assessed the risk of four additional obstetric outcomes: induction of labour, 
instrumental delivery, caesarean section delivery and low APGAR score. 
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The risk of being subjected to cesarean section in the transplanted patients was 
high. Interestingly, the rate of planned cesarean section increased over time in 
transplanted women. This increase was also seen in the general population. A 
plausible explanation for the increased planned cesarean section rate among the 
transplanted patients is that this subgroup would follow the general trend, 
although the cesarean section is not necessarily medically motivated. 
The main limitations of this study are related to three different facts: 
-The high proportion of renal transplanted patients (87%): a predisposing factor 
for preeclampsia in renal transplant patients is that a large proportion of these 
patients experience both hypertension and proteinuria after transplantation, 
which may make them more prone to develop preeclampsia. Moreover, these 
patients with a single functioning kidney would have a 2-3 fold increased risk 
of preeclampsia, which is indicated by studies of preeclampsia rates among 
kidney donors, before and after kidney donation. These facts could limit the 
external validity of the results to patients transplanted from other type of 
organs. 
-The low prevalence of congenital malformations, which also makes it difficult 
to draw conclusions about risks related to any specific malformations. 
However, there was no increased risk for congenital malformations overall, 
which is reassuring. It has also to be pointed out that diseases potentially related 
to immunosuppression and manifested later in life, such as autoimmune disease 
[254], were not included in our study. 
-The low number of patients and events when comparing births before and after 
transplantation within the same patient did not allow us to control for 
confounding factors when the regression analysis with propensity score was 
applied. As each patient was her own control and births were successive and 
close in time, we do believe that potential confounders would play little or no 
role in modifying risk estimates. Even if the number were low, it has to be 
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highlighted that our study included more than twice the number of births after 
transplantation as compared to the study of Bengt Källén and coworkers [199]. 
9.6 Papers	7,8,9-description	of	the	first	live	birth	after	allogeneic	
uterus	transplantation	in	the	human	
9.6.1 RESULTS	
9.6.1.1 Patients	
Thirty patients were initially offered to participate in the UTx trial. Ten of them 
met the inclusion/exclusion criteria and nine of them were finally included in 
the study. One of the recipients was excluded due to the presence of pelvic 
bilateral kidneys. The basal characteristics of the donors and the recipients are 
shown in Table 11. 
Table 11. Donors and recipients’ characteristics 
 
Values are means and standard deviations (between brackets) or absolute numbers and percentages. 
 
 
 Recipients Donors 
Age (years) 31.5 (3.9) 53.0 (7.0) 
BMI (kg/m2) 22.4 (1.5) 25.6 (4.2) 
Previous smoking n(%) 3 (33) 4 (44) 
Previous abdominal laparotomy n(%) 2 (22) 3 (33) 
Previous abdominal laparoscopy n(%) 6 (67) - 
Single kidney (orthotopic) n(%) 3 (33)  - 
Single kidney (pelvic) n(%) 1 (11) - 
Cause of absent uterus, n (%)   
      MRKH 8 (89) - 
      Cervical cancer  1 (11) - 
Type of vagina, n (%)   
      Normal 1 (11) 9 (100) 
      Self-dilated 3 (33) - 
      Therapeutically-dilated 1 (11) - 
      Skin 4 (44) - 
Pregnancies - 3.3 (1.3) 
Live births - 3.0 (0.9) 
Vaginal deliveries n(%) - 25 (93) 
Cesarean section n(%) - 2 (7) 
Premenopausal state n(%) - 4 (44) 
      Menopausal < 5 years n(%) - 2 (22) 
      Menopausal >5 years n(%) - 3 (33) 
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9.6.1.2 Surgical	outcomes	
A summary of the surgical outcomes is presented in Table 12.  
Table 12. Surgical, anesthesiologic, and hospitalization parameters. 
Values are means and standard deviations (between brackets) or absolute numbers and percentages. 
 
 
Donor surgeries lasted 11 h 37 min and recipient surgeries 4h 46 min in 
average. The longest cold ischemic period was 2 h and the longest warm 
ischemic period was 1 h 38 min. One of the donors had a major complication: a 
ureterovaginal fistula that had to be surgically corrected. After ureteric 
reimplantation, around 3 months after hysterectomy, she has not had any 
medical problems. Two of the recipients under went hysterectomy during the 
postoperative period. One early graft loss on was postoperative day 3 and this 
was secondary to thrombosis. The patient was heterozygote for the Leiden 
mutation and this may have been a contributing factor. The histopathology 
report confirmed extensive thrombosis formation in both uterine arteries and 
veins. Another patient underwent hysterectomy on postoperative day 105. She 
acquired an intrauterine infection by enterococcus faecalis around 1.5 months 
after UTx. Despite repeated attempts with iv antibiotic treatment and surgical 
drainage, she developed an intrauterine abscess. Around 3 months after UTx 
she showed initial signs of septicemia and it was decided to perform a 
 Recipients Donors 
Duration of anesthesia (hours and minutes) 9h4min (3h14min) 12h13min (60min) 
Duration of surgery (hours and minutes) 4h46min (30min) 11h37min (1h5min) 
Duration of back-table (hours and minutes) 1h18min (23min)  
Duration of vein anastomosis (minutes) 36 (11)  
Duration of arterial anastomosis (minutes) 30 (6.9)  
Duration of warm ischemia (minutes) 83 (9)   
Duration of cold ischemia (minutes) 78 (23)  
Duration of hospitalization (days) 6.7 (1.6) 6 (0) 
Complications (Clavien-Dindo classification)   
      Grade I - - 
      Grade II 4 (44) - 
      Grade III 2 (22) 1 (11) 
      Grade IV - - 
      Grade V - - 
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hysterectomy. The histopathology report showed patchy necrosis of the uterine 
wall.  
9.6.1.3 Summary	of	the	follow-up	
The other 7 patients that had their uteri intact resumed regular menstruations 
within the first two months after transplantation. Endometrial development was 
normal, reaching median thicknesses of 14mm [11-18] during the mid-luteal 
phase and normal Doppler indexes of the uterine arteries were recorded in all 
the patients.  
 
 
Rejec%on(pa+erns(and(a(grading(system(for(cervical(biopsies(a8er(human(uterus(
transplanta%on.(Proposed(by(Johan(Mölne,(Gothenburg(University,(Sweden(((((((((((((((((((((((((((
mail:(johan.molne@vgregion.se(
Borderline(changes(
More(than(one,(small(nested(foci(of(interphase(inﬂammaDon(in(the(basal(cell(layers,(dominated(
by(lymphocytes.(Focal(intercellular(edema.(Minimal(stromal(inﬂammaDon,(parDcularly(in(the((
papillary(dermis.(
Grade(1(rejec%on(
Mild(mixed(inﬂammatory(cell(inﬁltrate(in(the(basal(epidermal(layer,(dominated(by((
lymphocytes.(Single(epithelial(apoptoDc(bodies.(Low(grade(stromal(inﬂammaDon(and(edema.(
Grade(2(rejec%on(
Moderate(inﬂammatory(cell(inﬁltrate(with(intra(epidermal(inﬂux((exocytosis),(dominated(by(
lymphocytes(and(with(some(neutrophils.(Reduced(surface(epithelial(thickness,(some(epithelial((
apoptoDc(bodies.(Marked,(mixed(stromal(inﬂammaDon(and(edema(
Grade(3(rejec%on(
Signiﬁcant(diﬀuse,(mixed(inﬂammatory(cell(inﬁltrate(dominated(by(lymphocytes(and((
presence(of(neutrophils(and(eosinophils.(ApoptoDc(bodies.(Epithelial(erosions/ulceraDons,((
focal(to(total.(Focal(necrosis(can(be(seen.(Dense(and(conDnuous(stromal(inﬁltrate((mixed).(
Figure 12. Rejection score developed by Johan Mölne based on our previous experience in the rodent 
and non-human primate experience. 
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Rejection episodes occurred in 5 patients, and all of these rejections were 
subclinical. The diagnosis was made based on the pathological findings of the 
per-protocol cervical biopsies (mainly neutrophil and lymphocyte infiltration of 
the epithelial/stromal interfase-Figure 12). All the rejection episodes were 
successfully treated with corticosteroids (500mg methylprednisolone i.v./day 
for 3 days and then 10 mg prednisolone/day for 7 days). 
One of the patients experienced a cervical intraepithelial neoplasia type 2 (CIN 
2), positive for HPV 31. A loop conization was performed with a cone biopsy 
showing normal epithelium and no signs of remaining CIN. 
9.6.1.4 Description	of	the	first	pregnancy	after	allogeneic	UTx	in	the	human	
One year after transplantation, a 35-year-old patient with a type B MRKH 
syndrome with just one kidney and uterovaginal agenesis was the first patient to 
get pregnant and subsequently she would deliver a healthy baby. She received 
the uterus from a 61-year-old donor not genetically linked to the patient. The 
donor had two previous vaginal deliveries at term and she had been menopausal 
for seven years before the transplant. Sequential oral contraceptives were 
administered for three months before transplantation to test the functionality of 
the uterus.  
During the postoperatative follow-up the patient presented three episodes of 
rejection that were successfully treated with our standard protocol for acute 
rejection episodes. Even more, she was the patient undergoing conization due 
to a CIN2, as described in the previous paragraph. 
This patient had 11 embryos from three previous IVF cycles. Ten months after 
transplantation, MMF was discontinued and azathioprine at 2mg/kg/day was 
introduced. It has to be pointed out that prednisolone 5m/day was also kept in 
the patient after her third episode of rejection. Twelve months after UTx the 
patient got pregnant after her first single embryo transfer (SET) which was of a 
day 2 embryo in the natural cycle. All maternal and fetal controls during 
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pregnancy were normal until week 31 except for hemoglobin values in the 
lower range of the normality from the beginning of the pregnancy, requiring 
administration of ferric carboxymaltose and darbepoetine alpha. On pregnancy 
day 31+5 the patient came for the normal pregnancy control but was kept at the 
obstetric department, since preeclampsia was diagnosed. She had a blood 
pressure of 180/120 mmHg, proteinuria, low platelet count (96,000/microL) 
and the CTG of the fetus showed variable decelerations. Therefore a cesarean 
section was done and a neonate of 1775g (normal weight for date) APGAR 9-9-
10 was successfully delivered. The baby was doing fine after birth and did not 
need respiratory aid (oxygen or positive airway pressure). The inspection of the 
uterus revealed a normal graft that contracted correctly after the cesarean 
section and all their vessels were patent. 
9.6.2 COMMENTS	
The series of nine patients represent the first successful attempt to treat AUFI. 
The duration of the surgery was about 2-3 times longer than expected based on 
our previous experience in the non-human primates [73, 142] and the radical 
hysterectomy model [72]. Careful dissection of the tunnel of the ureter, just 
beneath the uterine artery, is a consuming step of the surgery, but this step is 
unavoidable if a living donor is used. After that step the uterine arteries and 
veins have to be dissected to include parts of the internal iliacs. The difficulty is 
mostly on the venous sides, since there are lots of venous branches and 
connections between the uterine veins. These have to be divided and sutured, 
one by one, since ligations or coagulation, will lead to bleeding after 
reperfusion of the organ.  
The only complication we evidenced in our donors also took place at this 
anatomic site: one of the patients got a ureterovaginal fistula due to ureteric 
damage probably related with the dissection of the ureter with use of too much 
diathermy close to the ureter. Thus, the complication occurred was evident first 
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10 days after uterus retrieval, which is a typical time for the development of 
thermal damage of the relatively thick ureteric wall. In the human case 
published by the group of Fageeh [69], they experienced such a ureteric 
laceration, but that was evident at surgery and could be repaired immediately. 
The occurrence of these two complications, highlights the difficulties linked to 
the surgical step of the dissection of the tunnel of the ureter, which is a 
component of a live donor UTx but not in a deceased donor situation. 
Two of the patients lost their uteri during the postoperatory follow-up. The 
patient who lost the uterus due to thrombosis during the early post-op was a 
heterozygous carrier of a protein C deficiency, but this is not a formal 
contraindication for transplantation. She was under anti-aggregation and anti-
thrombotic therapy and it is not clear if a shorter surgery could have minimized 
the risk of thrombosis. Another contributing factor, may have been that the 
uterine artery of the 62-year old uterus of this case were the thinnest in our 
study and consequently the measured blood flow at perfusion was the lowest. 
The second patient who lost the uterus due to infection was exposed to different 
potential risk factor that may have influence the lost of the graft: extended 
anesthesia time of almost 14 hours, vagina-to-vagina anastomosis placed very 
close to the cervix and of course the immunosuppression protocol. 
Despite these adverse effects in these three patients, it has to be kept in mind 
that this is the first series of a novel type of surgery and further experiences will 
provide an optimization of the procedure. 
The protocol of monitoring of rejection after transplantation was based in our 
previous experience with baboons [142]: cervical biopsies were easy to take 
and they correlated well with the clinical findings in this non-human primate 
species. In this trial all the acute rejections episodes were subclinical, so there 
could be a that we were overtreating. The fact that all the histological findings 
normalized after corticoid administration makes overtreatment a very unlikely 
hypothesis. The normal menstrual pattern, normal endometrial growth and the 
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normal vascular indexes found during ultrasound examination points toward a 
normal vascular influx during the non-pregnant state of the graft. 
Regarding the fertility outcomes, issues such as the time window between 
transplantation and embryo transfer, the suitability of IVF prior to 
transplantation and the fact of doing SET have been discussed before (“ART in 
uterus transplantation” section). Immunosuppression during pregnancy seemed 
to work better that before pregnancy, with only one episode of rejection as 
compared to the three previous episodes before pregnancy. Pregnancy itself can 
induce a local immunosuppression state and this could be beneficial for the 
graft. On the other hand physiologic requirements increase during pregnancy 
and some of the immunosuppression-related side-effect can become apparent, 
for example the anemia caused by anti-metabolites, the diabetogenic effect of 
tacrolimus and corticoids and the nephrotoxicity of tacrolimus. Anemia and 
increased levels of creatinine were evidenced in our pregnant patient and the 
doses of immunosuppressants had to be tapered (azathioprine was diminished 
from 2 mg/kg/day to 1.2 mg/kg/day). 
The development of preeclampsia during pregnancy may be related to different 
factors, all of them present in our patient: the more obvious is the fact of being 
transplanted [197], although after our population-based study, concerns about 
the real effect of transplantation could be raised; the patient was pregnant after 
IVF using frozen embryos and the transplanted uterus was beyond the age of 
sixty. Both pregnancy after IVF [255] and advanced maternal age [256] have 
been associated to an increased risk of preeclampsia; the last factor that could 
have had increased the risk of preeclampsia was that the patient only had one 
kidney: there exist data in the literature suggesting and increased rate of 
preeclampsia in healthy patients after kidney donation as compared to the 
double kidney population [257].  
The removal of the uterus after birth will allow diminishing the incidence of 
side effects of immunosuppression, but it was not performed at the time of the 
Fertility	and	immunosuppression	in	allogeneic	uterus	transplantation	
	128
cesarean section in order  (1) to let the uterus return to its normal size, which 
would simplify the hysterectomy procedure, (2) to ensure the health of the 
delivery baby and (3) to discuss with the patient about the completion of her 
reproductive wishes. 
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10 CONCLUDING REMARKS 
This thesis has proven for the first time that uterus transplantation is a feasible 
option to treat AUFI, allowing for live birth in humans. This opens a new door 
for women suffering from this type of infertility to become genetic mothers, 
especially in socio-political contexts where surrogacy is not allowed.  
Additionally, it provided reassuring data from population studies suggesting 
that transplantation and immunosuppression have moderate to no effect on the 
apparition of adverse perinatal outcomes when other confounding factors linked 
to the basal status of the mother are controlled. Complementing this is data 
from the murine model developed in this thesis, which showed normal 
evolution of the offspring born from mothers with a transplanted uterus. 
Finally, this thesis has proven that the calcineurin inhibitor cyclosporine-A, but 
not tacrolimus, decreases ovulation and implantation rates, which can be taken 
into account when planning the future fertility projects of transplanted women.  
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Extended Abstract 22 
Study question: Do cyclosporine-A and tacrolimus impair pregnancy/implantation rates when 23 
used at therapeutic doses for immunosuppression?  24 
Summary answer: Cyclosporine-A but not tacrolimus impairs pregnancy/implantation rate. 25 
What is known already:  Molecular mechanisms controlling implantation and placental 26 
development are susceptible to modulation by the calcineurin inhibitors that are used after 27 
virtually all types of allogeneic of organ/composite tissue transplantation. There exist some data 28 
suggesting that cyclosporine-A could negatively affect implantation after spontaneous mating in 29 
the rat but with uncertainties because of lack of data concerning numbers of implantable 30 
embryos. There exist no information of the effect of the more modern calcineurin inhibitor 31 
tacrolimus on implantation. 32 
Study design, size, duration: Experimental design. Random allocation to intervention.  33 
Participants/materials, setting, methods: Adult female B6CBAF1 mice (n=43) were allocated 34 
to one of the following immunosuppressant treatments: 1)tacrolimus 0.5mg/kg/day (TAC05; 35 
n=10); 2)tacrolimus 0.2mg/kg/day (TAC02; n=11); 3)cyclosporine-A 10mg/kg/day (CYA10; 36 
n=12); 4)normal saline 0.9% (Control; n=10). Fifteen days after commencement of 37 
immunosuppression, the mice underwent transfer of a specified number of blastocysts. On 38 
pregnancy day +12, animals from all the experimental groups underwent caesarean section in 39 
order to assess implantation rate, fetal viability and tissue sampling for uterine natural killers 40 
(uNK)/placentation markers/cytokines characterization by immunohistochemistry and RT-PCR. 41 
Main results and the role of chance: Pregnancy rate in the CYA10 group was lower than the 42 
control and TAC groups, although differences were only significant when compared to the 43 
TAC02 group (CYA10: 58.3% vs TAC02: 100%; p=0.03). Implantation rate was also significantly 44 
lower in the CYA group as compared to all the other groups (CYA10: 32.1%[0%-73.2%]; 45 
Control: 57.1%[32.1%-92.9%]; TAC02: 71.4%[64.3%-92.9%]); TAC05: 78.6 [37.5%-94.6%]; 46 
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p<0.001). No differences in numbers of uNK or in cytokine profiles were evidenced between 47 
groups. 48 
Limitations, reasons for caution: Immune responses and molecular mechanisms mediating the 49 
effect of calcineurin inhibitors may differ from mice to humans, which could limit the 50 
extrapolation of this study to a clinical set-up. 51 
Wider implications of the findings: The differential effects observed between tacrolimus and 52 
cyclosporine-A could imply that tacrolimus should be the preferred calcineurin inhibitor in 53 
organ-transplanted women during the reproductive ages as the preferred calcineurin drug in 54 
transplanted women with fertility wish. 55 
Study funding/competing interest(s): Swedish Research Council funded the study.  56 
 57 
Key words: cyclosporine, implantation, pregnancy, tacrolimus, uterus 58 
 59 
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Introduction 61 
Solid organ transplantation has become a common procedure nowadays, with more than 114000 62 
patients being transplanted with solid organs in 2012 (Global observatory on donation and 63 
transplantation. (Organización Nacional de Transplantes and World Health Organization. Organ 64 
and transplantation activities 2012. Available in http://issuu.com/o-n-t/docs/2012ad). Up to 65 
38.4% of the transplanted patients are women and among them 17.8% are still in reproductive 66 
age (18-34 years), according to the Organ Procurement and Transplantation Network (OPTN) 67 
data as of August 31, 2014.  68 
The effects of organ transplantation and the accompanying immunosuppressant regiments on 69 
subsequent fertility are poorly understood. It is well known that there commonly is a recovery of 70 
fertility after organ transplantation, since the women go from an end-stage disease with its major 71 
systemic influences to having a near to normal organ function (Douglas et al., 2007). Higher rates 72 
of adverse perinatal outcomes including preterm delivery, low birth weight and preeclampsia 73 
have been described after transplantation in studies using data from large registries of 74 
pregnancies after organ transplantation (McKay and Josephson, 2006). 75 
To what extent the effects of transplantation on fertility and perinatal outcomes are due to the 76 
underlying disease being the cause of transplantation or to the use of immunosuppressive 77 
medication is a question that has not been fully investigated. 78 
Implantation is a tremendously complex and highly organized biological process, in which 79 
numerous molecular mechanisms interact in a synchronized time-and-site-specific manner to 80 
enable the embryo to proper interaction with the decidualized, maternal surface (Guzeloglu-81 
Kayisli, 2011). Implantation defects can interfere with further events like placentation, that in 82 
turn may be related to obstetrical complications of placental origin such as intrauterine growth 83 
restriction and preeclampsia (Kim et al., 2003).  84 
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Several of the molecular mechanisms controlling implantation and placental development may be 85 
susceptible to negative modulation by immunosuppressants used to prevent rejection of a 86 
transplanted organ. Especially important in this context are the calcineurin inhibitors (CIN) 87 
tacrolimus and cyclosporine-A, with either of them being the main agent in all types of organ 88 
transplantation. The CINs bind to the calcium-dependent serine-threonine-protein-phosphatase, 89 
calcineurin (CaN) together with the so-called tacrolimus binding proteins (FK506BPs or FKBPs) 90 
or immunophilins. The immunosuppressive effect of CIN is mainly achieved through the 91 
interaction of CaN+FKBP12+tacrolimus or CaN+immunophilin-A+cyclosporine-A (Huai et al., 92 
2002). Such interactions block the phosphatase activity of CaN and prevent dephosphorylation 93 
of the transcription factor NFAT, inhibiting the expression of IL-2, which in turn leads to 94 
decreased proliferation and activation of T-lymphocytes. However, CINs could also negatively 95 
affect other biological processes by binding other types of immunophilins that are involved in 96 
modulating the transcriptional activity of different steroidal receptors, for example those driving 97 
implantation and placentation, like PR-receptors and also by modulating the uterine natural 98 
killers (uNK) repertoire and activity (Lin and Kuo, 2008; Morteau et al., 2010; Howell et al., 2013; 99 
Neudoerfl et al., 2013). 100 
In a previous report (Groth et al., 2010) from our group, we demonstrated that cyclosporine-A 101 
treatment of rats may result in a lowered pregnancy rate after natural mating and also that 102 
cyclosporine in-utero exposure of female offspring was associated with a significant reduction in 103 
fetal weight. Nevertheless, there were two main limitations in that study and animal model used. 104 
Firstly, natural mating was used and thus the true numbers of fertilized eggs and subsequent 105 
number of implanted embryos in each animal were unknown.  Ovulation rates and fertilization 106 
rates can also show differences between litters and strains. Secondly, there were no comparison 107 
between the two major CINs, cyclosporine-A and tacrolimus. Although the major mechanism of 108 
action to prevent rejection is similar, the effects of these two CINs differ in many aspects such as 109 
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effects on renal function, vascular function and metabolic profile (Setkowicz et al., 2004). Thus, 110 
their effects on the physiological events of the reproductive tract tissues could also be different. 111 
The aim of the present study was to elucidate if different doses of the most widely used CINs, 112 
cyclosporine-A and tacrolimus modify the implantation rate in an embryo transfer murine model 113 
in which the exact amount of embryos to be implanted is known. We examined fetal numbers 114 
and weight during mid pregnancy in order to investigate if there exist any effect of the CINs on 115 
the fetal size, and if any, to investigate if they take place during early or late stages of 116 
embryogenesis/fetal development and the parallel placentation process. We also examined 117 
molecular mechanisms involved in placentation that could be potentially affected by the use of 118 
CINs, focusing on gene expression of markers of vascularization and vascular proliferation 119 
(CD31, VEGF-A), cell adhesion (ICAM-1), presence of uNKs (NKG2D), and other molecules 120 
that modulate immune responses in the utero-placental junction, driving the implantation and 121 
placentation processes. These are the non-inflammatory, Th2-like cytokines interleukin (IL)-4, 122 
IL-5, IL-6, IL-10, IL-13 and leukemia inhibitory factor (LIF) and the inflammatory, Th1-like 123 
cytokines (tumor necrosis factor (TNF)-alpha and TNF-beta). 124 
 125 
Materials and methods 126 
Study design 127 
Adult female B6CBAF1 mice (n=43) were randomly allocated to receive daily doses of one of the 128 
following immunosuppressant treatments: 1) tacrolimus 0.5mg/kg/day (TAC05; n=10); 2) 129 
tacrolimus 0.2mg/kg/day (TAC02; n=11); 3) cyclosporine-A 10mg/kg/day (CYA10; n=12); 4) 130 
normal saline 0.9% (Control; n=10). Pseudo-pregnancy was induced in the experimental groups, 131 
10 days after starting the immunosuppression and five days after pseudo-pregnancy induction, 132 
the mice underwent embryo transfer of blastocysts derived from donors of the same strain (14 133 
blastocysts -7 blastocysts/horn- were transferred per mouse). On pregnancy day 12 (7 days after 134 
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embryo transfer), animals from all the experimental groups underwent cesarean sections in order 135 
to assess implantation rate, fetal viability and tissue sampling for NK/placentation markers 136 
characterization by immunohistochemistry and RT-PCR. 137 
Ethical approval 138 
The study was approved by the local animal ethics committee in Göteborg, and was carried out 139 
according to the principles and procedures outlined in the NIH Guide for Use of Laboratory Animals.  140 
Animals 141 
Females (6–8 weeks of age), proven fertility males (2-to 4 months-old) and vasectomized males 142 
(see below) of F1 hybrids of C57BL/6xCBA/ca mice (B6CBAF1) were used in this experiment. 143 
All B6CBAF1 males and females were obtained from Charles River (Chatillon-sur-Chalaronne, 144 
France). The animals were housed in controlled conditions (21–23°C, relative humidity of 50–145 
60%, illumination between 07:00 and 19:00 h) and had free access to water and pelleted food. 146 
Half of the B6CBAF1-males were vasectomized to be used for induction of pseudopregnancy in 147 
blastocyst recipient females. Briefly, the animal was anaesthetized with 2% isoflurane (Baxter; 148 
Kista, Sweden), and through a low midline incision the bladder was reached and located and the 149 
bilateral vas deferens were identified. A 4-0 silk suture was used to place two firm knots around 150 
the vas deferens, about 4-5 mm apart. Before cutting out a section of vas deferens, bipolar 151 
diathermy was applied over the vas deferens in between the two knots. After repeating the 152 
procedure on the contralateral side the midline incision was closed by interrupted sutures of the 153 
abdominal fascia, followed by skin-closure with three metallic clips. Two weeks after surgery, the 154 
effectiveness of the sterilization was checked by placing the males in a cage with 4-week-old 155 
B6CBAF1 female mice that had been superovulated by an i.p. injection of 5 IU pregnant mare’s 156 
serum gonadotrophin (Sigma-Aldrich Co., St Louis, MO, USA) followed 46 to 48 h later by an 157 
i.p. injection of 5 IU hCG (Sigma-Aldrich Co., St Louis, MO, USA). The females were examined 158 
for vaginal copulation plugs the next morning, and 46 h after hCG treatment the oviducts were 159 
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flushed with G-MOPS plus medium (Vitrolife AB, Göteborg, Sweden) using a 30-gauge needle 160 
to examine any possible the presence of oocyte/embryos. In all cases only unfertilized stage 161 
oocytes were found under the close examination under a dissection microscope.  162 
Pharmaceuticals  163 
The antibiotic cefuroxime (Zinacef, Glaxco Smith Kline, Uxbridge, UK) was given once 164 
immediately after any surgical procedure, s.c. at 40 mg/kg.  165 
Cyclosporine-A and tacrolimus were delivered by the means of subcutaneous miniosmotic 166 
pumps (model 2004, Alzet Osmotic Pumps, Cupertino, CA, USA). Each pump was loaded the 167 
day before insertion with a tacrolimus solution in 0.9% NaCl or a cyclosporine-A solution in 90% 168 
propylene glycol (Fluka, Buchs, Switzerland), adjusted for the weight of the animal, in order to 169 
release 0.2 or 0.5 mg/kg/day of tacrolimus or 10mg/kg/day of cyclosporine. This pump was 170 
subsequently inserted s.c. in the back of the neck under isoflurane anesthesia. The skin incision 171 
was closed with 2-3 metallic clips and the animal was placed under a heating lamp until fully 172 
awake. 173 
Blastocyst production 174 
B6CBAF1 females and B6CBAF1 males of proven fertility were used to obtain blastocysts: 175 
females were introduced to males in a 2:1 fashion on the day of pro-oestrus.  The day after 176 
mating, all females were screened for the presence of seminal vaginal plug. The mated females 177 
underwent cervical dislocation at 12:00 on day 4 and the uteri were flushed with G-MOPS plus 178 
medium (Vitrolife, Sweden). The obtained medium was examined under a Nomarski microscope 179 
to evaluate morphology of blastocysts. Only morphologically normal blastocysts were used for 180 
embryo transfer. 181 
Mating procedure and embryo transfer 182 
One week after insertion of the miniosmotic pump, the 8 to 10-week-old B6CBAF1 female 183 
mice were mated with vasectomized males in order to induce pseudo-pregnancy and 184 
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subsequently embryo transfer, with embryos from normally mated and synchronized female 185 
mice. The day after mating, all females were screened for the presence of seminal vaginal plug. 186 
Only mated females were included in the study.  187 
The embryo recipient females received blastocysts at 12:00 on day 4 of pseudopregnancy, by 188 
transmyometrial approach as previously described (Hogan et al., 1994). The blastocysts were held 189 
in Gamete 20 medium (Vitrolife, Göteborg, Sweden) for 20–30 min at 37°C and under 5% 190 
CO2. Under isoflurane anaesthesia, two dorsolateral incisions (10 mm) were made on both sides 191 
of the midline. The ovary, oviduct and proximal end of the uterus were externalized on each side, 192 
and seven blastocysts were transferred to each uterine horn, using a 30 gauge needle initially to 193 
penetrate the uterine wall; this was followed by transfer of blastocysts through a glass transfer 194 
pipette. The abdominal wall was closed in two separate layers with 6-0 sutures. All mice were 195 
placed under heat until fully awake and subsequently placed with one vasectomized male in the 196 
same cage.  197 
Assessment of implantation and tissue sampling 198 
On pregnancy day 12, all the animals were anaesthetized and underwent laparotomy, through a 199 
midline incision. After opening of the uterine horns, the number of viable fetuses was recorded. 200 
The number of resorbing implantation sites was also recorded. The size of all pups was 201 
measured. Fetuses and placentas were carefully dissected out and uterine and placental biopsies 202 
were taken and placed in 4% formaldehyde and RNA-Later for histology and gene-expression 203 
analysis. 204 
Tacrolimus and cyclosporine-A levels 205 
Samples of whole blood (250μl) were drawn from the aorta at the day 12 laparotomy. Tacrolimus 206 
levels were measured in whole blood by an automated chemiluminescent immunoassay (CMIA) 207 
developed for use on the ARCHITECT system (Abbott Scandinavia AB, Sweden). The 208 
interassay coefficient of variation varies between 1.16 % and 1.88 %. Cyclosporine-A levels were 209 
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measured by enzyme immunochemistry using a CyA-specific assay (Emit®2000, Dade Behring, 210 
Milton Keynes, UK), according to manufacturer’s instruction. The inter-assay coefficient of 211 
variation was below 9%. 212 
uNK characterization by histochemistry 213 
Immunohistochemistry was performed on 4 µm thick tissue sections after they had been 214 
deparafinized in xylene, rinsed in ethanol and brought to water through a series of decreasing 215 
concentrations of ethanol. Sections were washed with 1% H2O2 in phosphate buffered saline 216 
(PBS), and then blocked for 1h with 10% horse serum + 10% bovine serum albumin (BSA) in 217 
PBS with 0.1% Tween 20. Slides were subsequently probed with 50 µg/ml biotinylated DBA 218 
(Sigma-Aldrich, St. Louis, MO, USA) in 2% horse serum + 2% BSA in PBS for 1h at room 219 
temperature. Detection was performed using the streptavidin-horseradish peroxidase complex. 220 
Sections were counter-stained with hematoxylin. Ten sections per uterus were assessed by two 221 
blinded observers (SL, SHR), using a Leica microscope (LEICA DM4000B) and a calibrated eye-222 
grid at (10X) magnification. Quantification was performed by the same observers (SL, SH) based 223 
on high quality images (2048 x 1536 pixels) captured by the Image ProPlus 6.3 software (Media 224 
Cybernetics, Rockville, MD, USA).  225 
Gene expression analysis of implantation and placentation markers 226 
Total RNA was extracted from samples stored in RNA later (Sigma-Aldrich, St. Louis, MO, 227 
USA) of all experimental groups using the ‘Trizol method’ according to the protocol 228 
recommended by the manufacturer (Life Technologies Inc., Gaithersburg, MD, USA). cDNA 229 
retrotranscription was taken out with the MMLV enzyme contained in the Advantage™ RTfor-230 
PCR kit (Clontech, Saint-Germain-en-Laye, France) using the oligo (dT) 18 as primer.  231 
Specific Taqman probes were assayed by quantitative Real-Time PCR to assess the relative 232 
expression of the genes coding for a number of proteins (interleukin (IL)-4, IL-10, IL-5, IL-6, IL-233 
13, CD31, vascular endothelial growth factor (VEGF)-A, the natural killer lectin-like receptor 234 
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subfamily member 1 (NKG2D), tumor necrosis factor (TNF)-alpha, TNF-beta, intercellular 235 
adhesion molecule-1 (ICAM-1), leukemia inhibitory factor (LIF; Table 1). PCR reaction mixtures 236 
were prepared with 100 ng of cDNA as a template in the 1xTaqman Gene Expression Master 237 
Mix following the manufacturer´s protocol. Then samples were amplified in the 7900HT Fast 238 
PCR system (Applied Byosistems, Life Technologies Inc., Gaithersburg, MD, USA). PCR 239 
conditions consisted in an initial activation of uracyl-N-glycosylase at 50°C for 2 min., followed 240 
by AmpliTaq Gold activation at 95°C for 10 min. Then samples were cycled 40 times by 241 
denaturation at 95°C for 15 seconds, and an annealing extension at 60°C for 1 min per cycle. 242 
After controlling the amplification efficiency of the targets genes, the relative expression was 243 
obtained by the comparative Ct method (DDCt). The expression of target gene mRNA was 244 
normalized with the expression of the Actin-beta reporter gene. 245 
Statistics  246 
Variable values are presented as median and interquartile ranges [p25-p75] between square 247 
brackets for continuous variables except for CINs levels, that followed a normal distribution and 248 
they were presented as means ± standard deviations. Categorical variables were presented as 249 
absolute values and percentages. Continuous variables were compared using the Kruskall-Wallis 250 
test and also doing two-by-two comparisons with the control group using the Mann-Whitney’s 251 
U-test. Tacrolimus levels were compared with the Student’s t-test. Categorical variables were 252 
compared using the chi-square test and the Fisher exact test when needed. Differences showing a 253 
p<0.05 were considered as significant. 254 
 255 
Results 256 
Fertility outcomes 257 
Data related to pregnancy and implantation rates are displayed in Table 2. Pregnancy rate in the 258 
CYA10 group was lower than the control and TAC groups, although differences were only 259 
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significant when compared to the TAC02 group (CYA10: 58.3% vs TAC02: 100%; p=0.03). 260 
Implantation rate/animal was also significantly lower in the CYA group as compared to all the 261 
other groups (CYA10: 32.1%[0%-73.2%]; Control: 57.1%[32.1%-92.9%]; TAC02: 71.4%[64.3%-262 
92.9%]); TAC05: 78.6 [37.5%-94.6%]; p<0.001). All pups had crown-rump lengths between 6-8 263 
mm and no differences were seen between groups (data not shown). 264 
Tacrolimus and cyclosporine-A levels 265 
Concentration of cyclosporine in the CYA10 group was 120.25±42.28 ng/ml. Concentration of 266 
tacrolimus in TAC05 group was significantly higher than that of TAC02 (4.14±2.03 ng/ml vs 267 
1.05±0.45 ng/ml; p=0.02) 268 
uNK characterization 269 
Densities of immunostained cells in both placenta and decidua of pregnant animals were similar 270 
between groups. All groups showed surface areas with positive staining varying between 3% and 271 
6% in placenta samples and 16% and 28% in decidua samples (Fig 1A-G). Unspecific staining 272 
from fetal membranes was also seen in all samples (Fig 1A, C, D). DBA expression in non-273 
pregnant animals was almost absent and restricted to some cells in the subendometrial stroma 274 
(Fig 1H). Uteri from the CyA group showed lower densities of CD25+ cells (0.38%) than the 275 
other experimental groups (0.84% Control, 1.35% TAC0.2 and 1.15% TAC0.5, p<0.05). 276 
Expression of markers of implantation and placentation 277 
The gene expression of the studied genes did not differ between treatment groups when analyzed 278 
in decidua samples nor in placental samples (Table 3).  279 
 280 
Discussion 281 
To our knowledge this is the first systematic study in any species evaluating the effect of different 282 
CINs on the implantation process and the development of pregnancy and the utero-placental 283 
unit. In our previous studies in a natural mating model, CYA exposure before and during 284 
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pregnancy inversely correlated with the number of viable implantation sites resulting in live 285 
fetuses. Pregnancy rates were also compromised when the animals were exposed to high doses of 286 
cyclosporine-A (30mg/kg) (Groth et al., 2010). An essential limitation of that study was that the 287 
pregnancies were secondary to natural mating, and thus the accurate implantation/pregnancy rate 288 
was not known, since the numbers of embryos reaching the uterine cavity were unknown. In the 289 
current study the number of transferred embryos was defined by protocol, herein the 290 
implantation rate can be accurately calculated.  291 
Our results confirmed that the implantation rate was significantly decreased in CYA-exposed 292 
animals, even at doses of only one third (CYA10-group) of that used in our previous experiments 293 
involving natural mating (Groth et al. 2010). The CYA blood levels of the animals in the CYA10 294 
group was around 100 ng/ml, which is within the normal therapeutic level in the human. 295 
Contrary to what we anticipated, implantation and pregnancy rates in the TAC-treated animals 296 
(TAC02 and TAC05) were not different to that of controls. Furthermore, there was no tendency 297 
to a dose-response effect in the TAC-treated animals, since results were equivalent in TAC02 and 298 
TAC05 groups. It should be pointed out that the blood levels of the TAC05 group were within 299 
the normal therapeutic range in humans. 300 
As mentioned above, the doses chosen in this study are equivalent to those used in the clinical 301 
set-up in transplanted patients , and the differences observed between the experimental groups 302 
could be explained by the fact that different CINs cause CaN inhibition through the interaction 303 
with different molecules (immunophilins). While TAC binds to the FKBP immunophilin family 304 
(mainly to FKBP12), CYA binds to cyclophilin-A. The fusion of these immunophilin-305 
immunosuppressant complexes to CaN blocks its phosphatase activity and subsequently inhibits 306 
the calcium-dependent dephosphorylation of the transcription factor nuclear factor of activated 307 
T cell (NFAT), a factor that controls gene expression in many cell lines, not only immune cells 308 
but also endometrial and stromal cells (Abraham et al., 2012). The different effects caused by 309 
TAC and CYA can be explained by the fact that FKBP-TAC complexes bind to different 310 
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aminoacids of CaN as compared to cyclophilin-A-CYA complexes. This phenomenon induces 311 
different conformational changes in the catalytic and regulatory subunits of CaN, resulting in 312 
different degree of inhibition. The differential effects of CINs have also been described in other 313 
organs and systems and they are not exclusive to the reproductive organs (Setkowicz et al., 2004).  314 
Fetal growth retardation is a well-known side effect in pregnancies from immunosuppressed 315 
mothers (McKay and Josephson, 2006). In the present study we also evaluated this parameter, 316 
and at investigation of fetal size on pregnancy day +12, no differences between intervention 317 
groups were seen. In our previous experiments involving natural mating female pups born from 318 
mother treated with high doses (30mg/kg) of CYA presented lower birth weight than control 319 
animals (Groth et al., 2010). This difference may be explained by the fact that fetal weight was 320 
studied on pregnancy day +18, indicating that fetal growth restriction related to CYA is a late-321 
pregnancy event or that the dose used in our previous study was higher than of the present study. 322 
A uterine unique cell type is the uNK, which are abundant in the uterus and with a suggested 323 
major role both during implantation and placentation (Ruocco et al., 2014). The uNKs are 324 
recruited into the decidua and placenta early in pregnancy and they peak at mid pregnancy in the 325 
mouse, around gestational day +8, and they subsequently decrease in numbers (Paffaro et al., 326 
2003). The amount of uNKs present in placenta and decidua did not differ between groups when 327 
measured by immunohistochemistry (DBA) and qRT-PCR (NKG2D) and it was comparable to 328 
that found in previous reports when assessed in pregnancy day +12 (Paffaro et al., 2003). These 329 
facts indicate that if there were any effects of CIN on NK, they did not affect the amount of 330 
uNK at that time-point. On the other hand, CINs have also been shown to modulate the activity 331 
of NKs from other tissue sources (Lin and Kuo, 2008; Morteau et al., 2010; Howell et al., 2013; 332 
Neudoerfl et al., 2013). Uterine NKs produce different INF-γ, which regulate artery remodeling, 333 
decidualization and placentation through the induction of VEGF-A expression (Ashkar et al., 334 
2000), but in the present study we could not demonstrate any difference regarding the expression 335 
of this pro-angiogenic factor. VEGF-A also controls angiogenesis and cell adhesion through the 336 
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CIN-NFAT pathways, but again, the endothelial marker CD31 and the adhesion molecule 337 
ICAM-1 expression was similar in all the experimental groups.  338 
Another important factor that contributes to the maintenance and progression of pregnancy is 339 
the balance between the cytokines produced by T-helper cells in the placenta and the decidua. 340 
This balance contributes to the so called immuneprivileged status of the pregnant uterus 341 
(Druckmann and Druckmann, 2005). CaN-NFAT pathway is required to achieve the typical Th1 342 
to Th2 shift that has been classically described in successful pregnancies (Yamashita et al., 2000) 343 
and CINs impair Th2 cell development more intensively than that of Th1 cells (Yamashita et al., 344 
2000), resulting in a promotion of the Th1 pro-inflammatory profile. Although an explanation of 345 
implantation and placentation based on Th1 and Th2 immunologic profiles could be simplistic 346 
taking into account the complexity of such processes (Druckmann and Druckmann, 2005; 347 
Guzeloglu-Kayisli, 2011; Ruocco et al., 2014), alterations of such clusters of cells/cytokines have 348 
been frequently associated with infertility, recurrent miscarriage and placental pathology like 349 
preeclampsia or growth retardation (Druckmann and Druckmann, 2005; Guzeloglu-Kayisli, 2011; 350 
Ruocco et al., 2014). In our experiment, the expression pattern of pro-inflammatory, Th-1-like 351 
cytokines (TNFα and TNFβ) and that of the anti-inflammatory, Th-2-like (IL-4, IL-5, IL-6, IL-352 
10, IL-13 and LIF) did not differ between groups, indicating little or no general effect on the 353 
cytokines of the CIN in the placenta/decidua. 354 
In summary, this study shows that cyclosporine-A but not tacrolimus decreases implantation and 355 
pregnancy rates in a mouse model when used at doses similar to those of the clinical practice for 356 
immunosuppression. This fact indicates that tacrolimus should be used instead of cyclosporine-A 357 
as the drug of choice in women with fertility wishes that need calcineurin inhibitors. 358 
One limitation of the present experiments is that outcomes were evaluated on pregnancy day +12 359 
in order to clearly determine implantation sites and fetal size differences. Herein it is possible that 360 
even if we could not identify any difference in molecular mechanisms mediating the effect of 361 
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cyclosporine-A at that time-point, it would have existed earlier in pregnancy, which could be 362 
consistent with the decreased implantation rate. Therefore, further research is needed to 363 
investigate these mechanisms during the implantation window. Such investigations are underway 364 
in our research group, with a similar experiment evaluating the effect of the CIN cyclosporine-A 365 
and tacrolimus on the mouse uterus three days after mating. The analysis of these data will 366 
provide further information to characterize the effect of CIN during the implantation window. 367 
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Figure Legends:  431 
Figure 1 432 
Uterine sections (2.5x) showing the DBA positive pattern of  pregnant animals from Control (A), 433 
TAC 0.2 (B), TAC 0.5 (C) and CyA (D) groups. Detail of  DBA positive cells found in the 434 
myometrial layers from TAC05 sample (E). Placental DBA positive cells within the labyrinth, 435 
spongiotrophoblast and Giant cell layers from TAC05 group (F). Reichert´s membrane showing 436 
DBA + signal in CyA group (G). Sample from a non-pregnant control showing very low DBA 437 
signal (H). 438 
 439 
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Table 1. References of the probes used for gene expression analysis 
 
Gene UniGene sequence 
reference 
Reference of the probe 
(Life technologies) 
Actin-beta Mm.328431 Mm00607939_s1 
Interleukin-4 Mm.276360 Mm00445259_m1 
Interleukin-5 Mn.4461 Mm00439646_m1 
Interleukin-10 Mn.874 Mm00439614_m1 
Interleukin-13 Mn.1284 Mm00434204_m1 
CD31 Mm.343951 Mm01242584_m1 
VEGF-A Mn.282184 Mm01281449_m1 
ICAM-1 Mn.435508 Mm00516023_m1 
NKG2D Mn.8217 Mm00473603_m1 
IL-6 Mn.1019 Mm00446190_m1 
LIF Mn.4964 Mm00434762_g1 
TNF-alpha Mn.1293 Mm00443258_m1 
TNF-beta MN.87787 Mm00440228_gH 
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Table 2. Pregnancy and implantation rates after embryo transfer on recipients under 
calcineurin inhibitors treatment. 
 
 Control 
(n=10) 
CYA10 
(n=12) 
TAC02 
(n=11) 
TAC05 
(n=10) 
Pregnancy 8/10 (80%) 7/12 (58.3%)1 11/11 (100%) 8/10 (80%) 
Total number of embryos transferred 140 168 154 140 
Total implantation sites 81 62 115 93 
Live foetuses/mother 8.0 [1.5-13.0] 4.5 [0-10.0] 10 [7.0-13.0] 10.5 [4.5-13.0] 
Resorbed pregnancy/mother 0 [0-0.8] 0 0 [0-3.0] 0 [0-1.0] 
Implantation rate 57.1 [32.1-92.9] 32.1 [0-73.2]2 71.4 [64.3-92.9] 78.6 [37.5-94.6] 
 
1:CYA10 vs TAC02: p<0.03 
2:CYA vs Control: p<0.001; CYA vs TAC02: p<0.001; CYA vs TAC05: p<0.001. 
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Table 3. Gene expression levels in placenta and decidua. 
 
 PLACENTA DECIDUA 
GENE CONTROL TAC02 TAC05 CYA10 CONTROL TAC02 TAC05 CYA 
CD31 1,12 (0,86) 0,98 (0,47) 0,93 (0,59) 0,86 (0,04) 1,02 (0,20) 0,89 (0,37) 1,06 (0,18) 0,96 (0,19) 
VEGF-A 1,03 (0,38) 0,94 (0,17) 0,84 (0,36) 0,98 (0,08) 0,44 (0,29) 0,67 (0,64) 0,61 (0,95) 0,76 (0,19) 
ICAM 1,04 (0,63) 1,02 (0,69) 1,03 (0,84) 0,81 (0,28) 1,01 (0,28) 0,87 (0,69) 1,06 (0,44) 0,94 (0,51) 
NKG2D 1,26 (0,89) 0,67 (0,47) 1,01 (0,95) 0,71 (0,38) 0,99 (0,31) 0,98 (0,39) 1,06 (0,75) 0,96 (0,29) 
IL4 0,65 (0,39) 0,82 (0,19) 0,81 (0,36) N/A 0,79 (0,85) 1,03 (0,89) 1,07 (0,67) 0,73 (2,24) 
IL5 0,89 (0,77) 0,96 (0,23) 0,99 (0,32) 0,92 (0,38) 0,79 (0,57) 0,84 (0,64) 0,87 (0,44) 0,97 (0,77) 
IL6 0,74 (1,56) 0,74 (1,18) 0,76 (1,85) 0,81 (0,85) 1,10 (0,53) 0,84 (0,57) 1,03 (0,53) 0,91 (0,44) 
IL10 0,85 (1,38) 0,75 (0,58) 0,70 (0,78) 0,82 (0,42) 0,78 (0,74) 1,05 (0,58) 0,92 (0,47) 0,85 (0,63) 
IL13 0,44 (0,53) 0,79 (0,27) 0,90 (0,91) 0,25 (1,03) 0,41 (1,20) 0,65 (0,49) 0,75 (0,43) 0,82 (0,75) 
LIF 0,86 (1,17) 0,94 (0,25) 0,83 (0,24) 0,79 (0,11) 0,75 (0,85) 0,71 (0,50) 0,70 (0,60) 0,82 (0,44) 
TNFa 1,17 (0,66) 0,97 (0,26) 1,01 (0,26) 0,89 (0,20) 0,72 (0,55) 0,86 (0,40) 0,87 (0,58) 0,86 (0,28) 
TNFb 0,37 (1,40) 0,33 (0,87) 0,31 (0,71) 0,31 (0,04) 0,72 (1,14) 0,92 (0,92) 0,64 (0,58) 0,70 (0,47) 
Data are expressed as medians of the fold change (Interquartile range).  
Comparisons were made for each specific gene using the control group as reference group. 
No statistically significant differences were found for any comparison. 
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Abstract'
Introduction:!!Thousands!of!fertileTaged!women!around!the!globe!are!treated!with!any!of!the!
two! calcineurin! inhibitors,! cyclosporineTA! or! tacrolimus,! to! prevent! rejection! of! the!
transplanted! organ! that! they! are! carrying.! It! is! unclear! whether! these! drugs! affect! fertility.!
Since! ovulation! is! an! inflammationTlike! process! with! pivotal! roles! for! a! number! of! immune!
modulators!and!immune!cells!it!is!possible!that!the!calcineurin!inhibitors,!with!broad!effects!on!
the!immune!system,!could!affect!this!biologically!important!process.!!!!
Objective:! To! examine! whether! therapeutic! levels! of! cyclosporineTA! and! tacrolimus! affect!
ovulation!in!the!murine!gonadotropinTinduced!ovulation!model!
Methods:!
Results:!
Conclusion:! This! is! the! first! demonstration! that! cyclosporine! negative! affects! ovulation! in!
murine! models! and! the! findings! suggest! the! preferred! calcineurin! inhibitor! for! organ!
transplanted! females! that! hare! aiming! for! pregnancy! should! be! tacrolimus,! rather! that!
cyclosporine!A.!
Key'words'
cyclosporine,! calcineurin,! immunosuppression,! ovulation,! ovary,! rat,! tacrolimus,!
transplantation.!
Introduction:!
The!use!of!allogeneic!transplantation!of!solid!organs!and!composite!vascularized!tissues!in!the!
treatments! of! lifeTthreatening! diseases! or! to! compensate! for! loss! of! body! function! has!
increased! tremendously!during! the! last!decades.!The!key! to! the!success!of! these! treatments!
and! the! thereby! the! increased! number! of! transplantation! procedures! performed! and! the!
expansion!with!nonTlife!saving!organs/tissues,!such!as!the!hand,! face,! intestine!and!pancreas!
was! the! introduction!of!effective! immunosuppression!therapy,! in! the! form!of! the!calcineurin!
inhibitors! cyclosporine! A! in! the! early! 1980s.! This! was! followed! a! decade! later! by! the!
introduction!of!another!calcineurin!inhibitor,!tacrolimus1.!!
In!parallel!with!the!expansion!of!the!patients!groups!that!are!treated!with!transplantation,!the!
general!survival!of!the!patients!and!general!health!of!the!transplanted!patients!have!improved!
considerably.!The!medical!focus!on!the!transplanted!patient!has!also,!apart!from!graft!survival!
with! restored! organ! function,! come! to! include! several! issues! related! to! quality! of! life,! with!
fertility! being! one! important! issue.! Thus,! in! year! 2006! more! than! 14000! births! had! been!
reported!after!the!first!postTtransplantation!pregnancy,!which!took!place!more!than!50!years!
ago2.! Although! the! rate! of! obstetric! complications! seems! to! be! increased! among!
immunosuppressed! women! carrying! transplants,! the! risk! of! fetal! malformation! is! similar! to!
that!of!the!normal!population2.!!
The! effects! of! transplantation! on! subsequent! fertility! are! poorly! understood.! A! recovery! of!
fertility!after!organ! transplantation!has!been!widely!described! in! the! literature3,!but! this!has!
been! linked!to!the!considerable! improvement!of!the!health!status!of!the!female!when!she! is!
changing!from!a!severely!ill!patient!with!endTstage!disease!into!one!with!restored!and!normal!
organ! function.! There! may! exist! negative! effects! of! the! immunosuppressive! drugs! on! the!
function!of! the!reproductive!organs.!Animal!studies! in! rodents!suggest! that! the! implantation!
rate! is! decreased! and! the! miscarriage! rate! is! increased! due! to! exposure! to! cyclosporine4,5.!
There! also! exist! case! reports! on! affected! ovarian! function! after! organ! transplantation! in!
women6.!!
Ovulation!is!a!complex!biochemical!process!that!has!a!duration!of!around!36!hours!in!humans!
and! approximately! 12! h! in! rodent! species.! During! this! ovulatory! process! structural! and!
functional! changes! occur! and! this! allows! the! release! of! a! fertilizable! oocyte! and! the!
transformation!of!the!follicle!into!a!corpus!luteum.!Several!mediator!pathways!induce!changes!
in! the! follicle! that!are!necessary! for! follicular! rupture,!where!breakdown!of! the!extracellular!
matrix!on! the! follicular!apex! 7!and!expansion!of! the!extracellular!matrix!around! the!cumulus!
cells! (! Eppigre)! seem! to! be! the!most! important! components! for! normal! ovulation! to! occur.!
These! processes! bear! many! similarities! to! an! inflammatory! reaction,! with! participation! of!
classical!inflammatory!mediators!such!as!cytokines,!collagenases,!stromelysins,!gelatinases!and!
prostaglandins! as! well! as! pivotal! roles! for! certain! leukocyte! subsets8,9.! Several! of! these!
inflammatory! pathways! could! potentially! be! affected! by! the! immunosuppressive! effects! of!
calcineurin!inihibitors10.!!
Recent!attempts!of!human!uterus!transplantation11!have!further!shed!the!light!on!the!issue!of!
possible!effects!of!immunosuppressant!drugs!on!ovarian!function.!Since!this!is!the!first!type!of!
allogeneic!transplantation!where!restored!fertility!is!the!goal!and!with!menstruation!being!the!
first! obvious! sign! of! normal! ovarian! function! is! important! to! ascertain! that! ovarian! function!
proceeds! normally.! An! indication! that! ovarian! function! is! disturbed! after! uterus!
transplantation! is! that! in! the! first! two! cases! of! attempts! to! perform! human! uterus!
transplantation! exogenous! estrogenTprogestagen! therapy! were! initially! given! to! induce!
menstrual! bleedings.! However,! in! contrast! a!majority! of! the! patient! in! the! subsequent! first!
clinical!uterus!transplantation!resulting!in!live!birth12,!had!regular!spontaneous!menstruations!
from!2T3!months!after!transplantation13.!To!our!knowledge!there!exist!no!systematic!research!
studies!on!the!effects!of!immunosuppressant!drugs!on!ovarian!function!after!any!type!of!solid!
organ!transplantation,!where!kidney!transplantation!make!up!around!x!%!of!transplantations!
among!women!of!fertile!age.!The!main!type!of!immunosuppressant!in!all!immunosuppressant!
protocols! is! the! calcineurin! inhibitor,! with! either! cyclosporineTA! or! the! more! modern! drug!
tacrolimus,!being!the!drug!of!choice.!In!the!present!study!we!have!for!the!first!time!evaluated!
the!effects!of!the!calcineurin!inhibitors!on!the!ovulatory!process!in!any!species.!
!
Material'and'methods'
Experimental,design,and,animals:,
Immature! SpragueTDawley! rats! (Harlan! Nederlands,! Horst,! Netherlands)! were! used! in! this!
experiment.!The!animals!arrived!to!our!facilities!at!the!age!of!16!days!and!were!then!housed!in!
controlled!conditions!(21T23˚C;!illumination!0700T1900h)!and!had!access!to!food!adTlibitum.!At!
the! age! of! 21! days,! all! animals! were! weighed! and! then! randomly! allocated! to! 3! different!
groups!(15!animals/group):!group!1T0.9%!NaCl!(Control);!group!2TcyclosporineTA!10mg/kg/day!
(CyA)! and! group! 3Ttacrolimus! 0.5mg/kg/day! (TAC05).! All! animals! were! synchronized! for!
ovulation! at! 25! days! of! age,! according! our! standardized! protocol! for! ovulation! studies.14!
Briefly,! rats!aged!25!days!were! injected!with!10!UI!of!equine!chorionic!gonadotrophin! (eCG)!
s.c.! at! 12:00.! FortyTeight! hours! later,! the! rats! were! administered! 10! UI! of! human! chorionic!
gonadotrophin! (hCG)(Both! purchased! from! SigmaTAldrich,! Stockholm,! Sweden! AB,! Sweden),!
with! ovulation! occurring! 10T15! h! after! hCG! administration15.! Twenty! hours! after! ovulation!
induction! the!animals!underwent!euthanasia,!blood!samples!were! taken! for!white!blood!cell!
quantification! and! measurement! of! calcineurin! inhibitors! levels! and! ovulation! rate! was!
assessed.! Both! ovaries! were! also! taken! for! histological! and! molecular! studies.! The! present!
study! was! conducted! in! accordance! with! Swedish! legislations! and! was! approved! by! the!
Animals!Ethics!Committee!in!Gothenburg.!
!
Calcineurin,inhibitors,administration:!
Miniosmotic! pumps! (Alzet,! Durec! Corp,! Cupertino,! CA,! USA)! were! filled! with! a! solution! of!
tacrolimus!(diluted!in!NaClTpump!model!1007D)!or!cyclosporineTA!(diluted!in!1,2TpropanediolT
pump!model! 2001)! prepared! individually! for! each! animal! weight.!Miniosmotic! pumps! were!
filled! just!with!0.9%!NaCl! to!be!used! in! the!control!group.!Two!different!models! (1007D!and!
2001)!of!pumps,!with!identical!external!composition,!were!used!since!different!concentrations!
of! drugs! were! studied.! The! pumps! were! primed! in! NaCl! at! 37ºC! 12! h! prior! to! its! insertion!
according!to!the!manufacturer’s!instructions.!The!first!day!of!intervention!(postnatal!day!21),!a!
skin! incision! (5! mm)! was! made! in! the! back! of! each! animal! caudally! to! the! neck,! under!
isofluorane!anesthesia.!The!pump!was!placed!subcutaneously!in!a!parasagital!position,!and!the!
skin!subsequently!closed!with!two!polyglactin!stiches!(Vicryl!4T0,!Ethicon,!Somerville,!NJ,!USA).!
Calcineurin,inhibitors,levels:,
!Samples! of! whole! blood! (250μl)! were! drawn! from! the! aorta! at! ovulation! assessment.!
Tacrolimus! levels! were! measured! in! whole! blood! by! an! automated! chemiluminescent!
immunoassay! (CMIA)! developed! for! use! on! the! ARCHITECT! system! (Abbott! Scandinavia! AB,!
Solna,!Sweden).!The!coefficient!of!variation!between!runs!for!this!assay!varies!between!1.16!%!
and! 1.88! %.! Cyclosporin! levels! were! measured! by! enzyme! immunochemistry! using! a! CyAT
specific! assay! (Emit®2000,! Dade! Behring,! Milton! Keynes,! UK),! according! to! manufacturer’s!
instruction.!The!interTassay!coefficient!of!variation!was!below!9%.!
White,blood,cells,subpopulations,in,peripheral,blood,
Blood! samples!were! obtained! by! direct! puncture! of! the! aorta! during! euthanasia.! The! blood!
was! spread! on! a! glass! slide! and! dried! in! air.! Afterwards! it! was! fixed! by! immersion! in!
Romanowsky!stock!solution!during!5!minutes!and!subsequently!rinsed!in!distilled!water.!Then,!
the!slides!were!stained!for!25!minutes!with!the!diluted!Romanowsky!solution!(1:15! in!HEPES!
buffer!pH6.8+DMSO).!After!staining!the!samples!were!rinsed!in!distilled!water!and!dried!in!air!
and!cells!identified!according!to!their!specific!characteristics16.!
Assessment,of,ovulation,rate,and,preservation,of,ovaries,
The! ovulation! rate! was! assessed! 20! hours! after! injection! of! hCG.! The! oviduct! was! gently!
dissected!from!the!ovaries!and!the!uterine!horns.!The!left!ovary!was!kept!in!RNAlater!(Qiagen!
GmbH,! Hilden,! Germany)! and! stored! immediately! at! T20ºC.! The! right! ovary! was! kept! in! 4%!
formaldehyde.!The!ampullary!regions!of!both!Fallopian!tubes!were!then!isolated!and!opened!
to! release! the! oocytes.! In! order! to! scatter! these! oocytes! they! were! incubated! with!
hyaluronidase!(Hyase,!Vitrolife!AB,!Göteborg,!Sweden)!for!ten!minutes!over!a!glass!microscope!
slide.! Then,! the! oocytes! were! covered! with! a! coverslip! and! they! were! counted! under! a!
Nomarski!interference!microscope.!
Expression,of,ELANE,,Myeloperoxidase,,TIMP3,and,RUNX2,,
Elastase! (neutrophil! expressed;! ELANE)! and!myeloperoxydase! (MPO)! gene! expressions!were!
used!for!quantification!of!neutrophils!within!the!tissue.!Tissue!inhibitor!of!metalloproteinase!3!
(TIMP3)! and! runtTrelated! transcription! factor! 2! (RUNX2)!were! used! as!molecular!markers! of!
postTovulation.! Total!RNA!was! isolated! from! the! left!ovary!using!Trizol! (Invitrogen,!Carlsbad,!
CA,!USA).!Complementary!DNA!(cDNA)!was!made!using!2!mg!total!RNA!with!0.5!mg!random!
primer!(Promega,!Madison,!WI,!USA)!in!a!total!volume!of!17!µl.!This!mixture!was!denatured!at!
70°C!for!5!min.!Then,!0.5!mM!deoxyTNTP,!20!U!RNAsine,!RTTbuffer!and!200U!Moloney!murine!
leukemia! virus! reverse! transcriptase! (Promega,! Madison,! WI,! USA)! were! added! to! a! final!
volume!of!25!µl.!The!cDNA!synthesis!was!performed!for!60!min!at!37°C.!Quantitative!rtPCR!in!
an!ABI!Prism!7000!Sequence!Detector!(Applied!Biosystems,!Carlsbad,!CA,!USA)!was!performed!
to! evaluate! the! mRNA! expression.! Commercially! available! Taqman! MGB! probes! (Applied!
Biosystems,!Carlsbad,!CA,!USA)!were!used!for! the!target!genes!TIMP3!(ID:!Rn00441826_m1),!
RUNX2! (ID:! Rn01512298_m1),! ELANE! (ID:! Rn01535456_g1),!MPO! (ID:! Rn01460205_m1)! and!
control! (βTactin)! gene! (ID:! Rn01424440_s1).! Each! amplification! reaction! consisted! of! 20! ng!
cDNA,!1x!probeTmix!and!1x!TaqMan!Universal!PCR!mastermix! (Applied!Biosystems,!Carlsbad,!
CA,!USA)!to!a!final!volume!of!25!µl.!After!control!of!amplification!efficiency!of!the!targets!genes!
and! control,! the! relative! expressions! were! presented! using! the! comparative! Ct! method17.!
Expression! of! the! target! gene! mRNA! were! normalized! to! the! expression! of! the! control! (βT
actin).!
HHistology,,
The!right!ovary!was!kept!in!4%!buffered!formaldehyde,!dehydrated,!embedded!in!paraffin!and!
cut! into! 5µm! thick! sections.! Sections! were! subsequently! deparaffinized! and! rehydrated!
through!graded!ethanol,!rinsed!in!distilled!water!and!treated!with!0.3%!H2O2!and!10%!normal!
horse!serum!to!block!endogenous!peroxidase!and!nonTspecific!binding,! respectively.!Primary!
antibodies!against!CD4!(1:100,!Abbiotec!250592,!Nordic!biosite,!Täby,!Sweden),!CD8!(dilution!
1:75,! Serotec! MCA48R,! Nordic! biosite,! Täby,! Sweden),! CD163! (dilution! 1:50,! Serotec! MCA!
342R,! Nordic! biosite,! Sweden)! and! CD25! (dilution! 1:25,! Serotec! MCA! 273R,! Nordic! biosite,!!
Täby,!Sweden)!incubated!at!room!temperature!for!60!min.!
The!Envision! system! (K5007T500!Dako,! Copenhagen,!Denmark)!was!used! in! accordance!with!
the!manufacturer’s!instruction,!followed!by!detection!with!3,3´Tdiaminobenzidine.!Thymus!and!
spleen! tissue! were! used! as! positive! controls.! For! each! section,! the! adjacent! section! was!
incubated!with!5%!BSA/PBS!in!the!absence!of!the!primary!antibody!(negative!control).!Sections!
were!examined! independently!by! two!observers! in!a!blinded! fashion.!Five! luteinized! follicles!
were! randomly! chosen!per! section!and! stained! cells!were! counted!under! a! light!microscope!
(x400,!Leica!DM4000B,!Leica!Microsystems,!Madrid,!Spain).!The!mean!values!for!each!section!
were!used!as!individual!data!points.!The!intra!and!interTobserver!reliability!analysis!performed!
for! the!different! cell! subpopulations! showed! intraTclass! correlation! coefficients! ranging! from!
0.81!(95%CI:!0.68T0.95)!to!0.91!(95%CI:!0.81T0.95).!
HStatistics,,
Normal! distribution! of! the! data! was! tested! using! the! KolmogrovTSmirnoff! test.! Normally!
distributed!data!were!presented!as!means!and!standard!deviations.!Not!normally!distributed!
data!were!presented!as!medians!and!ranges!(between!square!brackets).!Pairwise!comparisons!
between!the!experimental!groups!and!the!control!group!were!done!using!the!Student!tTtest!or!
the!MannTWhitney!UTtest!when! appropriate.! P! values! <0.05!were! considered! as! statistically!
significant.!Calculations!were!done!using!SPSS!v!20!(IBM!Corp,!Chicago,!IL,!USA).!
Results'
Calcineurin'inhibitors'levels'
The!median! level!of!cyclosporin!and!tacrolimus! l!were!2128!ng/ml![1578T2892]!and!5.5ng/ml!
[4.6T6.6],! respectively.! Cyclosporine! and! tacrolimus! levels! in! the! control! group! were!
undetectable.!!
White'blood'cell'counts'
White! blood! cells! counts! are! showed! in! Table! 1.! No! significant! differences! were! evidenced!
between!groups.!The!use!of!calcineurin!inhibitors!did!not!modify!the!different!white!blood!cell!
subpopulations.!
Ovulation'rate'
Animals! in! cyclosporine! group! showed! a! decreased! number! (9[0T22],! p=0.03)! of! ovulated!
oocytes!when!compared!to!the!control!group!(22!oocytes![6T39]).!No!significant!difference!was!
found!between!control!and!the!tacrolimusTtreated!group!(21![8T41]).!
Ovarian'neutrophilic'markers'and'ovulation'markers'
The!MPO!expression!was!significantly!decreased!in!the!TAC05!and!CyATgroups!when!compared!
to! the! control! group! (p=0.019).! No! differences! between! groups! were! evidenced! regarding!
ELANE!expression.!The!antiTproteolytic!activity,!measured!through!RUNX2!and!TIMP3!was!not!
significantly! different! between! groups,! although! RUNX2! expression! from! TAC! group! ovaries!
tended!to!be!downregulated.!All!rtTPCR!results!are!showed!in!Figure!2.!
Histology'
Antibodies!against!CD163!recognize!a!specific!surface!glycoprotein!present!in!macrophages!of!
most!kind!of! tissues,!although! it!does!not!bind! to!monocytes.!Two!main!patterns!of!CD163+!
cells!were! identified! in!ovaries! from!this!experiment:!perivascular! (Figure!3A)!and!within! the!
newly!formed!corpus!luteum!(Figure!3B).!Such!distribution!was!reproduced!in!all!experimental!
groups.! The! total! amount! of! CD163+! cells/corpus! luteum! did! not! differ! between! groups!
(Control:! 14.9±6.7;TAC:! 16.2±8.2;! CyA:! 14.7±5.2;! n.s.).! CD4! is! mainly! expressed! by! TThelper!
lymphocytes.! CD4+! cells! were! absent! in! all! samples! but! two! (one! control! and! one! TAC).! In!
those! samples! with! CD4+! cells,! its! density! was! low! (0.4! and! 0.3! cells/corpus! luteum!
respectively).! The!CD8! coTreceptor! is! predominantly! expressed!on! the! surface!of! cytotoxic! T!
cells.! CD8Tpositive! cells! were! present! in! all! groups! and! no! statistical! differences! were! seen!
between!groups!(Control:!5.1±3.2!cells/corpus!luteum;!TAC:!6.2±2.9!cells/corpus!luteum;!CyA:!
7.1±4.0!cells/corpus!luteum;!n.s.).!
Discussion'
The! greatest! development! in! transplantation! surgery! was! the! introduction! of! effective!
immunosuppression! by! the! calcineurin! inhibitor! cyclosporineTA! in! the! 1980s! and! tacrolimus!
around! 15! years! later1.! Since! then! there! has! been! a! continuous! increased! utilization! of!
transplantation!as!treatment!of!severely!compromised!organ!function,!with!kidneys!being!the!
most!prevalent!transplanted!organ.!Moreover,!during!recent!years!also!vascularized!composite!
tissue! transplantation,! such! as! transplantation! of! the! hand! and! face! has! reached! the! stage!
clinical! routine! procedures.! Today! around! 18%! of! transplanted! women! are! of! fertile! age!
(according!to!the!Organ!Procurement!and!Transplantation!Network!TOPTNT,!data!as!of!August!
31,!2014)!and!with!continuously!increasing!graft!survival!and!the!issue!of!forming!a!family!is!a!
central! issue!among!the!younger!age!groups!of!transplanted!patients,!that!usually!go!back!to!
fully!normal!lives!after!transplantation.!It!is!generally!perceived!that!the!fertility!potential!of!a!
female! on! immunosuppressive! medication! is! compromised! although! no! systematic! studies!
have! been! carried! out! on! the! subject.! There! exist! human! case! reports! and! a! few! research!
studies! in! animal! models18,19,! that! could! indicate! that! the! calcineurin! inhibitors! decreases!
implantation!rate!and!increases!miscarriage!rate.!To!our!knowledge!there! is! limited!evidence!
on!the!effect!of!immunosuppressive!drugs!on!ovarian!function.!The!biologically!central!process!
of! ovulation! has! been! compared! to! a! local! inflammatory! reaction,! since! a! number! of!
inflammatory!mediators!and!also!some!subsets!of!leukocytes!are!central!to!carry!out!the!tissue!!
remodeling! of! the! extracellular!matrix,! blood! flow! changes! and! changes!within! the! cumulus!
cells,!that!are!so!important!for!this!procedure!to!continue!so!that!follicular!rupture!takes!place.!
The! intraovarian! biochemical! changes! of! ovulation! are! timeT! and! siteTspecific! and! involve!
various! types! of! molecules! with! antagonistic! effects,! essentially! metalloproteinases! and!
inhibitors!of!metalloproteinases,!and!also!different!type!of!cell!effectors!(theca!cells,!granulosa!
and!resident! leukocytes)! that! interact!promoting!matrix! remodeling.!The! final!purpose! is! the!
extracellular!digestion!of!the!stroma!surrounding!basal!lamina!and!the!follicle!to!this!release!or!
mature!oocyte!containing.!In!this!balancing!mechanism,!there!is!a!key!role!metalloproteinases!
secreted! by! white! blood! cells! in! the! ovary! residents! and! inhibitors! of! metalloproteinases!
secreted!by!theca!cells,!granulosa!and!fibrobasts!(Fedorcsak,!et!al.,!2010).!
Like! any! other! inflammatory! process,! immunosuppressive! drugs! that!modify! the! function! of!
the! different! leukocyte! subpopulations! could! potentially! regulate! ovulation.! ! Secretion! of!
metalloproteinase! inhibitors! from! ovarian! tissue! cells! could! also! be! regulated! by!
immunosuppressants!due!to!the!ubiquity!of!the!molecular!pathways!disrupted!by!these!drugs.!!
Data! in! the! literature! regarding! the! use! of! immunosuppressants! and! ovulation! may! seem!
contradictory:! while! an! improvement! in! fertility! parameters! is! experienced! after!
transplantation!of! solid!organs3,!ovarian!dysfunction! in! solid!organTtransplanted!patients!has!
also! been! describe,! usually! associated! to! midTluteal! phase! defects! associated! to! low!
progesterone!levels20.!
To! our! knowledge! this! is! the! first! study! upTtoTdate! to! systematically! evaluate! the! effect! of!
calcineurin! antagonists! on! ovulation.! Our! main! finding! is! that! cyclosporineTA,! but! not!
tacrolimus,!decreases!ovulation!rate!when!administered!for!at!least!two!estrous!cycles.!These!
differential!effects!on!ovulation!by!these!two!types!of!calcineurin!inhibitors!were!unexpected!
when! we! planned! the! experiment,! because! the! main! mechanism! of! both! is! the! specific!
inhibition!of!calcineurin,!with!the!major!and!common!secondary!effect!being!the!cessation!of!
interleukinT2! release! from!TTlymphocytes.!However,! the!differential!effects!of!cyclosporine!A!
and! tacrolimus! has! previously! been! seen! other! organs! and! systems! such! as! the! kidney,!
endothelium!or!different!metabolic!systems21.!!Although!both!cylosporinTA!and!tacrolimus!act!
on!the!same!molecular!pathway,!the!intermediary!proteins!mediating!their!effect!differ:!while!
tacrolimus! binds! to! calcineurin! through! a! complex! with! FKBPTfamily! proteins,! cyclosporine!
binds! to! calcineurin! through! a! cyclophilin! protein! complex.! The! binding! sites! of! FKBP! and!
cyclophilin! to! calcineurin! contain! different! aminoacids,! which! induces! distinctive!
conformational!changes!and!subsequently!differential!activity!patterns22.!
It!is!wellTdescribed!that!leukocytes,!especially!macrophages!and!neutrophils,!are!important!in!
ovulation,! since! leukocyte! supplementation! to! the! perfused! ovary! preparation! would!
considerably!increase!ovulation!rate!and!since!depletion!of!neutrophils!or!macrophages!from!
peripheral! blood! decreases! ovulation! rate! in! vivo14,23.! The! reduction! in! the! ovulation! rate!
evidenced!in!the!CyATgroup!does!not!appear!to!be!mediated!by!any!major!change!in!leukocyte!
infiltration! patterns! since! histological! examination! of! the! postTovulatory! ovaries! did! not! find!
any! difference! in! terms! of! numbers! and! distribution! of! neutrophils,! macrophages! and!
lymphocytes! in! the! three! experimental! groups.! Similarly,! peripheral! leukocyte! populations!
didn’t! vary! between! groups.! These! two! facts! indicate! that! CINs! do! not! affect! vascular!
permeability!and! recruitment!of! immune!cells! to! the!ovary.!There!exist! controversial!data! in!
the! literature! regarding! the! ability! of! CNIs! to! avoid! or! decrease! leukocyte! infiltration! on!
different! tissues:! while! most! of! the! available! evidence! suggest! that! CINs! may! affect! the!
chemotaxis!of!neutrophils!exerted!by!macrophages! 10,24,25!and! increase!endothelial!activation!
resulting! in! enhanced! neutrophil! infiltration26! and!macrophage26! and! neutrophil10! activation,!
there!are!studies!that!fail!to!evidence!any!significant!effect!of!CINs!on!neutrophil,!macrophage!
or! lymphocyte! infiltration27.! These! differences! between! studies! could! be! caused! by! the!
different! doses! and! route! of! administration! of! CINs,! the! target! organ! or! the! methodology!
employed.!
In!this!study!we!decided!to!use!ELANE!as!the!main!surrogate!marker!of!neutriphilic!infiltration!
beause! it! is! described! in! the! literature! that! CINs! only! alters! its! expression! during!
hematopoiesis28.! In! mature! neutrophils,! elastase! and! myeloperoxidase! accumulate! in!
intracellular! granules! until! they! undergo! exocytosis! during! neutrophil! activation29.! The!
presence! of! neutrophils! measured! by! a! surrogate! marker! for! RTTPCR! instead! of! using! a!
histological!marker!increases!the!reproducibility!of!the!determination.!Indeed,!during!a!parallel!
experiment!using!a!set!of!10!animals!neutrophil!phenotyping!was!performed!with!a!battery!of!
commercially!available!rat!antibodies!(data!not!shown).!We!found!a!very!low!specificity!for!all!
of!them,!since!other!leukocyte!subpopulations!were!stained,!mainly!macrophages.!This!would!
explain! some! of! the! discordant! results! that! exist! in! the! literature! regarding! the! role! of!
neutrophils!in!ovulation14,30,31.!
The!expression!of!MPO,!like!other!enzymes!involved!in!the!production!of!free!radical!species,!
can! be! decrased! by! the! effect! of! immunosuppressive! drugs32.!MPO! expression!was! reduced!
both! in! the!group!TAC05!as!CyA!group,! indicating!that!although!there! is!no!difference! in! the!
number! of! neutrophils! (measured! by! ELANE),! their! capacity! to! produce! oxygenTreactive!
species!is!diminished.!!
When!we!compared!the!molecular!markers!of!ovulation,!although!there!were!no!statistically!
significant!differences!between!groups,!a!tendency!to!downregulation!of!RUNX2!was!observed!
in!animals!treated!with!tacrolimus!(TAC05).!On!the!other!hand,!TIMP3!expression!was!similar!
between!groups.!This!is!consistent!with!the!fact!that!intracellular!signaling!pathways!involved!
in! TIMP3! regulation! seem! to!be! independent! from! calcineurin33.! These! findings! suggest! that!
the! detrimental! effect! on! the! ovulation! rate! observed! in! the! group! of! animals! treated!with!
cyclosporine!(CyA)!is!independent!of!the!expression!of!metalloproteinase!inhibitors!like!TIMP3!
by!ovarian!tissue.!
The!doses!used!in!this!experiment!were!chosen!because!they!allow!obtaining!plasma!levels!of!
CIN! similar! to! those! obtained! in! a! clinical! setting! of! immunosuppression! in! solid! organ!
transplant.! These! doses! are! efficient! enough! to! control! the! risk! of! organ! rejection! in! most!
clinical! scenarios.! Despite! the! differences! between! species,! pharmacokinetic! CINs! profiles! in!
mouse!and!human!models!are!quite!similar34,!as!it!is!their!pharmacodynamic!profile35.!
The!main!limitation!of!this!study!is!that!it!was!designed!to!assess!the!main!variable!effect,!the!
ovulation! rate.! Given! the! complexity! of! the! process! of! ovulation,! this! experiment! allowed!
studying! the!mechanisms! behind! such! effect! only! partially.!While! one! can! rule! out! that! the!
decrease! in! the! ovulation! rate! caused! by! calcineurin! is! due! to! numerical! alterations! or!
infiltration! of! leukocytes,! and! also! seems! unlikely! to! be! justified! by! imbalances! in! the!
production! of! metalloproteinase! inhibitors,! there! are! other! factors,! such! as! changes! in!
production! of! metalloproteinases28,! abnormal! vascularization36! or! follicle! contractility37! that!
should!be!further!explored.!
!
! !
Acknowledgements'
The! authors! thank! Ann! Wallin! for! technical! assistance! and! professor! Carmen! Carda! for!
technical! advice.! This! study! was! supported! by! the! Swedish! Research! Council! and! ALF! of!
Sahlgrenska!Academy,!Sweden.!CDG!benefited!from!a!Rio!Hortega!Grant!from!the!Instituto!de!
Salud!Carlos!III,!Spain!(CM09/00063).!
!! !
Bibliography'
1.! A!comparison!of!tacrolimus!(FK!506)!and!cyclosporine!for!immunosuppression!in!liver!
transplantation.!The!U.S.!Multicenter!FK506!Liver!Study!Group.!N!Engl!J!Med!1994;331:1110T5.!
2.! McKay!DB,! Josephson!MA.!Pregnancy! in!recipients!of!solid!organsTTeffects!on!mother!
and!child.!N!Engl!J!Med!2006;354:1281T93.!
3.! Douglas! NC,! Shah!M,! Sauer!MV.! Fertility! and! reproductive! disorders! in! female! solid!
organ!transplant!recipients.!Seminars!in!perinatology!2007;31:332T8.!
4.! Groth! K,! Brannstrom! M,! Molne! J,! Wranning! CA.! Cyclosporine! A! exposure! during!
pregnancy! in! mice:! effects! on! reproductive! performance! in! mothers! and! offspring.! Human!
reproduction!2010;25:697T704.!
5.! Mason!RJ,!Thomson!AW,!Whiting!PH,!et!al.!CyclosporineTinduced!fetotoxicity!in!the!rat.!
Transplantation!1985;39:9T12.!
6.! Cure! P,! Pileggi! A,! Froud! T,! et! al.! Alterations! of! the! female! reproductive! system! in!
recipients!of!islet!grafts.!Transplantation!2004;78:1576T81.!
7.! Li! F,! Curry! TE,! Jr.! Regulation! and! function! of! tissue! inhibitor! of! metalloproteinase!
(TIMP)!1!and!TIMP3!in!periovulatory!rat!granulosa!cells.!Endocrinology!2009;150:3903T12.!
8.! Brannstrom!M,!Pascoe!V,!Norman!RJ,!McClure!N.!Localization!of! leukocyte!subsets! in!
the!follicle!wall!and!in!the!corpus!luteum!throughout!the!human!menstrual!cycle.!Fertil!Steril!
1994;61:488T95.!
9.! Suzuki! T,! Sasano! H,! Takaya! R,! et! al.! Leukocytes! in! normalTcycling! human! ovaries:!
immunohistochemical! distribution! and! characterization.! Human! reproduction! 1998;13:2186T
91.!
10.! GarciaTCriado! FJ,! PalmaTVargas! JM,! ValduncielTGarcia! JJ,! et! al.! Tacrolimus! (FK506)!
downTregulates! free! radical! tissue! levels,! serum! cytokines,! and! neutrophil! infiltration! after!
severe!liver!ischemia.!Transplantation!1997;64:594T8.!
11.! Ozkan! O,! Akar! ME,! Erdogan! O,! et! al.! Preliminary! results! of! the! first! human! uterus!
transplantation!from!a!multiorgan!donor.!Fertility!and!sterility!2013;99:470T6.!
12.! Brannstrom! M,! Johannesson! L,! Bokstrom! H,! et! al.! Livebirth! after! uterus!
transplantation.!Lancet!2015;385:607T16.!
13.! Johannesson! L,! Kvarnstrom! N,! Molne! J,! et! al.! Uterus! transplantation! trial:! 1Tyear!
outcome.!Fertil!Steril!2015;103:199T204.!
14.! Brannstrom!M,!Bonello!N,!Norman!RJ,!Robertson!SA.!Reduction!of!ovulation!rate!in!the!
rat! by! administration! of! a! neutrophilTdepleting! monoclonal! antibody.! J! Reprod! Immunol!
1995;29:265T70.!
15.! Espey! L,! Shimada! H,! Okamura! H,! Mori! T.! Effect! of! various! agents! on! ovarian!
plasminogen! activator! activity! during! ovulation! in! pregnant! mare's! serum! gonadotropinT
primed!immature!rats.!Biol!Reprod!1985;32:1087T94.!
16.! haematology!Icfsi.!ICSH!reference!method!for!staining!of!blood!and!bone!marrow!films!
by! azure! B! and! eosin! Y! (Romanowsky! stain).! International! Committee! for! Standardization! in!
Haematology.!British!journal!of!haematology!1984;57:707T10.!
17.! Livak! KJ,! Schmittgen! TD.! Analysis! of! relative! gene! expression! data! using! realTtime!
quantitative!PCR!and!the!2(TDelta!Delta!C(T))!Method.!Methods!2001;25:402T8.!
18.! ElTAkouri! RR,! Molne! J,! Groth! K,! Kurlberg! G,! Brannstrom! M.! Rejection! patterns! in!
allogeneic!uterus!transplantation!in!the!mouse.!Hum!Reprod!2006;21:436T42.!
19.! Groth!K,!Akouri!R,!Wranning!CA,!Molne!J,!Brannstrom!M.!Rejection!of!allogenic!uterus!
transplant! in! the!mouse:! timeTdependent! and! siteTspecific! infiltration!of! leukocyte! subtypes.!
Hum!Reprod!2009;24:2746T54.!
20.! Yildirim! Y,! Tinar! S,! Yildirim! YK,! Inal! M.! Comparison! of! pituitaryTovarian! function! in!
patients!who! have! undergone! successful! renal! transplantation! and! healthy!women.! Fertility!
and!sterility!2005;83:1553T6.!
21.! Setkowicz!Z,!Ciarach!M,!Guzik!R,!Janeczko!K.!Different!effects!of!neuroprotectants!FKT
506! and! cyclosporin! A! on! susceptibility! to! pilocarpineTinduced! seizures! in! rats! with! brain!
injured!at!different!developmental!stages.!Epilepsy!research!2004;61:63T72.!
22.! Huai! Q,! Kim! HY,! Liu! Y,! et! al.! Crystal! structure! of! calcineurinTcyclophilinTcyclosporin!
shows!common!but!distinct!recognition!of!immunophilinTdrug!complexes.!Proc!Natl!Acad!Sci!U!
S!A!2002;99:12037T42.!
23.! Wu!R,!Van!der!Hoek!KH,!Ryan!NK,!Norman!RJ,!Robker!RL.!Macrophage!contributions!to!
ovarian!function.!Human!reproduction!update!2004;10:119T33.!
24.! Chang! KT,! Lin! HY,! Kuo! CH,! Hung! CH.! Tacrolimus! suppresses! atopic! dermatitisT
associated!cytokines!and!chemokines!in!monocytes.!Journal!of!microbiology,!immunology,!and!
infection!=!Wei!mian!yu!gan!ran!za!zhi!2014.!
25.! Sasakawa! Y,! Sakuma! S,! Higashi! Y,! Sasakawa! T,! Amaya! T,! Goto! T.! FK506! suppresses!
neutrophil! chemoattractant! production! by! peripheral! blood! mononuclear! cells.! European!
journal!of!pharmacology!2000;403:281T8.!
26.! Thomale! UW,! Bender! M,! Casalis! P,! et! al.! Tacrolimus! depresses! local! immune! cell!
infiltration!but!fails!to!reduce!cortical!contusion!volume!in!brainTinjured!rats.! Immunobiology!
2007;212:567T76.!
27.! Bayer!J,!Das!NA,!Baisden!CE,!et!al.!Effect!of!inhaled!tacrolimus!on!ischemia!reperfusion!
injury! in! rat! lung! transplant! model.! The! Journal! of! thoracic! and! cardiovascular! surgery!
2013;146:1213T9;!discussion!9.!
28.! Atilla!G,!Sorsa!T,!Ronka!H,!Emingil!G.!Matrix!metalloproteinases! (MMPT8!and! T9)!and!
neutrophil! elastase! in! gingival! crevicular! fluid! of! cyclosporinTtreated! patients.! Journal! of!
periodontology!2001;72:354T60.!
29.! GilmanTSachs! A,! Tikoo! A,! AkmanTAnderson! L,! Jaiswal! M,! Ntrivalas! E,! Beaman! K.!
Expression! and! role! of! a2! vacuolarTATPase! (a2V)! in! trafficking!of! human!neutrophil! granules!
and!exocytosis.!Journal!of!leukocyte!biology!2015;97:1121T31.!
30.! Oakley! OR,! Kim! H,! ElTAmouri! I,! et! al.! Periovulatory! leukocyte! infiltration! in! the! rat!
ovary.!Endocrinology!2010;151:4551T9.!
31.! Chun! SY,! DaphnaTIken! D,! Calman! D,! Tsafriri! A.! Severe! leukocyte! depletion! does! not!
affect!follicular!rupture!in!the!rat.!Biology!of!reproduction!1993;48:905T9.!
32.! Horl! WH,! Wanner! C,! Riegel! W,! Schlosser! W,! Wilms! H,! Schollmeyer! P.! Reduction! of!
degranulation!of!polymorphonuclear! leukocytes!by! immunosuppression! in!patients! following!
cadaveric!renal!transplantation.!Transplantation!1989;47:144T8.!
33.! GarciaTAlvarez! J,!Ramirez!R,!Checa!M,!et!al.!Tissue! inhibitor!of!metalloproteinaseT3! is!
upTregulated!by!transforming!growth!factorTbeta1!in!vitro!and!expressed!in!fibroblastic!foci!in!
vivo!in!idiopathic!pulmonary!fibrosis.!Experimental!lung!research!2006;32:201T14.!
34.! Venkataramanan!R,!Koneru!B,!Wang!CC,!Burckart!GJ,!Caritis!SN,!Starzl!TE.!Cyclosporine!
and!its!metabolites!in!mother!and!baby.!Transplantation!1988;46:468T9.!
35.! Saso! S,! Logan! K,! Abdallah! Y,! et! al.! Use! of! cyclosporine! in! uterine! transplantation.!
Journal!of!transplantation!2012;2012:134936.!
36.! Jiang!X,!Nguyen!TT,!Tian!W,!et!al.!Cyclosporine!Does!Not!Prevent!Microvascular!Loss!in!
Transplantation! but! Can! Synergize! With! a! Neutrophil! Elastase! Inhibitor,! Elafin,! to! Maintain!
Graft!Perfusion!During!Acute!Rejection.!American!journal!of!transplantation!:!official!journal!of!
the! American! Society! of! Transplantation! and! the! American! Society! of! Transplant! Surgeons!
2015.!
37.! Takeda!Y,!Yoneda!T,!Ito!Y,!Miyamori!I,!Takeda!R.!Stimulation!of!endothelin!mRNA!and!
secretion! in! human! endothelial! cells! by! FK! 506.! Journal! of! cardiovascular! pharmacology!
1993;22!Suppl!8:S310T2.!
!
Table!1.!White!Blood!Cells!counts!and!WBC!subpopulations!in!peripheral!blood.!
Control! Control! Cya! TAC05! p!value!
WBC!(cells/microL)! 3063±1560! 3178±1246! 1958±645! n.s.!
Lymphocytes!(%)! 86±3! 77±6! 85±6! n.s.!
Neutrophils!(%)! 10±4! 13±3! 8±6! n.s.!
Monocytes!(%)! 3±1! 7±5! 5±3! n.s.!
Eosinophils!(%)! 0.1±0.3! 0.5±0.5! 0.8±0.7! n.s.!
Basophils!(%)! 0.1±0.3! 0±0.0! 0±0.0! n.s.!
Comparisons! were! done! using! the! Control! group! as! reference.! Student’s! tTtest! was! used.!
Differences!were!considered!significant!if!p<0.05.!
Figure!1.!Scheme!of!the!experimental!design.!!
Animals!were!synchronized!for!ovulation!by!injecting!10UI!of!equine!chorionic!gonadotrophin!
(eCG)! s.c.;! 48h! later! ovulation! was! induced! by! injecting! 10UI! of! human! chorionic!
gonadotrophin!(hCG)! i.p.!and!20!hours!after! induction!the!animal!was!euthanized!by!cervical!
dislocation.!During!the!7!days!prior!to!euthanasia!the!animals!received!tacrolimus!tacrolimus!
0.5mg/kg/day! (Tac0.5;! n=15);! cyclosporin! 10mg/kg/day! (CyA10;! n=15)! and! normal! saline!
(Control;!n=15).!!
!
Figure!2.!Expression!analysis!of!ELANE,!MPO,!RUNX2!and!TIMP3!mRNA.!
Columns! represent! fold! changes! using! the! control! group! as! reference! (1Tfold! change).! Bars!
represent!standard!deviations!of!deltaTCt!measurements.!
Figure!3.!Macrophage!distribution!within!the!ovaries.!
A/!Macrophages!disposed!around!vascular!structures!(asterisk).!B/!Macrophages!within!luteal!
cells.!(x400)!
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background: Uterus transplantation (UTx) research aims towards the introduction of UTx as a treatment for uterine factor infertility.
The rat model is the principal rodent model used and this study aims to assess the potential for pregnancy and to assess effects on pregnancy
outcome.
methods: Female Lewis rats underwent hysterectomy and received syngeneic uterine transplants (with one horn removed) by end-to-
side anastomosis between the common iliac vessels of the recipient and the graft. The graft was placed in an orthotopic position with ana-
stomosis to the upper part of the native uterine horn and vagina to allow for pregnancy by mating. Controls had only one uterine horn
removed. Mating and pregnancy frequencies, successful deliveries and pup weight trajectory were compared.
results: Pregnancy was achieved in rats after UTx with the pregnancy rate, number of pups and growth trajectory of pups being similar
to controls. However, numbers of resorbed pregnancies and arrested parturitions were more common in the UTx group.
conclusions: A model for orthotopic UTx was developed and pregnancies with live offspring were for the first time demonstrated in
the rat model of UTx. The model will be useful in future studies of fertility after UTx.
Key words: uterus / transplantation / syngeneic / fertility / pregnancy
Introduction
Transplantation of solid organs is one of the greatest achievements of
modern medicine and the main therapeutic alternative for some
patient groups with end-stage organ failure. Substantial advancements
in this clinical field have recently allowed for transplantation also of
composite tissue (face, hand and forearm) that are not vital for survi-
val but imperative for normal function and quality of life (Dubernard
et al., 1999; Devauchelle et al., 2006). Since infertility can interfere
substantially with socio-psychological health (Stanton et al., 2002),
transplantation of reproductive organs or tissues as infertility treat-
ment may also be encouraged in the future. Untreatable uterine
factor infertility exists in women with congenital uterine agenesis
and after hysterectomy and may also be present in patients with
intrauterine adhesions or large uterine leiomyoma. Despite the
advances during the last decades in infertility treatment and transplan-
tation surgery, this group of patients still lack a treatment for their
infertility. Transplantation of the uterus has been proposed as a poss-
ible temporary curative treatment (Brannstrom et al., 2003, Sieunarine
et al., 2005) and an alternative to adoption or IVF surrogacy for these
women.
There has been one attempt of uterus transplantation (UTx) in a
woman, and although successful in terms of short-term outcome of
surgery, a necrotic uterus was removed after 3 months (Fageeh et al.,
2002). It is not clear whether the cause of necrosis was related to
surgical techniques, rejection or other factors. Nevertheless, UTx may
have a place as infertility treatment in the future since large patient
groups with uterine factor infertility exist (Sieunarine et al., 2005;
Brannstrom et al., 2010). However, before another attempt to
transplant a uterus in a woman is performed, the feasibility, safety
and benefits of the procedure must be determined by in-depth
studies in appropriate animal models.
The aim of any organ transplantation is to re-establish organ func-
tion in the recipient, and in UTx, the natural end-point proving
organ function is pregnancy with healthy offspring. There are several
aspects of UTx that can disturb implantation and pregnancy. The
surgery may alter blood flow, lymphatic drainage, structural support
and innervation of the uterus so that conditions to establish and
& The Author 2010. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
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continue pregnancy become suboptimal. Moreover, drugs used to
prevent rejection of the transplant may affect implantation as well as
the development of the fetus and future health of the offspring
(Groth et al., 2010). We have previously presented a method for het-
erotopic UTx in the rat (Wranning et al., 2008), showing normal
uterine morphology after syngeneic transplantation. The present
study presents a modification of this model with orthotopic placement
of the uterus graft with the objective to study pregnancy potential after
mating.
Materials and Methods
Animals
Female, virgin Lewis rats (weight 170–200 g) were used as uterus
donors/recipients and male Lewis rats (Charles River, Sulzfeld,
Germany) of proven fertility were used for mating. The animals were
housed in controlled conditions (21–238C; illumination 07:00–19:00 h)
with free access to water and standard food. The study was approved
by the Animals Ethics Committee in Gothenburg and conducted in
accordance with Swedish legislations and the principles and procedures
outlined in the ‘Guide for the Care and Use of Laboratory Animals’
(Commission on Life Sciences, Institute of Laboratory Animal Resources,
1996).
Study design
Rats were randomly allocated for syngeneic uterine transplantation
(UTx group) or removal of the left uterine horn (sham group) based on
an estimated surgical success rate of 70% in the UTx group (Wranning
et al., 2008) and 100% in the sham group. Inclusion criteria for both
groups were (i) satisfactory post-operative recovery according to
scoring of animal health and (ii) healthy appearance of the uterus at
second-look laparotomy 2 weeks after surgery. Included animals were
left to recover after surgery for an additional 4–8 weeks and then intro-
duced to males of proven fertility on a one female to one male basis.
Mating pairs were kept together until weaning of pups or for 10 weeks.
Mating and pregnancy frequency, number of deliveries and pup weights
were recorded.
Transplantation surgery
The donor surgery was performed as previously described (Wranning et al.,
2008) with modifications for orthotopic placement of the grafted uterus.
Briefly, a graft containing the right uterine horn, the common uterine
cavity with the cervix and upper vagina plus a vascular pedicle including
the arteries and veins from the right uterine vessels up to, and including,
the right common iliac vessels, was isolated. To allow for anastomosis of
the uterine horn of the graft to the upper part of the recipient uterine
horn, the donor uterine horn was divided 7–8 mm from the Fallopian
tube after cauterizing the utero-ovarian pedicle at the same level. The
uterus was flushed in situ through the common iliac artery with 2 ml of
cold (48C) Perfadex preservation solution (Vitrolife AB, Mo¨lndal, Sweden)
supplemented with xylocaine (0.4 mg/ml) and heparin (50 IU/ml) and
then submerged in cold (48C) Perfadex during preparation of the recipient.
In the recipient, a simple hysterectomy was performed with dissection
and mobilization of the upper third of the vagina from the rectum and the
bladder. A titanium clip was placed en bloc over the tip of the left uterine
horn. On the right side, a 7–8 mm segment of the upper portion of the
uterus was preserved for later anastomosis to the uterine graft.
The right common iliac vessels were separated and mobilized up to the
aortic/caval bifurcation. Atraumatic vascular clamps (S&TMicrosurgery,Neu-
hausen, Switzerland) were placed on each side of the intended anastomosis
sites on the common iliac vessels. The common iliac vessels of the graft
were anastomosed to the recipient in an end-to-side fashion using two semi-
continuous 10-0 nylon sutures (S&T Microsurgery) on each vessel (Fig. 1a).
The vaginal cuff of the transplant was sutured to the vaginal vault of the
recipient by six to seven interrupted 6.0 polyglactin sutures (Ethicon, New
Brunswick, NJ, USA). The uterine horn of the graft was anastomosed
end-to-end (Fig. 1b) to the remaining cranial uterine segment of the reci-
pient uterus using five to seven interrupted 7-0 nylon sutures (Ethicon).
Control animals were operated under the same conditions as the trans-
planted rats. Via a midline laparotomy, two titanium clips (Hemoclips;
Weck Closure System, Triangle Park, NC, USA) were placed on the left
uterine horn; one just caudal to the Fallopian tube and the second one
just cranial of the bifurcation from the common uterine cavity. The
uterine tissue between these clips was removed. No modifications were
made on the remaining horn and only blood vessels and nerves coming
through the left infundibulopelvic ligament were excluded. Peri- and
post-operative care of all operated animals was performed according to
previously described protocols (Wranning et al., 2008).
Figure 1 Schematic drawing of the UTx procedure in the rat. (A) The grafted uterus is shown in grey and the site of vascular anastomosis of the
graft iliac vessels to the recipient common iliac vessels is highlighted in the circle. Arrows mark the ligations of graft vessels caudal of the uterine branch
on the iliac vessels. (B) Photograph of the anastomosis between the distal end of the native uterine horn (N) and the grafted uterus (G).
554 Wranning et al.
 at Servicio Valenciano de Salud on October 25, 2011
http://humrep.oxfordjournals.org/
Downloaded from 
Evaluation of surgical success
All UTx and sham animals were observed during the first 5 post-operative
days to assess post-operative recovery. Animals not showing satisfactory
recovery according to health scores approximating signs of pain or distress
such as piloerection, lethargy and hunched back (Morton and Griffiths,
1985) were excluded.
Two weeks after surgery, all animals were anaesthetized and the lapar-
otomy scar was opened. The uterus transplants (UTx group) or the right
uterine horns (sham group) were examined. Animals with uteri displaying
signs of thrombosis, constricted uterus–uterus anastomosis or major
intestinal–uterine adhesions were excluded.
Assessment of reproductive performance
Four to 8 weeks after uterus evaluation, UTx and sham animals were
introduced to males of proven fertility. Females were examined every
morning for the first 4 days for indications of mating. Those displaying a
vaginal semen plug and/or the presence of sperm in vaginal lavage were
concluded as having mated.
Two weeks after detected mating, mated females were weighed and
gently palpated to determine pregnancy status. Pregnant females were
observed for nesting behaviour and the presence of pups every morning
from Days 20 to 24 after mating. The number of pups in a litter was deter-
mined on Day 1 after birth to allow time for undisturbed establishment of
maternal behaviour. Females displaying palpable pregnancies later during
the study period were monitored in the same manner every morning
after determination of pregnancy. At the end of the experiments, UTx
and sham animals were euthanized and their uteri were examined for
signs of resorbed and/or ongoing pregnancies. Pups born by sham and
UTx mothers were weighed weekly from Day 7 after birth until 6
weeks of age.
Statistics
The duration of graft cold ischaemia and recipient surgery was compared
between included and excluded animals using the Wilcoxon signed-ranks
test. Comparisons of mating, pregnancy and conception frequencies
between sham and UTx groups were performed using x2 test. All tests
were two-tailed and a P-value of ,0.05 was considered statistically
significant.
Results
Outcome of surgery
A total of 27 UTx procedures were performed and 19 animals were
included in the study, resulting in a surgical success rate of 70%. The
causes for exclusion of eight UTx animals were: death due to bleeding
within the first 3 post-operative days (n ¼ 3), unsatisfactory post-
operative recovery (n ¼ 1) and pathological findings [graft thrombosis
(n ¼ 1), intra-abdominal adhesions (n ¼ 1) and constricted uterus–
uterus anastomosis (n ¼ 2)] during the check-up surgery. The dur-
ations (medians) of different stages of the surgery were comparable
between included and excluded animals (P . 0.05). The median
graft cold ischaemia duration was 120 (range: 60–210) and 122
(range: 70–160) min for included and excluded animals, respectively.
The median recipient surgery duration was 215 (range: 170–270) and
215 (range: 190–250) min for included and excluded animals, respect-
ively. In the sham group, 19 surgical procedures were performed. The
duration of surgery was between 35 and 40 min and surgical success
was 100%.
Mating and pregnancy rate
Mating rates during the first oestrus cycle after introduction to the
male were comparable in UTx (17 of 19) and sham (16 of 19)
animals. Pregnancy rates, determined by palpation on Day 15 after
these first matings, were similar between groups: 47% (8 of 17) in
the UTx group and 50% (8 of 16) in the sham group. At later time
points, an additional three animals in the UTx group and four in the
sham group became pregnant (Table I). The overall pregnancy rate
for the UTx group (11 of 19; 58%) was not significantly different
from that of the sham group (12 of 19; 63%). Mating and pregnancy
rates are illustrated in Fig. 2.
Pregnancy outcome
All sham animals that conceived during the first oestrus cycle delivered
litters of three to seven pups (median ¼ 3.5 pups) on Days 22–24 of
Figure 2 Mating and pregnancy performance in animals after UTx
and in sham-operated animals (sham). The black area represents the
animals that became pregnant during the first cycle of mating. The
squared area represents the animals that became pregnant during
subsequent cycles. The striped area represents animals that mated
but did not get pregnant. The white area represents the animals
that did not mate.
...........................
........................................................................................
Table I Breeding performance after UTx and sham
surgery.
Number of animals
Utx Sham
Animals 19 19 n.s.
Mated (first cycle) 17 16 n.s.
Pregnant animals 11 12 n.s.
Successfully delivered litters 1 8 P, 0.01
Total number of pups or fetuses 32 45
Pups/pregnancya 3 (2–6) 3.5 (3–7) n.s.
Number of resorptions 6 0 P, 0.01
aExpressed as median (range).
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pregnancy and initiated normal maternal behaviour. Of the eight UTx
animals that conceived during the first cycle, seven showed signs of
initiation of labour (nesting behaviour, dilation of vagina) on Days
23–25 after mating. One UTx rat delivered two male pups and
showed normal maternal behaviour. Two other UTx females gave
birth to at least two pups each (concluded by observation through
the transparent cage bottom on the morning after delivery) but com-
mitted infanticide before the pups were counted. The remaining four
pregnant UTx animals displayed signs of distress and labour cessation
and were euthanized. At examination, dead pups of full-term size were
found in the vagina of the recipient and in the common cavity and right
horn of the graft (2–6 pups, median 3).
The UTx and sham females that did not have pregnancies com-
pleted from the first cycle of mating were euthanized and examined
10 weeks after introduction to the male. There were four sham and
two UTx animals which carried viable fetuses of sizes and weights cor-
responding to approximately mid-gestational age. Also, two UTx
females that previously had been concluded pregnant by palpation
and weight gain displayed completely resorbed pregnancies (2 and
4, respectively). Pregnancy outcome is summarized in Table I and
Fig. 2. The weight trajectory for the only 2 surviving pups (males)
born from one UTx rats was similar to the 32 born pups
(18 females and 14 males in 8 litters) of sham rats (Fig. 3). Animals
that had not conceived during the study period showed uterine
gross morphology similar to what had been noted on examination
14 days after surgery.
Discussion
Although UTx research has been ongoing for many years, only a few
studies have tested the pregnancy potential of a transplanted uterus.
Early experiments studying severance and re-anastomosis of the
uterine vessels in the dog reported a limited number of pregnancies
(Mattingly et al., 1970; Barzilai et al., 1973). Also, after autologous
UTx in the rhesus macaque with neovascularization from the
omentum, menstruation was resumed but no pregnancies occurred
(Scott et al., 1987). Recently, we reported pregnancies in the sheep
after autotransplantation of a uterine-tubal-ovarian graft and spon-
taneous mating several weeks after the procedure (Wranning et al.,
2010). The first pregnancy after transplantation of a uterus from
one animal to another was reported in the mouse after syngeneic
UTx (Racho El-Akouri et al., 2003a,b). In this mouse UTx model,
the graft was placed in a heterotopic position and pregnancies were
achieved by transmyometrial embryo transfer (Racho El-Akouri
et al., 2003a,b). The present study represents the first report of ferti-
lity and live offspring after mating involving any animal that has under-
gone transplantation of the uterus from one animal to another.
There are several rationales for using an orthotopic rat model
instead of the previously reported heterotopic mouse (Wranning
et al., 2010) or rat (Wranning et al., 2008) models. The larger size
of the rat makes the surgical procedure easier and thus increases
model reproducibility (Wranning et al., 2008). The present orthotopic
model shows similar animal and graft survival rates as in the previously
presented heterotopic mouse (Racho El-Akouri et al., 2003a) and rat
(Wranning et al., 2008) models. Also, by this orthotopic model, con-
ception by mating could be achieved. Even though feasible, ovulation
induction and embryo transfer in rats are fairly inefficient in inbred
rats (Corbin and McCabe, 2002; Popova et al., 2005) and may add
confounding factors to the experiment.
An important step in UTx research is to investigate the capacity of
an allogeneic uterus transplant to carry a pregnancy. Others have
reported that doses of immunosuppressants that are needed to
control rejection in rats are, in comparison to that in mice, more in
the human range (Kawahara et al., 1980; Giardina et al., 1990). In
our mouse model, daily doses of cyclosporine at 20 mg/kg prevented
macroscopic signs of rejection during a short study period (Wranning
et al., 2007), but increased lymphocytic infiltration indicated that long-
term survival may not be feasible even at this high dose. Furthermore,
high doses of cyclosporine in mice have been shown to impair implan-
tation rates and fetal survival (Groth et al., 2010).
In the present study, the pregnancy rate was similar between sham
and UTx animals, with no difference in the median numbers of pups
per pregnancy. However, under the assumption that each uterine
horn carries half the litter, the median number of pups in the
present model was lower than that reported by other authors in
normal animals (Gill et al., 1979; Lord et al., 1999). This may reflect
that not only the transplantation procedure but also the insult
caused by sham surgery affects the fertility capacity of the uterus.
The increased number of resorbed pregnancies in the UTx group indi-
cates that conditions supporting fetal survival after UTx are subopti-
mal. Whether they are caused by altered blood flow, interrupted
lymph drainage, denervation or other changes in the transplanted
uterus is unclear and further studies are needed to determine this.
The rate of successful deliveries in the UTx group was markedly
lower than in the sham group. In seven UTx rats, parturition was
initiated but four of these could not proceed to delivery. Pups
found at euthanasia of these females were dead but of appropriate
size for gestational age and with no signs of maceration, indicating
that the pups died during arrested labour. The initiation and pro-
gression of labour in the rat is a complex and incompletely understood
process (Zakar and Hertelendy, 2007). Nerve reflexes via the viscer-
ocutaneous branch of the pelvic nerve have been shown to influence
parturition (Martinez-Gomez et al., 1998), and in the present study,
Figure 3 Growth trajectory of offspring of sham and UTx animals.
Open triangles represents male pup weights, open circles represents
female pup weights and weights of two male pups born from UTx rat
are indicated by filled stars.
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the transplanted uterus was completely denervated. This may provide
one explanation for the high percentage of failed deliveries since no
such complications were found in the sham group where the uterine
and cervical innervation was unmanipulated. Another plausible cause
may be scarring at the vaginal anastomosis or at other vaginal sites
due to the surgical manipulations, in line with findings that vaginal
adhesions may cause dystocia in the sheep (Winter, 2000). In our
material, macroscopic examination of the vaginal anastomosis revealed
no signs of stenosis, but tests of elasticity and detailed morphological
evaluations were not performed. Since the surgical denervation did
not seem to affect the duration of gestation, it may be possible to
prevent this adverse perinatal outcome by performing a Caesarean
section in future experiments using this model.
Two of the rats in the UTx group managed to deliver but com-
mitted infanticide within 24 h. Infanticidal tendencies in female rats
are uncommon after 22 days of pregnancy (Peters and Kristal,
1983), but female rats in all reproductive conditions are likely to eat
stillborn pups or even healthy pups if conditions are stressful (Miley
et al., 1982). It can be speculated that these females either gave
birth to dead pups or that the parturition itself was stressful and
induced infanticide. However, since the newborns were not examined
immediately after delivery, this remains unclear.
The present study demonstrates that syngeneic, orthotopic UTx
allows for conception by mating and pregnancies that are comparable
to the control group. This UTx model may be useful in future studies
regarding fertility, pregnancy and offspring development after allo-
geneic UTx under immunosuppression.
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First report on fertility after allogeneic uterus transplantation
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Abstract
Uterus transplantation may become the ﬁrst available treatment for uterine factor infertility, which is due to the absence or
malfunction of the uterus. Here we describe for the ﬁrst time pregnancy after allogeneic uterus transplantation, as a proof of
concept of uterine function in a transplanted uterus in a standardized animal model (rat) under immunosuppression.
Key words: Allogeneic, infertility, pregnancy, transplantation, uterus
Introduction
Transplantation of the uterus may in the future
become a treatment for women with uterine factor
infertility, which is due to either the absence of the
uterus (uterine agenesis/previous hysterectomy) or
the presence of a uterus that is not able to carry a
pregnancy (intrauterine adhesions/congenital malfor-
mation/myoma). Women with uterine factor infertil-
ity make up the largest subgroup of infertile women
that lack treatment in spite of the great advancements
in the clinical area of reproductive medicine. Exper-
imental uterus transplantation (UTx) has developed
extensively after the only human trial 10 years ago (1).
This human UTx attempt was not successful but
stimulated research efforts on several UTx-speciﬁc
issues such as surgical technique (2–7), uterus rejec-
tion (5,8,9) and ischemia–reperfusion events (10–15).
Studies have reported pregnancies in non-rejection
settings of syngeneic UTx among inbred strains of
mice (12,16) and after autologous UTx in the
sheep (17). Here we describe the ﬁrst pregnancy
ever reported after allogeneic UTx, with the uterus
recipient being under continuous immunosuppres-
sion to avoid rejection of the graft.
Material and methods
Female, virgin Dark Agouti (histocompatibility hap-
lotype: RT1av1, RT2b, RT3a, RT7a) rats were used
as uterus donors and female, virgin Lewis rats (his-
tocompatibility haplotype: RT1l, RT2a, RT3a, RT7a,
RT8b) were used as uterus recipients. Male Sprague–
Dawley rats of proven fertility were used for mating.
All animals (weight 170–200 g) were from Harlan
Nederlands (Horst, Netherlands). All surgical proce-
dures were performed under aseptic conditions and
with the aid of an operating microscope (6–40-fold
magniﬁcation) and bipolar diathermy (Coa Comp,
Billdal, Sweden).
The uterus donor animal was anesthetized and
given a subcutaneous injection of heparin (1,000
IU!kg"1). After disinfection of the abdominal wall
a midline laparotomy was performed. The small
intestines and appendix were exteriorized from the
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abdominal cavity and protected. To acquire a reason-
able operating ﬁeld around the uterus and its vascular
connections, the rectum and bladder were removed
from the pelvis after cauterization of their vascular
pedicles. The vaginal vessels and descending branches
of the uterine vessels were cauterized close to the cervix
at the level of the ureters. These were then divided
bilaterally after cauterization. The left uterine horn was
removed from the remaining uterus after placements of
titanium clips at its proximal and distal portions. The
cervical/vaginal portion of the intended graft was dis-
sected from the remaining surrounding tissue and
subsequently the vagina was carefully divided with
the aid of bipolar diathermy at a level 3 mm caudal
of the cervix. All the vessels branching from the iliacs
between the origin of the uterine vessels and the aorta
were carefully ligated (8-0 nylon) and sectioned.
The iliac vessels were separated from each other by
gentle dissection from the level of the aortic/caval
bifurcation down to the branching of the uterine
vessels. The right uterine horn was then cut 2 mm
caudally to the utero-tubal junction after placing a
titanium clip around the Fallopian tube. Ligatures
(8-0 nylon) were placed separately around the left
common iliac artery and vein in proximity to the
aortic and caval bifurcations and the left common
iliac artery was cannulated with a 27G cannula
which was secured by an 8-0 nylon ligature. The
common iliac vein was then cut just caudally of
the ligature at the bifurcation of the vena cava. The
uterus was brought out from the abdomen and ﬂu-
shed (0.8 ml!min"1) through the iliac artery cannula
with cold (4#C) Perfadex preservation solution
(Vitrolife AB, Mölndal, Sweden), which was supple-
mented with xylocaine (0.4 mg!ml"1) and heparin (50
IU!ml"1). Flushing was performed until clear ﬂuid
drained from the venous side of the graft and the graft
was then preserved in Perfadex at 4#C until trans-
plantation into the recipient (see below).
The uterus recipient was anesthetized and given a
subcutaneous injection of low molecular weight hep-
arin (100 IU!kg"1). The small intestines were gently
exteriorized, soaked in warm saline/glucose solution
and kept at sterile conditions. The bladder was ten-
derly mobilized from the anterior aspects of the uter-
ine cervix with caution to preserve all the bladder
vessels. The uterine arteries and veins were cauterized
at their most distal ends, preserving the vaginal
branches. After that a hysterectomy was performed.
A titanium clip was placed en bloc over the tip of the
left uterine horn. On the right side, a 6-mm segment
of the upper portion of the uterus was preserved for
later anastomosis to the uterus graft. The right com-
mon iliac vessels were dissected up to the aortic/
caval bifurcation to free them from each other and
allow for anastomosis surgery. After vascular clamps
had been applied proximal and distal to the anasto-
mosis site, the common iliac vessels of the graft were
anastomosed to the recipient in an end-to-side fash-
ion. Vascular anastomosis was accomplished by two
hemicontinuous 10-0 nylon sutures for the vein and
8 interrupted 10-0 nylon sutures for the artery. The
vagina of the graft was then sutured to the vaginal
vault of the recipient using interrupted 6-0 polyglactin
sutures. The uterine horn of the graft was anasto-
mosed end-to-end (Figure 1A) to the remaining
cranial uterine segment of the recipient uterus, using
six interrupted 7-0 nylon sutures which were placed
so that they did not enter the uterine cavity. The
midline incision was closed in two layers. The median
and range of the cold and warm ischemic times
were 102.5 [60–150] and 75 minutes [55–105]
respectively.
Sham-operated animals were anesthetized as above
and operated to remove one uterine horn to create an
anatomically similar uterus as compared to the uterine
A.
B.
Figure 1. Demonstration of fertility after allogeneic uterus trans-
plantation in the rat. (A) Uterine graft (white arrow) and native tip
of uterine horn (black arrow) separated by the anastomosis sutures
and with indistinguishable gross morphology. (B) Fetus in its
amniotic sac at cesarean section of allogeneic transplanted uterus.
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graft (see above). Thus, the left uterine horn was
removed after placements of two titanium clips; one
just caudal to the Fallopian tube and the second one
just cranial to the uterine bifurcation from the com-
mon uterine cavity. The median and range of the total
surgery time for the Sham-operated animals were
21 minutes [17–25].
Animals receiving tacrolimus were weighted
before surgery. A dose of 0.5 mg!kg"1!day"1 tacroli-
mus diluted in NaCl (ﬁnal volume 0.2 ml) was
injected during surgery. The tacrolimus dose used
was chosen according to an initial dose-study (0.2–0.5
mg!kg"1!day"1), demonstrating the absence of mor-
phological signs of uterus rejection by this dose (data
not shown). The same day a 2ML4 miniosmotic
pump (Alzet, Durec Corp, Cupertino, CA) was ﬁlled
with a solution of tacrolimus prepared individually for
each animal. This solution contained between 2.1 and
2.8 mg of tacrolimus depending on the animal weight.
The pump was primed in NaCl at 37#C 12 hours
prior to its insertion according to the manufacturer’s
instructions.
Twelve hours after transplantation/sham surgery a
skin incision (10 mm) was made in the back, caudally
to the neck and the pump was placed subcutaneously
in a parasagittal position under isoﬂuorane anesthesia.
The ﬁnal amount of tacrolimus that was released from
each pump was estimated to 0.02 mg!kg"1!h"1. The
pumps were kept for 27 days and then exchanged with
a new pump prepared as described above.
For assessment of blood levels of tacrolimus,
samples of whole blood (250 ml) were drawn from the
aorta at cesarean section. Tacrolimus levels were
measured in whole blood by an automated chemilumi-
nescent immunoassay (CMIA) developed for use on
the ARCHITECT system (Abbott Scandinavia AB,
Solna, Sweden). The coefﬁcient of variation between
runs for this assay varies between 1.16 and 1.88%.
The UTx fertility experiments consisted of three
groups, with all groups being exposed to fertile males
during one estrous cycle between 35 and 38 days after
surgical intervention. The ﬁrst group consisted of
eight female rats that had undergone UTx and
were immunosuppressed by tacrolimus (UTx-Tac-
group). The other groups consisted of sham-operated
(excision of one uterine horn) rats treated with either
an identical tacrolimus protocol (Sham-Tac-group;
n = 5) or sham-operated without tacrolimus treatment
(Sham-nonTac-group; n = 6). All animals underwent
cesarean section 17 days after initiation of the mating
period. Presence of adhesions, color, size and consis-
tence of the graft were noted according to a pre-
viously published scale (3). The anastomosis sites
were evaluated regarding pulsation of the artery and
reﬁlling of the vein. Pregnancies and fetuses were
counted; pregnancy was deﬁned by the presence of
at least one identiﬁable placenta; living fetuses were
deﬁned as those showing movements and/or heart
beating activity under the surgical microscope and
resorbed pregnancies as those having no identiﬁable
fetus or having no living fetuses. Tissue samples were
collected from uterus. If the rat was not pregnant
transversal biopsies including endometrium, myome-
trium and serosa were taken randomly. If the rat was
pregnant transversal biopsies were taken from the
implantation sites and from non-implantation areas.
The biopsies were stained with eosin and hematoxylin
and analyzed under light microscopy for indications
of inﬂammation according to a previous morphology
study of uterine rejection (8).
Although this Dark Agouti-to-Lewis allogeneic
rat model has been used in research on other types
of organ transplantations, with proven promi-
nent rejection under non-immunosuppressed condi-
tions (18,19), we tested three animals with uterine
grafts and no immunosuppression. After 10 days all
showed rejected graft with massive necrosis. The
surgical model described here is a modiﬁcation of a
rat transplantation model described before (3), even
though a series of 10 surgeries were performed in
order to avoid learning-curve related problems before
starting the experiment.
Results
Before the transplantation experiment started, 10 pre-
study transplantation procedures were performed to
study the pelvic vascular anatomy of this strain com-
bination in detail and to optimize the procedure. In
these 10 trials, perioperative deaths of the donors due
to major bleeding occurred during the ﬁrst three
procedures and complete transplantations could not
be performed. In pre-study transplantation trials num-
ber 4–6, death of the recipients occurred because of
major bleeding from the vascular tree of the graft at non-
anastomotic sites. The following four pre-study trials
were successful in terms of survival of the recipient and
graft, when examined 7 days postoperatively.
The tacrolimus levels (median [ranges]) at end of
experiment were within the same range in the UTx-
Tac-group (11.4 mg!L"1 [4.6–18]) as in the Sham-
Tac-group (9.4 mg!L"1 [5.7–25]). The pregnancy
rates (deﬁned as number of pregnant females/
total number of females within group) were 62.5%
in the UTx-Tac-group, 60% in the Sham-Tac-group,
and 83% in the Sham-nonTac-group. In the UTx-
Tac-group all pregnancy sites were present in the
uterine graft and none was seen in the small native
remnant of the uterine horn. The medians [ranges] of
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fetuses (Figure 1B) per pregnant rat were 1 [0–3] in
the UTx-Tac-group, 1 [1–5] in the Sham-Tac-group
and 3 [1–4] in the Sham-nonTac-group. Resorbed
pregnancies were seen in four of ﬁve pregnant rats of
the UTx-Tac-group (median 1 resorbed pregnancy
[0–3]) and in one (1 resorbed) of four and one
(1 resorbed) of ﬁve of the Sham-nonTac-group and
Sham-Tac-group, respectively. None of the uteri
showed macroscopic signs of thrombosis and/or rejec-
tion. Uterine morphology (gross/light microscopy)
was similar in uteri of all groups with no signs of
inﬂammation or necrosis in any group.
Discussion
Although there are more than 15,000 human live
births reported after allogeneic transplantation of
organs such as the kidney, liver and heart (20), it is
important to ascertain that the delicate physiological
processes of implantation and pregnancy can occur as
well in a transplanted uterus with novel vascular
connections and immunosuppression to prevent
rejection of that speciﬁc organ. The demonstration
of pregnancy in this allogeneic UTx model is a central
proof of concept of UTx and thereby an essential step
in the research toward clinical application of UTx in
the human. The occurrence of resorbed pregnancies
and a low pregnancy rate in the allogeneic uterine
grafts suggest that both UTx and tacrolimus treat-
ment negatively affects the implantation/pregnancy
rate. Advances in immunosuppression treatment or
novel modalities to induce tolerance of a transplanted
organ may minimize these problems in the future.
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Pregnancy after allogeneic uterus
transplantation in the rat: perinatal
outcome and growth trajectory
C!esar Díaz-García, M.D.,a,b,c Liza Johannesson, M.D., Ph.D.,a Ruijin Shao, Ph.D.,d H"akan Bilig, M.D., Ph.D.,d
and Mats Br€annstr€om, M.D., Ph.D.a,e
a Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, G€oteborg, Sweden;
b Fertility Preservation Unit, Women's Health Area, La Fe University Hospital, University of Valencia, Valencia, Spain;
c Instituto de Investigaciones Sanitarias La Fe, Valencia, Spain; d Department of Neurophysiology/Endocrinology,
Sahlgrenska Academy, University of Gothenburg, G€oteborg, Sweden; and e Stockholm IVF, Stockholm, Sweden
Objective: To investigate whether allogeneic uterine grafts in a rat model, with tacrolimus immunosuppression, can harbor pregnan-
cies that result in offspring with normal postnatal growth.
Design: Experimental animal study.
Setting: Obstetrics and gynecology department at a university hospital.
Animal(s): Lewis rats as uterus donors and Piebald-Virol-Glaxo rats as recipients.
Intervention(s): Animals were allocated to one of the following three groups: allogeneic uterus transplantation with end-to-side
anastomosis to the external iliac vessels and immunosuppression with tacrolimus (UTþTac; n ¼ 10); sham surgery and
immunosuppression with tacrolimus (ShamþTac; n ¼ 10); or sham surgery (Sham; n ¼ 10). The rats were subsequently introduced
to male rats with proven fertility and in the event of resulting pregnancy cesarean sections were performed on day 22 of pregnancy.
Main Outcome Measure(s): Graft viability, fertility rate, perinatal death, birth weight, postnatal birth trajectory.
Result(s): Pregnancy rate was higher in the control groups (70% Sham and 80% ShamþTac) than in the transplanted group (50%
UTþTac), although these differences did not reach the signiﬁcance threshold. There were no differences between groups regarding num-
ber of living pups or neonatal deaths. Pups born from UTþTac mothers had birth weights similar to external control animals from our
breeding colony (BC): UTþTac males 6.2 # 0.2 g, UTþTac females 5.5 # 0.6 g, BC males 5.8# 0.2 g, BC females 5.2 # 0.3 g; n.s. Eval-
uation of uteri and placentas of pregnant animals revealed a somewhat reduced vascular density in both tissues in the UTþTac group,
and that was not seen in the ShamþTac group.
Conclusion(s): Allogeneic uterus transplantation and immunosuppression with tacrolimus is
compatible with normal pregnancy and perinatal outcome in a rat model. (Fertil Steril!
2014;-:-–-. "2014 by American Society for Reproductive Medicine.)
Key Words: Rat, uterus, transplantation, allogeneic, immunosuppression, pregnancy, offspring
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D espite the signiﬁcant progressaccomplished in reproductivemedicine during the past de-
cades, women with absolute uterine-
factor infertility (AUFI) still lack any
infertility treatment. This group of
patients includes those lacking a uterus
(congenital/hysterectomy) or having a
nonfunctional uterus (Asherman syn-
drome, major uterinemalformation) (1).
Uterus transplantation (UT) has
been proposed as a method to treat
women with AUFI and to achieve ge-
netic motherhood in settings where
surrogacy is not a valid option. Howev-
er, before clinical introduction of UT,
several aspects should be evaluated
thoroughly in nonhuman animal
models to optimize the procedure
before clinical introduction and to
ascertain that the procedure is safe.
Uterus transplantation is a novel surgi-
cal procedure, and the introduction
should follow the recently launched
IDEAL concept (2), where nonhuman
research is proposed to be a funda-
mental base before any surgical proce-
dure enters the human clinical arena.
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The importance of nonhuman research and training to gain
success in an experimental human setting was illustrated
by the extensive research primarily conducted in rats before
performance of the ﬁrst full face transplantation in the hu-
man (3).
Human UT is, like face transplantation, a quality of life–
enhancing type of transplantation, rather than a life-saving
procedure. Therefore, in such a situation it is of uttermost
importance to perform thorough preclinical preparations,
because there is not only the recipient who is affected by
the risks involved but also the prospective child, that will
develop in the grafted uterus.
Our group initiated research on UT in experimental ani-
mal models more than 10 years ago, and we have extensively
studied several aspects of UT, such as surgical techniques,
tolerance to ischemia-reperfusion events, rejection patterns,
and immunosuppressive protocols (4–8). However, the
important and natural end point of UT is the delivery of
healthy offspring, and this aspect has been studied only
after syngeneic UT in mice and rats (9, 10). The important
added factor in an allogeneic setting is the immunogenicity
of the nonself uterine graft, with the need of effective
immunosuppression to avoid rejection. Our group
demonstrated already in 2010 the ﬁrst pregnancies after
allogeneic UT experiments performed in the rat model (11).
However, the main outcome of that study was pregnancy
and not achievement of viable offspring, so evaluations
were done at pregnancy day 17 and not at term.
Large databases exist on pregnancies in humans with
solid organ transplants under immunosuppression. Higher
rates of low birth weight, preterm birth, hypertension, and
preeclampsia were noted (12). However, it is not clear whether
these obstetrical complications were secondary to immuno-
suppression or to the underlying disease, because a complete
population-based study with reliable data also from pregnan-
cies before transplantation showed a similar increase of these
complications in the pregnancies occurring before transplan-
tation (13).
It is clear that it is of great concern to evaluate the
outcome of allogeneic UT, where adverse effects on the preg-
nancy and fetus may be mediated not only by the immuno-
suppressive medication but also by factors such as altered
uterine blood supply and denervation. In the present paper,
we present the ﬁrst data on the perinatal outcome of offspring
from allogeneic uterine grafts, evaluating the effect of the
anatomic modiﬁcations and the immunosuppression caused
by the transplantation procedure on their growth phenotype.
MATERIALS AND METHODS
Animals
Virgin Lewis (LW) rats (histocompatibility haplotype RT1l,
RT2a, RT3a, RT7a, RT8b) were uterus donors, and virgin
Piebald-Virol-Glaxo (PVG) rats (histocompatibility haplotype
RT1c, RT2b, RT3a, RT6a, RT7a, RT8b) were used as recipients.
All female rats weighed 170–200 g. Male Sprague-Dawley
(SD) rats of proven fertility were used for mating. All animals
were provided by Harlan Nederlands and were fed ad libitum
with standard pelleted food under 12-hour dark-light cycles.
The study design and animal procedures were approved by the
Animals Ethics Committee in Gothenburg.
Study Design
PVG female rats were randomly allocated to three different
experimental interventions: 1) allogeneic UT under immuno-
suppressive treatment with tacrolimus (UTþTac group;
n ¼ 10); 2) surgical removal of the left uterine horn under
immunosuppressive treatment (ShamþTac group; n ¼ 10);
and 3) surgical removal of the left uterine horn without any
immunosuppressive treatment (Sham group; n ¼ 10).
Only animals showing a satisfactory postoperative recov-
ery and healthy appearance of the uterus at second-look lap-
arotomy 2 weeks after surgery were included in the
experiment. Nine weeks after surgery, the female rats were
introduced to male rats of proven fertility and the mating
and pregnancy rates, numbers and sex of pups, weights,
and perinatal mortality rate were recorded and compared.
Two breeding colonies were used as external control
groups for weight: 1) pups born from PVG females (BC;
n ¼ 52); and 2) pups born from PVG females undergoing an
identical immunosuppressive treatment as the experimental
groups during pregnancy (BCþTac; n ¼ 86). Comparisons
were made between pups born from the three experimental
groups as well as between pups born from the UTþTac group
compared with those of the breeding colonies (Supplemental
Fig. 1, available online at www.fertstert.org).
Surgical Procedures
The transplantation, sham surgeries, and postoperative care
of the animals have been described in detail elsewhere (14).
Brieﬂy, a graft containing the right uterine horn, the uterine
cervix, the uterine pedicle, and a vaginal rim was retrieved
from the Lewis donors. The unilateral vasculature pedicle en-
compassed the arteries and veins of the uterine vessels, the in-
ternal iliac vessels, and the major part of the common iliacs.
The harvested uterus was kept under cold ischemia while
the PGV recipient was prepared by both hysterectomy and
clearance of the anastomosis sites on the right common iliacs.
Vascular anastomosis was performed in an end-to-side
fashion to the external iliac vessels of the recipient by contin-
uous 10-0 Prolene sutures. The vaginal rim of the graft was
sutured to the vaginal vault of the recipient, and the abdomen
was closed by standard two-layered procedure.
Immunosuppression
The immunosuppression protocol was based on monotherapy
with tacrolimus, according to our observations in nonpreg-
nant rats with the allogeneic uterine grafts (15). The dose
was higher during the initial 8 weeks and then reduced to
50% of the starting dose. This was kept during the remainder
of the experimental period, which included pregnancy. This
immunosuppression reduction after the initial post-
transplantation period is common in clinical solid organ
transplantation.
In the immunosuppressed groups, an initial dose of
0.4 mg/kg tacrolimus (Prograf; Astellas Pharma) was
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delivered by subcutaneous injection just after transplanta-
tion/sham surgery. A 2ML4 miniosmotic pump (Alzet; Durec
Corp.) was immediately placed subcutaneously in the back of
the rat. The pump was loaded with a tacrolimus solution in
0.9% NaCl, adjusted for the weight of the animal, to release
0.4 mg/kg/d of tacrolimus. This pump was subsequently re-
placed after 4 weeks by a similar pump and then every 4th
week by a 2004-model miniosmotic pump (Alzet) adjusted
to deliver 0.2 mg/kg/d of tacrolimus until the end of the
experiment. In the nonimmunosuppressed group, the pumps
were ﬁlled with the 0.9% NaCl vehicle only.
Mating, Pregnancy, and Delivery
Nine weeks after surgery (1 week after the insertion of the
third miniosmotic pump) the female rats were introduced to
the male rats of proven fertility in a 2 female:1 male fashion.
They were kept together for a complete estrus cycle, and mat-
ing was assessed every morning by vaginal plug examination.
If pregnancy occurred, the day in which the plug was visual-
ized was considered to be pregnancy day 0. All of the females
underwent abdominal palpation 2 weeks after withdrawal
from the male. If pregnancy was suspected, a cesarean section
was performed on pregnancy day 22. When pregnancy was
not obvious, a midline minilaparotomy was performed to
rule out the possibility of a single-order pregnancy or an early
miscarriage in which the uterus would not be easily detectable
by palpation. Animals that did not get pregnant during the
ﬁrst mating cycle underwent a second cycle of mating during
the subsequent estrus cycle.
Macroscopic Evaluation of Uteri and Pups after
Cesarean Section/Laparotomy
All uteri were macroscopically evaluated during cesarean sec-
tion or laparotomy (if not pregnant) with the use of a vali-
dated scale accounting for color, texture, and size of the
uterus, patency of the uterine vessels, vascularization of the
myometrium, and presence of abdominal adhesions (16).
The numbers and sexes of live pups, as well as the
numbers of dead fetuses and implantation sites were noted.
The placentas were placed in formaldehyde for histologic
analysis. The live pups were introduced to foster mothers.
Histologic Evaluation of the Graft/Sham-Operated
Uteri
Uterine and placental samples were systematically taken at
the time of cesarean section/minilaparotomy and ﬁxed in
4% buffered formaldehyde, dehydrated, and embedded in
parafﬁn. Tissue sections were made every 5 mm. One-half of
the sections were stained with eosin and hematoxylin and
the other half were subjected to immunohistochemistry. The
slides were deparafﬁnized in xylene and rehydrated before
antigen retrieval. Sections were blocked with 5% normal
goat serum in 0.01 mol/L Tris-buffered saline solution (pH
7.6) with Triton X-100 (TBST) in a humidity chamber for
1 hour at room temperature (RT) before incubation with poly-
clonal rabbit antiendothelin A receptor (1:100, ab85163; Ab-
cam) or polyclonal rabbit antiendothelin B receptor (1:100,
ab39960; Abcam) overnight at 4!C. Sections were washed
with TBST (3", 5 min) at RT before incubation with goat
anti–rabbit IgG coupled to Alexa 488 (1:250; Invitrogen) for
1 hour at RT in a humidity chamber. Secondary antibody
was removed and tissues washed again with TBST (3",
5 min) before mounted with ﬂuorescent Vectashield (Vector
Laboratories) with 40,6-diamidino-2-phenylindole (DAPI).
Slides were viewed on an Axiovert 200 confocal microscope
(Carl Zeiss) equipped with a laser-scanning confocal imaging
LSM 510 Meta system (Carl Zeiss) and photomicrographed.
Background settings were adjusted from examination of
negative control specimens. Controls for nonspeciﬁc staining
have been described elsewhere (17).
Tacrolimus Levels
Peripheral blood samples, to measure tacrolimus levels, were
taken by incision of the distal edge of the tail twice: on day 17
of pregnancy and at the time of cesarean section/minilaparot-
omy. Tacrolimus levels were measured in whole blood by an
automated chemiluminescent immunoassay (CMIA) devel-
oped for use on the Architect system (Abbott Scandinavia).
The intra-assay coefﬁcient of variation was <1.9%.
Weight of the Pups
Pups were weighed at birth and then every week until the age
of 16 weeks, with the use of a precision scale (Classic series;
Mettler-Toledo). Low birth weight (LBW), adjusted for age
and sex, was deﬁned as the <10th percentile of the weight
of the pup population born from normal animals (PVG fe-
males " SD males) that were mated in the same room, under
the same housing conditions, and at the same time as our
experiment was carried out (i.e., pups from BC group).
Statistics
Variable values are presented as median and ranges for
continuous variables (except for the weights of the pups,
which are expressed as means and standard deviation) or ab-
solute values and percentages for categoric variables.
Normality of the data was tested with the use of normality
plots and Shapiro-Wilk and Kolmogorov-Smirnov tests.
Data following a normal distribution were compared with
the use of the analysis of variance test. Nonnormal distributed
data were compared with the use of the Kruskal-Wallis test.
Categoric variables were compared with the use of the chi-
square test and the Fisher exact test when needed. Differences
showing P< .05 were considered to be signiﬁcant.
RESULTS
Surgical Outcomes
To achieve group sizes of 10 animals per intervention group,
10 rats were operated in the Sham group, 10 in the ShamþTac
group, and 14 in the UTþTac group. There were different
causes for exclusions in the latter group: one animal died
during the ﬁrst postoperative day, the cause being intra-
abdominal hemorrhage secondary to leakage from the anas-
tomosis site; another animal died from anesthetic
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complications while a miniosmotic pump was being replaced
4 weeks after transplantation; one rat presented a necrotic
uterus during second-look laparotomy 2 weeks after UT;
and the fourth animal was excluded because of extensive
left-side hydronephrosis that was found at second-look lapa-
rotomy. All animals primarily included in the Sham group
and the ShamþTac group had normal appearances at
second-look laparotomy.
Fertility Outcomes
Pregnancy rates were higher in the control groups with sham
surgery (70% in Sham group, 80% ShamþTac group) than in
the UTþTac group (50%), but these differences did not reach
the signiﬁcance threshold. There were no differences between
groups regarding number of living pups or neonatal deaths
(Table 1). Litter size was signiﬁcantly larger, although
showing a great range, in animals of the BCþTac group (13
[range 0–14]) than in the other experimental groups.
Macroscopic Appearance of Uteri
Twenty-nine out of the30 rats of the three experimental groups
showedmacroscopically normal uteri at ocular examination at
the time of cesarean section. One rat in the ShamþTac group
showed a whitish pale uterus with increased size (microscopic
examination is described below in the ‘‘Histologic Evaluation’’
section). This was one of the nonpregnant animals with two
cycles of mating attempts. Mild intra-abdominal adhesions
were seen between the intestines and uterus in 4 out of 10
UTþTac rats. Macroscopic signs of thrombosis or rejection
were not present in any animal of the UTþTac group.
Tacrolimus Levels
Tacrolimus levels were similar between the tacrolimus-treated
animals during mid-pregnancy (UTþTac 1.88 " 0.60 ng/mL,
ShamþTac 1.77 " 0.49 ng/mL, BCþTac 1.92 " 0.45 ng/mL;
n.s.) and at the time of cesarean section/laparotomy (UTþTac
1.50 " 0.20 ng/mL, ShamþTac 1.63 " 0.63 ng/mL, BCþTac
1.71 " 0.48 ng/mL; n.s.).
Histologic Evaluation
Microscopic examination of the uteri of the nonpregnant rats
showed similar endometrial and myometrial patterns in all
experimental groups, except for one animal in the ShamþTac
group that showed evident ﬁbrosis in all uterine compart-
ments. Thrombi were present in both arterial and venous
vessels in that animal. Variations of different phases of the
estrus cycle were seen in uteri from nonpregnant animals,
suggesting that these animals were normally cycling. Evalu-
ation of uteri and placentas of pregnant animals revealed no
major disruptions of placental structures in any of the three
experimental groups. The vascular density in both the suben-
dometrial location and the spongiotrophoblast had a clear
appearance of being lower in the UTþTac group compared
with the Sham and ShamþTac groups (Fig. 1). No differences
were found in pattern or expression of endothelin receptors A
and B when uteri and placentas were compared (Fig. 2).
Weight and Weight Progression of the Offspring
Male pups from UTþTac mothers had higher birth weight than
male offpring from the Sham group (6.2" 0.2 g vs. 5.3" 0.1 g;
P< .001) but not compared with those from the ShamþTac
group (5.9" 0.6 g). There were no differences between experi-
mental groups regarding birth weight of female offspring
(UTþTac 5.5" 0.6 g, ShamþTac 5.3" 0.3 g, Sham5.1" 0.5 g).
Compared with control animals of the breeding colony,
both males and females born from UTþTac mothers had
similar birth weights (UT-Tac males 6.2 " 0.2 g, UT-Tac fe-
males 5.5 " 0.6 g, BC males 5.8 " 0.2 g, BC females 5.2 "
0.3 g; n.s.). The proportion of low-birth-weight pups did not
differ signiﬁcantly between experimental groups (UTþTac
10.5%, Sham 7.7%, ShamþTac 11.3%) or with the BC group
(10% by deﬁnition).
Growth trajectories until postnatal week 16 are shown in
Figure 3. No weight differences were seen at any time point
between female offspring from the different groups. The
male offspring from the UTþTac groups showed a trend to
be heavier compared with the other experimental groups
and to the external breeding colony control groups. This dif-
ference was signiﬁcant from postnatal week 10 (Fig. 3B) but
not at earlier time points.
DISCUSSION
This study evaluates for the ﬁrst time postnatal outcome in an
allogeneic UT setting. The main ﬁnding is that the birth
weight of offspring is not affected. However, vascular density
of the uterus was affected, although placental weights were
unchanged. Moreover, the postnatal growth of male pups
from the UTþTac group was slightly accelerated after post-
natal week 10.
Fertility and perinatal outcomes after UT have already
been reported by our group as well as by other groups in
TABLE 1
Fertility and perinatal outcomes after allogeneic uterine
transplantation.
Outcome UT ShamDTac Sham BC BCDTac
Mating
(1st cycle)
9/10 10/10 8/10 10/10 10/10
Mating
(2nd cycle)
4/6 5/5 6/6 – –
Pregnancy rate 5/10 8/10 7/10 8/10 8/10
Live pups
Mothers 5/5 8/8 7/7 7/8 6/8
Pups 5 (1–7) 2.5 (1–7) 1 (1–5)a 5.5 (0–14) 13 (0–14)a
Stillborns
Mothers 1/5 3/8 0/7 2/8 2/8
Pups 0 (0–1) 0 (0–1) 0 0 (0–7) 0 (0–4)
Neonatal deaths
Mothers 1/5 2/8 1/7 1/8 1/8
Pups 0 (0–2) 0 (0–2) 0 (0–2) 0 (0–1) 0 (0–1)
Note: Values are presented as raw data for dichotomous variables and median (range) for
continuous variables. For each perinatal outcome, ‘‘mothers’’ represent the number of rats
whose offspring presented the event/number of pregnant rats; ‘‘pups’’ represent the median
(range) number of pups per litter size presenting the event. UT¼ uterine transplantation; Tac
¼ tacrolimus; BC ¼ breeding colony.
a Sham vs. BCþTac: P< .05.
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nonrejecting settings in rodents (9, 14, 18) and large animals
(10, 19). In the syngeneic setting of UT, where
immunosuppression is not needed, experiments, evaluating
pregnancy as the main outcome, are mostly testing the
effects of surgery, altered vascular connections, altered
position of the uterus, and denervation of the uterus. The
studies carried out in the syngeneic mouse model with a
heterotopically positioned uterus demonstrated normal birth
weight and normal growth trajectory over 8 weeks after
full-term pregnancies that had been initiated by embryo
FIGURE 1
Histologic sections of uteri from pregnant rats. Hematoxylin and eosin staining. A lower vascular density is seen in the uterine transplantation (UTx)
group. Such decreased vascularization pattern is noticed in both (A) nonimplantation sites and (B) implantation sites. TAC ¼ tacrolimus; L ¼
labyrinth zone; JZ ¼ junctional zone; D ¼ decidual basalis cells; Syn C ¼ syncytiotrophoblast cells; Spo C ¼ spongiotrophoblast cells. Yellow
arrows: maternal vascular compartment; black arrows: Fetal capillary space.
Díaz-García. Offspring after allogeneic uterus transplantation. Fertil Steril 2014.
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transfer (9). Such results were later replicated in the rat ortho-
topic and syngeneic UT model, with pregnancies after sponta-
neousmating (14). In an autologous transplantation setting in
sheep, pregnancy was seen in three out of ﬁve transplant re-
cipientss (three out of four animals that mated), but the
offspring were evaluated only at birth (10). There is also a
case report of live offspring after autologous UT in a primate
species (cynomolgus macaque); a cesarean section was ur-
gently performed after diagnosis of placental abruption in
pregnancy day 143, but resuscitation of the neonate was
not performed and consequently no follow-up was performed
on that offspring (19). It should be pointed out that to date,
this is the only reported pregnancy with live offspring in
any primate species.
FIGURE 2
Uteri with immunoﬂuorescence staining. (A) Endothelin A and (B) B receptors show a similar distribution pattern between groups, being expressed
in both epithelial (epi) and stromal (Str) compartments. DAPI ¼ 40,6-diamidino-2-phenylindole; TAC ¼ tacrolimus; Tx ¼ uterine transplantation.
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In an allogeneic setting, the effect of immunosuppression
to avoid organ rejection is an additional nonphysiologic fac-
tor that has to be taken into account. There exist two reports
in the literature describing pregnancies after allogeneic UT. In
2010 we published experiments in which Lewis rats received
uteri from Dark Agouti donors (11). In that particular exper-
imental design, involving monotherapy with tacrolimus,
pups were delivered at day 17 of pregnancy (term pregnancy
is 20 days) because the major end point was pregnancy rate.
Subsequently, a study of allogeneic UT in sheep, with the
use of immunosuppression by cyclosporine, described a single
preterm lamb born at day 138 of pregnancy (20). Pregnancies
in a nonhuman primate species after allogeneic UT have not
yet been demonstrated.
The fertility rate in the UTþTac group of the present study
is similar to that of our previous study in an allogeneic rat UT
setting (11). Animals in all three experimental groups of the
present study had smaller litter sizes than animals of the
breeding colony. A plausible explanation of this is the 50%
reduction of potentially implantable endometrium, because
all animals of the experimental groups had undergone surgi-
cal excision of one uterine horn. The animals of the breeding
colony groups (BC and BCþTac) were intact and had normal
bicornuate uteri.
Overall, our data regarding pregnancy rates suggest that
the implantation potential of a transplanted uterus is not
impaired compared with a native one. Another fact support-
ing this hypothesis is that offspring born from UTþTac
mothers did not show lower birth weights or a higher rate
of low birth weight than offspring from the Sham group or
the breeding colonies, suggesting that the blood ﬂow entering
the graft is enough to support a normal pregnancy. If the
pregnancy-related increase in uterine blood ﬂow to the graft,
through the single uterine-iliac arterial vascular tree, in com-
bination with the side-positioned outﬂow from the native
common iliacs, would be restricted or decreased to a large
extent, the birth weight should have been reduced. Experi-
mental data in several animal species indicate a direct rela-
tionship between uterine blood ﬂow and size of offspring.
In a model with experimentally lowered uterine blood ﬂow
during pregnancy in the rat, the reduced uteroplacental perfu-
sion affected birth weight of the offspring, regardless of
whether the reduction was initiated before (day 12) or after
(day 14) the initiation of the physiologic substantial fetal
growth increase (21).
The morphologic analysis in the present study showed
that microvessel densities were decreased in both the uterus
and the placenta of the UTþTac group. Importantly, this
was not seen in the ShamþTac group, which would indicate
that it is an effect solely of the surgical tissue trauma, dener-
vation, and altered vascular supply/drainage after UT, or of
those factors in combination with added negative inﬂuences
of tacrolimus. Despite the change in microvascular density,
fetal growth was not affected. This could be explained by
the fact that the complex and not completely understood
(22) mechanisms controlling uteroplacental blood ﬂow are
multifaceted and that compensatory mechanisms exist and
neutralize any possible negative effect on fetal growth by
the impaired microvascularization.
In the present study we also examined the expression of
endothelin and its receptor in the uterine tissue. Endothelin
is a potent vasoconstrictive substance released by endothelial
cells. Several studies suggest a link between altered expres-
sion of endothelin and its receptor in the uteroplacental
unit and obstetrical complications. The local levels of endo-
thelins are increased up to three times in uteroplacental disor-
ders such as preeclampsia and fetal growth restriction (23, 24).
Endothelin receptors in patients with preeclampsia and low-
birth-weight offspring are usually down-regulated in utero-
placental circulation. This probably reﬂects a mechanism
FIGURE 3
Comparison of weight evolution between pups from the different experimental groups and the two breeding colonies. The y-axis presents the
weight in grams, and the x-axis presents the age in days. Data are presented for (A) female and (B) male offspring. Abbreviations as in Figure 1.
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aiming to maintain the maternal blood supply to the fetus
(22). In the present study, such down-regulation was not
seen in any placental sample from either group, indicating
that endothelin-mediated responses in the uteroplacental cir-
culation are not dysregulated by UT or immunosuppression.
In summary, this is the ﬁrst report evaluating postnatal
outcome of offspring after allogeneic UT in any species. The
data showing normal growth up to an age well after sexual
maturation, despite pregnancy in a uterine graft under immu-
nosuppression, indicates that allogeneic UT may be regarded
to be a safe procedure in terms of perinatal outcomes. Howev-
er, one has to bear in mind that these results come from a ro-
dent species and that it could not directly be extrapolated to
larger animals, including nonhuman primates and humans.
Moreover, further research is needed to ascertain that the
offspring after allogeneic UT also develop normally at older
ages and that the phenotype is normal when examining mul-
tiple aspects. Such investigations are underway in our
research group; the cohort of pups from this study were fol-
lowed for 24 months, which represents two-thirds of the life
of a rat, and aspects such as behavior, metabolism, urinary
function, and fertility have been recorded for phenotype char-
acterization. The subsequent analysis of these data will pro-
vide further information to characterize the safety of UT.
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SUPPLEMENTAL FIGURE 1
Schematic illustration of the study design. UTxþTAC ¼ allogeneic uterine transplantation and immunosuppression by tacrolimus; ShamþTAC ¼
surgical removal of the left uterine horn and immunosuppression by tacrolimus; Sham ¼ surgical removal of the left uterine horn without any
immunosuppressiion; BC ¼ external breeding colony; BCþTAC ¼ external breeding colony and immunosuppression by tacrolimus. All animals
under immunosuppression were administered tacrolimus at a dose of 0.4 mg/kg/d for 8 weeks and then 0.2 mg/kg/d until the end of the
experiment.
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“What this paper adds”  
What is already known on this subject: 
Data issued from case reports, case series and voluntary registries suggest that pregnant 
women transplanted with solid organ present increased rates of adverse perinatal outcomes 
such as pre-eclampsia, preterm delivery and small for gestational age. Given the source of 
such information, incomplete data collection and selection bias is likely to occur. 
What this study adds to the subject: 
Our findings suggest a somewhat lower risk of preeclampsia and preterm delivery than 
previously reported in the literature. This study also suggests that the observed increase in 
adverse perinatal outcome could be explained by the underlying disease motivating the 
transplantation and not by the transplantation itself. From a methodological point of view the 
strength of the present study is that being a nationwide population-based study, the cohorts 
include pregnancies from virtually all transplanted women and non-transplanted women 
taking place during the study period, so that the risk of introducing bias is minimized. 
Summary statistics: 
A total of 195 deliveries after transplantation were identified, in which the majority occurred 
during 1990-2009. The absolute risks of preeclampsia (21.6%, 42/195) and preterm delivery 
(34.0%, 66/195) were lower than previously reported. In comparison to the general female 
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population, transplanted women had increased risk of preeclampsia (AOR: 6.5, 95%CI: 5.0-
9.1), preterm delivery (AOR: 7.1, 95%CI: 5.3-9.6) and cesarean section (AOR: 9.7, 95%CI: 
7.2-13.0). The infants had increased risk of small-for-gestational-age (AOR: 2.5, 95%CI: 1.7-
3.5), low birth weight (AOR: 2.7, 95%CI: 1.7-4.1), stillbirth (AOR: 2.9, 95%CI: 1.2-7.0) and 
perinatal death (AOR: 3.2, 95%CI: 1.5-6.7), but the risk of congenital malformations was not 
increased (AOR: 1.6, 95%CI: 0.8-3.3). No increase in adverse perinatal outcome was found 
when comparing pregnancies before transplantation with pregnancies after transplantation. 
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ABSTRACT 
Objective: To compare the risk of adverse perinatal outcome in pregnant women before and 
after transplantation and to that of non-transplanted women. 
Design and setting: Cross-linked population based nation-wide retrospective cohort study 
including 130 pregnant women transplanted with a solid organ and 2511202 non-transplanted 
pregnant women. The study period was 1967-2009. All pregnancies were registered in the 
Medical Birth Registry of Norway (MBRN). Transplanted patients were identified through 
the Transplantation registry from Oslo University Hospital. Perinatal outcomes are 
systematically reported to the MBRN. Adjusted risk estimates for adverse perinatal outcomes 
were obtained using logistic regression analysis. 
Results: A total of 195 deliveries after transplantation were identified, in which the majority 
occurred during 1990-2009. The absolute risks of preeclampsia (21.6%, 42/195) and preterm 
delivery (34.0%, 66/195) were lower than previously reported, but an increasing preterm (<37 
and <34 weeks) delivery proportion over time was found. In comparison to the general female 
population, transplanted women had increased risk of preeclampsia (AOR: 6.5, 95%CI: 5.0-
9.1), preterm delivery (AOR: 7.1, 95%CI: 5.3-9.6) and cesarean section (AOR: 9.7, 95%CI: 
7.2-13.0). The infants had increased risk of small-for-gestational-age (AOR: 2.5, 95%CI: 1.7-
3.5), low birth weight (AOR: 2.7, 95%CI: 1.7-4.1), stillbirth (AOR: 2.9, 95%CI: 1.2-7.0) and 
perinatal death (AOR: 3.2, 95%CI: 1.5-6.7), but the risk of congenital malformations was not 
increased (AOR: 1.6, 95%CI: 0.8-3.3). No increase in adverse perinatal outcome was found 
when comparing pregnancies before transplantation with pregnancies after transplantation. 
Conclusions: Transplanted women have a high risk of adverse pregnancy outcome when 
compared to the general population. Notably, our findings suggest a somewhat lower risk of 
preeclampsia and preterm delivery than has previously been reported from registries on 
pregnancies after transplantation. Such increase in adverse perinatal outcome could be 
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explained by the underlying disease motivating the transplantation and not by the 
transplantation itself.
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Introduction 
In the early era of solid organ transplantation, great concerns about possible teratogenic 
effects of immunosuppressive agents were raised 1 and the general advice was to avoid 
pregnancy.2-4 Today, more than 50 years after the first birth from a transplanted women,5 
planned pregnancies in transplanted females are common, with more than 14000 births being 
reported up to 2006 in the three transplantation-pregnancy registries that cover USA and 
Europe.3 Increased rates of adverse perinatal outcomes such as preeclampsia, preterm delivery 
and small for gestational age were reported in the data from these registries. Importantly, no 
such study has found any increased risk of fetal malformation after in utero exposure to 
standard immunosuppressive drugs.3 The current knowledge of possible adverse effects of 
immunosuppressants, in relation to pregnancy and perinatal outcomes, and the resulting 
guidelines for antenatal management of these patients are mainly based on data accumulated 
from single case reports, case series or studies from voluntary registries,3 in which incomplete 
data collection and selection bias is likely to occur. 
The objectives of the current study were to assess the risks of congenital malformations and 
adverse outcomes of pregnancy, delivery and the perinatal period in pregnancies after 
maternal solid organ transplantation in Norway, with data obtained from two large and 
complete databases spanning a period of 40 years.  
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Material and methods 
Data source and study population 
A national cross-linked population-based cohort study was designed, using data from the 
Medical Birth Registry of Norway (MBRN) and the Transplantation registry from Oslo 
University Hospital, from 1967 to the end of 2009. The MBRN was established in 1967 by 
the Norwegian Directorate of Health and was the first complete national medical birth registry 
in the world. It is based on compulsory notification of all live births and stillbirths, initially 
(1967-2001) registered from gestational week 16 and since 2002 from week 12. A 
standardized notification form is used to collect data on demographic variables, maternal 
health before and during pregnancy, previous reproductive history, complications during 
pregnancy and delivery as well as pregnancy outcomes. The form is completed by the 
midwife or the attending obstetrician and was unchanged from 1967 up to and including 1998, 
with the exception of the addition of Apgar scores in 1978. In 1999, a new and more detailed 
form was introduced, in which smoking habits and ultrasound-based estimated dates of 
parturition were included. All records in the MBRN are matched with the files of the Central 
Person Register to ensure medical notification of every newborn in Norway6 and to collect 
dates of deaths.  
All transplanted males and females were identified from the Transplantation registry of Oslo 
University Hospital. Oslo University Hospital has since 1969 kept complete records of all 
transplanted patients in the country. Renal transplantation was the only type of transplantation 
conducted in Norway during the initial 15 years of the study period (1969-1984). Our analysis 
included all female patients that received a transplant during the period from January 1969 up 
to and including 2009. Transplanted males were identified to exclude any pregnancy 
emerging from couples with both parents being immunosuppressed, and thereby to exclude 
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possible influences carried over from the male.  Linkage between the Transplantation registry 
from Oslo University Hospital and the MBRN was performed by utilizing the unique personal 
identification number given to every Norwegian citizen. Information about type of 
transplanted organ and date of transplant were collected from the Transplantation registry, 
whereas data on pregnancy, delivery, perinatal complications and congenital malformations 
were obtained from the MBRN.  
 
Definitions 
Preeclampsia, induction of labor, operative vaginal delivery (forceps or vacuum delivery) and 
cesarean section has been registered in the MBRN since its start. The following sources of the 
MBRN were available to estimate gestational age: 1) last menstrual period (registered from 
1967) and 2) expected date of parturition according to ultrasound (registered from 1999). The 
latter source was used if available and preterm delivery was defined as a delivery occurring 
<37 completed weeks of gestation. Small for gestational age (SGA) was defined as an infant 
birth weight by gestational age that was below the 10th percentile according to a national birth 
weight standard based on data from the MBRN.7 This criterion is in accordance with common 
clinical practice.7 Similarly, and in accordance with the same national birth weight standard, 
large for gestational age was defined as infant birth weight by gestational age above the 90th 
percentile. Low birth weight (LBW) was defined as infant birth weight below 2500g.  
Perinatal mortality included fetal death in utero (stillbirth, from week 23+0) and death within 
seven days after birth. Congenital malformations are registered as ICD-8, 9 and 10 codes in 
the MBRN and were defined as major malformations, i.e., not including insignificant 
diagnoses in accordance with a previously used definition.8 Data were divided into four time 
periods (1969-1979, 1980-1989, 1990-1999 and 2000-2009).  
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Statistical analysis 
Proportions were compared using the chi-square test; continuous variables were compared 
using the Student-t test and p-values below 0.05 were considered statistically significant. Risk 
estimates were calculated as odds ratios (OR) and adjusted odds ratios (AOR) with 95% 
confidence intervals (CI) using logistic regression analysis (IBM SPSS Statistics 20.0.0 SPSS 
Inc, Chicago, IL, USA). Adjustments for maternal and paternal age, parity, and year of 
delivery were performed if not stated otherwise. Couples in which both mother and father had 
been transplanted were excluded. Pregnancies from mothers who had undergone organ 
transplantation after giving birth were excluded from comparative general population. 
Perinatal outcomes of patients giving birth both before and after transplantation were 
compared using the most recent birth before transplantation and the first one after 
transplantation. In these patients, McNemar’s test was used to compare proportions of events, 
conditional regression analysis was performed using a propensity score controlled for the 
same confounding factors controlled when comparing to the general population (R software, 
Matching -v.4.8-3.1- and Ime4 -v. 1.0-4- packages).9 Associations were considered 
statistically significant if the CI did not include 1.  
 
Ethical review board approval 
The regional ethics committee in Southern Norway approved the study (REK Sør-Øst A 
2010/2028a-2).  
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Results 
A total of 2511202 births were reported in the general population during the time period 
(1967-2009) and 195 births were from 130 mothers after transplantation (1969 to 2009). The 
majority of pregnancies in the transplanted group (Fig. 1) occurred among renal transplant 
patients (170 pregnancies, 87%). The other types of organ transplantations were 
kidney+pancreas (7 pregnancies, 3.6%), kidney+liver (1 pregnancy, 0.5%), liver alone (13 
pregnancies, 6.7%) and thoracic organs (4 pregnancies, 2.1%). Number of deliveries by time 
period for the 195 deliveries is illustrated in Fig. 1. The vast majority (80.5%) of the 195 
deliveries occurred during the last two decades (after 1990). 
Demographic characteristics of all pregnancies are shown in Table 1. The ages of both the 
mother and the father of the maternal transplant group were higher, but the parity was lower 
than in the general population.  
Numbers, percentages and crude and adjusted odds ratios for pregnancy and perinatal 
outcomes are shown in Table 2. Almost 22% of all pregnancies after organ transplantation 
developed preeclampsia, which is a more than 6 times increased risk (AOR: 6.5, 95%CI: 5.0-
9.1) as compared to the general population.  
The proportion of preterm delivery before 37 weeks among transplant patients was 34%, as 
compared to 6.1% in the general population (AOR: 7.1, 95%CI: 5.3-9.6).  
At separate analysis of the renal transplant patients, we found almost similar overall 
proportions for preeclampsia (20.6%) and preterm delivery (34.1%) as in the total (n = 195) 
transplant population. The proportions of preterm delivery (<37 and <34 gestational weeks) 
after renal transplantation increased significantly over time (p-trend= 0.017 and 0.002, 
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respectively: Figure 2). The proportions of preeclampsia in this renal transplant subgroup for 
the four time periods were: 14.3, 19.4, 11.7 and 29.2%, respectively (p-trend=0.10). 
 
The overall proportion of cesarean section was 62.4 % and the corresponding adjusted odds 
ratio was 9.7 (7.2-13.0). This proportion was 71.4% during the time period 1967-79 and 
64.4% in 2000-09. 
 In a sub-analysis of the type of cesarean section (emergency or planned) with recorded data 
from during the time periods 1990-1999 and 2000-2009, the proportion of planned cesarean 
sections increased both among the transplanted group and in the general population 
(transplanted: 45.7% vs 60.9%, p<0.001; non-transplanted: 37.5% vs 45.4%, p<0.001).  
Numbers, percentages and crude and adjusted odds ratios for adverse perinatal outcomes and 
major malformations are shown in Table 3. Infants of transplanted women were at increased 
risk of SGA (AOR: 2.5, 95%CI: 1.7-3.5) and of LBW (AOR: 2.7, 95%CI: 1.7-4.1). They 
were also at increased risk of stillbirth (AOR: 2.9, 95%CI: 1.2-7.0) and perinatal death (AOR: 
3.2, 95%CI: 1.5-6.7). The risk of major malformations was not significantly increased (AOR: 
1.6, 95%CI: 0.8-3.3), but numbers were small. Of the 8 registered major malformations, 6 
occurred among 87 deliveries during 2000-2009, giving an overall proportion of 6.9%. This 
malformation rate was 8.3% when assessing patients with renal transplants alone. 
We also analyzed the births after transplantation in comparison to the births of the same 
women before transplantation. In transplanted patients, 1192 transplanted mothers gave birth 
to 2260 newborns before transplantation. After controlling for confounding factors, no 
increase in adverse perinatal outcome was found when comparing pregnancies before 
transplantation with pregnancies after transplantation (the exact numbers and risk estimates 
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are added in the supplementary appendix in Tables 1 and 2). To avoid mixing independent 
and dependent observations, perinatal outcomes were further compared in patients giving 
birth after and before transplantation (Table 4). This part of analysis only included the most 
recent birth before transplantation and the first birth after transplantation in patients having 
more than one birth prior to or after transplantation. In this analysis births after transplantation 
showed a lower incidence of all adverse perinatal outcomes, although no statistically 
significant differences were evident, except for cesarean section, which was more prevalent 
after transplantation (OR: 3.2, 95%CI: 1.0-10.1). 
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Discussion 
The present study represents a unique complete nationwide population-based study to assess 
the outcomes of pregnancy and neonates of immunosuppressed mothers with solid organ 
transplants. The major findings of the study are that of major (> 6-fold) increments of 
preeclampsia and preterm delivery rates among females with organ transplants.  
 
The number of births worldwide from transplanted mothers are today likely to be more than 
20000, based on the fact that more than 14000 births were reported in 2006 to the three major 
voluntary registers of pregnancy in transplanted patients and that these registries mainly cover 
Europe and the USA.3 There would most likely exist underreporting into these registries. 
Furthermore, the recent introduction of new types of organ and composite tissue 
transplantations, the development of assisted reproductive technologies and the increased 
survival of transplant patients will most likely lead to an increased birth rate among 
immunosuppressed women that have undergone transplantation.  
In our study, encompassing a period from the late 1960s up until today, it was found that more 
than 80% of all pregnancies after solid organ transplantation in Norway occurred after 1990 
and 87% of these pregnancies were after renal transplants. This was expected, as rather few 
patients were transplanted during the early time periods of the study and renal transplantation 
alone represents the majority of all organ transplants in most countries. 
 
Frequent pregnancy complications, as seen in the present study, confirm earlier findings of a 
generally increased risk of several pregnancy-associated problems that may affect both the 
transplanted mother and her infant, when compared to the general population of pregnant 
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women. Our finding of 22% preeclampsia among the transplanted females is somewhat lower 
than previously reported in large studies of data from voluntary registries 3.  The preeclampsia 
proportion for all transplanted patients found in data from the UK Transplant Pregnancy 
Registry was 36% and in the US National Transplant Pregnancy Registry it was 29%10. A 
validation study of preeclampsia in the MBRN showed that registered preeclampsia 
corresponds well with medical records.11 A recent study on trends for preeclampsia in 
Norway also concluded an increase in the condition over the period 1967-98, due to an 
improved case ascertainment over time.12 A predisposing factor for preeclampsia in renal 
transplant patients is that a large proportion of these patients experience both hypertension 
and proteinuria after transplantation, which may make them more prone to develop 
preeclampsia. There is little reason to believe that the findings of the present study, with 
comparatively lower preeclampsia rates, were due to underreporting, at least not in the latter 
periods. Also, the compulsory nature of the MBRN should lead to valid data. The overall 
preeclampsia proportion in this study is similar to data from a Swedish population-based 
study of births after maternal organ transplantation.13  Interestingly, our data shows that the 
proportion of preeclampsia does not increase over time and it could thus not explain the 
observed increase seen in preterm delivery. 
A striking difference in our results compared to previous reports from voluntary registry data 
is the much lower preterm delivery proportion that we report.3 10 14-18 The overall rate of 
preterm delivery in our material of transplanted mothers was 34% and, in a sub-analysis of 
time trends, revealed an increase over time.  Previous studies with data mostly accumulated 
from voluntary transplant pregnancy registries from Europe, UK and the US have indicated 
rates of preterm delivery of around 50%, but with some variations depending on type of organ 
transplantation. The very high odds ratio of preterm delivery (7.1) in our material, despite the 
Page 14 of 30
http://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
15 
 
relatively lower rate of preterm birth, is due to a very low preterm delivery proportion in the 
general population (6.1 %), which is about half of what is reported in the general US 
population.19 This difference in overall preterm delivery proportion may also be partly 
dependent on differences in routines for delivery of high-risk pregnancies. 
Differences may exist in preterm rate depending on the mother’s specific type of transplanted 
organ. Earlier studies have indicated an increased rate of preterm delivery among renal 
transplant patients as compared to liver or heart transplant patients.3 However, the proportion 
of preterm delivery in our data was similar when examining renal transplant patients alone as 
compared to the entire group of transplanted women.  
When analyzing births before and after transplantation, we could not detect any significant 
increase in adverse perinatal outcomes after adjustment for confounding factors. These data 
are in line with those published by Kallen and coworkers,13 suggesting that the morbidity 
status of the patients could be the underlying cause of adverse outcomes. Moreover, when 
comparing births within the same patient before and after transplantation, we found a lower 
rate of preeclampsia, preterm birth, growth restriction problems and perinatal mortality, 
indicating that the transplant may have a protective effect on both fetus and mother. This 
could be explained by a better general health of the women after transplantation, which of 
course may be partly counterbalanced by possible negative effects of immunosuppression. It 
bears mentioning that, in our series, the incidence of adverse pregnancy events was lower than 
in the previous publication, which compared pregnancies before and after transplantation.13 
The risk of being subjected to cesarean section in the transplanted patients was high. 
Interestingly, the rate of planned cesarean section increased over time in transplanted women. 
This increase was also seen in the general population. A plausible explanation for the 
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increased planned cesarean section rate among the transplanted patients is that this subgroup 
would follow the general trend, although it is not necessarily medically motivated. 
Strengths and limitations 
The completeness and the compulsory data collection of the MBRN and the Transplantation 
registry at Oslo University Hospital enabled identification of all transplanted and non-
transplanted women and men in the country becoming parents during the last four decades. 
This is a complete nationwide population-based study on pregnancy, delivery and perinatal 
outcome in transplanted females. Norway has a national health care system, where priority 
assignment of patients is determined by the parliament in terms of laws and regulations.20 
This should guarantee that the patients were treated uniformly during their pregnancies, 
regardless of their geographic location within Norway. The Norwegian Society for Obstetrics 
and Gynecology has, for almost 20 years, had national guidelines for management of all 
pregnancies in the country, contributing to equitable care of pregnancies and its complications 
throughout the country. Norway was ranked second highest among OECD countries in 2010 
(after the United States) in terms of health care spending per capita (www.oecd.org). All in-
patient care is provided free of charge21 and public resources accounted for 85.5% of health 
care spending in the country (www.oecd.org).  
Despite strengths of the study, we are aware that there are some limitations. The majority of 
transplanted patients (87%) were renal patients and consequently firm conclusions 
considering pregnancies of mothers with other types of organ transplants are impossible. The 
various congenital malformations are rare events, which also makes it difficult to draw 
conclusions about risks related to any specific malformations, as previous studies have 
encountered. However, there was no increased risk for congenital malformations overall, 
which is reassuring news for all transplanted women planning for pregnancy. It should also be 
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pointed out that the fetal immunosuppression exposure during the entire pregnancy may 
induce more subtle changes in the child, which is not detected at birth and may well be related 
to small changes in the immune system of the child. Thus, there exist case reports suggesting 
increased prevalence of autoimmune disease later in life among those born from transplanted 
mothers.22 
The low number of patients and events when comparing births before and after transplantation 
in the same patient did not allow us to control for confounding factors when the regression 
analysis with propensity score was applied. As each patient was her own control and births 
were successive and close in time, we do believe that potential confounders would play little 
or no role in modifying risk estimates.  
Conclusions 
The completeness of the data presented in the current study provides near accurate risk 
estimated for pregnancy complications in transplanted females. The preterm and preeclampsia 
rates were increased 6- and 7-fold over the general population. The SGA rate was increased 
2.5 fold. More important, no increased rate of major malformations was found. It is concluded 
that pregnancies of transplanted mothers should always be regarded as high risk.  
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Table 1. Demographic characteristics of the general population and pregnancies after solid organ transplantation, Norway 1969-2009. 
 General population After transplantation  
Fathers 
 
Age group    
      <19 31782 (1.3) 1 (0.5)  
 
 
p<0.001 
      20-24 380835 (15.3) 12 (6.5) 
      25-29 780008 (31.4) 45 (24.2) 
      30-34 709725 (28.6) 47 (25.3) 
      35-39 378431 (15.2) 46 (24.7) 
      40-44 141177 (5.7) 25 (13.4) 
      45-49 44245 (1.8) 4 (2.2) 
      >50 17388 (0.7) 6 (3.2) 
      Total 2483591 (100.0) 186 (100.0)  
Mothers 
 
Age group    
      =<19 143372 (5.7)  2 (1.0)  
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      20-24 649775 (25.9) 27 (13.0)  
 
p<0.001 
      25-29 857129 (34.1) 58 (29.7) 
      30-34 589846 (23.5) 63 (32.3) 
      35-39 228408 (9.1) 43 (22.1) 
      >=40 42724 (1.7) 2 (1.0) 
      Total 2511154 (100.0) 195 (100.0)  
Parity    
      0 1038409 (41.4) 105 (53.8)  
 
p<0.001 
      1 873136 (34.8) 72 (36.9) 
      2 409303 (16.3) 17 (8.7) 
      3  126986 (5.1) 1 (0.5) 
      >=4 63368 (2.5) 0 (0.0) 
      Total 2511202 (100.0) 195 (100.0)  
Multiple pregnancies    
Births from twin pregnancies 66836 (2.7) 8 (4.7) n.s. 
Total 2511202 (100.0) 195 (100.0)  
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Table 2. 
Complications during pregnancy and delivery when comparing pregnancies after transplant in mothers with pregnancies in the general 
population, Norway 1969-2009. Odds ratios (OR) with 95% confidence intervals (CI) were obtained using logistic regression analysis and 
adjusted for year of birth, mothers and fathers age, parity and plurality. 
 195 births after 
transplant 
n (%) 
2511202 births in the 
general population 
n (%) 
Crude  
OR (95% CI) 
Adjusted 
OR (95% CI) 
Preeclampsia 42 (21.6) 77457 (3.1) 8.7 (6.2-12.2) 6.5 (5.0-9.1) 
Preterm delivery (<37 weeks) 66 (34.0) 154027 (6.1) 7.9 (5.8-10.6) 7.1 (5.3-9.6) 
Preterm delivery (<34 weeks) 28 (14.4) 51575 (2.1) 8.0 (5.4-12.0) 7.5 (5.0-11.1) 
Induction of labor 46 (23.7) 387823 (15.4) 1.7 (1.2-2.4) 1.6 (1.2-2.2) 
Operative vaginal delivery 10 (5.2) 170490 (6.8) 1.3 (0.7-2.5) 0.5 (0.2-0.9) 
Caesarean section 121 (62.4) 257660 (10.3) 15.0 (10.8-19.4) 9.7 (7.2-13.0) 
Apgar<7 at 5 min 2 (1.1) 26779 (1.5) 0.7 (0.2-2.9) 0.6 (0.2-2.6) 
*Only 185 transplanted patients and 1798146 non-transplanted patients were considered in the analysis of this variable 
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Table 3. 
Perinatal complications and malformations when pregnancies after transplant were compared to pregnancies in the general population, Norway 1969-2009. 
Odds ratios (OR) with 95% confidence intervals (CI) were obtained using logistic regression analysis and adjusted for year of birth, mother’s age and parity. 
Low birth weight was also adjusted for gestational age. 
 195 births after 
transplant 
n (%) 
2511202 births in the 
general population 
n (%) 
Crude  
OR 
(95% CI) 
Adjusted 
OR 
(95% CI) 
Small for Gestational Age 
(<10 percentile)* 
42 (22.7) 269944 (11.3) 2.3 (1.6-3.2) 2.5 (1.7-3.5) 
Large for Gestational Age  
(>90 percentile)* 
4 (2.2) 227807 (9.6) 0.2 (0.1-0.6) 0.21 (0.1-0.6) 
Low Birth Weight 57 (29.4) 131130 (5.2) 7.5 (5.5-10.3) 2.7 (1.7-4.1) 
Stillbirth 5 (2.6) 26081 (1.0) 2.5 (1.0-6.1) 2.9 (1.2-7.0) 
Perinatal mortality 7 (3.6) 36554 (1.5) 2.5 (1.2-5.4) 3.2 (1.5-6.7) 
Major malformations 8 (4.1) 52359 (2.1) 2.0 (0.99-4.1) 1.6 (0.8-3.3) 
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Table 4. 
Complications during pregnancy and delivery and perinatal outcomes when comparing pregnancies before and after transplantation in the same 
patient. Norway 1969-2009. O ds ratios (OR) with 95% confidence intervals (CI) were obtained using logistic regression analysis and adjusted 
for year of birth, mothers and fathers age, parity and plurality. Low birth weight was also adjusted for gestational age. 
 
 26 births after transplant 
n (%) 
26 births before transplant 
n (%) 
Crude OR 
(95% CI) 
Preeclampsia 5 (19.2) 7 (26.9) 0.6 (0.2-2.4) 
Preterm delivery (<37 weeks) 10 (38.5) 10 (38.5) 1 (0.3-3.1) 
Induction of labor 5 (19.2) 11 (42.3) 0.3 (0.1-1.1) 
Operative vaginal delivery 1 (3.8) 3 (11.5) 0.3 (0.0-3.2) 
Caesarean section 19 (73.1) 12 (46.2) 3.2 (1.0-10.1) 
Small for Gestational Age (<10 percentile) 6 (23.1) 8 (30.8) 0.6 (0.2-2.2) 
Large for Gestational Age  (>90 percentile) 0 0  
Low Birth Weight 11 (42.3) 13 (50) 0.7 (0.2-2.2) 
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Stillbirth 1 (3.8) 5 (19.2) 0.2 (0.0-1.6) 
Perinatal mortality 1 (3.8) 5 (19.2) 0.2 (0.0-1.6) 
Major malformations 1 (3.8) 1 (3.8) 1 (0.1-16.9) 
*Only the last birth before transplantation and the first birth after transplantation were considered in the analysis. 
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Figure Legend 
 
Figure 1  
Number of pregnancies after solid organ transplantation by time period, Medical Birth 
Registry of Norway, 1969 to 2009. 
 
Figure 2 
Proportion of preterm delivery (PTD) in pregnancies after kidney transplantation by time 
period, Medical Birth Registry of Norway, 1969-2009. 
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Figure 1 
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Figure 2 
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Supplementary Table 1. 
Complications during pregnancy and delivery when comparing pregnancies after and before transplantation, Norway 1967-2009. Odds ratios 
(OR) with 95% confidence intervals (CI) were obtained using logistic regression analysis and adjusted for confounders as given. 
 2260 births before 
transplant 
n (%) 
 
195 births after 
transplant 
n (%) 
Crude  
OR 
(95% CI) 
Adjusted 
OR 
(95% CI) 
Preeclampsia 244 (10.8) 42 (21.6) 2.3 (1.6-3.3) 0.97 (0.63-1.49) 
Prelabor rupture 
of membranes 
52 (2.3) 12 (6.2) 2.8 (1.5-5.3) 1.47 (0.67-3.20) 
Bleeding during 
pregnancy 
127 (5.6) 32 (16.5) 3.3 (2.2-5.0) 1.27 (0.77-2.10) 
Preterm delivery 
(<37 weeks) 
318 (14.1) 66 (34.0) 3.1 (2.3-4.3) 1.32 (0.91-1.94) 
Induction of labor 489 (21.6) 46 (23.7) 1.1 (0.8-1.6) 0.73 (0.49-1.07) 
Operative vaginal 
delivery 
115 (5.1) 10 (5.2) 1.0 (0.5-2.0) 0.57 (0.27-1.21) 
Caesarean section 342 (15.1) 121 (62.4) 9.3 (6.8-12.7) 2.81 (1.95-4.03) 
All OR are adjusted for year of birth, mother’s age and parity.   
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Supplementary Table 2. 
Perinatal complications and malformations when mothers were transplanted, before and after transplantation, Norway 1967-2009. Odds ratios (OR) with 95% 
confidence intervals (CI) were obtained using logistic regression analysis and adjusted for confounders as given. 
 2260 births 
before transplant 
n (%) 
195 births after 
transplant 
n (%) 
Crude  
OR 
(95% CI) 
Adjusted 
OR 
(95% CI) 
Small for Gestational 
Age (<10 percentile)* 
430 (20.4) 42 (22.7) 1.1 (0.8-1.6) 1.16 (0.76-1.76) 
Large for Gestational 
Age  (>90 percentile)* 
175 (8.3) 4 (2.2) 0.2 (0.1-0.7) 0.26 (0.09-0.74) 
Low Birth Weight 325 (14.4) 57 (29.4) 2.5 (1.8-3.5) 1.73 (0.45-1.20) 
Apgar <7 at 5 min* 40 (4.1) 2 (1.1) 0.3 (0.1-1.1) 0.12 (0.03-0.53) 
Stillbirth 75 (3.3) 5 (2.6) 0.8 (0.3-1.9) 0.53 (0.19-1.47) 
Perinatal mortality 106 (4.7) 7 (3.6) 0.8 (0.4-1.7) 0.61 (0.26-1.44) 
Infant death 52 (2.3) 2 (1.0) 0.4 (0.1-1.8) 0.37 (0.08-1.71) 
Major malformations 57 (2.5) 8 (4.1) 1.7 (0.8-3.5) 0.82 (0.34-1.95) 
All OR are adjusted for year of birth, mother’s age and parity. Low birth weight is also adjusted for gestational age. 
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First clinical uterus transplantation
trial: a six-month report
Mats Br€annstr€om, M.D., Ph.D.,a Liza Johannesson, M.D., Ph.D.,a Pernilla Dahm-K€ahler, M.D., Ph.D.,a
Anders Enskog, M.D., Ph.D.,b Johan M€olne, M.D., Ph.D.,c Niclas Kvarnstr€om, M.D.,d Cesar Diaz-Garcia, M.D.,f
Ash Hanafy, M.D.,g Cecilia Lundmark, B.Sc.,a Janusz Marcickiewicz, M.D., Ph.D.,a Markus G€abel, M.D.,d
Klaus Groth, M.D., Ph.D.,a Randa Akouri, M.D., Ph.D.,a Saskia Eklind, M.D., Ph.D.,a
Jan Holgersson, M.D., Ph.D.,e Andreas Tzakis, M.D.,h and Michael Olausson, M.D., Ph.D.d
a Department of Obstetrics and Gynecology, b Department of Anesthesiology and Intensive Care, c Department of Clinical
Pathology, d Department of Transplantation, and e Department of Clinical Chemistry and Transfusion Medicine,
Sahlgrenska Academy at University of Gothenburg, G€oteborg, Sweden; f Department of Gynecology and Obstetrics, La
Fe University Hospital, University of Valencia, Valencia, Spain; g Department of Obstetrics and Gynecology, Grifﬁth
University, Gold Coast, Southport, Queensland, Australia; and h Department of Surgery, Cleveland Clinic, Weston, Florida
Objective: To report the 6-month results of the ﬁrst clinical uterus transplantation (UTx) trial. This type of transplantation may become
a treatment of absolute uterine-factor infertility (AUFI).
Design: Prospective observational study.
Setting: University hospital.
Patient(s): Nine AUFI women and their live uterine donors, the majority being mothers.
Intervention(s): Live-donor UTx and low-dose induction immunosuppression.
Main Outcome Measure(s): Data from preoperative investigations, surgery and follow-up for 6 months.
Result(s): Durations of donor and recipient surgery ranged from 10 to 13 hours and from 4 to 6 hours, respectively. No immediate
perioperative complications occurred in any of the recipients. After 6 months, seven uteri remained viable with regular menses.
Mild rejection episodes occurred in four of these patients. These rejection episodes were effectively reversed by corticosteroid boluses.
The two graft losses were because of acute bilateral thrombotic uterine artery occlusions and persistent intrauterine infection.
Conclusion(s): The results demonstrate the feasibility of live-donor UTx with a low-dose
immunosuppressive protocol.
Clinical trial registration number: NCT01844362. (Fertil Steril! 2014;101:1228–36."2014 by
American Society for Reproductive Medicine.)
Key Words: Infertility, human, transplantation, uterus
Discuss: You can discuss this article with its authors and with other ASRM members at http://
fertstertforum.com/brannstromm-uterus-transplantation-2/
Use your smartphone
to scan this QR code
and connect to the
discussion forum for
this article now.*
* Download a free QR code scanner by searching for “QR
scanner” in your smartphone’s app store or app marketplace.
U terine-factor infertility is causedby absence or dysfunction of theuterus. This untreatable condi-
tion, which is either congenital or
acquired, affects 1 in 500 fertile-age
women (1–4), corresponding to
!200,000 women in Europe. Surrogacy
or adoption may be satisfactory options
for many women with uterine-factor
infertility but may be unacceptable for
others owing to ethical, legal, or religious
concerns (5). In Sweden, surrogacy is not
legally approved.
Wehaveexamineduterus transplan-
tation (UTx) as a possible infertility
treatment. During the past decade, we
have stepwise studied and optimized
the procedure in animals, with the aim
of clinical implementation (6–8). The
ethics around UTx are unquestionably
complex and have been the focus of
several publications (9, 10). A controlled
trial on human UTx would shed some
light on important questions, such
as medical and psychologic risks
and beneﬁts. Unlike any other
transplantation currently performed,
UTx is ephemeral; it is not intended for
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lifelong duration. The graft is removed after one or two healthy
babies have been born, to limit the immunosuppression period.
Since the ﬁrst birth in a woman transplanted with a solid
organ half a century ago (11), more than 15,000 babies have
been born to transplanted and immunosuppressed mothers,
with no reported increased risk of fetal malformation (12).
This indicates that human UTx and accompanying immuno-
suppression are compatible with normal pregnancy and
progeny.
There have been two previous UTx attempts, both by
teams with no preceding research records in the ﬁeld. The ﬁrst
case, in 2000, resulted in graft failure with hysterectomy after
3 months (13). The reason for failure was not clear, but the
authors stated that the likely cause was prolapse of the
organ due to poor pelvic ﬁxation, which led to compression
of blood vessels and vascular thrombosis. The second case,
in 2011, involved a uterine graft from a deceased female
multiorgan donor (14). This case has also presented two
pregnancies but with early miscarriage (15).
Our research on UTx started more than 10 years ago (16)
and we have, by a scientiﬁc step-by-step approach, examined
and optimized the UTx procedure. This animal-based research
has been carried out in rodents, large domestic animals, and a
nonhuman primate (7, 8). In 2012, we were granted ethical
permission to conduct a clinical trial on human UTx at
Sahlgrenska University hospital with uteri from live donors.
At the time of writing, the entire cohort of nine recipients,
with their donors, has been monitored for 6 months after
transplantation. In the present paper, we report the
perioperative and 6-month postoperative outcome of the
nine donor-recipient pairs entering the UTx trial.
METHODS
Patients and Pretransplantation Investigations
The Regional Human Ethics Committee approved a study of
up to ten live-donation UTx procedures. We performed two
initial cases in September 2012, and after an extended
observation period of these cases we later decided to
perform a prospective observational study, with the trial
being registered at ClinicalTrials.gov (registration no.
NCT01844362). A preliminary screening process of 30 pro-
spective recipients ended in selection of ten suitable
women. The reasons for exclusion were medical or psycho-
logic risk factors in recipients or planned donors. All of the
recipients and their partners had been thoroughly coun-
seled about their national and international options to
gain parenthood through adoption or surrogacy. Multiple
visits to psychologists and independent doctors (Table 1)
assured that they were fully aware of the research nature
of the trial. In vitro fertilization was performed to exclude
any sterility factor related to fertilization failure and to
cryopreserve embryos for transfer more than 12 months
after transplantation, according to international transplan-
tation recommendations (17). An independent Transplanta-
tion Board ﬁnally assessed each donor-recipient pair and
excluded one pair because the recipient was found to
have bilateral pelvic kidneys. Written informed consents
were obtained from all donors, recipients, and their
partners. All investigation procedures, surgeries, and
follow-up visits were at the Sahlgrenska University
hospital.
The characteristics of recipients and donors are presented
in Table 2. Five of the donors were mothers of recipients, and
four of these were postmenopausal. Eight patients had the
Mayer-Rokitansky-K€uster-Hauser (MRKH) syndrome with
congenital absence of the uterus and vagina (18), and one
recipient had undergone radical hysterectomy for cervical
cancer. All recipients had been in a steady relationship with
their partners forR3 years.
Immunology and Microbiology
Donors' and recipients' human leukocyte antigen (HLA) A, B,
C, DRb1, and DQb1 loci were typed with the use of polymerase
chain reaction (PCR); reverse sequence-speciﬁc oligonucleo-
tides (LABtype; One Lambda) and their degrees of HLA
mismatch (at the A, B, and DRb1 loci) were determined.
HLA antibodies were detected with the use of the Luminex-
based LABscreen panel reactive antibodies assay (One
Lambda). A mean ﬂuorescence intensity (MFI) value >1,000
TABLE 1
Preoperative medical investigations of recipients and donors.
Radiology MRI (abdominal and pelvic)
Chest x-ray
Vaginal ultrasound scan
Clinical Electrocardiography (ECG)
Exercise ECGa
Pap smear
Blood chemistry
Liver function Alanine transaminase (ALT)
Aspartate transaminase (AST)
Alkaline phosphatase (ALP)
Albumin
Total protein
Bilirubin
Kidney function Creatinine
Urea
Electrolytes
Dissolved salts
General Hemoglobin
White blood cells (WBC)
Prothrombin time (PT)
Activated partial thromboplastin time (APTT)
Total particle concentration (TPC)
C-Reactive protein (CRP)
Microbiology Cytomegalovirus (CMV)
Epstein-Barr virus (EBV)
Human immunodeﬁciency virus (HIV)
Hepatitis A, B, C
Chlamydia
Human papilloma virus (HPV)
Gonorrhea
Syphilis
Assessment by
specialist in
Gynecology
Transplantation surgery
Psychology
Clinical immunology
Anesthesiology
Internal medicine
Radiology
Note: MRI ¼ magnetic resonance imaging.
a Donors only.
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above the negative control was considered to be positive. Both
standard complement-dependent cytotoxicity and ﬂow-
cytometric crossmatch tests with the use of T and B lympho-
cytes were performed. Flow cytometry was performed on a
FACScalibur cytometer using a 1,024 linear scale and the
Cellquest Pro software (BD Biosciences). They were also tested
for relevant viral and bacterial infections (Table 1) with stan-
dard techniques. The partners were tested for HIV, hepatitis B
and C, and syphilis.
Anesthesia and Postoperative Medication
Anesthesia was similar in donors and recipients. Before the
start of general anesthesia, a mixture of 10 mg bupivacaine
(Marcain Spinal; AstraZeneca) and 0.1 mg morphine (Morﬁn
Special; Biophausia) was given intrathecally at the L3–4 or
L4–5 level. Subsequent induction of anesthesia started with
intravenous (IV) infusions of remifentanil (Ultiva; GlaxoS-
mithKline) at a rate of 0.25 mg/kg/min, together with a bolus
(2–3 mg/kg body weight [bw]) of propofol (Fresenius), fol-
lowed by 40–50 mg rocuronium bromide (Esmeron; MSD)
intravenously. The patient was then intubated and mainte-
nance anesthesia administered with sevoﬂurane (Sevoﬂuran
Baxter; Baxter) and remifentanil infusion (Ultiva). Anesthesia
depth was monitored and adjusted, with a target minimal
alveolar concentration of 0.5–0.7, and further monitored by
maintaining electroencephalographic and frontal electro-
myographic signal activity (Entropy; GE Healthcare) at a level
of !25%–35%.
Up to 3 L Ringer acetate and 0.5 L dextran-70 (Macrodex;
Meda) were given perioperatively. To maintain ﬂuid balance,
500 mL hydroxyethyl starch (Tetraspan; Braun,) or 20 g albu-
min (Albumin Baxter; Baxter Medical ) was administered as
needed. Dopamine (Giludop; Abcur) infusion was used to
keep mean arterial pressure at a level of >65 mm Hg. An
autologous blood recovery system (Cell Saver; Haemonetics)
was available during surgeries. The surgical duration for
each patient was deﬁned as the period from the ﬁrst skin
incision to completed skin closure.
To reduce postoperative nausea, 4–8 mg ondansetron
(Ondansetron; Braun), 4 mg betamethasone (Betapred; Sobi),
and 0.5–1 mg droperidol (Dridol; Postrakan) were adminis-
tered intravenously at the end of surgery. Paracetamol (Per-
falgan; Bristol-Myers Squibb), parecoxid (Dynastat; Pﬁzer),
tramadol (Tradolan; Nordic Drugs), and morphine (Morﬁn
Meda; Meda) were used as initial postoperative pain relief.
Antibiotics (4 g; Piperacillin/Tazobactam; Farmaplus)
were given once preoperatively and three times daily for 1
day in donors and 3 days in recipients. Thrombosis prophy-
laxis for donors was with dalteparin (5,000 IU; Fragmin;
Pﬁzer) during postoperative days (PODs) 1–21. Thrombosis
prophylaxis for recipients was with acetylsalicylic acid (75
mg; Trombyl; Pﬁzer) once daily throughout the 6-month
follow-up period and with dalteparin (5,000 IU; Fragmin)
during PODs 1–42.
Donor Surgery
Donor surgery involved amidline incision from the pubic bone
to the umbilicus, followed by isolation of the uterus with long
vascular pedicles consisting of the bilateral uterine arteries
and veins up to and including parts of the internal iliac vessels
(Fig. 1A). Substantial parts of the round ligaments and the sac-
routerine ligaments, as well as an extensive sheet of the
bladder peritoneum, were preserved on the graft side to enable
stable ﬁxation of the uterus in the recipient. Bilateral salpin-
gectomy was performed, preserving the uterine branch of
the utero-ovarian vein (Fig. 1A). Dissections on the pelvic
sidewalls included dissection of the ureters from their passages
over the iliac vessel bifurcations distally to their inlets into the
bladder. This included meticulous dissection of the uterine
veins and uterine arteries from their ﬁrm attachments to the
ureters. When the ureters had been completely mobilized
from the cervix and uterine vessels, vascular dissection aimed
at mobilizing the internal iliac arteries and veins started from
the bifurcations of the internal and external iliac vessels and
proceeded distally (Fig. 1A). This dissection included sever-
ance of multiple major vascular branches. The vagina was
transected 10–15 mm caudal to the vaginal fornix, and the
uterus was eventually attached to the donor by only its two
arterial and two venous vascular pedicles. The major feeding
arteries and veins were then clamped and severed, before the
uterus was removed from the pelvis to a back-table setting.
TABLE 2
Subjects' characteristics.
Recipients Donors Partners
n 9 9 9
Age (y) 31.5 " 3.9 53.0 " 7.0 34.3 " 4.0
BMI 22.4 " 1.5 25.6 " 4.2
Previous smoking,
n (%)
3 (33) 4 (44)
Previous abdominal surgery, n (%)
Laparotomy 2 (22) 3 (33)
Laparoscopy 6 (67)
Urogynecologic characteristics, n (%)
Kidney malformation 4 (44)
Single kidney 3 (33)
Unilateral pelvic
kidney
1 (11)
Cause of absent uterus, n (%)
MRKH 8 (89)
Cervical cancer 1 (11)
Type of vagina, n (%)
Normal 1 (11) 9 (100)
Self-dilated 3 (33)
Therapeutically
dilated
1 (11)
Skin 4 (44)
Pregnancies 3.3 " 1.3
Live births 3.0 " 0.9
Deliveries, n (%)
Vaginal 25 (93)
Cesarean section 2 (7)
Menopausal state, n (%)
Premenopausal 4 (44)
Postmenopausal
<5 y 2 (22)
>5 y 3 (33)
Note: Plus-minus values are mean " SD. BMI ¼ body mass index; MRKH ¼ Mayer-Rokitan-
sky-K€uster-Hauser syndrome.
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The clamping points of the donor's internal iliac vessels were
closed with continuous polypropylene (6-0) sutures and the
abdomen was closed in standard three-layered manner. A
suprapubic bladder catheter was inserted to avoid urinary
retention secondary to the extensive dissection around the
bladder. The suprapubic catheter was removed on day 4 or 5
after surgery, when the residual urinary volume had decreased
to <150 mL. Anesthesia was discontinued and the donor was
brought to the postoperative recovery unit.
Graft Preparation
The uterus was quickly brought to the back-table and initially
ﬂushed with 10 mL heparinized saline solution through each
artery, followed by ﬂushing for 10–20minutes with cold pres-
ervation solution (Custodiol HTK-solution; Nordmedica), until
the organwas blanched and the venous efﬂuent was clear. The
graft was kept on ice until transplanted into the recipient. In
some patients, back-table preparation involved anastomosing
(7-0 polypropylene) one ovarian vein end-to-side to the uter-
ine vein (Fig. 1B) to achieve greater venous drainage, whereas
this branch of the ovarian-uterine vein was subsequently
directly anastomosed to the external iliac vein of the recipient
in others (see below). Organ ischemia was divided into three
distinct periods. The ﬁrst warm ischemia period was from
cross-clamping at organ retrieval to commencement of cold
ﬂushing. The cold ischemia period was from initiation of
organﬂushing to as long as the organwas kept on ice. The sec-
ond warm ischemia period was the time from removal of the
organ from ice to blood reperfusion. Because the ﬁrst warm
ischemia period was <2 minutes in all cases, this period was
added to the longer second warm ischemia period and data
on warm ischemia are presented as the sum of these periods.
Recipient Surgery
To synchronize donor and recipient surgeries, thereby avoid-
ing a long cold ischemia period for the uterine graft, a second
team of surgeons started the preparatory surgery of the recip-
ient in an adjacent operating room well before the anticipated
procurement of the organ. This laparotomy also was per-
formed through a subumbilical midline incision. First, the
vaginal vault was dissected free from the bladder and the
rectum. In the eight MRKH patients, the uterine rudiment
had to be cleaved to reach the top of the vagina. Sutures
(1-0 polypropylene) for subsequent organ ﬁxation were
attached to the round ligaments, the sacrouterine ligaments,
and the two lateralized parts of the uterine rudiment (MRKH
patients) or the paravaginal connective tissue (cervical cancer
patient). The surgery was then directed toward preparation of
the external iliac vessels for subsequent anastomosis. The
external iliac artery and vein were bilaterally separated from
each other and from adjacent tissue to a distance of!60 mm.
The uterine graft was then brought, still on ice, into the
recipient's operating room. It was placed in its normal posi-
tion in the pelvis and bilateral end-to-side vascular anasto-
moses were performed between the graft vessels and the
external iliac vessels with the use of continuous 7-0 (arterial
anastomosis) or 8-0 (venous anastomosis) polypropylene
sutures. After each venous anastomosis had been sutured,
the vascular clamp over the external iliac vein was opened.
In some cases, single sutures were used to seal any leakage
from the anastomosis line. In six patients, the uterine branch
of the ovarian-uterine vein was used and anastomosed to the
ipsilateral uterine vein or prepared for direct anastomosis to
the external iliac vein (Fig. 1B). Mannitol (30 g; Mannitol
Baxter Viaﬂo; Baxter Medical) was given as an IV bolus
just before the arterial clamps were removed, and systolic
blood pressure was carefully monitored and maintained at
>100 mm Hg. After completed vascular anastomosis surgery,
adequate blood ﬂow through the uterine arteries of the vessels
was veriﬁed and quantiﬁed with a vascular Doppler probe
(Vascular TTFM Probe; Medistim) placed around the uterine
artery.
The recipient's vaginal vault was then opened by a longi-
tudinal incision of !40 mm. The vaginal rim of the graft was
anastomosed to the top of the recipient0s vagina with a
FIGURE 1
Overview of transections, ligations, and anastomosis lines at uterus transplantation. (A) Schematic drawing of the arteries (red) and veins (blue)
connected to the uterus. Transection lines are indicated by black lines. (B) The uterus in place in the pelvis of the recipient with bilateral end-to-
side anastomoses on the recipient's external iliac vessels.
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continuous absorbable 2-0 suture. The uterus was ﬁxed in its
pelvic location by attaching the uterine ligaments to their pel-
vic counterparts with the previously placed ﬁxation sutures,
and by overlaying the extensive bladder peritoneum of the
graft over the recipient's bladder fundus. A Doppler probe
with a silicon cuff (Cook-Schwartz Doppler probe; Cook Med-
ical) was then placed around one uterine artery to ascertain
that pulsatile blood ﬂow was maintained during the initial
72-hour postoperative period, with the signal transduced
from a 20-MHz crystal on the tip of a thin cable through
the midline incision. The cable, with its crystal, was then
gently pulled out from its intra-abdominal position, leaving
the silicon cuff in situ. The surgery and anesthesia of the
recipients were terminated identically to the donors.
Immunosuppression and Long-Term Medication
The recipients followed a standardized protocol of induction
and maintenance immunosuppression. Preoperatively, the
recipient had received 1g mycophenolate mofetil (MMF; Cell-
cept; Roche). During transplantation, before reperfusion, she
was given 500 mg methylprednisolone (Solu-Medrol; Pﬁzer)
and antithymocyte antibodies, to deplete T lymphocytes,
either thymoglobulin (IV, 2.5 mg/kg bw; Genzyme Aps) or an-
tithymocyte globulin (ATG; IV, 5 mg/kg bw; ATG-Fresenius;
Fresenius), with identical doses of each drug repeated 12
hours later.
Maintenance immunosuppressive therapy was continued
with tacrolimus (Prograf,-Astellas Pharma) twice daily
(adjusted to trough levels of 10–15 ng/mL during weeks 1–5
and 5–10 ng/mL duringweek 6 and thereafter) andMMF twice
daily with MMF area under the curve trough levels of 40–60
mg$h/L. Oral glucocorticosteroids (Prednisolon; Pﬁzer) were
administered once daily on the day of surgery and during
the ﬁrst 4 postoperative days.
Antiviral prophylaxis consisted of a daily oral dose (450
mg) of valganciclovir (Valcyte; Roche), which was given
for 3 or 6 months, depending on cytomegalovirus status
(3 months when both donor and recipient were positive;
6 months when donor was positive and recipient negative).
When both donor and recipient were negative, prophylaxis
was not given.
Follow-up
Surgical complications were registered with the use of
Clavien-Dindo classiﬁcation (19). The recipients were moni-
tored by clinical examination twice weekly during the 1st
month, once weekly during months 2–3, and thereafter every
other week. The uterus and endometrium were examined with
vaginal and abdominal two-dimensional ultrasonography
(Flex Focus 400; BK Medical). Color Doppler ultrasound was
used to assess that blood ﬂow was maintained through the
uterine arteries. Clinical examination included visual inspec-
tion of the uterine cervix as well as cervical cultures and
biopsies. The biopsies were obtained at predetermined time
points (1, 2, and 4 weeks, and monthly thereafter) as well as
on suspicion of graft rejection based on clinical examination
(discolored cervix, abnormal vaginal discharge, enlarged
uterus, fever, abdominal pain). Drug levels (tacrolimus,
MMF) were monitored by standard assays, and routine blood
tests were performed to assess liver and kidney function and
to detect infection.
Rejection was diagnosed based on histopathologic exam-
ination of cervical biopsies and graded according to the
proposed rejection classiﬁcation for the primate uterus (6).
Statistics
Values are presented as individual values and as mean ! SD.
RESULTS
Matching and Immunology of Patients
Seven donor/recipient pairs were ABO identical, and two were
compatible. Both cytotoxic and ﬂow-cytometric crossmatch
tests were negative in all patients, and no patients had HLA
antibodies. The degree of HLA mismatch among the donor
and recipient pairs varied from 1/0 to 3/2 (Table 3).
Surgery
Surgical parameters are presented in Table 3. Donor surgery
lasted 10–13 hours. Recipients 1 and 2 underwent pro-
longed anesthesia because recipient and donor surgeries
were improperly synchronized, so that 9- to 10-hour wait-
ing periods occurred before graft anastomosis. Blood trans-
fusion was not required during any surgery, although
volumes <0.6 L were returned by the autologous blood
recovery system in seven cases. Cold ischemia periods
lasted 1 to 2 hours. Major interindividual variation in
dominant uterine artery blood ﬂow, recorded by Doppler,
was observed (Table 3).
Postoperative Period and Complications: Donors
The initial postoperative hospital stay of the donors was 6
days (Table 3), with no need for intensive care. One grade
IIIb surgical complication occurred. Donor 2 presented on
POD 16 with watery vaginal discharge due to a ureterovaginal
ﬁstula. A pyelostomy catheter was inserted and her ureter
was reimplanted on POD 134, after which recovery was
uneventful.
PostoperativePeriodandComplications: Recipients
The ﬁrst two recipients experienced nausea and dyspnea on
POD 1, with chest x-rays revealing pleural ﬂuid (grade I com-
plications). They were observed at an intermediary care unit
until the symptoms ceased and the pleural ﬂuid resorbed
spontaneously (POD 2–3). No other recipient experienced
these symptoms. A grade II complication (blood transfusion)
occurred in one recipient on POD 2 (Table 3), and a retroper-
itoneal hematoma was visualized on computerized tomo-
graphic (CT) scan.
Two recipients developed complications necessitating
surgical removal of the graft (grade IIIb complications). Recip-
ient 2 was readmitted on POD 33 with abdominal pain, fever,
and vaginal discharge. Gynecologic examination revealed
signs of cervical/uterine infection, conﬁrmed by positive
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TABLE 3
Surgical, anesthesiologic, and hospitalization parameters.
Pair
Age
(y)
Donors'
relation to
recipients
HLA
mismatch
Cytomegalovirus
Ig
Epstein-
Barr
virus Ig
Duration
Arterial
blood ﬂow
(mL/min)a
Blood
loss (L)
Intraop.
autoblood
(L)
Blood
transfusion
(L)b
Highest
grade of
complicationc
Postop.
hospitalization
(d)Anesthesia Surgery
Back-table Anastomoses Ischemia
Preparation Veins Arteries Warm Cold
Recipient 1 33 Mother 2/0 pos pos 15 h 0 min 4 h 10 min 1 h 30 min 39 min 35 min 1 h 18 min 1 h 30 min 63 0.4 0 0 Grade II 8
Donor 1 52 neg pos 12 h 4 min 10 h 54 min 0.3 0 0 6
Recipient 2 38 Mother 2/1 neg neg 13 h 57 min 4 h 17 min 1 h 47 min 43 min 29 min 1 h 38 min 1 h 47 min 50 1.6 0.49 0 Grade IIIb 9
Donor 2 58 pos pos 13 h 46 min 12 h 37 min 2.4 0.49 0 Grade IIIb 6
Recipient 3 28 Mother's
sister
3/1 pos pos 10 h 50 min 4 h 50 min 1 h 4 min 31 min 25 min 1 h 34 min 1 h 4 min 50 0.8 0.2 0 6
Donor 3 54 neg pos 13 h 37 min 12 h 53 min 0.8 0 0 6
Recipient 4 27 Mother 2/1 neg pos 6 h 5 min 5 h 4 min 0 h 57 min 32 min 30 min 1 h 17 min 0 h 57 min 43 0.25 0 0 6
Donor 4 50 neg neg 11 h 11 min 10 h 34 min 0.6 0 0 6
Recipient 5 35 Family
friend
3/2 pos pos 5 h 45 min 4 h 55 min 1 h 6 min 32 min 30 min 1 h 13 min 1 h 6 min 40 0.75 0 1.2 Grade II 6
Donor 5 61 pos pos 11 h 6 min 10 h 17 min 0.6 0 0 6
Recipient 6 27 Mother 1/1 neg pos 8 h 17 min 4 h 30 min 2 h 0 min 60 min 23 min 1 h 24 min 2 h 0 min 75 0.7 0.18 0 3
Donor 6 53 pos pos 11 h 50 min 10 h 52 min 0.7 0.11 0 6
Recipient 7 28 Mother 1/0 pos pos 6 h 35 min 4 h 44 min 0 h 54 min 20 min 30 min 1 h 15 min 0 h 54 min 30 0.3 0 0 Grade II 7
Donor 7 50 pos pos 11 h 35 min 10 h 17 min 0.4 0 0 6
Recipient 8 33 Sister 1/1 pos pos 7 h 53 min 5 h 56 min 0 h 56 min 25 min 24 min 1 h 14 min 0 h 56 min 30 0.75 0.2 0 Grade II 8
Donor 8 37 pos pos 11 h 55 min 11 h 23 min 0.4 0 0 6
Recipient 9 35 Mother-
in-law
3/2 neg neg 8 h 14 min 4 h 31 min 1 h 28 min 42 min 47 min 1 h 32 min 1 h 28 min 10 0.5 0 0 Grade IIIb 7
Donor 9 62 pos pos 14 h 5 min 13 h 8 min 2.1 0.52 0 6
All recipients 31.5 ! 3.9 9 h 4 min !
3 h 14 min
4 h 46 min !
30 min
1 h 18 min !
23 min
36 !
11 min
30 !
6.9 min
1 h 23 min !
9 min
1 h 18 min !
23 min
44 ! 18 0.67 !
0.38
0.12 !
0.15
0.13 !
0.36
6.7 ! 1.6
All donors 53.0 ! 7 12 h 13 min !
60 min
11 h 37 min !
1 h 5 min
0.92 !
0.73
0.12 !
0.21
0 ! 0 6.0 ! 0
Note: Plus-minus values are mean ! SD.
a Peak value of the dominant artery.
b Packed red cells.
c According to the Clavien-Dindo classiﬁcation of surgical complications (17).
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Enterococcus faecalis culture. After 4 days of intravenous an-
tibiotics, the symptoms resolved; the recipient was discharged
on POD 38 with oral antibiotics. She was kept on oral antibi-
otics owing to persisting Enterococci in cervical cultures and a
modest increase in C-reactive protein (CRP), except during
one febrile episode (POD 78–83) when IV antibiotics were
temporarily reintroduced. She was readmitted on POD 98
owing to aggravated symptoms, and an intrauterine abscess
measuring 3! 4 cmwas seen on CT scan. Despite two surgical
drainage attempts, the abscess persisted and the patient
developed initial signs of septicemia. Hysterectomy was per-
formed on POD 105. Morphologic examination revealed
extensive areas of necrosis, with some neutrophil-
dominated inﬂammation, but no signs of rejection. Subse-
quent recovery was uneventful.
Recipient 9 had sudden cessation of the uterine artery
Doppler signal on the morning of POD 3, and gynecologic ex-
amination revealed a blood-congested cervix. Acute laparot-
omy revealed a congested uterus and uterine arteries without
palpable pulses. The entire graft was removed and morpho-
logic examination revealed focal necrosis and moderate
ischemic myometrial damage, but no signs of rejection.
Occluding thrombi were found in both major arteries and
veins. The patient was discharged from the hospital 5 days
after hysterectomy, with frequent initial follow-up visits
and contacts with the team's doctors and psychologist. At
6-month follow-up, she was back at work and had experi-
enced no physical sequelae.
Rejection and Uterine and Renal Function
Three (numbers 1, 5, and 7) of the seven recipients with viable
uteri throughout the observation period, suffered single epi-
sodes of mild rejection during the 1st month. One recipient
(number 8) had two episodes of mild rejection (month 1 and
month 3). Morphologic analysis of the cervical tissue showed
mild inﬁltration of lymphocytes and neutrophils, mainly in
the basal squamous epithelium of the ectocervix. All rejection
episodes (grade II complications) were successfully treated
with corticosteroids for 7–10 days. Spontaneous menstrua-
tions resumed within 2 months in the seven patients with reg-
ular menstrual patterns (interval 27–32 days) andwith amean
maximum endometrial thickness of 14 " 3 mm.
Preoperative creatinine levels, mirroring renal function,
were 7.35 " 9.1 mmol/L, and a reversible increase (maximal
increase 37.1 " 20.6 mmol/L) occurred during the initial 1–2
months of immunosuppression.
DISCUSSION
This study represents the ﬁrst clinical trial of human UTx, af-
ter two solitary human UTx attempts in 2000 (13) and 2011
(14). In contrast to those single cases, which were not
preceded by any internal UTx research, our team has
been involved in animal-based UTx research for several years
(6–8). In the rodent models, we have studied rejection patterns
in a uterine allograft, immunosuppression to avoid uterine
graft rejection, and, importantly, pregnancies and offspring
after UTx. Large animal models, including primates, have
mostly been used to optimize the surgery at UTx and to
evaluate suitable combinations of immunosuppressants. Our
introduction of human UTx to the clinical arena complies
with the recently released IDEAL recommendations for
clinical introduction of major surgical procedures (20).
Uterus transplantation, as a non–life-saving transplanta-
tion and a technically complicated infertility treatment, raises
several ethical questions (21–23) regarding priorities in the
health care sector, as well as the risks and beneﬁts of the
procedure. A clinical trial such as ours generates important
data on the risks and beneﬁts, which will also be
advantageous in an ethical analysis of UTx.
We recovered the uterine grafts from live donors. Live
donation of organs is most common in renal transplantation;
#40% of transplanted kidneys are from live donors in the
United States (24). Because our prior UTx research in sheep
(25) and baboons (6, 26) followed the live donor concept,
our team was well prepared for that particular surgical
procedure. All donors had undergone at least one normal
pregnancy. In the recent UTx case in Turkey (14), the uterus
was obtained from a nulliparous deceased donor and the
local team assembled on short notice for surgery. The
recipient has subsequently undergone two pregnancies, with
early miscarriages occurring both times (15). The cause of
these pregnancy failures may be related to intrinsic factors
in the particular uterus or to the triple immunosuppression
still administered. As recently outlined by Donnez (27),
there may exist speciﬁc factors of a transplanted uterus,
such as decreased vascular plasticity, placentation defects,
and loss of innervation, that may negatively affect the
pregnancy potential in a uterine allograft.
Our team, with surgeons from three continents, had to
plan the exact dates of the surgeries well in advance. Further-
more, our hospital board required that all surgeries be done
during weekends in operating rooms that were usually closed
on weekends. Deceased-donor UTx would not be a realistic
option under these conditions.
Before the ﬁrst UTx procedure, we had anticipated
considerably easier and faster retrieval surgery than was actu-
ally the case, because uterus retrieval in our baboon UTx
studies took #2.5 hours (6, 26). Therefore, and based on our
feasibility study of uterine vessel dissection at radical
hysterectomy, we had predicted a duration of 3–4 hours
(28). In that study, the median surgery duration was #5
hours, when uterine vessel dissections were included in the
hysterectomy and lymph node dissection procedure. The
most time-consuming surgical step in retrieval surgery in
the present study was ureter and uterine vessel dissection,
which took#4–6 hours. In a radical hysterectomy, the uterine
arteries are transected at their inlets into the anterior division
of the internal iliac arteries, and ureteric dissection is fairly
easy. In the present cases, all uterine vessels were preserved,
and extremely meticulous dissection is unavoidable in this
surgically inaccessible area of the funnel-shaped pelvis. In
all novel types of surgery, procedure duration tends to
decrease as it becomes more standardized. This would most
likely be the case for UTx live donor surgery in the future.
Naturally, as in all live organ donations, our surgery
involved a person, with no direct health beneﬁt from the
donation, being exposed to a surgical risk. In live kidney
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and liver donation, the risks of major surgical complications
(grade III) are !4% (29, 30). In the present study, one donor
developed a ureterovaginal ﬁstula which necessitated
hysterectomy (grade IIIb complication). The late appearance
of the ﬁstula indicates that the cause was partial damage,
possibly by diathermy, followed by a gradual weakening of
ureteral wall. This particular donor surgery, spanning >12
hours, was extremely difﬁcult, owing to the absence of
natural dissection planes, and involved an older donor. This
ureteric complication in the present study and the
perioperative ureteric laceration, which occurred in the
original case in year 2000 (13), indicates that extremely
gentle surgery should be used in close proximity to the
ureters.
Two of the nine recipients lost their grafts during this
6-month period reported here. The cause of graft loss was
escalating uterine infection in one case and acute thrombosis
in the other. The lengthy procurement procedure (12 hours)
and poor synchronization of donor and recipient surgeries,
with a resulting very long anesthesia time for the recipient,
may have been other predisposing factors behind uterine
infection. Moreover, the vaginal-vaginal anastomosis sutures
were placed in close proximity to the cervix in that case, for
anatomic reasons. This may have negatively affected the
normal cervical barrier to ascending infections, especially in
an immunosuppressed recipient.
The recipient with acute uterine artery thrombosis was
heterozygous for protein C deﬁciency, which does not exclude
a patient from any type of clinical transplantation surgery.
However, this mutation is associated with 3–6-fold increased
risk of venous thromboembolism (31). It is unclear whether
the complication in this case of increased risk for thromboem-
bolism might have been avoided if more intense or prolonged
anticoagulants had been administered (31) or if the total sur-
gical time of>16 hours that the uterus and its vasculature are
exposed to could have been considerably shortened. Other
factors, which may have predisposed to thrombosis of this
case, are that this transplantation involved the oldest donor
and that the uterine artery blood ﬂow, after anastomosis,
was the lowest of all cases. The total failure rate of 2/9 should
be viewed in the light of this being a novel type of transplan-
tation, with major potential for further optimization.
Our immunosuppression protocol was milder than in the
two previous cases of human UTx (13, 14) as well as in
those initially used for hand and face transplantations (32).
Nowadays, the general understanding is that less
immunosuppression is sufﬁcient in any type of composite
tissue transplantation (33). The fact that we observed only
mild rejection episodes in four of the seven recipients
indicates that it is unlikely that immunosuppression was
suboptimal.
Effective monitoring of each speciﬁc organ to detect any
rejection at an early stage, when it is reversible and has not
caused organ damage, is a major challenge in organ trans-
plantation. Because UTx is a novel type of transplantation,
the ideal mode for monitoring the organ is not known. In
the ﬁrst human UTx case in 2000, repeated Doppler examina-
tions and CD4/CD8 ratios in blood were used to detect rejec-
tion (13). One rejection episode was detected and effectively
reversed, but the uterus had to be removed later. In the
more recent case from 2011, Doppler and biopsies of the
graft's vaginal portion were used and no rejection episodes
were reported (14).
The mild rejection episodes in our patients were asymp-
tomatic, with normal results on ultrasound and gynecologic
examination. We based our rejection diagnosis on the
assumption that a human uterine allograft would react simi-
larly to that of a baboon, in which we observed the wide spec-
trum from mild to severe rejection (6). The fact that
corticosteroids were effective in normalizing the histologic
pattern in our human cases indicates that these were true
rejection episodes.
The plan for this cohort is to start embryo transfer 12–
18 months after UTx if the clinical course has been
uneventful, with no rejection episodes for R4–6 months.
The uterus will be removed after one or two successful
pregnancies.
In summary, this study shows that a live-donor UTx pro-
cedure has a low risk despite extended surgery duration. The
report of the ﬁrst successful human UTx case, deﬁned as a live
birth from a transplanted human uterus, has yet to be
published.
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Objective: To report the 12-month outcome of seven patients with viable uteri after uterus transplantation (UTx).
Design: Prospective observational study.
Setting: University hospital.
Patient(s): Seven patients with absolute uterine infertility and viable uteri for 12 months after live-donor UTx.
Intervention(s): Predetermined immunosuppression was with tacrolimus andmychophenolate mofetil (MMF) during 6months, where-
upon MMF should be withdrawn. Frequent ultrasound examinations were performed to assess uterine appearance and uterine artery
blood ﬂow. Cervical biopsies (for histological detection of rejection) were obtained at preset time points, with temporary adjustments
of immunosuppression if there were signs of rejection. Menstruations were systematically recorded.
Main Outcome Measure(s): Menstruation, uterine artery blood ﬂow, histology of cervical biopsies, and blood levels of tacrolimus.
Result(s): All patients showed regular menses after 1–2 months. Uterine artery blood ﬂow was unchanged, with a median pulsatility
index of 1.9 (range, 0.5–5.4). Blood levels of tacrolimus were approximately 10, 9, and 8 (mg/L) during months 2, 9, and 12, respectively.
Four recipients showed mild inﬂammation in biopsies after MMF withdrawal and were treated with corticosteroids and azathioprine
during the remainder of the 12months. Subclinical rejection episodes were detected on ectocervical biopsies in ﬁve recipients. Histology
showed apoptotic bodies and occasional spongiosis in the squamous epithelium. Moderate inﬁltration of lymphocytes and neutrophils
was seen in the epithelial/stromal interface. All rejection episodes were successfully treated for 2 weeks with corticosteroids or dose
increments of tacrolimus.
Conclusion(s): We demonstrate long-term uterine viability after UTx, with continued menstruation and unaltered uterine artery blood
ﬂow. Subclinical rejection episodes were effectively reversed by temporary increase of
immunosuppression.
Clinical Trial Registration Number: NCT01844362. (Fertil Steril! 2015;103:199–204. "2015
by American Society for Reproductive Medicine.)
Key Words: Infertility, MRKH, rejection, transplantation, uterus
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A bsolute uterine factor infertility(AUFI) is considered to be theonly major cause of female
infertility that remains untreatable.
Uterus transplantation (UTx) has been
proposed as one possible AUFI treat-
ment. Recently, we initiated the ﬁrst
clinical UTx trial after more than a
decade of animal-based research (1, 2).
Nine AUFI women were transplanted
with uteri from live donors, with the
majority of donors being mothers of
the recipients. The surgical technique
involved isolation of the donor uterus,
with substantial vascular pedicles to
include parts of the internal iliacs
bilaterally, and then transplantation
into the recipient by vascular
anastomoses to the external iliac
vessels. The results of the surgery and
postoperative period have been
reported in detail (3). The main
ﬁndings of our previous study
included data on unexpectedly long
(10–13 hours) surgery times for
uterine retrieval with one surgical
complication (ureteric-vaginal ﬁstula)
in a donor. Furthermore, two of the
nine uterine grafts had to be removed
during the initial months, with the
causes being uterine vessel thrombosis
and severe intrauterine infection.
It should be noted that experi-
mental humanUTx had been performed
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2 times before our UTx trial, but in both cases in the absence
of research preparations by the teams. The ﬁrst was a
live-donor case performed in Saudi Arabia in 2000, with pro-
gressive uterine necrosis occurring during the initial months
(4). The other experimental case of UTx was performed in
Turkey 2011 and involved a uterus from a deceased donor
(5). The patient underwent embryo transfer 18 months post
UTx, and two early clinical pregnancies, which miscarried,
were reported (6).
In the present paper we report on the clinical course dur-
ing the ﬁrst 12 months among the seven women of our UTx
trial who have kept their transplanted uterus during this ﬁrst
post-transplantation year.
MATERIALS AND METHODS
Patients
The study was approved by the Human Ethics Committee of
the University of Gothenburg and was registered in Clinical
Trials.gov (NCT01844362). Written informed consent was
obtained from all donors, recipients, and their partners.
Nine patients, evaluated extensively by a multidisciplinary
team, underwent UTx as reported by us in detail in our previ-
ous publication (3). Two uterine grafts were removed during
the initial 6-month period. One was due to persistent intra-
uterine infection (recipient 2), and the other was because of
bilateral uterine vessel thrombosis (recipient 9).
The characteristics of the patients, their donors, and the
surgeries are given in detail in our initial publication (3). In
the present report and in all future publications, the original
numbering of the patients will be kept to enable the reader
to follow the medical, psychological, and quality-of-life
outcome of each individual patient. Thus, in the present pub-
lication, recipients 2 and 9 are excluded, since their uterine
grafts were removed during the initial 6-month period. The
remaining seven women who kept their transplanted uterus
throughout the ﬁrst postoperative year had a median age of
28 (range, 27–35) years, had been in a steady relationship
with their partners for R3 years, and had before the trans-
plantation undergone IVF to exclude couples with fertiliza-
tion failure and also to cryopreserve embryos for transfer,
when >12 months had passed after transplantation. Six of
the remaining recipients (numbers 3–8), had AUFI because
of congenital uterine agenesis, and one (recipient 1) had un-
dergone hysterectomy due to cervical cancer. The trans-
planted uteri were from the mother in four cases (recipients
1, 4, 6, 7), and in the other cases from a sister (recipient 8),
mother's sister (recipient 3), and family friend (recipient 5).
The human leukocyte antigen mismatch in the seven cases
varied between 1/0 (recipient 7) and 3/2 (recipient 9). Throm-
bosis prophylaxis was with acetylsalicylic acid (75 mg;
Trombyl, Pﬁzer) once daily, and this continued during the
entire 12-month period.
Immunosuppression
Immunosuppression followed a standardized protocol, which
is used for kidney transplantation at our transplantation cen-
ter, and the protocol has been described in detail elsewhere (3).
In short, the recipients received induction with methylpred-
nisolone (500 mg; Solu-Medrol, Pﬁzer) 10 minutes before
uterine reperfusion, and depending on local availability,
thymocyte antibodies were given as either thymoglobulin
(IV, 2.5 mg/kg body weight; Genzyme) or ATG (IV, 5 mg/kg
bw; ATG-Fresenius; Fresenius) just before UTx and at a sec-
ond occasion 12 hours later. All recipients were continuously
treated with tacrolimus (Prograf/Advagraf, Astellas) with the
aim to lower the trough levels in two steps: 10–15 ng/mL dur-
ing the ﬁrst month, followed by 5–10 ng/mL from the second
month and onward. Mycophenolate mofetil (MMF; Cellcept,
Roche) was given (1 g) preoperatively by the oral route. Start-
ing from postoperative day 1, MMF was administered twice
daily, and the aim was to keep the MMF area under the curve
(MMF-AUC) trough levels at 40–60 mg ! hour/L. Owing to
the potentially teratogenic effects of MMF, this treatment
should be discontinued after 6 months, which is a time at least
6 months before the planned initial ET. The aim was to treat
the patients with solely tacrolimus from month 7.
Follow-up
All recipients were monitored by regular clinical visits and
laboratory examinations. The frequency of these was initially
twice weekly, and after a month they were spaced to fort-
nightly visits during months 2–6 and then monthly visits.
The clinical examinations comprised macroscopic inspection
of the transplanted uterine cervix and vaginal rim as well as
cervical cultures and biopsies. The biopsies were obtained at
predetermined time points (1, 2, and 4 weeks and thereafter
monthly), and the protocol also included biopsies at suspicion
(discoloured cervix, abnormal vaginal discharge, fever,
abdominal pain) of any pathological condition, such as infec-
tion or graft rejection. The histopathological examination of
the cervix was graded according to our proposed rejection
classiﬁcation for the primate uterus (7). In the events of veri-
ﬁed rejection on cervical biopsy, the immunosuppression was
temporarily elevated. In the event the planned withdrawal of
MMF after 6 months resulted in a cervical biopsy that was, per
protocol, obtained 2 weeks after withdrawal of MMF or any
later biopsy showed signs of accumulation of inﬂammatory
cells, azathioprine (Imurel, Orion Pharma), and prednisolone
(Prednisolon, Pﬁzer) were added as continuous immunosup-
pression. In the event of cervical intraepithelial neoplasia
(CIN) on a cervical biopsy, a real-time polymerase chain reac-
tion assay for typing of human papilloma virus (HPV), which
included primers for HPV16, 18, 31, 33, 35, 39, 45, 52, 58, and
67 (8, 9), was used, after DNA had been extracted from
cervical brushings by a MagNA Pure LC methodology after
isolation with a total nucleic acid kit.
At each clinical visit, transvaginal and abdominal two-
dimensional ultrasound (Flex Focus 400, BK Medical AB)
were performed to assess the endometrial and myometrial
thickness and echogenicity. Doppler ultrasound was used
to evaluate the uterine artery blood ﬂow on both sides.
Waveform characteristics and measurement of blood ﬂow
velocity at peak systole (PSV) and peak diastole were ob-
tained to calculate the resistance index (RI) and pulsatility
index (PI).
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Routine blood tests were performed to assess blood status
and liver and kidney function and to detect infection. Tacro-
limus levels were measured in whole blood by an automated
chemiluminescent immunoassay developed for use on the
ARCHITECT system (Abbott Scandinavia AB). The intra-
assay coefﬁcient of variation is <1.9%. Levels of MMF were
measured by an enzyme multiplied immunoassay technique
on a Horiba ABX Pentra 400 clinical chemistry analyser
(Thermo Fisher Scientiﬁc Inc.).
All complications of the recipients that occurred were
registered and classiﬁed according to the Clavien-Dindo
classiﬁcation of surgical complications (10). Herein compli-
cations are classiﬁed into four major grades, where grade
I accounts for complications requiring pharmacological
treatment with antiemetics, antipyretics, analgetics, di-
uretics, and electrolytes. Grade II includes treatments with
drugs other than the ones allowed in grade I or blood
transfusions and total parenteral nutrition. Grade III compli-
cations include surgical, endoscopic, or radiological inter-
vention under (grade IIIb) or not (grade IIIa) general
anesthesia.
Statistics
Quantitative variables are given as individual values and me-
dian and ranges.
RESULTS
Menstrual Pattern and Endometrial Thickness
Spontaneous menstrual bleedings occurred within 2 months
in all seven recipients. Although some occasional irregular-
ities appeared, regular menses with intervals between 27 and
32 days were seen in all patients (Fig. 1). The uterine appear-
ances on two-dimensional ultrasound were unchanged dur-
ing the study period. Typical cyclic changes of the
endometrial thickness were seen, and the endometrium
increased from 7.3 (3.2–10.4) mm (median [range]) during
cycle days 5–8 to a maximum thickness of 14.4 (11.2–
18.7) at cycle days 20–24. A trilaminar pattern was seen
in all measurements done during the follicular phase, and
a hyperechogenic pattern in those done during the luteal
phase.
Uterine Blood Flow
Doppler examination of the anastomosed uterine arteries
showed normal uterine artery ﬂow velocity waveforms in
all patients and at all occasions. Calculated PI, RI, and PSV
for each recipient and at multiple times showed only minor
variations over time (Fig. 2), with median PI, RI, and PSV of
1.9 (0.5–5.4), 0.8 (0.3–1.4), and 25.4 cm/second (9.2–59.4),
respectively.
Rejection Episodes
All rejection episodes were without any clinical symptoms,
and the ectocervix had on all occasions a normal appearance
on visual inspection. Rejection episodes were detected in ﬁve
of the seven recipients (Fig. 3), and eight out of nine of these
episodes were classiﬁed as Clavien-Dindo grade II complica-
tions. The episodes were categorized as mild rejections, and in
one case as a borderline rejection (second rejection episode of
recipient 5). Morphologic analysis of biopsies from ectocervix
showed occasional spongiosis in the basal layers of the squa-
mous epithelium and sporadic apoptotic bodies among the
squamous cells. There was an increased amount of leukocytes,
predominantly neutrophils and lymphocytes, in the epithe-
lial/stromal interphase.
Two of the recipients showed three episodes of rejection
each (recipients 5 and 8). With one exception, the rejection
episodes were treated with corticosteroids (500 mg IV daily
for 3 days; Solu-Medrol, Pﬁzer) and thereafter tapered oral
corticosteroids for 7 days (Prednisolon, Pﬁzer). One episode
of borderline rejection (recipient 5, episode two) was treated
only with oral glucocorticoids. On all occasions of detected
rejections, control cervical biopsies 2 weeks post–rejection
treatment showed normal histopathology. All the rejection
episodes were without any clinical symptoms, and the ecto-
cervix had on all occasions a normal appearance on visual
inspection.
In recipient 5, the per-protocol cervical biopsy obtained
8 months post-transplantation showed cervical intraepithe-
lial neoplasia 2 (CIN 2), with the presence of HPV of
subtype 31. A small loop excision, with inclusion of the bi-
opsy site, was done under anesthesia 2 weeks later, and the
event was thus classiﬁed as a Clavien-Dindo grade II
complication. The cone biopsy showed normal epithelium
and no signs of residual CIN. Subsequent biopsies have
been normal.
Immunosuppression
The blood levels of tacrolimus are shown in Figure 3. The
MMF-AUC in all seven patients was within the 40–60 mg !
hour/L during the ﬁrst 6 months, with a median of 47.0
(35.0–78.0) mg ! hour/L. Occasional high and low values
were shown during the initial month (data not shown). With-
drawal of MMF after 6months was initially uneventful in four
women (recipients 1, 3, 4, and 6), and monotherapy with ta-
crolimus was introduced. Recipient 3 presented with normal
cervical biopsies during the initial 3 months after MMF with-
drawal. However, mild inﬂammation was seen on the biopsy
taken 9 months after UTx, and she was treated with the
FIGURE 1
Menstrual bleeding (black boxes) in recipients 1 and 3–8 during the
ﬁrst year after UTx.
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addition of azathioprine and prednisolone from that time
point. In three recipients (recipients 5, 7, 9) the control biopsy
2 weeks after MMF withdrawal showed low inﬁltration of in-
ﬂammatory cells, and thus azathioprine and prednisolone
were introduced already at this stage. These recipients were
then on triple immunosuppression during the remainder of
the observation period.
DISCUSSION
UTx, as a possible future treatment option for patients with
AUFI, is presently at its clinical experimental stage. The
seven patients of our prospective observational study and
one previous experimental single case of UTx in 2011
make up the total worldwide cohort of eight UTx patients
with viable uterine grafts today. Three additional UTx cases
that have been performed ended in removal of the uterus.
Two of these unsuccessful cases were recipients of our study,
with removal of a uterus with thrombotic uterine vessels
within 1 week post UTx in one case and hysterectomy after
4 months in the other case. That hysterectomy was because
of persistent infection inside the uterine cavity that was
resistant to IV antibiotic treatments and multiple attempts
of surgical drainage.
It is naturally of great importance that the ongoing hu-
man UTx cases are closely followed to gain all possible infor-
mation that may be beneﬁcial for the design of future research
studies in the ﬁeld and of course in the long run for the large
group of women worldwide who have AUFI. Our aim is to
publish scientiﬁc reports at different intervals after UTx and
to cover all aspects of the procedure.
The main ﬁndings of the present study were that all seven
patients who had an uneventful postoperative recovery dur-
ing the ﬁrst few months also did well during a 1-year time
frame. Importantly, menstrual patterns and uterine blood
ﬂow were normal. Rejection episodes could be detected by
the aid of cervical biopsies and effectively reversed by
increased immunosuppression during a short time.
Spontaneous menstruations occurred within 2 months in
all seven patients, which was expected, considering their age
and normal ovarian function. In the experimental live-donor
UTx case in Saudi Arabia (4), estrogen and P were given
FIGURE 2
(A–C) Doppler indices of left (A,C,E) and right (B,D, F) uterine arteries theﬁrst year afterUTx. RI (A,B), PI (C,D), peak systolic velocity (cm/second;E, F).
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during the ﬁrst 3 months and two withdrawal bleedings fol-
lowed cessations of the hormone therapy. Also in the exper-
imental deceased donor UTx case in Turkey (5), initial
menstrual bleedings were induced by sequential hormone
therapy, with the ﬁrst menses appearing 20 days post-UTx.
In light of the early appearance of spontaneous menstrua-
tions in our seven uneventful cases, it is incomprehensible
why hormone therapy had to be used in the two single
and highly experimental cases, which included recipients
aged only 26 (4) and 22 (5) years, with presumably good
ovarian reserves.
Rejection of any transplanted organ is commonly diag-
nosed by ﬁndings of decreased function of the organ and/or
typical changes of tissue biopsies. Considering the uterus,
menstruation is the only obvious functional parameter that
can be easily monitored by the patient. In our study, the
rejection episodes were not accompanied by any obvious
menstrual irregularities or any other clinical signs.
FIGURE 3
Blood levels of tacrolimus during the ﬁrst postoperative year after UTx and schematic overview of additional immunosuppressive medication with
MMF, corticosteroids (PREDN), and azathioprine (AZATH) in each recipient are shown. Rejection episodes are indicated by R.
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Before our UTx trial we had some, but limited, knowledge
from our animal research studies of the means to detect rejec-
tion of a uterine graft. In the allogeneic mouse model we
described the uterine rejection patterns, both in relation to
gross morphological changes and blood ﬂow (11) as well
as of what speciﬁc subtypes of leukocytes invade the myome-
trium at rejection (12). However, collection of myometrial bi-
opsies would be a difﬁcult and highly invasive procedure after
human UTx. Consequently, we based our rejection diagnosis
in the human UTx trial on histological examinations of cervi-
cal biopsies. The assumption that the morphology of the cer-
vical biopsies at rejection would mimic the morphology of the
uterine body was based on results of our study on allogeneic
UTx in the baboon (7, 13). In these studies, the morphology of
cervical biopsies correlated well with the clinical picture of
rejection, in the wide spectrum from mild to severe
rejection. Additionally, the morphological analysis of the
biopsy was not inﬂuenced by the cyclic changes of ovarian
hormones or menstrual bleedings, and all the rejection
episodes were reversible with increased immunosuppression.
In the present study a total of nine rejection episodes,
restricted to ﬁve patients, occurred during the ﬁrst postoper-
ative year. All episodes were successfully resolved by tempo-
rary therapy with glucocorticoids. It is noteworthy that all the
rejection episodes of the UTx trial were subclinical and
asymptomatic and only detected by the cervical biopsy.
To possibly detect rejection or other uterine pathologies
we applied two-dimensional ultrasound to examine the uter-
ine size and echogenicity, as well as Doppler for measure-
ments of uterine blood ﬂow. Ultrasound examination has
previously been tested as a means for detection of rejection
after kidney transplantation, but it was found that this imag-
ing method has limited value in diagnosing renal rejection
(14). In our study, PIs were also within normal ranges accord-
ing to the moment of the menstrual cycle (15). This would
reﬂect that uterine vascularization is not compromised in
the transplanted uterus, at least in a nonpregnant state.
The immunosuppression protocol used in the UTx trial is a
standard immunosuppression protocol used in the transplan-
tation of solid organs such as the kidney and the liver. In the
experimental deceased donor UTx case in Turkey (5), the
doses of immunosuppression were considerably higher than
in the present study, with trough levels of tacrolimus being
around 3-fold higher than in the present study. Moreover,
MMF and corticosteroids were administered at high doses
during the entire ﬁrst year after UTx, which is in contrast to
the short treatment with corticosteroids and the 6-month
MMF treatment that were used in the present study. Even if
UTx is an ephemeral transplantation, it is of importance to
minimize the quantity of immunosuppressive medications
to the patient to avoid serious dose- and time-related side
effects.
The levels of immunosuppression used in the UTx trial
together with the low numbers of rejection episodes indicate
that the protocol used is sufﬁcient to effectively suppress
the immune system to avoid damage to the grafted uterus.
Importantly, a fetus growing in a transplanted uterus
will unconditionally be exposed to the immunosuppressive
treatment. As of 2006, more than 14,000 children born from
immunosuppressed organ transplanted women have been re-
ported, and no increased incidence of congenital malforma-
tions has been detected (16).
The predetermined plan for the seven women with viable
uteri in this study is to start ET 12–18 months after UTx given
an uneventful clinical course, with no severe rejection epi-
sodes forR4months. After completion of one or two success-
ful pregnancies, the uterus will be removed.
In summary, the results of the present study demonstrate
long-term uterine viability and function after live-donor UTx.
Asymptomatic rejection episodes can be detected by cervical
tissue biopsies and resolved by temporary addition of gluco-
corticoid treatment.
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Livebirth after uterus transplantation
Mats Brännström, Liza Johannesson, Hans Bokström, Niclas Kvarnström, Johan Mölne, Pernilla Dahm-Kähler, Anders Enskog, Milan Milenkovic , 
Jana Ekberg, Cesar Diaz-Garcia, Markus Gäbel, Ash Hanafy, Henrik Hagberg, Michael Olausson, Lars Nilsson
Summary
Background Uterus transplantation is the first available treatment for absolute uterine infertility, which is caused by 
absence of the uterus or the presence of a non-functional uterus. Eleven human uterus transplantation attempts have 
been done worldwide but no livebirth has yet been reported.
Methods In 2013, a 35-year-old woman with congenital absence of the uterus (Rokitansky syndrome) underwent 
transplantation of the uterus in Sahlgrenska University Hospital, Gothenburg, Sweden. The uterus was donated from 
a living, 61-year-old, two-parous woman. In-vitro fertilisation treatment of the recipient and her partner had been 
done before transplantation, from which 11 embryos were cryopreserved.
Findings The recipient and the donor had essentially uneventful postoperative recoveries. The recipient’s first menstruation 
occurred 43 days after transplantation and she continued to menstruate at regular intervals of between 26 and 36 days 
(median 32 days). 1 year after transplantation, the recipient underwent her first single embryo transfer, which resulted in 
pregnancy. She was then given triple immunosuppression (tacrolimus, azathioprine, and corticosteroids), which was 
continued throughout pregnancy. She had three episodes of mild rejection, one of which occurred during pregnancy. 
These episodes were all reversed by corticosteroid treatment. Fetal growth parameters and blood flows of the uterine 
arteries and umbilical cord were normal throughout pregnancy. The patient was admitted with pre-eclampsia at 31 full 
weeks and 5 days, and 16 h later a caesarean section was done because of abnormal cardiotocography. A male baby with a 
normal birthweight for gestational age (1775 g) and with APGAR scores 9, 9, 10 was born.
Interpretation We describe the first livebirth after uterus transplantation. This report is a proof-of-concept for uterus 
transplantation as a treatment for uterine factor infertility. Furthermore, the results show the feasibility of live uterus 
donation, even from a postmenopausal donor.
Funding Jane and Dan Olsson Foundation for Science.
Introduction
Absolute uterine factor infertility is the only major type 
of female infertility that is still viewed as untreatable. 
The major causes are congenital absence of the uterus 
(Rokitansky syndrome, also called Mayer-Rokitansky-
Küster-Hauser syndrome), previous hysterectomy, and 
severe intrauterine adhesions.1–4 In the UK alone, more 
than 12 000 women of childbearing age are thought to 
have absolute uterine factor infertility.5 The available 
motherhood options for women with this disorder are 
adoption (to acquire legal motherhood), or pregnancy in 
a gestational surrogate carrier to acquire genetic 
motherhood, followed by adoption to also acquire legal 
motherhood. However, surrogacy is not allowed in many 
countries because of ethical, legal, or religious reasons.
We have undertaken preclinical research into uterus 
transplantation for more than a decade, using a step-by-step 
logical developmental approach, in which we have used 
several animal species, ranging from rodents to 
non-human primates.6,7 Recently, we initiated the first 
clinical trial of transplantation, involving nine women who 
received uteri from live donors. Two of the women had to 
undergo hysterectomy during the initial months, with the 
causes being uterine artery thrombosis and severe 
intrauterine infection.8 The other seven women began 
menstruation during the first 2–3 months and the grafts 
remained viable, with regular menstruations during the 
first post-transplantation year. Occasional subclinical 
episodes of mild rejection were detected on cervical 
biopsies, which were eﬀectively reversed by short courses 
of increased immunosuppression.
Except for our clinical trial of nine women, only 
two other human uterus transplantation eﬀorts have been 
reported. The first case resulted in progressive uterine 
necrosis during the initial months, and a fully necrotic 
uterus was removed 3 months after transplantation.9 The 
second case involved a uterus from a deceased donor 
being transplanted into a patient with Rokitansky 
syndrome.10 The patient underwent embryo transfer 
18 months after transplantation and two pregnancies that 
miscarried before gestational week 6 have been reported.11 
No further reports exist about this case.
In this report, we describe the clinical course of the 
first patient in our cohort who achieved a clinical 
pregnancy resulting in delivery of a baby.
Methods
Patient
In 2013, a 35-year-old patient underwent uterus 
transplantation at Sahlgrenska University Hospital 
(Gothenberg, Sweden) as part of our clinical trial of 
uterus transplantation in nine women with absolute 
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uterine factor infertility (ClinicalTrials.gov number 
NCT01844362). The study was approved by the regional 
ethics board of the University of Gothenburg. The donor, 
recipient, and her male partner had given their written 
informed consent. The 6-month outcomes of the study 
have been published.8
The recipient (blood group O+) was born with Rokitansky 
syndrome (Müllerian agenesis). She belongs to the atypical 
Rokitansky syndrome category12 since she was also born 
with only one kidney and has vaginal and uterine aplasia. 
A functional neovagina had been created by self-dilatation. 
She was a non-smoker, was not on any medication, and 
had a body-mass index (BMI) of 21 kg/m². The recipient 
was, before transplantation and at several times during the 
post-transplantation period, informed that surgical 
removal could later be recommended for medical reasons, 
owing to rejection, surgical complications at caesarean 
section, or side-eﬀects of immunosuppression. The ethics 
approval and consent forms state that the uterus should be 
removed after a maximum of two successful pregnancies.
The donor (blood group O+) is a close family friend of 
the recipient. At surgery, she was 61 years old. She is 
two-parous with two previous vaginal deliveries, at 
26 years of age (birthweight 3000 g) and at 29 years of 
age (birthweight 3250 g). Both deliveries were 
spontaneous and at gestational week 41. She is a healthy 
non-smoker and her BMI at surgery was 20 kg/m². 
Menopause occurred around 7 years before 
transplantation. To ascertain menstrual functionality of 
the uterus before transplantation and to possibly 
increase uterine artery blood flow preoperatively, she 
was treated for 3 months with a sequential oral 
contraceptive pill, containing ethinylestradiol (30–40 μg 
daily) and levonorgestrel (50–125 μg daily). Bleedings 
occurred as expected.
The HLA mismatch between donor and recipient was 
3/2 and no HLA antibodies were present. Both donor 
and recipient were seropositive for cytomegalovirus and 
Epstein–Barr virus infections.
In-vitro fertilisation
In-vitro fertilisation was done during the period from 
18 to 6 months before transplantation. The patient’s 
Rokitansky syndrome, with no menstruation to aid 
in synchronisation of gonadotrophin stimulation and 
the cranially and laterally positioned ovaries, caused 
diﬃculties in initiation and monitoring of gonadotropin 
stimulation. Her blood concentration of anti-Müllerian 
hormone was 1·9 ng/mL. She underwent three full cycles 
of gonadotrophin stimulation. All cycles involved ovarian 
downregulation for 2–3 weeks by nasal administration 
three times daily with 300 μg of the gonadotropin-releasing 
hormone agonist buserelin (Suprecur; Hoechst, Frankfurt, 
Germany); this treatment began 7–9 days after a positive 
luteinizing hormone urine test, indicating the spontaneous 
gonadotrophin surge. We used ultrasound with abdominal 
probe and blood analysis of oestradiol values to assess 
follicle maturation. Human menopausal gonadotrophin 
(Menopur; Ferring, Copenhagen, Denmark) was used as 
the primary gonadotrophin in the first cycle (150 IU 
human menopausal gonadotrophin for 11 days) and 
recombinant follicle-stimulating hormone (Gonal-F; 
Merck Serono, Darmstadt, Germany) was added to the 
second and third cycles (225 IU human menopausal 
gonadotrophin plus 150 IU follicle-stimulating hormone, 
for 12 days in cycle 2 and for 14 days in cycle 3). Ovulation 
was triggered by injection of 250 μg recombinant human 
chorionic gonadotrophin (Ovitrelle; Merck Serono, 
Darmstadt, Germany). Oocyte pick-up was done 
transabdominally by abdominal ultrasound guidance. The 
oocytes were fertilised by intracytoplasmic sperm injection. 
Single embryo transfer was done around 12 months after 
transplantation during the natural menstrual cycle 
according to our local routine for frozen embryo transfer, 
with a soft embryo transfer catheter under abdominal 
ultrasound guidance.
Surgery
The surgical procedures of the donor and the recipient, 
and the anaesthesia, have previously been described in 
detail.8 Uterus transplantation surgery entails isolation 
of the uterus with bilateral, long venous, and arterial 
vascular pedicles. The complexity of the surgery is 
mostly related to the extensive vascular dissection that 
includes the distal parts of the internal iliac veins and 
arteries. In this specific case, two large uterine veins on 
each side converged into one major uterine vein that 
drained into the internal iliac veins. On the patient’s left 
side, one of these veins passed over the ureter and the 
other went under the ureter, and therefore one of these 
veins had to be transected to enable removal of the 
uterus with an intact ureter. After surgical isolation, the 
For clinical trial see 
http://clinicaltrials.gov/show/
NCT01844362]
Figure 1: Schematic drawing of the vessel connections of the transplanted uterus
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uterus was flushed bilaterally through the arterial ends 
with cold histidine–tryptophan–ketoglutarate solution 
(Custodiol-HTK; NordMedica AS, Gentofte, Denmark). 
The vascular ends of the graft were trimmed and the 
left-sided vein that had been divided was anastomosed 
end-to-end by a continuous suture (8-0 polypropylene).
1 h before final graft retrieval from the donor, surgery 
to prepare the recipient for transplantation was initiated 
in an adjacent operating theatre. Through a midline 
incision, the external iliac vessels were dissected and 
prepared for anastomosis. The vaginal vault was 
separated from the bladder and rectum. Sutures, to be 
used for uterine fixation, were placed bilaterally through 
the round ligaments, sacrouterine ligaments, and the 
paravaginal connective tissues. The uterus was brought 
into the pelvis and end-to-side vascular anastomoses 
were done to connect the uterine veins to the external 
iliac veins (with 8-0 polypropylene sutures) and the 
anterior divisions of the internal iliac arteries to the 
external iliac arteries (with 7-0 polypropylene sutures) on 
both sides (figure 1). We then opened the blood flow to 
the uterus and ascertained that good pulses existed distal 
to the arterial anastomosis sites and that the uterine 
tissue changed from pale to reddish, which is a sign of 
peripheral tissue perfusion. Then, we fixed the uterus to 
the ligaments and sutured the extensive bladder 
peritoneum on the uterine graft on top of the recipient’s 
bladder to provide extra structural support.
To establish that blood flow through the uterine 
arteries continued during the first post-transplantation 
days, we placed a 20-MHz Doppler probe with a silicon 
cuﬀ (Cook-Schwartz Doppler probe; CookMedical, 
Bloomington, IN, USA) around the left uterine artery. 
The signal was transduced through a thin cable, which 
was exteriorised through the midline incision. The 
probe could then be easily pulled out after the 3-day 
observation period.
The surgeries of the donor and recipient proceeded 
uneventfully. The skin-to-skin durations of surgeries 
were 10 h 7 min for the donor and 4 h 55 min for the 
recipient. The anastomoses were created in the 
sequence of left venous, left arterial, right venous, and 
right arterial. After unclamping for reperfusion, we 
placed one extra suture over the arterial anastomosis 
site on the right side to prevent blood leakage. The 
estimated (Doppler) blood flow through the right 
uterine artery was then 40 mL per min. The uterus 
(figure 2A) was then attached to the orthotopic position 
(figure 2B). Perioperative blood loss was 0·6 L in the 
donor and 0·75 L in the recipient. The total ischaemic 
time of the uterine graft was 2 h 19 min (cold ischaemia: 
1 h 6 min; warm ischaemia: 1 h 13 min). A retroperitoneal 
haematoma was diagnosed in the recipient on the 
second postoperative day and she was transfused with 
two units of leukocyte-reduced packed red blood cells. 
Both the donor and the recipient were discharged from 
the hospital after 6 days of postoperative care.
Immunosuppression and follow-up
The recipient received induction immunosuppression 
with intravenous anti-thymocyte globulin (Thymoglobulin; 
Genzyme, Cambridge, MA, USA) 2·5 mg/kg just before 
surgery and 12 h later. One dose of 500 mg 
methylprednisolone (Solu-Medrol; Pfizer, New York, NY, 
USA) was administered intravenously just before uterine 
reperfusion.
Maintenance immunosuppression was achieved with 
oral tacrolimus aiming at trough levels of 5–10 ng/mL 
(Prograf/Advagraf; Astellas Pharma, Chertsey, UK), and 
myco phenolate mofetil aiming at trough levels of 
40–60 mg·h/L (Cellcept; Roche, Basel, Switzerland) was 
also administered orally during the first 10 months 
post-surgery. Azathioprine 2 mg/kg per day (Imurel; Orion 
Pharma, Sollentuna, Sweden) was then used instead of 
mycophenolate mofetil after 10 months, to avoid the 
potentially teratogenic eﬀects of mycophenolate mofetil in 
the run-up to the embryo transfer attempts. Moreover, 
prednisolone (Prednisolon; Pfizer, New York, NY, USA) 
5 mg daily was added from month 6 post-transplantation 
because of repeated rejection episodes (see Results section).
Figure 2: Uterus transplantation procedure
(A) The uterus with its long vascular pedicles is removed from the donor. (B) The uterine graft is revascularised and 
fixed in the pelvis of the recipient.
A
B
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The recipient was followed up by frequent clinical 
visits and laboratory examinations, initially twice 
weekly during the first postoperative month and then 
every 2 weeks in months 2–6. Subsequently, she was 
seen monthly. The clinical examination involved a 
gynaecological examination with visual inspection of 
the transplanted uterine cervix, bacterial culture from 
the cervical canal, and occasional cervical biopsies. 
Ultrasound scans with transvaginal and abdominal 
probes were done to assess uterine size, and 
endometrial thickness and echogenicity. Uterine artery 
flow velocity waveforms on both sides were assessed by 
Doppler ultrasound, with the abdominal probe placed 
just above the inguinal ligament.
Biopsies of the uterine cervix were obtained at 
predetermined timepoints (at 1, 2, and 4 weeks, and 
monthly thereafter) and in the event of pathological 
signs (abnormal vaginal discharge, fever, discoloured 
cervix, or abdominal pain) that could be related to 
local infection or graft rejection. The histological 
examination of the biopsies used a uterine rejection 
grading system that was initially developed for the 
non-human primate uterus.13 Any presence of cervical 
intraepithelial neoplasia was followed by tests for 
human papillomavirus.
Clinical follow-up also included monitoring of blood 
pressure and bodyweight, and laboratory monitoring 
of: serum creatinine and liver enzymes; blood 
haemoglobin, leukocytes, platelets, iron store, and 
glucose; urine albumin or creatinine; blood tacrolimus 
concentration (measured in whole blood by an 
automated chemiluminescent immunoassay; Abbott 
Diagnostics, Abbott Park, IL, USA) and concentrations 
of mycophenolate mofetil (measured by an enzyme 
multiplied immunoassay technique [Horiba ABX 
Pentra; Thermo Fisher Scientific, Waltham, MA, USA]).
During pregnancy, the patient was monitored according 
to Sahlgrenska University Hospital’s routine programme 
for pregnant transplant patients, including frequent visits 
(every 2–3 weeks) to specialists in high-risk obstetrics and 
transplantation. Ultrasound data relating to the pulsatility 
index of the uterine arteries and umbilical artery and fetal 
growth were compared against data from the normal 
population.14,15
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
The first menstruation in the recipient occurred 
spontaneously 43 days post-transplantation and 
continued for 4 days. She then had regular menses with 
a median interval of 32 days and ranging between 
26–36 days. The endometrium showed typical changes 
in median width (maximum 11·3 mm; range 
7·9–15·3 mm). The blood flow velocity waveforms of 
the uterine arteries were similar on the left and right 
side and were within the low to normal range 
throughout the observation period. Median pulsatility 
indices were 1·27 (range 0·89–2·37) on the left side and 
1·83 (1·30–2·54) on the right side.
Two mild rejection episodes (one after 9 days and the 
other at 6 months and 24 days) and one borderline 
Week 8 Week 12 Week 13 Week 15 Week 19 Week 25 Week 27 Week 29 Week 31
Weight (kg) 66 66 65 64 66 69 70 71 74
Cervical length (mm)* ·· ·· 44 43 45 48 50 49 31
Blood pressure (mm Hg) 100/75 100/75 110/60 110/60 110/70 120/75 110/70 120/80 170/105
Proteinuria (g/L) 0 0 0 0 0 0 0 0 1–3
Haemoglobin (g/L) 84 99 99 99 89 98 100 102 107
*Cervical length was not measured before week 13.
Table: Maternal characteristics during pregnancy by completed week of gestation
Figure 3: 3D image of the fetus’ face at organ ultrasound screening in 
gestational week 18
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episode (at 2 months and 28 days) were diagnosed by 
cervical biopsies. These episodes occurred without any 
clinical symptoms. The rejection diagnosis was based 
on changed histology with a moderate increase in 
lymphocyte density in the stroma and the epithelium, 
with some spongiosis in the basal level of the 
epithelium. Occasional apoptotic cells were recorded 
in the basal epithelium together with reactive changes 
in the surface epithelium. The rejection episodes 
were successfully reversed by corticosteroid treatment 
(see later).
A biopsy 8 months and 12 days after transplantation 
showed moderate squamous epithelial dysplasia (p16 
positive) and koilocytosis. Human papillomavirus typing 
Figure 4: Ultrasound estimates of fetal growth and flow velocity in maternal uterine arteries and fetal umbilical artery during pregnancy
(A) The femur length, biparietal diameter, abdominal diameter, and estimated fetal weight were all within the normal range. (B) The uterine artery flow velocity 
waveform (pulsatility index) was low to normal on both sides; (C) shows a typical recording. (D) The pulsatility index in the umbilical artery was within the normal 
range during pregnancy; a recording is displayed in (E).
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identified subtype 31. A follow-up mini-conisation 
2 weeks later, with inclusion of the biopsy site, was 
normal and subsequent biopsies displayed no dysplasia 
or koilocytosis.
The median blood concentrations of tacrolimus were 
9·5 ng/mL (range 3·0–12·0) during the first 3 months, 
8·9 ng/mL (8·5–9·9) during months 4–6, 12 ng/mL 
(7·9–12·0) during months 7–9, and 10·0 (9·5–12·0) 
during months 10–12. The median blood tacrolimus 
concentration for the entire pre-pregnancy period was 
9·8 ng/mL (range 3·0–12·0). The mycophenolate 
mofetil area under the curve was 51·3 mg·h/L (range 
36·5–96·7) during the 10 months of treatment. The 
first mild rejection episode (on day 9) was treated with 
methylprednisolone 500 mg intravenously for 3 days, 
followed by oral prednisolone (starting dose 10 mg 
twice daily) for 4 weeks in a tapered protocol. The 
borderline episode (at 2 months and 28 days) was only 
treated with oral prednisolone in the 4 weeks-tapered 
protocol. The second mild rejection episode (at 
6 months and 24 days) was initially treated in the same 
way as the previous mild rejection episode (see above) 
but the patient continued with oral prednisolone (5 mg 
daily) for the whole pre-pregnancy period. Since the 
recipient experienced two clear rejection episodes and 
because one was fairly close in time to the planned 
omission of mycophenolate mofetil, we decided that 
the patient would stay on mycophenolate mofetil for a 
total of 10 months and that azathioprine (2 mg/kg per 
day) would then be the replacement antiproliferative 
immunosuppression. Blood pressure and haemoglobin 
concentration during this initial post-transplantation 
year were stable at around 120/70 mm Hg and 100 g/L, 
respectively.
After in-vitro fertilisation, before transplantation, 
one cryopreserved embryo was obtained from one oocyte 
in cycle 1, four embryos from nine oocytes in cycle 2, and 
six embryos from eight oocytes in cycle 3. The embryo 
transfer was done 1 year after uterus transplantation and 
took place in the early luteal phase of the menstrual 
cycle. 3 days after a positive urinary luteinizing hormone 
test, three embryos were thawed, one of which was 
acceptable for transfer. The four-cell embryo had 
three surviving blastomeres. At embryo transfer, the 
endometrial thickness was 6 mm. The patient was on 
continuous treatment with 75 mg acetylsalicylic acid 
once daily since transplantation. She was treated with 
oral folic acid (250 μg twice daily) from 2 weeks before 
embryo transfer and vaginal progesterone (Lutinus; 
Ferring, Copenhagen, Denmark) 100 mg three-times 
daily for 9 weeks after embryo transfer.
A pregnancy test was positive 3 weeks after embryo 
transfer and 2 weeks later the intrauterine location and 
heartbeat of the fetus was detected by ultrasound. The 
pregnancy proceeded normally between 8 and 31 weeks 
of gestation—ie, the pregnant woman gained 8 kg in 
weight, cervical length was between 43 mm and 50 mm, 
haemoglobin was around 100 g/L (except for week 20 
[see later]), blood pressure and blood glucose 
concentrations were in the normal range, and no 
proteinuria occurred (table). 3D ultrasound organ 
screening in gestational week 18 was normal (figure 3). 
Creatinine concentrations, in this patient with a single 
kidney, were somewhat raised during the pre-pregnancy 
period (median 94 μmol/L [range 80–111]) and were 
further elevated during pregnancy (106 μmol/L [86–147]), 
with creatinine concentrations constantly higher than 
100 μmol/L from gestational week 27. Ultrasound 
examination then showed a slight hydronephrosis in the 
single right kidney. She was working full time until the 
day before delivery. 
During pregnancy, growth in fetal femur length, 
biparietal diameter, abdominal diameter, and estimated 
weight were normal (figure 4A). The blood flow velocity 
waveform of the uterine arteries remained within the 
normal to low range during pregnancy (figure 4B, C). 
The pulsatility index of the umbilical artery was normal 
throughout pregnancy (figure 4D, E).
The patient was admitted to the obstetrics division at 
Sahlgrenska University Hospital (Gothenburg, Sweden) at 
31 weeks and 5 days because of pre-eclampsia, with a blood 
pressure of 180/120 mm Hg, mild headache, proteinuria 
(urine albumin 18 mg/L), and lowered platelet count 
(96 × 10⁹/L). She was given labetalol (200 mg three times 
daily) and nifedipine (10 mg twice daily), both administered 
orally, to reduce the raised blood pressure. Betamethasone 
(12 mg intravenously) was administered as respiratory 
distress syndrome prophylaxis. The patient had an 
increasing number of uterine contractions and cardio-
tocography showed occasional variable decelerations from 
around 10 h after admission. We applied continuous 
cardiotocography surveillance and because of ongoing 
repeated episodes of an abnormal cardiotocography Figure 5: The newborn baby just after birth
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pattern, a caesarean section was done 16 h after admission. 
The caesarean section was undertaken in spinal analgesia 
through a midline incision. Only mild adhesions existed. 
After careful dissection of the bladder peritoneum, with 
localisation of the major uterine vessels, a low-transverse 
uterine incision was made. The child was in breech 
position and was delivered 26 min after skin incision. The 
placenta (weight 375 g) was delivered immediately 
afterwards. Histological examination of the placenta 
showed a normal umbilical cord with tree vessels and no 
inflammation. The placental villi showed pre-eclampsia-like 
changes with villi of small calibre in relation to gestational 
length. Increased fibrin deposits and signs of fibrin 
thrombi were recorded in villous capillaries. Inflammation 
was not seen. After delivery, the uterus contracted well on 
intravenous oxytocin (10 IU). The uterine incision was 
sutured with a standard two-layered technique. A small 
myometrial biopsy was taken from the fundus uteri and 
the histology of this was normal.
The birthweight of the neonate was 1775 g, length was 
40 cm, and head circumference 28·5 cm (figure 5). 
APGAR scores were 9, 9, 10 and the umbilical artery pH 
was 7·21. The first postnatal week was uneventful and 
the baby was in good condition, requiring only 
phototherapy and room air. The mother was in a good 
condition the day after delivery and her blood pressure 
was normalised spontaneously, with no further 
treatment. She was discharged from the hospital 3 days 
after caesarean section and is followed up in regular 
outpatient visits. The creatinine concentrations had 
decreased from 143 μmol/L on the day of delivery to 
98 μmol/L 5 days later. The baby was discharged in good 
health from the neonatal unit 16 days after birth and the 
weight 21 days after delivery was 2040 g. 
During pregnancy, the recipient continued with triple 
immunosuppression consisting of tacrolimus, azathio-
prine, and prednisolone. Tacrolimus concen trations 
tended to decrease during the first trimester and the 
tacrolimus dose was gradually increased to 40% of the 
pre-pregnancy dose (which was 10 mg daily) to achieve 
intended blood concentrations between 8 and 10 ng/mL. 
The median tacrolimus concentration during the entire 
pregnancy period was 7·3 ng/mL (range 4·6–13·0). 
During the first trimester, the patient presented with 
increasing leucopenia and anaemia, and the dose of 
azathioprine was consequently lowered from 2 mg/kg 
per day to 1·2 mg/kg per day during a period of 4 weeks. 
After 18 full weeks and 2 days of gestation, the protocol 
cervical biopsy showed mild rejection but the patient was 
asymptomatic. Inflammation was seen both in the 
subepithelial stroma and in the basal parts of the 
squamous cell epithelium (figure 6A). Apoptosis was 
also evident in the epithelium. No donor-specific HLA 
antibodies were detected at that time. She was treated 
with intravenous methylprednisolone for 3 days (250 mg 
on day 1, and 125 mg on days 2 and 3). The control biopsy 
after 20 full gestational weeks and 1 day (figure 6B) and 
the per-protocol biopsy after 30 full gestational weeks and 
6 days were normal. The dose of azathioprine was then 
increased to its original dose (2 mg/kg per day) and the 
patient continued on this dose until delivery. The blood 
concentrations of tacrolimus during pregnancy were 
similar to those during the initial post-transplantation 
year (median 8·1 ng/mL [range 6·1–13·0]).
The haemoglobin concentration 3 days before embryo 
transfer was 101 g/L and the patient started treatment with 
oral ferrous sulphate 100 mg twice daily. In gestational 
week 8, haemoglobin fell to 84 g/L despite the ferrous 
sulphate treatment. One dose of 500 mg intravenous 
ferric carboxymaltose (Ferinject; Orifarm AB, Stockholm, 
Sweden) was administered and treatment with 60 μg 
weekly subcutaneous darbepoetinalfa (Aranesp; Amgen, 
Thousand Oaks, CA, USA) was initiated. Table 1 provides 
the blood haemoglobin concentrations throughout 
the pregnancy.
Discussion
Despite remarkable advances in infertility treatment, 
since the birth of the first in-vitro fertilisation baby in 
197816 major forms of uterine factor infertility have 
remained untreatable. Our demonstration of a livebirth 
after uterus transplantation in a woman born with no 
uterus has eradicated the diagnosis of absolute uterine 
factor infertility.
This livebirth after human uterus transplantation 
comes after more than a decade of intensive animal 
research in this specialty by several groups worldwide. 
The ethical issues surrounding uterus transplantation 
are complex in their specific facets of non-maleficence, 
autonomy, beneficence, justice, and dignity. Modern 
uterus transplantation research began shortly after the 
first human hand transplantation in 1998,17 which in 
many ways opened up the field of transplantation surgery 
to also include non-vital tissues or organs that after 
transplantation would have the chance to substantially 
increase an individual’s quality of life. Thus, face and 
larynx transplantation have also now reached the stage as 
established clinical procedures.
Figure 6: Light micrographs from cervical biopsies showing rejection and normalisation 2 weeks after treatment
(A) Biopsy showing mild rejection. A dense infiltrate of leukocytes, mainly lymphocytes, exists in the stroma and 
infiltrates into the basal layers of the epithelium, where occasional apoptotic cells can be seen (arrows). (B) 1 week 
later, after anti-rejection treatment, the leukocyte infiltration is almost completely reversed. The slides are stained 
with haematoxylin and eosin.
A B
100 µm
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Most types of organ and tissue transplantation that are 
done today use graft obtained from a deceased donor. 
The live donor concept is established for renal 
transplantation and for liver transplantation, but rates of 
live renal and liver donation vary greatly between 
countries. In the present study, the live donor was a close 
family friend of the recipient, by contrast with the other 
donors of our study cohort who were all family members. 
Our patient’s first choice of donor was her mother, but 
blood group incompatibility prevented her from taking 
part in the study.
Uterus donation from live donors adds another key 
element into a risk–benefit analysis concerning uterus 
transplantation.18 Uterine donation from a deceased donor 
would obviously substantially reduce the overall risks and 
complexity of the surgical procedure. In the uterus 
transplantation that was done in Turkey in 2011, the uterus 
was from a heart-beating, brain-dead, 22-year-old female, 
donor who had never been pregnant. Naturally, the young 
age of that uterus and its extensive vasculature would oﬀer 
a benefit but this has to be balanced against the advantage 
of a uterine graft that has proved its functionality in terms 
of normal pregnancies. Moreover, the live donor concept 
allows for meticulous diagnostic workup of the uterine 
graft to exclude pathologies that could interfere with fertility 
potential, such as adenomyosis and endometrial polyps.
A specific concern with uterine donation is of course to 
exclude pathological disorders of the uterus that might 
be related to precancerous disorders. Both the donor and 
the recipient were human papillomavirus negative at our 
pretransplantation examinations and the presence of 
cervical dysplasia with human papillomavirus at 
9 months after transplantation was unexpected. The 
reason for the temporary human papillomavirus 
positivity and secondary dysplasia is unknown.
A major reason to do in-vitro fertilisation before 
transplantation was that we needed to ascertain that 
fertility, in terms of fertilisation and initial embryo 
development, existed within the couple. Moreover, an 
in-vitro fertilisation procedure after transplantation 
might be more diﬃcult than one before transplantation 
because of the abnormal uterine vascular pedicles and 
anastomosis sites that might increase the risk of bleeding 
at oocyte pick-up and because the immunosuppressed 
patient may have an increased risk of pelvic infection 
after the pick-up procedure. The first in-vitro fertilisation 
cycle of the patient only generated one embryo for 
cryopreservation and she was subsequently stimulated 
with very high gonadotrophin doses to obtain the normal 
oocyte yield. A previous report on surrogate in-vitro 
fertilisation outcome of patients with Rokitansky 
syndrome,19 shows that women with the atypical 
Rokitansky form—as was the case with our patient—are 
poor responders and have a lower fertilisation rate than 
do women with the typical form of Rokitansky syndrome.
The patient became pregnant at her first transfer of a 
frozen-thawed embryo. The chance of that occurring in 
our setting and in her age group is around 16%.20 
Naturally, we did a single embryo transfer to avoid the 
risk of any multiple pregnancy, which would be an 
unnecessary additional obstetrical risk factor.
We diagnosed one episode of mild rejection during 
pregnancy. The histological rejection signs of the uterine 
cervix were reversible with a short course of increased 
corticosteroid treatment. The pregnancy itself induces a 
local immunosuppressed state and the myometrial and 
endometrial tissue of the uterine body might well have 
not shown the type of rejection-related inflammation that 
we diagnosed in the uterine cervix.
The pregnancy of our patient proceeded essentially 
normally for the first 31 weeks. The growth curves and the 
blood velocity waveforms of the umbilical cord were normal 
throughout pregnancy. In autologous uterus transplantation 
in sheep—which have pelvic vessels sizes similar to those 
in human beings—normal birthweights were also 
recorded.21 Pulsatility indices of uterine arteries were within 
the normal to low range. A lower pulsatility index indicates 
decreased resistance of the blood vessels, which might well 
be caused by the denervated nature of the uterine graft and 
the absence of normal nerve-mediated vasocontrictive 
mechanisms. The normal to low pulsatility index of the 
uterine arteries would suggest a low, rather than high, risk 
of pre-eclampsia development. However, this specific 
situation of vascular supply from the external iliacs and 
with a transplanted uterus might ultimately reduce the 
predictive value of changes in uterine artery waveforms.
Panel: Research in context
Systematic review
We searched PubMed for all publications with the search terms “uterus” AND 
“transplantation” AND “human”, and we also ran a search for “uterine” AND 
“transplantation” AND “human”. The searches included all papers, published in English 
language only, from 1956 up until Sept 30, 2014. The first search yielded 998 published 
papers and the second search provided 2228. All titles and abstracts, when available, were 
read to find out if they contained information about any human cases. Published data on 
11 human uterus transplantation cases were found. The first human case (transplantation 
done in 2000) was reported in one research paper and the second case (in 2011) was 
reported in three research papers, covering surgery with 12-month follow-up, in-vitro 
fertilisation, and embryo transfer attempts with two early miscarriages, and one video 
presentation of surgical technique. The other nine cases were reported in our study 
detailing the surgery and 6-months outcome. Additionally, four reports existed on the 
surgical techniques of uterus retrieval from human deceased donors. The searches found 
nine articles about the ethics of uterus transplantation and 48 general reviews that at 
least partly covered the topic of human uterus transplantation.
Interpretation
Our present study is the first report of a livebirth after uterus transplantation and is 
thereby a proof of concept for this treatment of absolute uterine factor infertility. The 
eﬃciency of uterus transplantation as an infertility treatment is unclear and remains to be 
established. The livebirth rate of the complete cohort of the first clinical trial of uterus 
transplantation, which our patient belongs to, and results of future cohort studies will 
shed light on the eﬃciency of the procedure but also about what medical and 
psychological risks are involved. 
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The reason for the development of pre-eclampsia in 
this specific case is not known, but several plausible 
explanations exist. Immunosuppression might increase 
the risk of pre-eclampsia, and after kidney transplantation 
the pre-eclampsia rate is as high as 22%.22 This situation 
is similar to the patient in our study, who also had 
one kidney and was on immunosuppression. The fact 
that a single kidney by itself could be an underlying 
factor of pre-eclampsia development is indicated by the 
fact that the rate of pre-eclampsia is about two-times 
higher in kidney donors than in their pregnancies before 
donation.23 Other factors that might underlie the 
development of pre-eclampsia are the old age of the 
uterus, as indicated by the sevenfold increased rate of 
pre-eclampsia in women 50–60 years of age undergoing 
oocyte donation.24 However, whether or not this increased 
rate is due to uterine factors is unclear since it can also be 
caused by age-related changes in other organs. Moreover, 
pre-eclampsia is more common in in-vitro fertilisation 
pregnancies25 than after natural conception, and the total 
allogeneic situation, with a donated uterus or a donated 
oocyte, can increase the risk of pre-eclampsia.26
Our patient had periods of anaemia, leucopenia, and 
increased creatinine concentrations during pregnancy, 
which were probably immunosuppression-related 
side-eﬀects that became apparent during pregnancy, with 
its added demands on several systemic functions. Thus, 
the potential side-eﬀects of immunosuppression—such 
as nephrotoxicity (tacrolimus), bone marrow toxicity 
(azathioprine), diabetogenic eﬀect (corticosteroids and 
tacrolimus)—should be taken in account in the planning 
of a pregnancy attempt after uterus transplantation, to 
decide the best possible time for embryo transfer in 
relation to immuno suppressive medication.
Uterus transplantation is the first ephemeral type of 
transplantation that has been introduced in which the 
graft is not intended for lifelong use. The uterus can be 
removed after one or two babies have been born, which 
would reduce the long-term side-eﬀects caused by the 
immunosuppressive drugs. The patient of our present 
study had been informed that we can recommend surgical 
removal of the uterus before a second pregnancy attempt 
in the case of any major side-eﬀects of immunosuppression. 
Such a decision should not be taken during the first few 
months after delivery, to allow for spontaneous reversion 
of side-eﬀects that might have been aggravated by the 
pregnancy. Moreover, this delay would provide further 
observation time to ensure that the delivered baby is 
healthy and allow the uterus to return to its normal size, 
which would simplify any hysterectomy surgery. The 
autonomy of the patients should be respected and any 
future decision to surgically remove the uterus needs to be 
made in consensus with the recipient and her partner.
In conclusion, our demonstration of the first livebirth 
after uterus transplantation opens up the possibility to 
treat the many young women with uterine factor 
infertility worldwide.
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